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1The end of the first century of drug control (it all started 
in Shanghai in 1909) coincided with the closing of the 
UNGASS decade (launched in 1998 by a General 
Assembly Special Session on Drugs). These anniversaries 
stimulated reflection on the effectiveness, and the limi-
tations, of drug policy. The review resulted in the reaf-
firmation that illicit drugs continue to pose a health 
danger to humanity. That’s why drugs are, and should 
remain, controlled. With this sanction in mind, Member 
States confirmed unequivocal support for the UN Con-
ventions that have established the world drug control 
system. 
At the same time, UNODC has highlighted some nega-
tive, obviously unintended effects of drug control, fore-
shadowing a needed debate about the ways and means 
to deal with them. Of late, there has been a limited but 
growing chorus among politicians, the press, and even 
in public opinion saying: drug control is not working. The 
broadcasting volume is still rising and the message 
spreading.
Much of this public debate is characterized by sweeping 
generalizations and simplistic solutions. Yet, the very 
heart of the discussion underlines the need to evaluate 
the effectiveness of the current approach. Having stud-
ied the issue on the basis of our data, UNODC has 
concluded that, while changes are needed, they should 
be in favour of different means to protect society against 
drugs, rather than by pursuing the different goal of 
abandoning such protection. 
A. What’s the repeal debate about?
Several arguments have been put forward in favour of 
repealing drug controls, based on (i) economic, (ii) 
health, and (iii) security grounds, and a combination 
thereof. 
I. The economic argument for drug legalization says: 
legalize drugs, and generate tax income. This argument is 
gaining favour, as national administrations seek new 
sources of revenue during the current economic crisis. 
This legalize and tax argument is un-ethical and un-
economical. It proposes a perverse tax, generation upon 
generation, on marginalized cohorts (lost to addiction) 
to stimulate economic recovery. Are the partisans of this 
cause also in favour of legalizing and taxing other seem-
ingly intractable crimes like human trafficking? Mod-
ern-day slaves (and there are millions of them) would 
surely generate good tax revenue to rescue failed banks. 
The economic argument is also based on poor fiscal 
logic: any reduction in the cost of drug control (due to 
lower law enforcement expenditure) will be offset by 
much higher expenditure on public health (due to the 
surge of drug consumption). The moral of the story: 
don’t make wicked transactions legal just because they 
are hard to control. 
II. Others have argued that, following legalization, a 
health threat (in the form of a drug epidemic) could be 
avoided by state regulation of the drug market. Again, 
this is naive and myopic. First, the tighter the controls 
(on anything), the bigger and the faster a parallel (crim-
inal) market will emerge – thus invalidating the concept. 
Second, only a few (rich) countries could afford such 
elaborate controls. What about the rest (the majority) of 
humanity? Why unleash a drug epidemic in the develop-
ing world for the sake of libertarian arguments made by 
a pro-drug lobby that has the luxury of access to drug 
treatment? Drugs are not harmful because they are con-
trolled – they are controlled because they are harmful; 
and they do harm whether the addict is rich and beauti-
ful, or poor and marginalized. 
Drug statistics keep speaking loud and clear. Past run-
away growth has flattened out and the drug crisis of the 
1990s seems under control. This 2009 Report provides 
further evidence that drug cultivation (opium and coca) 
are flat or down. Most importantly, major markets for 
opiates (Europe and South East Asia), cocaine (North 
America), and cannabis (North America, Oceania and 
Europe) are in decline. The increase in consumption of 
synthetic stimulants, particularly in East Asia and the 
Middle East, is cause for concern, although use is declin-
ing in developed countries. 
III. The most serious issue concerns organized crime. 
All market activity controlled by the authority generates 
parallel, illegal transactions, as stated above. Inevitably, 
drug controls have generated a criminal market of mac-
ro-economic dimensions that uses violence and corrup-
tion to mediate between demand and supply. Legalize 
drugs, and organized crime will lose its most profitable line 
of activity, critics therefore say. 
Not so fast. UNODC is well aware of the threats posed 
by international drug mafias. Our estimates of the value 
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2of the drug market (in 2005) were ground-breaking. 
The Office was also first to ring the alarm bell on the 
threat of drug trafficking to countries in West and East 
Africa, the Caribbean, Central America and the Balkans. 
In doing so we have highlighted the security menace 
posed by organized crime, a matter now periodically 
addressed by the UN Security Council.
Having started this drugs/crime debate, and having 
pondered it extensively, we have concluded that these 
drug-related, organized crime arguments are valid. They 
must be addressed. I urge governments to recalibrate the 
policy mix, without delay, in the direction of more con-
trols on crime, without fewer controls on drugs. In other 
words, while the crime argument is right, the conclu-
sions reached by its proponents are flawed. 
Why? Because we are not counting beans here: we are 
counting lives. Economic policy is the art of counting 
beans (money) and handling trade-offs: inflation vs. 
employment, consumption vs. savings, internal vs. exter-
nal balances. Lives are different. If we start trading them 
off, we end up violating somebody’s human rights. There 
cannot be exchanges, no quid-pro-quos, when health and 
security are at stake: modern society must, and can, 
protect both these assets with unmitigated determina-
tion.
I appeal to the heroic partisans of the human rights 
cause worldwide, to help UNODC promote the right to 
health of drug addicts: they must be assisted and reinte-
grated into society. Addiction is a health condition and 
those affected by it should not be imprisoned, shot-at or, 
as suggested by the proponent of this argument, traded-
off in order to reduce the security threat posed by inter-
national mafias. Of course, the latter must be addressed, 
and below is our advice.
B. A better policy mix
The crime/drugs nexus was the subject of a Report enti-
tled Organized Crime and its Threat to Security: tackling 
a disturbing consequence of drug control1 that I presented 
to the Commission on Narcotic Drugs and the Crime 
Commission in 2009. Because of the importance of this 
subject, we have devoted the thematic chapter of this 
1  E/CN.15/2009/CRP.4 - E/CN.7/2009/CRP.4; http://www.unodc.
org/unodc/en/commissions/CCPCJ/session/18.html
year’s Report to examining further the issue and its 
policy implications. Here are some of the main points. 
First, law enforcement should shift its focus from drug 
users to drug traffickers. Drug addiction is a health con-
dition: people who take drugs need medical help, not 
criminal retribution. Attention must be devoted to heavy 
drug users. They consume the most drugs, cause the 
greatest harm to themselves and society – and generate 
the most income to drug mafias. Drug courts and med-
ical assistance are more likely to build healthier and safer 
societies than incarceration. I appeal to Member States 
to pursue the goal of universal access to drug treatment 
as a commitment to save lives and reduce drug demand: 
the fall of supply, and associated crime revenues, will 
follow. Let’s progress towards this goal in the years ahead, 
and then assess its beneficial impact on the next occasion 
Member States will meet to review the effectiveness of 
drug policy (2015). 
Second, we must put an end to the tragedy of cities out 
of control. Drug deals, like other crimes, take place 
mostly in urban settings controlled by criminal groups. 
This problem will worsen in the mega-cities of the 
future, if governance does not keep pace with urbaniza-
tion. Yet, arresting individuals and seizing drugs for their 
personal use is like pulling weeds – it needs to be done 
again the next day. The problem can only be solved by 
addressing the problem of slums and dereliction in our 
cities, through renewal of infrastructures and investment 
in people – especially by assisting the youth, who are 
vulnerable to drugs and crime, with education, jobs and 
sport. Ghettos do not create junkies and the jobless: it is 
often the other way around. And in the process mafias 
thrive.
Third, and this is the most important point, govern-
ments must make use, individually and collectively, of 
the international agreements against uncivil society. This 
means to ratify and apply the UN Conventions against 
Organized Crime (TOC) and against Corruption 
(CAC), and related protocols against the trafficking of 
people, arms and migrants. So far, the international 
community has not taken these international obligations 
seriously. While slum dwellers suffer, Africa is under 
attack, drug cartels threaten Latin America, and mafias 
penetrate bankrupt financial institutions, junior nego-
tiators at these Conventions’ Conferences of the Parties 
have been arguing about bureaucratic processes and 
PREFACE
3arcane notions of inclusiveness, ownership, comprehen-
siveness, and non-ranking. There are large gaps in the 
implementation of the Palermo and the Merida Con-
ventions, years after their entry into force, to the point 
that a number of countries now face a crime situation 
largely caused by their own choice. This is bad enough. 
Worse is the fact that, quite often vulnerable neighbors 
pay an even greater price. 
There is much more our countries can do to face the 
brutal force of organized crime: the context within 
which mafias operate must also be addressed.
Money-laundering s  is rampant and practically unop-
posed, at a time when interbank-lending has dried up. 
The recommendations devised to prevent the use of ﬁ-
nancial institutions to launder criminal money, today 
are honored mostly in the breach. At a time of major 
bank failures, money doesn’t smell, bankers seem to be-
lieve. Honest citizens, struggling in a time of economic 
hardship, wonder why the proceeds of crime – turned 
into ostentatious real estate, cars, boats and planes – are 
not seized.
Another context deserving attention concerns one of  s
humanity’s biggest assets, the internet. It has changed 
our life, especially the way we conduct business, com-
munication, research and entertainment. But the web 
has also been turned into a weapon of mass destruction 
by criminals (and terrorists). 
Surprisingly, and despite the current crime wave, calls 
for new international arrangements against money-laun-
dering and cyber-crime remain un-answered. In the 
process, drug policy gets the blame and is subverted.
C. A double “NO”
To conclude, transnational organized crime will never be 
stopped by drug legalization. Mafias coffers are equally 
nourished by the trafficking of arms, people and their 
organs, by counterfeiting and smuggling, racketeering 
and loan-sharking, kidnapping and piracy, and by vio-
lence against the environment (illegal logging, dumping 
of toxic waste, etc). The drug/crime trade-off argument, 
debated above, is no other than the pursuit of the old 
drug legalization agenda, persistently advocated by the 
pro-drug-lobby (Note that the partisans of this argu-
ment would not extend it to guns whose control – they 
say – should actually be enforced and extended: namely, 
no to guns, yes to drugs). 
So far the drug legalization agenda has been opposed 
fiercely, and successfully, by the majority of our society. 
Yet, anti-crime policy must change. It is no longer suf-
ficient to say: no to drugs. We have to state an equally 
vehement: no to crime.
There is no alternative to improving both security and 
health. The termination of drug control would be an 
epic mistake. Equally catastrophic is the current disre-
gard of the security threat posed by organized crime.
Antonio Maria Costa 
Executive Director 
United Nations Office on Drugs and Crime
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Drug control has been on the global agenda for more 
than a century. As documented in the 2008 World Drug 
Report, the Chinese opium epidemic in the early twenti-
eth century spurred concerted international action, 
chiefly in the form of a series of treaties passed over 
several decades. These treaties, in particular the 1961 
Single Convention on Narcotic Drugs, the 1971 Con-
vention on Psychotropic Substances, and the 1988 Con-
vention against the Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, continue to define the interna-
tional drug control system. The United Nations Office 
on Drugs and Crime (UNODC) is the guardian of these 
treaties and the United Nations lead agency on drug 
control.
At the twentieth special session of the General Assembly 
in 1998, Member States agreed to make significant 
progress towards the control of supply and demand for 
illicit drugs by the year 2008. They noted that this 
objective could only be achieved by means of the ‘bal-
anced approach’ (giving demand as much attention as 
supply), and on the basis of regular assessments of global 
drug trends. UNODC has published such assessments 
annually since 1999.  
Moreover, the General Assembly, in its resolution 61/183 
of 13 March 2007, requested UNODC to continue to 
“publish the World Drug Report with comprehensive and 
balanced information about the world drug problem.” 
This year, UNODC will continue to fulfil this mandate 
with the publication of the 2009 World Drug Report.
The World Drug Report aims to enhance Member States’ 
understanding of global illicit drug trends, and to sensi-
tize all Governments about the need for more systematic 
collection and reporting of data related to illicit drugs. 
UNODC relies on Member States to provide data, pri-
marily through the annual reports questionnaire (ARQ). 
This year, out of some 200 distributed questionnaires, 
UNODC received 118 replies to the drug abuse section 
and 116 replies to the illicit supply of drugs section. In 
general, the ability of Member States to provide infor-
mation on illicit drug supply is significantly better than 
their ability to provide demand-related data. Despite 
commendable progress, for example in the area of prev-
alence estimates, far more remains to be done to provide 
a solid, reliable basis for trend and policy analysis. 
6Types of drugs:
ATS – Amphetamine-type stimulants (ATS) are a group 
of substances comprised of synthetic stimulants includ-
ing amphetamine, methamphetamine, methcathinone 
and ecstasy-group substances (MDMA and its ana-
logues). In cases where countries report to UNODC 
without indicating the specific ATS they are referring to, 
the term non-specified amphetamines is used.
Coca paste (or cocaine base) – An extract of the leaves of 
the coca bush. Purification of coca paste yields cocaine 
(hydrochloride).
Crack (cocaine) – Cocaine base obtained from cocaine 
hydrochloride through conversion processes to make it 
suitable for smoking.
Heroin HCl (heroin hydrochloride) – Injectable form of 
heroin, sometimes referred to as “Heroin no. 4”
Heroin no. 3 – A less refined form of heroin suitable for 
smoking.
Poppy straw – All parts (except the seeds) of the opium 
poppy, after mowing.
Terms: Since there is some scientific and legal ambiguity 
about the distinctions between drug 'use', 'misuse' and 
'abuse', this report uses the neutral terms, drug 'use' or 
'consumption'.
Annual prevalence means the number of people who 
have used a given drug at least once in the past year. 
Annual prevalence rate refers to the percentage of a pop-
ulation (for example, in one country, or globally) that 
has used a given drug at least once in the past year.
Maps: The boundaries and names shown and the desig-
nations used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line rep-
resents approximately the line of control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final 
status of Jammu and Kashmir has not yet been agreed 
upon by the parties. Disputed boundaries (China/India) 
are represented by cross hatch due to the difficulty of 
showing sufficient detail. 
Population data: The data on population used in this 
report comes from: United Nations, Department of Eco-
nomic and Social Affairs, Population Division (2007). 
World Population Prospects: The 2006 Revision. 
Regions: In various sections, this report uses a number 
of regional designations. These are not official designa-
tions. They are defined as follows:
East Europe: European countries belonging to the  s
Commonwealth of Independent States
South-East Europe: Turkey and the non-European  s
Union (EU) Balkan countries 
West and Central Europe: EU 25, European Free  s
Trade Association, San Marino and Andorra 
North America: Canada, Mexico and the United  s
States of America (USA) 
Near and Middle East/South-West Asia: Afghani- s
stan, Bahrain, Iran (Islamic Republic of ), Iraq, Isra-
el, Jordan, Kuwait, Lebanon, Oman, Pakistan, Qa-
tar, Palestinian Territory, Saudi Arabia, Syrian Arab 
Republic, United Arab Emirates and Yemen.
East and South-East Asia: Brunei Darussalam, Cam- s
bodia, China (and Hong Kong, Macao, and Taiwan 
Province of China), Indonesia, Japan, Republic of 
Korea, Lao People’s Democratic Republic, Malaysia, 
Mongolia, Myanmar, Philippines, Singapore, Thai-
land and Viet Nam
South Asia: Bangladesh, India, Maldives, Nepal and  s
Sri Lanka 
Central Asia and Transcaucasia: Armenia, Azerbai- s
jan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, 
Turkmenistan and Uzbekistan
Oceania: Australia, Fiji, Kiribati, Marshall Islands,  s
Micronesia, Nauru, New Zealand, Palau, Papua 
New Guinea, Samoa, Solomon Islands, Tonga, Tu-
valu, Vanuatu, and other Paciﬁc island states and 
territories
West and Central Africa: Angola, Burkina Faso,  s
Cameroon, Cape Verde, Central African Republic, 
Chad, Congo (the Republic of ), Côte d’Ivoire, Ga-
bon, Ghana, Guinea, Liberia, Mali, Niger, Nigeria, 
Sao Tome and Principe, Senegal, Sierra Leone and 
Togo   
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7AIDS Acquired Immune-Deficiency  
Syndrome
ARQ UNODC annual reports questionnaire
ATS amphetamine-type stimulants
CICAD Inter-American Drug Abuse Control 
Commission
CIS Commonwealth of Independent States
COP Colombian peso
DAINAP Drug Abuse Information Network for 
Asia and the Pacific
DELTA UNODC Database on Estimates and 
Long Term Trend Analysis
DIRAN Colombian National Police  
– Antinarcotics Directorate
DUMA Drug Use Monitoring in Australia
EMCDDA European Monitoring Centre for 
Drugs and Drug Addiction
ESPAD European School Survey Project  
on Alcohol and other Drugs
EUROPOL European Police Office
F.O. UNODC Field Office
GAP UNODC Global Assessment  
Programme on Drug Abuse
Govt. Government
HIV Human Immunodeficiency Virus
HONLEA Heads of National Drug Law  
Enforcement Agencies
IDU injecting drug use
INCB International Narcotics Control Board
INTERPOL International Criminal Police  
Organization
LSD lysergic acid diethylamide
MDA 3,4-methylenedioxyamphetamine 
(tenamfetamine)
MDE 3,4-methylenedioxyethylamphetamine
MDMA 3,4-methylenedioxymethamphetamine
NGO Non-governmental organization
NIDA National Institute of Drug Abuse 
(USA)
OECD Organization for Economic  
Co-operation and Development 
ONDCP Office of National Drug Control Policy 
(USA)
P-2-P 1-phenyl-2-propanone (BMK)
SACENDU South African Community  
Epidemiology Network on Drug Use
SAMHSA 
 
SOCA
Substance Abuse and Mental Health 
Services Administration (USA)
Serious Organised Crime Agency (UK)
THC Tetrahydrocannabinol
UAE United Arab Emirates
UNAIDS Joint United Nations Programme on 
HIV/AIDS
UNODC United Nations Office on Drugs and 
Crime
USA United States of America
WCO World Customs Organization
WDR
WHO 
World Drug Report
World Health Organization
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-pro-
panone (PMK)
 Weights and measurements:
l litre
mg milligram
kg kilogram
mt metric ton
The following abbreviations have been used in this Report:
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Overview
The year 2008 saw some encouraging reductions in the 
production of cocaine and heroin. In cooperation with 
the affected states, UNODC conducts annual crop sur-
veys in the countries that produce the vast bulk of these 
drugs. These surveys show a reduction in opium poppy 
cultivation in Afghanistan of 19% and a reduction in 
coca cultivation in Colombia of 18%. Trends in other 
production countries are mixed, but are not large enough 
to offset the declines in these two major producers. 
Although data are not complete enough to give a precise 
estimate of the global reduction in opium and coca pro-
duction, there can be little doubt that it did, in fact, 
decrease.
Production of the other illicit drugs is more difficult to 
track, and data on drug use are also limited. But surveys 
of users in the world’s biggest markets for cannabis, 
cocaine and opiates suggest these markets are shrinking. 
According to recent surveys of young people in Western 
Europe, North America and Oceania, cannabis use 
appears to be declining in these regions. Data from the 
world’s biggest cocaine consuming region, North Amer-
ica, show a decrease, and the European market appears 
to be stabilizing. Reports from traditional opium-using 
countries in South-East Asia also suggest the use of this 
drug may be declining there. Heroin use in Western 
Europe appears to be stable. 
In contrast, there are several indications that the global 
problem with amphetamine-type stimulants (ATS) is 
worsening. Global seizures are increasing, and ATS are 
being made in a growing number of countries, with 
diversifying locations and manufacture techniques. 
Close to 30% of global  seizures in 2007 were made in 
the Near and Middle East, where amphetamine use may 
also be significant. Methamphetamine precursors are 
increasingly being trafficked to Central and South 
America to manufacture ATS for the North American 
market, and local use also appears to be going up. The 
size of the ATS market is large, and likely still growing 
in East Asia. Data on ATS are particularly problematic, 
however, and UNODC is making a concerted effort to 
improve monitoring of trends in this area.
Of course, all these markets are clandestine, and tracking 
changes requires the use of a variety of estimation tech-
niques. Data are sparse, particularly in the developing 
world, and the level of uncertainty in many matters is 
high. For the first time, this year’s World Drug Report is 
explicit about the level of uncertainty, presenting ranges 
rather than point estimates. This shift complicates com-
parison of this year’s estimates with estimates from pre-
vious editions of the World Drug Report, but it is an 
essential step forward in presenting accurate estimates.1
The level of uncertainty is smallest concerning the cul-
tivation of coca and opium poppy, where scientific crop 
surveys have been made in the handful of countries that 
host the bulk of production. Scientific crop yield studies 
have also been done, but there is less certainty around 
the production of these drugs than the cultivation of 
drug crops. Since synthetic drugs and cannabis can be 
produced almost anywhere in the world, less is known 
about their production. Trafficking patterns are reflected 
by seizure data, a mixed indicator that reflects both the 
underlying flow and enforcement action against it. Data 
on drug use comes from surveys and treatment informa-
tion, but a limited number of countries collect this 
information. The level of uncertainty about drug use is 
not uniform, either across drug types or across regions. 
For example, there is less certainty concerning estimates 
of past-year ATS and cannabis users than there is around 
users of opiates and cocaine; more is known about drug 
use in Europe and the Americas than in Africa and parts 
of Asia. 
Global trends in drug production
Opiates
The total area under opium poppy cultivation in the 
major cultivating countries decreased to 189,000 hec-
tares (ha) in 2008. This 16% decrease over the past year 
1 At the fifty-second session of the Commission on Narcotic Drugs, a 
High-Level Segment issued a Political Declaration and Plan of Action 
on International Cooperation towards an Integrated and Balanced Strat-
egy to Counter the World Drug Problem, asserting that policy must be 
evidence-based, and that sound data are crucial. Altough drug data 
quality has improved over the last decade, there remain large gaps 
in the data. Member States adopted a resolution on improving data 
collection, reporting and analysis and asked UNODC to review data 
collection tools and reporting systems. This will include holding inter-
governmental expert consultations and proposing a revised set of survey 
instruments for consideration by the Commission in March 2010. 
For more detail on this resolution, and on the importance of high 
quality data, please see the Special Features section.
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was mainly due to a large decrease in Afghanistan. The 
level of cultivation in Myanmar and Lao People’s Demo-
cratic Republic was approximately the same as in 2007. 
Total potential opium production in the major illicit 
opium poppy cultivating countries has thus decreased 
from the previous year. 
In Afghanistan, opium poppy cultivation continued to 
be concentrated mainly in the southern provinces, while 
more provinces in the centre and north of the country 
became poppy-free. Two thirds of the area under opium 
poppy cultivation in 2008 – more than 100,000 ha - 
were located in the southern province of Hilmand alone. 
The decline in cultivation occurred despite a sharp 
decline in opium poppy eradication, from 19,047 ha in 
2007 to 5,480 ha in 2008. 
Myanmar reported opium poppy cultivation of 28,500 
ha. As in the past, cultivation of opium poppy was 
heavily concentrated in the Shan State in the east of the 
country. In Lao People’s Democratic Republic, a low 
level of opium poppy cultivation was found in the 
northern provinces. In Pakistan, about 2,000 ha of 
opium poppy were cultivated in the border area with 
Afghanistan, about the same level of cultivation reported 
over the past five years.
Opium yields in Afghanistan remained high in 2008. 
Opium poppy cultivation in the major cultivating countries (ha), 1994-2008
Opium production in the major cultivating countries (mt), 1994-2008
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Executive Summary
The potential opium production was estimated at 7,700 
mt (range 6,330 to 9,308 mt). Some 60% of this is 
believed to be converted into morphine and heroin 
within the country. The amount of morphine and heroin 
produced in Afghanistan available for export was esti-
mated at 630 mt (range 519 to 774 mt). Almost 40% of 
the total production was exported as opium.
Cocaine
Despite small increases in the Plurinational State of 
Bolivia (6%) and Peru (4%), the total area under coca 
cultivation decreased by 8% in 2008, due to a signifi-
cant decrease in Colombia (18%). The total area under 
coca cultivation fell to 167,600 ha, close to the average 
level of coca cultivation between 2002 and 2008, and 
well below the levels reached in the 1990s. In spite of 
this year’s decrease, Colombia remained the world’s 
largest cultivator of coca bush, with 81,000 ha, followed 
by Peru (56,100 ha) and Bolivia (30,500 ha). Estimated 
global cocaine production decreased by 15% from 994 
metric tons (mt) in 2007 to 845 mt in 2008. This 
decrease is due to a strong reduction in cocaine produc-
tion in Colombia (28%), which was not offset by 
increases in Bolivia and Peru.
Global coca bush cultivation (ha), 1994-2008
Global cocaine production (mt), 1994-2008
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Cannabis
Estimating the global area under cannabis is considera-
bly more complicated, given that it is grown in most 
countries in the world and can be produced indoors or 
outdoors. The total estimated area for outdoor produc-
tion of cannabis in 2008 ranges from 200,000 ha to 
642,000 ha. The total cannabis herb production is esti-
mated to range from 13,300 mt to 66,100 mt, and for 
cannabis resin, the estimated production range is 2,200 
mt to 9,900 mt. Due to high levels of uncertainty in 
estimating cultivation, it is not possible to produce more 
precise data, as is done for opiates and cocaine. 
ATS
Like cannabis, amphetamine-type stimulants (ATS) can 
be produced virtually anywhere at relatively low cost. 
Since 1990, ATS manufacture has been reported in 
more than 60 countries worldwide, with more being 
added each year. In 2007, UNODC estimated between 
230 and 640 mt of amphetamines-group2 were manufac-
tured; ecstasy-group3 manufacture was estimated to be 
between 72 and 137 mt. 
Shifts in the location of production–often from developed 
to developing countries–illustrate the way criminal organ-
izations are able to make use of more vulnerable countries. 
Additionally, as interest from transnational organized 
crime groups grows, operations of previously unimagina-
ble size and sophistication continue to emerge.
2 The amphetamines-group substances includes predominately 
methamphetamine and amphetamine, but also includes non-
specified amphetamines-group (for example, tablets sold as Captagon, 
methcathinone, fenetylline, methylphenidate and others), however it 
excludes substances purportedly of the ecstasy-group of substances
3 The ecstasy-group substances include predominately MDMA, with 
MDA and MDEA/MDE. However, limited forensic capacity by 
Member States often leads to confusion about the actual content of 
tablets believed to be “ecstasy” (MDMA).
Global trends in drug trafficking
Opiates
In 2007, seizures of opium and heroin grew 33% and 
14%, respectively. This increase reflects the sustained 
high levels of opium production in Afghanistan, and may 
also include some of the accumulated stocks from 2005, 
when global opium production exceeded global con-
sumption. Morphine seizures, however, declined by 41%. 
Overall opiate seizures remained stable in 2007 though 
at a higher level, having almost doubled since 1998. 
 
Ranges of global estimates of cannabis herb production by methodology
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Executive Summary
Cocaine
Following five years of expansion, the quantity of cocaine 
seized fell in 2006 and remained at the lower level in 
2007 (5% over the 2005-07 period). This is consistent 
with a leveling off of production. In 2008, a significant 
decline in trafficking towards North America, the world’s 
largest cocaine consumer market, was seen. This was 
reflected in rapidly rising prices and falling purity levels. 
The United Kingdom also reported falling cocaine 
purity levels in 2008. 
Cannabis
Total cannabis herb seizures amounted to 5,557 mt in 
2007, an increase of about 7% from the previous year. 
Cannabis resin seizures increased by some 29% to 1,300 
mt. In addition, small quantities of cannabis oil were 
seized (equivalent to 418 kg) in 2007. As in 2006, the 
majority of cannabis herb seizures in 2007 were reported 
from Mexico (39% of the world total) and the USA 
(26%). Most of the increase in cannabis resin seizures 
was due to a strong increase in West and Central Europe, 
where seizures increased by 33% compared to 2006. 
Global cocaine seizures, 1987-2007
* including Caribbean and Central America. 
Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
Cannabis herb and resin seizures (mt), 1985-2007
Source: UNODC, Annual Reports Questionnaire / DELTA
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ATS
Global seizures of ATS have continued to increase, total-
ling nearly 52 mt in 2007, surpassing their 2000 peak 
by more than 3 mt.4 The amphetamines-group domi-
nates ATS seizures, accounting for 84% of all seizures by 
volume, with methamphetamine making up the largest 
part. The year 2007 also saw a dramatic jump in ecstasy-
group seizures (16% of all ATS seized); significant 
increases were noted in several large markets. Trafficking 
in ATS substances is most commonly intraregional, thus 
crossing fewer international borders, but precursor 
chemicals from which ATS materials are made continue 
to be trafficked throughout the world. They are often 
diverted from licit manufacture in South, East and 
South-East Asia.
4 To standardize, seizures reported in kilograms, litres and dose/units/
pills/tablets are transformed into kg equivalents: a dose of “ecstasy” 
was assumed to contain on average 100 mg of psychoactive ingredient 
(MDMA); a dose of amphetamine/methamphetamine was assumed 
to contain 30 mg of active ingredient; a litre was assumed to equal a 
kilogram.
Global trends in drug consumption
UNODC estimates that between 172 and 250 million 
persons used illicit drugs at least once in the past year in 
2007.5 But these large figures include many casual con-
sumers who may have tried drugs only once in the whole 
year. It is important, therefore, to also have estimates of 
the number of people who are heavy or “problematic” 
drug users. This group consumes most of the drugs used 
each year; they are very likely to be dependent upon 
drugs, would benefit from treatment, and many of the 
impacts upon public health and public order are likely 
to be affected by their levels of use. Estimates made by 
UNODC suggest that there were between 18 and 38 
million problem drug users aged 15-64 years in 2007. 
Different drugs pose different problems for different 
regions. For example, in Africa and Oceania, more 
people presented for treatment due to problems with 
cannabis than any other drug (63% in Africa; 47% in 
Australia and New Zealand). In contrast, opiates were 
the primary drug treated in Asia and Europe (65% and 
60%, respectively). Cocaine was more prominent in 
North America (34%) and South America (52%) than 
in other regions; and ATS were more prominent in Asia 
(18%), North America (18%) and Oceania (20%). Can-
nabis is playing an increasingly large role in drug treat-
ment in Europe, South America and Oceania since the 
late 1990s; and ATS use now comprises a greater share 
of drug treatment in North and South America than in 
the past. Many Member States are working to expand 
their responses to dependent drug use among their citi-
zens; UNODC and WHO have recently begun joint 
programmatic work to increase drug treatment quality 
and capacity around the globe.
5 For further details on the methods used to make these estimates 
please see the Special Features and Methodology sections below.
Global seizures of amphetamine-type stimulants (ATS), 1990 - 2007
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (Brussels, 2008) and previous years.
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Executive Summary
Opiates
The number of people who used opiates at least once in 
2007 is estimated at between 15 and 21 million people 
at the global level.6 More than half of the world’s opiate-
using population is thought to live in Asia. The highest 
levels of use (in terms of the proportion of the popula-
tion aged 15-64 years) are found along the main drug 
trafficking routes close to Afghanistan. Opiates remain 
the world’s main problem drug in terms of treatment. 
Europe has the largest opiates market in economic terms, 
and altough use appears to be stable in many Western 
European countries, increases have been reported in 
Eastern Europe. 
Cocaine
The total number of people who used cocaine at least 
once in 2007 is estimated to range between 16 and 21 
million. The largest market remains North America, fol-
lowed by West and Central Europe and South America. 
Significant declines in cocaine use were reported in 
North America, notably from the USA, which in abso-
lute numbers is still the world’s largest cocaine market. 
Cocaine was used at least once in the past year by some 
5.7 million people in the USA in 2007. Following strong 
increases in recent years, a number of surveys in West 
6 The lack of robust data on the levels of drug use, particularly in large 
countries such as China, is a huge impediment to an accurate under-
standing of the size of the population of drug users. When direct 
estimates are only available for a comparatively small proportion of a 
region’s population, the ranges of estimated drug users in that region 
are obviously large. Subregional and regional estimates were only 
made where direct estimates were published for at least two countries 
covering at least 20% of the region’s or subregion’s population aged 
15-64 years. In estimating ranges for countries with no published 
estimate, estimates from other countries in the subregion/region were 
applied. Please see the Methodology and Special Features sections 
below for more detail.
European countries showed the first signs of a stabiliza-
tion, whereas cocaine use still appears to be increasing in 
South America. Some African countries, notably in 
Western and Southern Africa, appear to show rising 
levels of cocaine use, although data are sparse.
Cannabis
The global number of people who used cannabis at least 
once in 2007 is estimated to be between 143 and 190 
million persons. The highest levels of use remain in the 
established markets of North America and Western 
Europe, although there are signs from recent studies that 
the levels of use are declining in developed countries, 
particularly among young people.
ATS
UNODC estimates that between 16 and 51 million 
people aged 15-64 used amphetamines-group substances 
at least once in 2007; the number who used ecstasy-
group drugs at least once is estimated at between 12 and 
24 million worldwide. The width of these ranges is far 
greater than for cocaine and heroin, given the high level 
of uncertainty in relation to this drug group in terms of 
both use and production. Amphetamines-group users in 
East and South-East Asia primarily consume metham-
phetamine. Tablets sold as Captagon often contain 
amphetamine, and are used throughout the Near and 
Middle East. In Europe, users primarily consume 
amphetamine, whereas about half of stimulant users in 
North America use methamphetamine.
Illicit drug use at the global level
Number of people who inject drugs
aged 15-64 years : 11-21 million persons
Number of "problem drug users" 
aged 15-64 years : 18-38 million persons
Number of people who have used drugs
at least once in the past year aged 
15-64 years : 172-250 million persons
Total number of people aged 15-64 years
in 2007: 4,343 million persons
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1. Improving the quality of drug data
In the last decade, there have been substantial improve-
ments in the quality and availability of illicit drug data, 
but a number of challenges remain. The use and produc-
tion of illicit drugs affect a population which is difficult 
to reach. In many countries, a full account of the extent 
of use and production of illicit drugs has not yet been 
made. Accurately measuring the level of drug use in a 
country, and monitoring trends across time, requires 
technical and financial resources, as well as political will. 
In many countries, at least one of these three compo-
nents is still missing. The result is that for some regions, 
and for some types of drugs, particularly ATS, data are 
very scarce. 
The cultivation of opium and cocaine is concentrated in 
few countries. Because of remote sensing techniques, 
this cultivation can be monitored with considerable 
accuracy. Estimates of the production of opium and 
cocaine, however, require information on the yield of 
the cultivated crop, which is measured with less cer-
tainty. UNODC is continuing its work to improve 
estimates of these yields, but the lack of access to some 
cultivation areas and continuous meteorological and 
agronomical changes, all pose considerable challenges. 
There is a high degree of uncertainty in estimating cul-
tivation and production of cannabis, and manufacture 
of ATS. These two drugs can be produced virtually any-
where; this makes systematic and comprehensive moni-
toring difficult. Considering the data currently available, 
global estimates of cannabis cultivation and ATS manu-
facture have been made on the basis of information on 
the number of users (and their estimated annual con-
sumption), and seizures. 
Considering the level of confidence in data on the pro-
duction and use of illicit drugs, it is not always possible 
to provide precise information on levels and trends. In 
order to produce reliable and comparable national, 
regional and global estimates, a number of assumptions 
and adjustments often need to be made. This year the 
Report explicitly addresses the question of uncertainty, 
and an attempt has been made to make the statistics 
more transparent. Country-level estimates of drug use 
are, for the first time in this Report, presented in ranges 
where the level of confidence is not sufficient to support 
point estimates. Additional information is also provided 
on the source of the data and on the adjustments made 
to the original data to produce the estimate. 
Regional and global estimates of drug use, as well as the 
production of ATS and cannabis, are also presented as 
ranges. The level of confidence in the different ranges, 
in terms of their ‘width’, obviously reflects the level of 
uncertainty that surrounds the figures. 
1.1 Decisions at the fifty-second session of 
the Commission on Narcotic Drugs
The fifty-second session of the Commission on Narcotic 
Drugs, held in Vienna in March 2009, included a High-
Level Segment which reviewed international drug control 
in the decade since UNGASS in 1998. The High-Level 
Segment adopted a Political Declaration and Plan of 
Action on International Cooperation towards an Integrated 
and Balanced Strategy to Counter the World Drug Problem. 
Throughout the session, there was much discussion 
about the importance of evidence as a basis for drug 
policy. The Political Declaration stated specifically that 
policy must be evidence-based, and that sound data are 
crucial for planning and evaluating interventions.
States Members of the United Nations also debated the 
challenges of drug data collection. Over the past decade, 
there have been considerable improvements in many 
countries in the collection and analysis of drug data on 
both supply and demand. In regions where concerted 
efforts have been made to collect, synthesize and reflect 
upon drug data (for example, North America, Oceania, 
Central and Western Europe, Latin America and to 
some extent East and South-East Asia), the capacity to 
evaluate trends has improved. In many countries, how-
ever, progress in developing drug information systems 
has been limited. There are also comparatively few coun-
tries that conduct studies to estimate the prevalence of 
illicit drug use. For example, only 65 countries have an 
estimate in the past ten years of the prevalence of ATS 
use in the general population or among school/universi-
ty-aged young people. UNODC has made tentative 
estimates from other data in 31 countries. The remain-
ing Member States, including some very populous coun-
tries such as China and India, have no direct estimates 
of ATS use. This obviously reduces the capacity to make 
evidence-based decisions about international drug 
policy.
features
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Acknowledging such gaps, Member States adopted a 
resolution that focused on improving data collection, 
reporting and analysis. UNODC was asked to review 
and improve data collection tools and reporting systems 
in order to get a more accurate picture of the world drug 
situation. This will include holding intergovernmental 
expert consultations to review current data collection 
tools, and proposing a revised set of survey instruments 
for consideration by the Commission on Narcotic Drugs 
in March 2010. 
The aim is to develop simpler, more integrated data col-
lection processes, and to increase the capacity of coun-
tries to collect and report information on their drug 
situation. UNODC invites Member States to join in 
this effort to improve data collection at the national 
level, and reporting at the global level.
1.2 Making national estimates of the number 
of drug users 
It is challenging to measure accurately how many people 
use drugs in a given country. Two broad approaches are 
“direct” survey approaches and “indirect” estimation 
approaches. No one method is perfect for all drugs or 
across all countries.
 “Direct” methods of estimating drug use prevalence.
General population or “household” surveys. A common 
way to assess drug use is to conduct surveys of the general 
population, where people are asked if they have used 
drugs at least once in the past month, the past year or in 
their lifetime (generally referred to as ‘monthly’, ‘annual’ 
and ‘lifetime’ prevalence). 
The benefits of this approach include the relatively 
straightforward calculation of prevalence estimates. The 
approach would generate accurate estimates if (1) a 
representative population sample was obtained, (2) 
people honestly disclosed their drug use, and (3) drug 
users were spread equitably around the country.
The limitations of this approach include the typical 
exclusion of marginalised groups, and the fact that drug 
use is often geographically concentrated. People may 
also feel uncomfortable disclosing drug use. These limi-
tations will lead to underestimates of the actual levels of 
drug use. 
School surveys. These take the same approach as general 
population surveys, whereby school-attending children/
young people (typically in high school) are asked about 
their drug use. 
The benefits and limitations of this approach are simi-
lar to those of the general population surveys, with the 
additional limitation that young people who have left 
school are not included. This may be a large proportion 
in some countries, and it is significant because young 
people who leave school early are more likely to use 
drugs than those who remain in school. 
“Indirect” methods of estimating  
drug use prevalence. 
These estimates do not rely on “direct” measurements, 
but use different sources of data to estimate the total 
population of drug users. One common approach is 
termed multiplier methods. This involves two pieces of 
data: one source (for example, the number of people 
who receive drug treatment in a year) is considered with 
another (for example, the proportion of a sample of 
drug users who received treatment) and these two are 
multiplied to estimate the drug-using population. 
One benefit of this approach is that no expensive and 
technically challenging field survey is required and it 
does not require people to admit to drug use. It is prefer-
able, however, to make multiple indirect estimates of 
drug use to overcome statistical limitations in any one 
approach of this kind.
1.3 Making regional and global estimates  
of the number of drug users
Making estimates of the population who uses illicit 
drugs presents many challenges. The first challenge is 
that many countries have not done any studies to esti-
mate how many people use drugs. In addition to this, 
although a variety of methods of estimating the preva-
lence of illicit drug use may be used, no one method is 
free of methodological or other biases, which means that 
country level estimates can never be 100% accurate. 
To better reflect the resulting uncertainty, a conscious 
decision was made to present ranges rather than point 
estimates in this year’s Report. Global and regional esti-
mates of the number of people who have used illicit 
drugs at least once in the past year, as well as estimates 
of “problem” drug users, are therefore shown as ranges. 
This shift is an essential step forward in getting more 
accurate estimates. It does mean, however, that the esti-
mates for this year should not be compared to those 
from previous editions of the World Drug Report. As 
documented in the following sections of the Report, 
there is less certainty for ATS and cannabis use estimates 
than there is for opiate and cocaine use. The uncertainty 
for ATS is particularly marked in Asia, which contains a 
significant proportion of the world’s population. In 
contrast, in regions such as North America and Western 
Europe, more is known about drug use levels, and there 
are smaller ranges in the estimated number of users. 
Summary of new methods
The lack of robust data on the levels of drug use, par-
ticularly in large countries such as China, are huge 
impediments to an accurate understanding of the size of 
the population of drug users. Because of these gaps, 
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absolute numbers are not provided for regions where 
estimates of drug use prevalence are not available for 
every country. Rather, ranges have been presented, which 
reflect the uncertainty that exists when data are being 
either extrapolated or imputed. 
Larger ranges exist for those regions where there is less 
certainty about the likely level of drug use – in other 
words, those regions for which direct estimates are avail-
able for a comparatively smaller proportion of the 
region’s population. In contrast, those regions with esti-
mates from most countries have much more precise 
estimates. 
Subregional and regional estimates were only made 
where direct estimates were published for at least two 
countries covering at least 20% of the region’s or subre-
gion’s population aged 15-64 years. 
In estimating ranges for countries with no published 
estimate, estimates from other countries in the subre-
gion/region were applied. This means that wider ranges 
appear in subregions/regions where there is variance in 
the levels of drug use across the published country-level 
estimates. Regions with fewer data – and therefore less 
certainty – also typically have greater ranges. 
2. Trends in drug use among young   
 people: what do we know?
Analysing drug use among young people matters for 
several key reasons. First, most people start to use drugs 
during their youth and it is among young people that 
drug prevention activities are best targeted. Secondly, 
trends in the use of illicit drugs among young people 
may indicate shifts in drug markets, since young people 
usually react to changes in drug availability or social 
perceptions about drug use more quickly than older 
people; such use is likely to be occasional drug use. 
Thirdly, starting drug use at an early age has been linked 
to negative health and social outcomes in later years.
A review of the most recent data reported to UNODC 
on drug use among young people across the world found 
quite marked variation across regions. Among the high-
est levels across all drug types were reported in North 
America, Oceania and Western Europe, although there 
are signs of a decreasing trend in some of the major 
drugs. Recent data suggest decreases in the level of can-
nabis use in developed countries. Decreases have also 
been recorded in cocaine use among young people in 
North America and some European countries although 
increases are still visible in many other European coun-
tries. There are large data gaps in regions across Asia and 
Africa, so less is known about drug use among young 
people there. Where data is available it suggests that 
levels of use among young people in developing coun-
tries remain lower than the ones in developed countries. 
However the trend for cannabis and cocaine is upwards 
in the few countries where statistics are available for 
more than one year. A similar trend can be observed for 
ecstasy which is still gaining popularity among students 
in some developing countries, while showing decreasing 
or stabilizing trends in the most developed countries. 
The data presented suggests that drug use patterns are 
changing among young people. In the United States, 
cannabis and cocaine, long associated with alternatives 
to the mainstream, now appear to be less attractive. The 
same behaviour is gradually spreading in Europe, but 
has not yet reached Eastern Europe and developing 
countries where there are still signs of increasing can-
nabis and cocaine use. 
The overall decline in illicit drug use among young 
people in the United States and in some European coun-
tries is an encouraging sign. However, there are a number 
of published reports, particularly in the US indicating 
that the abuse of prescription drugs is on the rise among 
young people10. This needs more research, but these 
reports suggest that young people may be shifting from 
illicit drugs to pharmaceutical drugs, which may be 
more easily accessible and socially acceptable. 
Data on young people can help to better understand the 
different use of illicit drugs among male and female 
populations. In general girls are less likely to use drugs 
than boys, although the gender disparities are less pro-
nounced than among the adult population. Data for 
European countries in 2007 show that the proportion of 
students (aged 15-16 years) who used cannabis in the 
previous month has large variations between male and 
female. Gender disparities measured in terms of male to 
female drug use ratios range from 1.1 in Spain (almost 
parity) to 3 in Poland. Despite the existence of large dif-
ferences between boys and girls, there are indications 
that the gender gap may be narrowing in a few countries 
and for some types of drugs.11 
Most of the data on the use of illicit drugs among young 
people has been collected through school surveys. These 
surveys are important tools and can be implemented in 
a relatively cost-effective environment since large num-
bers of young people are easily accessible and usually 
ready to participate in the survey. They have also been 
found to be accurate, if properly implemented. How-
ever, they do not capture the situation among out-of-
school youth, which may be a significant proportion of 
youth in less developed countries. 
10 Arria AM, Caldeira KM, O’Grady KE, Vincent KB, Johnson EP, 
Wish ED. Nonmedical use of prescription stimulants among col-
lege students: Associations with attention-deficit-hyperactivity dis-
order and polydrug use. Pharmacotherapy. 2008;28(2):156–169. 
National Institute on Drug Abuse (NIDA), NIDA Community Drug 
Alert Bulletin – Prescription Drugs, NIDA website: http://www.nida.
nih.gov/PrescripAlert/. 
11 EMCDDA, Annual Report 2006, selected issues: Gender differences 
in prevalence and patterns of drug use by type of substance, 2006. 
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cannabis among students in 2007 saw an increase or a 
stabilization when compared with 2003.16 Although the 
decline in cannabis use among US students was stronger 
than in Europe, cannabis use continues to be more 
widespread among US students.
 
16 Similar trends have been observed in the “Health Behavior in School 
Aged Children”(HBSC) studies conducted in Europe and in North 
America in 2001/02 and in 2005/06 under the auspices of the 
WHO. 
Cannabis use declined among both male and female 
students (on average by around 3 percentage points) 
over the 2003-2007 period. In 2007 male pupils still 
have, on average, higher prevalence rates of cannabis use 
(22% in 2007) than female students (16%). In all coun-
tries, except Monaco and Slovenia, male cannabis use 
was higher than female cannabis use among 15-16 year 
old students. 
Annual prevalence of cannabis use among high school students (8th, 10th and 12th grade)  
in selected South American countries, 2006 
Source: UNODC, Jóvenes y drogas en países sudamericanos: un desafío para las políticas públicas, Sept. 2006.
Lifetime prevalence of cannabis use in Europe and the USA 
* unweighted average of all participating countries 
Source: Council of Europe, The 2007 ESPAD Report, Substance Use Among Students in 35 European countries, Stockholm. February 2009.
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Changes* between 2003 and 2007 in lifetime use of cannabis among students in Europe, aged 15-16
* Colour code: ‘red’ indicates clear increases (more than 3 percentage points); ‘yellow’ indicates largely stable levels and ‘blue’  
indicates clear declines (more than 3 percentage points) in life-time prevalence over the 2003-07 period.  
Source: Council of Europe, The 2007 ESPAD Report, Substance Use Among Students in 35 European countries, Stockholm. February 
2009. 
Lifetime prevalence of cannabis use in Europe* among 15-16 year old students  
– breakdown by gender, 1995-2007
* unweighted average of all participating countries (as reported). Source: Council of Europe, The 2007 ESPAD Report, Substance Use 
Among Students in 35 European countries, Stockholm. February 2009. 
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In Australia, lifetime prevalence of cocaine among stu-
dents 12-17 years old declined from 4% in 1999 to 3% 
in 2005. Data obtained in the general population survey 
over the period 2004-2007 show a different trend among 
the young and adult population, with increases among 
adults but not young people. 
2.3 Amphetamine-type-stimulant use trends 
among young people
Following strong declines around the turn of the century 
in relation to ecstasy use in the USA and Canada, 2008 
and 2007 student survey data indicate that little has 
changed since 2003. In 2008, United States students 
(8-12th grades) had an annual prevalence rate of ecstasy 
use of 3% while Canadian students in Ontario (7-12th 
grades) had a rate of 3.5%. 
In South America, there was a general increase in the use 
of ecstasy among high-school students. In Argentina the 
annual prevalence rate increased from 0.2% to 2.2% 
and in Chile from 1.1% to 1.5%. An increase was also 
seen in Colombia between 2001 and 2004/5 where the 
annual prevalence among urban secondary students 
doubled from 1.6% to 3%. 
Between 1995 and 2007, European students (age 15-16) 
reported overall increased lifetime use of ecstasy-group 
substances. However, there are diverging trends by sub-
region. Students in countries of West and Central 
Europe20 reported relatively stable rates since 2003 while 
students from Eastern Europe21 reported increasing 
20 Students of West and Central Europe include: Austria, Belgium 
(Flanders), Cyprus, Denmark, Faroe Islands, Finland, France, 
Germany (6 states), Greece, Greenland, Iceland, Ireland, Isle of Man, 
Italy, Malta, Netherlands, Norway, Portugal, Sweden, Switzerland, 
and the United Kingdom.
21 Students of Eastern Europe include: Bulgaria, Croatia, Czech 
lifetime prevalence during the same period. 22
No recent data is available in Oceania for ATS use from 
school surveys. However, the latest data showed a down-
ward trend among students 12-17 years old, from life 
Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, 
Russia (Moscow), Slovak Republic, Slovenia, and the Ukraine.
22 Council of Europe, The 2007 ESPAD Report, Substance Use Among 
Students in 35 European countries, Stockholm. February 2009.
Annual prevalence amphetamines-group drugs 
among secondary students in select South 
American countries (rank ordered): 2004/05 
Source: UNODC/CICAD/OEA (2006). Jóvenes y drogas en 
países sudamericanos: Un desafio par alas políticas públicas: 
Primer estudio comparativo sobre uso de drogas en población 
escolar secundaria de Argentina, Bolivia, Brasil, Colombia, 
Chile, Ecuador, Paraguay, Perú y Uruguay. Lima, Peru (Sep-
tiembre 2006).
Unweighted lifetime prevalence of European stu-
dents (age 15-16) ecstasy-group use: 1995-2007
Source: Hibell, B., Guttormsson, U., Ahlström, S., Balakireva, 
O., Bjarnason, T., Kokkevi, A., & Kraus, L. (2009). The 2007 
ESPAD Report Substance Use Among Students in 35 European 
Countries. The Swedish Council for Information on Alcohol 
and other Drugs (CAN). Stockholm.
Lifetime use of cocaine among European  
students, 2003 and 2007
* weighted by population age 16.  
Sources: Council of Europe, The 2007 ESPAD Report –  
Substance Use Among Students in 35 European Countries and 
Council of Europe, The ESPAD Report 2003, Alcohol and 
Other Drug Use Among Students in 35 European Countries.
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time prevalence of 7% in 1999 to 5% in 2005. For the 
use of ecstasy, the lifetime prevalence remained stable at 
around 4%. 
3. Police-recorded drug offences
Crime recorded by law enforcement agencies may be 
directly or indirectly related to drugs. On the one hand, 
a proportion of crimes such as robbery, theft, assault or 
burglary are driven by underlying factors such as drug 
use. From a statistical point of view, the extent to which 
drug use is responsible for such crimes is not easily cap-
tured by and rarely forms part of official reports. On the 
other hand, law enforcement agencies in most countries 
produce and retain information on drug offences, which 
can be broken into two broad categories: drug-related 
crime/possession/abuse which corresponds more closely to 
personal use offences and drug trafficking (sale). Many 
countries report this data at the international and regional 
level, including through UNODC data collection mech-
anisms.23 These data are not usually presented in their 
raw form because they can be confusing. The number of 
drug offences recorded is a product of both the extent of 
drug activity and the extent of drug enforcement activi-
ties. As a result, it is possible that countries with rela-
tively minor drug problems can have drug offence rates 
higher than those with very severe ones, making com-
parison between countries a particular challenge.
This problem can be partly overcome by limiting the 
analysis to trends within countries. For those countries 
reporting this information to UNODC, a majority show 
an increase in the number of drug crimes in recent years. 
Some 62% of countries showed an increase in possession 
offences24 and 56% of countries showed an increase in 
drug trafficking offences.25 
23 The primary instrument used by UNODC for collection of crime 
and criminal justice data is the United Nations Survey of Crime 
Trends and Operations of Criminal Justice Systems (the “UN-CTS”). 
Data from the UN-CTS may be accessed at: http://www.unodc.
org/unodc/en/data-and-analysis/United-Nations-Surveys-on-Crime-
Trends-and-the-Operations-of-Criminal-Justice-Systems.html. Part 
III of the ARQ requests data on the number of persons arrested/total 
recorded offences for possession/abuse of drugs and for trafficking of 
drugs.
24 See 1988 Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, Article 3(2). Cross-national analysis of 
trends must be carried out with a very high degree of caution. This is 
due not least to differences in national definitions of crime involving 
drugs. ‘Personal use’ of drugs may be defined in national law on the 
basis of the amount of drug substance involved, and/or with respect 
to the nature of the act, such as cultivation, production, manufacture, 
preparation, offering for sale, distribution, or sale. Drug amount 
thresholds in criminal law can also vary between countries, as can the 
nature and type of narcotic drug or psychotropic substance or pre-
cursor. Legal regimes sometimes create administrative drug offences, 
which may or may not be recorded and reported together with 
criminal offences. Finally, in addition to varying legal definitions, 
differences in capacity, criteria and approaches to case recording, as 
well as the effect of law enforcement resources and priorities, can have 
a significant impact on numbers recorded and reported. 
25 The UN-CTS defines ‘drug trafficking’ as meaning drug offences, 
which are not in connection with personal use.
Still, it is difficult to say whether this trend is the result 
of a growing problem or increased enforcement activity. 
Of those countries that showed an increase in drug traf-
ficking offences, almost 70% showed an increase in 
possession offences. This strong association suggests 
these increases may be driven by increased drug law 
enforcement, rather than changes in the drug situation 
itself. In some regions, increases in recorded drug-traf-
ficking offences are in line with increases in total drug 
seizures, including East Asia, South America, Central 
America and the Caribbean and East Europe. In West 
and Central Europe, however, the increase in drug pos-
session/use does correspond to an increase in the per-
ceived severity of the drug problem, as reflected in public 
surveys.27 
26 Where possible, data for the years 2005 and 2007 is compared. 
Where data for either of these years was not available, the closest 
available year is used instead.
27 Criminal Victimisation in International Perspective: Key findings from 
the 2004-2005 International Crime Victims Survey and European 
Crime and Safety Survey. Research and Documentation Centre of the 
Country-level trends for police- Fig. 15: 
recorded drug-related crime/pos-
session/abuse and drug trafficking 
(change over two year period, ending 
with most recent year available)26
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Another way to make use of these data is to compare 
between the two categories of offences. The ratio of drug 
possession offences to drug trafficking offences gives a 
good indication of the enforcement approach taken in 
any given country. For countries in East Asia, Central 
America and the Caribbean, North America, and West 
and Central Europe, law enforcement agencies record 
above four times as many possession offences as they do 
trafficking offences.28 Countries in these subregions, in 
particular, show a significant number of offences that 
fall within the broad ‘less serious’ category, relative to the 
number of more serious offences. 
Dutch Ministry of Justice (WODC) 2007. p. 97
28 See Fig. 15 
In contrast, subregional ratios for South-East Europe, 
East Europe and Central Asia and Transcaucasia show 
only small differences in the number of offences recorded 
in each category. Central Asia and Transcaucasia, in 
particular, shows more recorded offences in the more 
serious category of drug trafficking than in the less seri-
ous category of drug-related crime/possession/abuse. 
The underlying reasons for this may include a relatively 
lower estimated prevalence of drug use, particularly can-
nabis, cocaine, and amphetamines than for other subre-
gions, combined with the existence of key drug transit 
routes.29 In addition, the effect of different national 
drug policies, including the national legal definition of 
‘drug trafficking’ may have a very significant effect on 
the relative distribution of serious and less-serious 
recorded offences.
29 Crime and its impact on the Balkans and affected countries. United 
Nations Office on Drugs and Crime 2008. p.59.
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1. TRENDS IN THE WORLD DRUG MARKETS

1.1 Opium / heroin market
33
1.1.1 Summary trend overview
Opium poppy cultivation in Afghanistan, the source 
country for most of the world’s opium, decreased by 
19% in 2008. As a result, the total area under cultiva-
tion in the three major cultivating countries thus 
decreased to 189,000 hectares, in spite of small increases 
in Myanmar and the Lao People’s Democratic Republic. 
Total potential opium production also decreased to a 
total of some 8,000 metric tons; a high level, in spite of 
the decrease.
Overall opiate seizures remained stable – at a high level 
- in 2007, due to a large decrease in morphine seizures. 
Opium and heroin seizures increased by 33% and 14%, 
respectively. Although opiate trafficking is global, more 
than two thirds of seizures were reported by South-West 
Asian countries in 2007. Europe accounted for the 
second largest share of seizures, mainly from south-
eastern countries.   
Opiates remain the world’s main problem drug in terms 
of treatment, and a majority of the world’s opiate users 
live in Asia. The highest levels of use (in terms of the 
proportion of the population aged 15-64 years) are 
found along the main drug trafficking routes close to 
Afghanistan. UNODC estimates that the number of 
people who used opiates at least once in 2007 was 
between 15 and 21 million people worldwide.1 
1 The lack of robust data on the levels of drug use, particularly in 
large countries such as China and India, is a huge impediment to an 
accurate understanding of the size of the population of drug users. 
Please see the Methodology and Special Features sections below for 
more detail.
1.1.2 Production
Cultivation
The area under opium poppy cultivation in major culti-
vating countries decreased by 16% over the past year, 
mainly due to a large decrease in Afghanistan. Opium 
poppy cultivation did not change much in Myanmar 
and the Lao People’s Democratic Republic. Overall, the 
level of opium poppy cultivation in Afghanistan, Myan-
mar and Lao PDR was about the same as in 2006. 
In Afghanistan, opium poppy cultivation continued to 
be concentrated mainly in the southern provinces, while 
more provinces in the centre and north of the country 
became poppy-free. Two thirds of the area under opium 
poppy cultivation in 2008 – more than 100,000 ha - 
were located in the southern province of Hilmand alone. 
The decline in cultivation happened in spite of less 
opium poppy eradication in 2008 (5,480 ha) than in 
2007 (19,047 ha). In 2008, opium poppy cultivation 
continued to be associated with insecurity. Almost the 
entire opium poppy-cultivating area was located in 
regions characterized by high levels of insecurity. 
In Pakistan, opium poppy continued to be cultivated in 
the border area with Afghanistan at about the same rela-
tively low level of about 2,000 ha reported over the past 
5 years.  
In Myanmar, opium poppy cultivation remained below 
levels reached in 2004 and before. As in the past, cultiva-
tion of opium poppy was heavily concentrated in the 
Shan State in eastern Myanmar. In Lao PDR, a low level 
of opium poppy cultivation was found in the northern 
provinces. 
34
World Drug Report 2009 
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 SOUTH-WEST ASIA
   Afghanistan (b) 71,470 53,759 56,824 58,416 63,674 90,583    82,171 7,606 74,100 80,000 131,000 104,000 165,000 193,000 157,000
   Pakistan (c) 5,759 5,091 873 874 950 284 260 213 622 2,500 1,500 2,438 1,545 1,701 1,909
   Subtotal 77,229 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545 194,701 158,909
 SOUTH-EAST ASIA
   Lao PDR (d) 18,520 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500 1,500 1,600
   Myanmar (e) 146,600 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500 27,700 28,500
   Thailand (f) 478 168 368 352 716 702 890 820 750
   Viet Nam (f) 3,066 1,880 1,743 340 442 442
   Subtotal 168,664 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000 29,200 30,100
 LATIN AMERICA
   Colombia (g) 15,091 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,153 4,026 3,950 1,950 1,023 714 394
   Mexico (h) 5,795 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300 5,000 6,900 n.a.
   Subtotal 20,886 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,853 8,826 7,450 5,250 6,023 7,614 n.a.
 OTHER 
   Combined (i) 5,700 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,074 5,190 5,212 4,432 4,185 n.a.
 GRAND TOTAL 272,479 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,225 168,600 195,940 151,500 201,000 235,700 n.a.
 SOUTH-WEST ASIA
   Afghanistan (b) 3,416     2,335     2,248     2,804     2,693     4,565     3,276     185        3,400     3,600     4,200 4,100 6,100 8,200 7,700
   Pakistan (c) 128        112        24          24          26          9            8            5            5            52          40 36 39 43 48
   Subtotal 3,544 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240 4,136 6,139 8,243 7,748
 SOUTH-EAST ASIA
   Lao PDR (d) 120        128        140        147        124        124        167        134        112        120        43 14 20 9 10
   Myanmar (e) 1,583     1,664     1,760     1,676     1,303     895        1,087     1,097     828        810        370 312 315 460 410
   Thailand (f) 3            2            5            4            8            8            6            6            9            
   Viet Nam (f) 15          9            9            2            2            2            
   Subtotal 1,721     1,803     1,914     1,829     1,437     1,029     1,260     1,237     949        930 413 326 335 469 420
 LATIN AMERICA
   Colombia (g) 205        71          67          90          100        88          88          80          52          50          49          24 13 14 10
   Mexico (h) 60          53          54          46          60          43          21          91          58          101        73          71 108 149 n.a.
   Subtotal 265        124        121        136        160        131        109        171        110        151 122 95 121 163 n.a.
 OTHER
   Combined (i) 90          78          48          30          30          30          38          32 56 50          75 63 16 15 n.a.
 GRAND TOTAL 5,620      4,452      4,355      4,823      4,346      5,764      4,691      1,630      4,520      4,783      4,850 4,620 6,610 8,890 n.a.
Potential HEROIN (k) 562         445         436         482         435         576         469         163         452         478         495 472 606 735 n.a.
CULTIVATION(a) IN HECTARES
HEROIN
 POTENTIAL PRODUCTION IN METRIC TONS
OPIUM(j) 
(a) Opium poppy harvestable after eradication.
(b Afghanistan, sources: 1994-2002: UNODC; since 2003: National Illicit Crop Monitoring System supported by UNODC.
(c) Pakistan, sources: ARQ, Government of Pakistan, US Department of State
(d) Lao PDR, sources: 1994-1995: US Department of State; 1996-1999: UNODC; since 2000: National Illicit Crop Monitoring System supported by 
UNODC.
(e) Myanmar, sources: 1994-2000: US Department of State; since 2001: National Illicit Crop Monitoring System supported by UNODC.
(f ) Due to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category "Other".
(g) Colombia, sources: 1994-1999: various sources, since 2000: Government of Colombia. In Colombia, opium is produced as opium latex, which has 
a higher moisture content than opium produced in other regions of the world. To maintain comparability with other countries, opium production 
in Colombia was calculated by dividing the potential annual heroin production by 10.
(h) Figures derived from US Government surveys. In 2006, the Government of Mexico reported a gross opium poppy cultivation of 19,147 hectares and 
estimated potential gross opium production at 211 mt. These gross figures are not directly comparable to the net figures presented in this table.
(i) Reports from different sources indicate that illicit opium poppy cultivation also exists in other countries and regions, including the Baltic countries, 
Balkan countries, Egypt, India, Guatemala, Iraq, Lebanon, Nepal, Peru, Russian Federation and other C.I.S. countries, Thailand, Ukraine, Viet 
Nam, as well as in Central Asia and Caucasus region. The cultivation level in these countries and regions is thought to be low. Due to the difficulties 
of estimating cultivation and production based on the available information, no estimate is provided for 2008.
(j) All figures refer to dry opium.
(k) Heroin estimates for Afghanistan are based on the Afghanistan Opium Surveys (since 2004). For other countries, a 10:1 ratio is used for conversion 
from opium to heroin.
Global illicit cultivation of opium poppy and production of opium, 1994-2008Table 1: 
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Reports on eradication of opium poppy from Bangla-
desh, India, Nepal, Thailand and Viet Nam indicated 
the existence of cultivation in these countries. However, 
the extent of illicit opium poppy cultivation in these 
countries is not known, with the exception of Thailand, 
which reported the detection of 288 ha of opium poppy, 
most of which was subsequently eradicated. 
In the Americas, opium poppy cultivation was reported 
from Colombia and Mexico, and reports on eradication 
in Ecuador, Guatemala, Peru and the Bolivarian Repub-
lic of Venezuela over the past years point to the existence 
of opium poppy cultivation in these countries as well. 
Reports from different sources indicate that opium poppy 
cultivation also exists in other countries and regions, includ-
ing the Baltic countries, Balkan countries, Egypt, Iraq, 
Lebanon, Russian Federation, Ukraine, and countries in 
Central Asia and the Caucasus region. The cultivation 
levels in these countries and regions are thought to be low.
Production
The potential opium production in the major opium 
poppy cultivating countries decreased slightly but is still 
high compared to previous years. 
Opium yields in Afghanistan remained high in 2008. 
The potential opium production was estimated at 7,700 
mt (range 6,330-9,308 mt). Some 60% is believed to be 
converted into morphine and heroin within the country. 
The amount of morphine and heroin produced in 
Afghanistan available for export was estimated at 630 mt 
(range 519-774 mt). Almost 40% of the total produc-
tion was exported as opium.
Opium poppy cultivation in major cultivating countries (ha), 1994-2008Fig. 1: 
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Opium production in Myanmar was estimated at 410 
mt, which is much lower than in the years before 2004. 
Afghanistan remained the world’s largest opium pro-
ducer, followed by Myanmar. 
Prices
Farm-gate prices in Afghanistan and Myanmar differ 
considerably both in trend and level. In 2004, farmers 
in both countries received about US$ 150/kg for one 
kilogram of dry opium. Since then, farm-gate prices in 
Afghanistan have roughly halved, whereas they doubled 
in Myanmar. A similar diverging trend can be observed 
in trader prices in opium production areas, which have 
been available since 1999. 
A comparison of average opium production levels in 
Afghanistan and Myanmar supports the assumption that 
local opium production levels had a strong influence on 
these prices. In Afghanistan, annual opium production 
before the Taliban opium ban in 2001 was at about 
3,000 mt on average (1994-2000). Since 2002, opium 
production has been much higher in every single year, 
and amounted to an average of some 5,300 mt. Reflect-
ing these high supply levels, Afghan opium prices have 
been on the decrease since 2003. In Myanmar, on the 
other hand, average annual opium production fell from 
about 1,400 mt (1994-2001) to an annual average of 
just 500 mt (2002-2008). As a consequence, opium 
prices in Myanmar increased considerably. In these two 
cases, the laws of supply and demand seem to hold some 
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explanatory power for prices in production areas. How-
ever, it should be noted that illicit markets do not neces-
sarily show the same behaviour as licit markets. 
Relatively high opium prices of over US$ 1,000/kg in 
neighbouring Lao PDR and Thailand, where very little 
opium is produced, also indicate that the demand for 
opium is high compared to the amount available on the 
market in the region. 
Compared to Asia, farm-gate prices for opium latex in 
Colombia were high, at US$ 318/kg in 2008. This would 
correspond to more than US$ 600/kg in dry opium 
equivalents. It should be noted that in the countries 
discussed, opium is traded in the respective local curren-
cies, and that prices were not adjusted for inflation. 
Laboratories
In 2007, the detection of 638 opiates-producing clan-
destine laboratories was reported to UNODC. In 2006, 
originally, a similar number of laboratories were reported 
by Governments (619), which was later updated to 873 
based on additional reports received. Ukraine and 
Moldova, which reported high numbers of laboratories 
destroyed in 2006, did not report the detection of labo-
ratories in 2007. 
The Russian Federation reported the highest total 
number of opiate-processing laboratories (547) and, 
included in this number, also the highest number of 
heroin laboratories (187) of all countries reporting.2 
However, the amount of heroin seized at the laboratory 
sites does not indicate that these were large-scale process-
ing facilities. Opiate processing laboratories were also 
detected in Afghanistan (57 heroin-processing), where 
most of the world’s illicit opium is produced, Australia 
(9 heroin-processing), China (9 heroin-processing), 
Myanmar (8 heroin-processing), Mexico (4 heroin-
processing), Colombia (2 heroin-processing), Germany 
(1 fentanyl-processing) and India (1 heroin-processing 
laboratory). 
Laboratories in Moldova, the Russian Federation and 
Ukraine tend to produce acetylated opium from locally 
cultivated poppy straw. Indeed, most of the laboratories 
detected in the Russian Federation (347) were produc-
ing acetylated opium. The 2007 figures and the infor-
mation received in connection to these figures indicate 
that most morphine and heroin processing takes place 
close the source, that is, in or close to the countries were 
opium poppy is cultivated, or, in the case of Germany 
and Australia, where opiates may be diverted from legal 
channels. 
2 The number of detected heroin laboratories in the Russian Federa-
tion indicated in the text (187) relates to locations where different 
types of drugs were processed on a small scale and of low quality 
(so-called ''kitchen production"). Russia did not report the detection 
of significant heroin-processing laboratories in 2007.
Precursors
Illicit morphine and heroin production in Afghanistan 
requires large quantities of precursor chemicals such as 
acetic anhydride, a substance which is essential in the 
refinement of morphine to heroin. All acetic anhydride 
has to be imported as there are no known production 
facilities and no reported legitimate use of the chemical 
in the country. Following increased cooperation between 
countries in the region within the framework of the 
Paris Pact Initiative, more precursor seizures were 
reported from Afghanistan and neighbouring countries 
as well as from the countries of origin. During operation 
TARCET (Targeted Anti-trafficking Regional Commu-
nication, Expertise and Training) and subsequent back-
tracking investigations, almost 20 mt of acetic anhydride 
and more than 27 mt of other precursor chemicals were 
seized in Afghanistan, the Islamic Republic of Iran, Kyr-
gyzstan, Pakistan, Tajikistan and Uzbekistan in 2008.3 
In Afghanistan, an additional 14,000 l of acetic anhy-
dride plus several other substances typically used for 
heroin production were seized on other occasions. Sev-
eral cases of attempted diversion of precursor shipments 
for illicit purposes were detected and prevented and 
significant precursor seizures were made in countries of 
origin in Europe and Asia as well as in countries along 
the heroin trafficking routes. The seizures and related 
investigations confirmed the assumption that large-scale 
trafficking of morphine and heroin precursor to Afghan-
istan and neighbouring countries occurs. It is not known 
to what extent uncontrolled chemicals are brought into 
the region to produce controlled substances such as 
acetic anhydride locally to avoid increased international 
control of precursor shipments. There are indications 
that precursors have become a major cost factor 
for clandestine laboratories producing heroin in 
Afghanistan.
 
3 International Narcotics Control Board, E/INCB/2008/4
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Annual opium poppy cultivation and opium production in main producing countries,  Fig. 5: 
1994-2008
AFGHANISTAN - OPIUM POPPY CULTIVATION (ha), 1994-2008 AFGHANISTAN - OPIUM PRODUCTION (mt), 1994-2008
MYANMAR - OPIUM POPPY CULTIVATION (ha), 1994-2008 MYANMAR - OPIUM PRODUCTION (mt), 1994-2008
  LAO PDR - OPIUM POPPY CULTIVATION (ha), 1994-2008 LAO PDR - OPIUM PRODUCTION (mt), 1994-2008
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Signiﬁcant opium poppy eradication reported (ha), 1995-2008Table 2: 
* Although eradication took place in 2004, it was not officially reported to UNODC.
 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Afghanistan     400 121   21,430 * 5,103 15,300 19,047 5,480
Colombia 3,466 6,885 6,988 2,901 8,249 9,254 2,385 3,577 3,266 3,866 2,121 1,929 375 381
Egypt        15 34 65 45 50 98  
Guatemala           489 720 449 536
India   29 96 248 153 18 219 494 167 12 247 7,753 595
Lao PDR         4,134 3,556 2,575 1,518 779 575
Lebanon         4 67 27  8  
Mexico 15,389 14,671 17,732 17,449 15,461 15,717 15,350 19,157 20,034 15,926 21,609 16,890 11,046 13,095
Myanmar 3,310 1,938 3,093 3,172 9,824 1,643 9,317 7,469 638 2,820 3,907 3,970 3,598 4,820
Pakistan  867 654 2,194 1,197 1,704 1,484  4,185 5,200 391 354 614 0
Peru    4 18 26 155 14 57 98 92 88 88 16
Thailand 580 886 1,053 716 808 757 832 507 767 122 110 153 220 285
Venezuela 148 51 266 148 137 215 39 0 0 87 154 0 0 0
Viet Nam 477 1,142 340 439  426  125 100 32   38 99
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Estimating opium cultivation  
and production
Illicit crop cultivation is often associated with insecurity, 
insurgency and lack of alternative livelihood options. 
Knowing where poppy is cultivated and how much 
opium and heroin can be produced is important for 
Governments and the international community to 
understand and tackle the issue. 
In Afghanistan, Myanmar and the Lao People’s Demo-
cratic Republic, UNODC supports the efforts of the 
respective Governments to estimate the annual area 
under opium poppy cultivation. In Afghanistan and 
Myanmar, this is mainly done by using high-resolution 
satellite images. Opium poppy plants, like other crops, 
reflect sunlight in a specific way. This is not because of 
its colourful flower, but rather, a certain shade of green, 
which is different from other crops. This enables an 
image analyst to identify poppy. Other characteristics, 
such as the texture, shape or size of the field, are also 
used. 
Important information comes from surveyors on the 
ground who map small portions of the area covered by 
the image and identify which crop is grown where. The 
growth stages of all crops and their exact locations are 
documented with photos and GPS devices. This infor-
mation serves as an interpretation template for the 
image. If there is still uncertainty, a second image taken 
after the opium harvest can help. Farmers in Afghani-
stan, for example, plough poppy fields after the harvest, 
whereas they leave wheat fields for the cattle to graze on 
the stubble. The freshly ploughed poppy fields show 
clearly on the images with a darker tone. 
Hundreds of satellite images are taken every year over 
different parts of the countries. This sample of images 
can be compared to a poll. If well designed, a poll ena-
bles analysts to understand the preferences of the popu-
lation as a whole, although only a sample of the 
population is interviewed. Similarly, a sample of satellite 
images representing the total agricultural area in the 
country can be used to calculate the area under opium 
poppy cultivation, based on the results of the image 
analysis. 
To be able to estimate opium production, surveyors visit 
fields in several hundred villages and measure the number 
of poppy capsules as well as their size in sample plots. 
Using a scientific formula, the measured poppy capsule 
volume indicate how much opium gum each plant can 
potentially yield. Thus, the opium yield per hectare can 
be estimated. Because of irrigation and climate, the yield 
can differ considerably from year to year and from region 
to region. 
Opium yield and the total poppy cultivation area form 
the basis for estimating annual opium production. The 
bulk of the opium undergoes a transformation process to 
morphine and finally heroin. This is done by so-called 
“chemists” or “cooks” who know which precursor chem-
icals are necessary and in which quantities. Information 
on the efficiency of this transformation process comes 
mainly from law enforcement agencies which obtain 
detailed information from apprehended traffickers. With 
this information it is possible to estimate potential heroin 
production in a country.
1.1.3 Trafficking
1. Trends in the world drug markets Opium / heroin market
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Opiate trafficking is global,  
but seizures are stabilizing 
In 2007, global seizures of opiates amounted to 143 mt 
(expressed in heroin equivalents1), about the same as in 
2006 (142 mt). Compared to 1998, global opiate sei-
zures almost doubled (93% increase). 
Out of 143 countries that reported seizures to UNODC 
for 2007, 109 reported seizures of opiates. Trafficking in 
heroin is in geographical terms more widespread than 
trafficking in opium or morphine, as 107 countries 
reported seizures of heroin (75% of reporting countries), 
whereas 57 reported opium seizures and 36 morphine.
Opium seizures continue to rise in and around 
Afghanistan while morphine seizures decline
Although global opiate seizures remained stable between 
2006 and 2007, there were significant market shifts 
among opium, heroin and morphine. Global opium sei-
zures increased by 33% in 2007, in line with the rise in 
opium production reported in 2007 (34%). Some of the 
largest increases in opium seizures in 2007 were reported 
in and around Afghanistan (opium seizures in Tajikistan 
increased by 83%; Pakistan 71%; the Islamic Republic of 
Iran 37%; Afghanistan 28%). Most of the opium was 
seized in Iran (427 mt or 84% of the global total), fol-
lowed by Afghanistan (52 mt) and Pakistan (6 mt). 
In contrast, morphine seizures fell by 41% in 2007, 
mainly due to lower seizures reported by Pakistan (66% 
decrease) and the Islamic Republic of Iran (9% decrease). 
The world’s largest morphine seizures continued to be 
reported by Pakistan (11 mt or 40% of the global total), 
Iran (10 mt) and Afghanistan (5 mt). 
Heroin seizures increase, but at a lower rate than 
opium production 
Heroin seizures rose by 14% between 2006 and 2007, 
which is a smaller increase than the one observed in 
opium production in 2007 (34%). Some of the largest 
increases in heroin seizures were reported by countries 
along the main trafficking routes from Afghanistan to 
Europe.2  
1 For the purposes of this calculation it is assumed that 10 kg of opium 
are equivalent to 1 kg of morphine or 1 kg of heroin. 
2 Afghanistan (+24%), Islamic Republic of Iran (+49%), Turkey 
The largest heroin seizures in 2007 were reported by the 
Islamic Republic of Iran (16 mt or 25% of the world 
total), Turkey (13 mt) and Afghanistan (5 mt). 
Processing of opium into heroin appears to be  
less frequent  
Between 2003 and 2007, combined heroin and mor-
phine seizures remained basically stable. Combined with 
the data on sharp increases in opium seizures, this sug-
gests that transformation of opium into morphine and 
heroin is becoming more difficult and less frequent3 in 
Afghanistan. It also suggests that the large increases in 
opium production in 2006/07 did not result in large 
increases in morphine and heroin flows out of Afghani-
stan. 
(+28%), Bulgaria (+66%), Italy (+43%), Germany (+22%), Belgium 
(+212%) as well as, along the Northern Route, Kyrgyzstan (65%), 
Turkmenistan (+62%) and the Russian Federation (+20%)
3 Increases in the price of precursors in Afghanistan is an indication of 
the lack of supply of precursors which could make the production of 
heroin and morphine more difficult. 
Global opiate seizures, expressed in Fig. 6: 
heroin equivalents*, by substance, 
1998-2007
* based on a conversion rate of 10 kilograms of opium for 1 
kg of morphine or 1 kg of heroin. 
Source: UNODC, Annual reports Questionnaire Data / DELTA.
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The calculated global interception rate declines  
as more opiates are being stock-piled
The global interception rate for opiates4 rose from 9% 
in 1990 to 26% in 2005. The rate started to decline after 
2005, reaching 19% in 2007. Following the 2006 and 
2007 increases in opium production which exceeded 
global demand, there are indications that a portion of 
opiates has been stockpiled. Prices continue to fall and 
trafficking out of Afghanistan did not grow as fast as 
opium production. 
The falling levels of global opium production in 2008 
may not translate into reduced trafficking flows in the 
near future as production shortfalls could be compen-
sated by reducing the size of existing stocks.     
The bulk of seizures take place close to opium pro-
duction centers
Despite of the large number of countries affected by 
trafficking in opiates, there are clear concentrations of 
trafficking flows and seizures. 
The most important subregion for opiate seizures in 
2007 continued to be South-West Asia, accounting for 
70% of global opiate seizures. The large seizures in this 
region clearly reflect the dominant position of Afghani-
stan as the world’s largest opium producer.
Europe accounted for almost 19% of global opiate sei-
zures. Most opiate seizures there were made in South-
East Europe (11% of the total), notably by Turkey. Most 
of the opiates that reach Western Europe are trafficked 
from Afghanistan through Turkey and the Islamic 
Republic of Iran.  
4 Interception rate is defined as the total seizures of opiates of a given 
year over the global illicit opiate production in the same year. 
Opiate seizures made in East and South-East Asia, and 
Oceania, accounted for 5% of the global total in 2007. 
Seizures in Africa account for only 0.2% of the world 
total. Traditionally, Africa has been supplied from South-
West Asia (typically via Pakistan or India) and South-East 
Asia (typically via Thailand), though lately the opiates 
supply is almost exclusively from South-West Asia.  
The Americas – which seem to be largely ‘self-sufficient’ 
in terms of opiate production and consumption - 
accounted for 3% of global opiate seizures. Most of the 
seizures in this region were made in the USA, the region’s 
main opiate-consuming country.   
Seizures rising in regions affected by Afghan opiates 
The proportion of seizures related to Afghan opium 
production5  increased from 77% of the world total in 
2002 to 92% in 2007, reflecting the strong increases in 
Afghan opium production between 2002 and 2007. 
Opiate seizures in the countries of South-West Asia rose 
by 177% over the same period, and in Europe by 19%. 
In contrast, opiate seizures in the countries of Central 
Asia declined by 19%.  
Seizures declined in regions typically supplied by 
South-East Asian opiates 
The proportion of opiate seizures in the countries mainly 
supplied by opiates produced in Myanmar and the Lao 
People’s Democratic Republic6 fell from 16% of the 
world total in 2002 to 5% in 2007. Reported seizures 
from countries in East and South-East Asia declined by 
43% over the 2002-07 period. Opiate seizures reported 
by countries in Oceania fell by 86% over this period.   
5 Seizures made by countries in South-West Asia, Central Asia, South 
Asia and Europe.
6 Countries in South-East Asia and Oceania.
Calculated global interception rate of Fig. 7: 
opiates* 
* seizures of opiates in a given year (in heroin equivalents) 
shown as a proportion of global illicit opiate production (in 
heroin equivalents) 
Source: UNODC, 2008 World Drug Report and UNODC, ARQ 
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Seizures declined in North America,  
but they are increasing again 
The proportion of opiate seizures made in the Americas 
fell from 6% of the world total in 2002 to 3% in 2007. 
This mainly reflected falling opiate seizures in South 
America (-52% over the 2002-07 period), which is in 
line with reports of falling levels of opium production in 
Colombia. Opiate seizures reported from North Amer-
ica started rising again in 2007, after a downward trend 
in 2006 in Mexico and the USA.   
The vast majority of opiates found in the USA (96%) 
originate in Mexico and Colombia.   
Trafficking in opiates continues to be concentrated 
along three major routes … 
Three distinct production centres for opiates still supply 
three distinct markets. The main trafficking flows con-
tinue to be:
from Afghanistan to neighbouring countries,   s
the Middle East, Africa and Europe;
from Myanmar/Laos to neighbouring   s
countries of South-East Asia, (notably China) 
and to the Oceania region (mainly Australia);
from Latin America (Mexico, Colombia,   s
Guatemala and Peru) to North America  
(notably USA)  
…although alternative routes are emerging from 
South-West Asia to South-East Asia and the Oceania 
region 
A number of reports show that trafficking activities have 
started to diversify from established market connections. 
Though the bulk of opiates found on the Chinese market 
is still from Myanmar, there have been reports of  ship-
ments of heroin from Afghanistan via Pakistan to Chi-
na.7 The heroin is being shipped either directly (mainly 
by air) from Pakistan to various Chinese destinations as 
well as indirectly, via Dubai (United Arab Emirates).8 
The amounts involved are still modest, but may repre-
sent emerging trafficking patterns.9 
In 2007, Pakistan reported an additional new route to 
Malaysia, both direct and via Dubai. Until recently, 
heroin in Malaysia originated exclusively in Myanmar. 
This new route shows that Afghan opiates may now reach 
other destinations since Malaysia has been mentioned 
among the key embarkation points for heroin shipments 
into Australia.10  
… and from South-West Asia to North America 
New trafficking routes from South-West Asia to North 
America are emerging. Canada reported that 98% of the 
heroin found on their market in 2007 originated in 
South-West Asia. The heroin was mainly trafficked by 
air via India and Pakistan into Canada.11 Organized 
crime groups in Ontario and British Columbia are 
involved in heroin imports.12
 
7 UNODC, ARQ data for 2007
8 UNODC, ARQ data for 2007. 
9 Data collected on individual drug seizures show from 2004 to 2006 a 
marked upward trend of heroin seizures made in Pakistan with final 
destinations in  China. This upward trend did not continue in 2007 
and in 2008.
10 Australian Crime Commission, Illicit Drug Data Report 2006-07, 
revised edition, Canberra, March 2009. 
11 UNODC, ARQ data for 2007. 
12 Criminal Intelligence Service Canada (CISC), Report on Organized 
Crime, Ottawa, Ontario 2008.
Global opiate seizures, expressed in heroin equivalents*, regional breakdown, 1998-2007Fig. 9: 
*  For this calculation it is assumed that 10 kg of opium are equivalent to 1 kg of morphine and1 kg of heroin.  
Source: UNODC, ARQ data / DELTA
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Most heroin continues to be trafficked in the  
countries surrounding Afghanistan and along  
the Balkan route towards Western Europe 
The bulk of all opiates produced in Afghanistan is des-
tined for consumption in the neighbouring Islamic 
Republic of Iran, Pakistan, Central Asian countries and, 
to a lesser extent, India. These markets are, in fact, larger 
(about 5 million users)  than the opiate market in West 
and Central Europe (about 1.4 million). The opiate 
markets in Western Europe are, however, financially 
more lucrative. Therefore, opiates also leave Afghanistan 
via Iran and Pakistan along the Balkan route towards 
Western Europe. 
UNODC estimates for 2008 suggest that most of the 
opium exports from Afghanistan cross the border in the 
Islamic Republic of Iran (83%; range: 71%-96%).  Mor-
phine and heroin exports go to Pakistan (41%; range: 
28%-51%) and Iran (39%; range: 32% - 44%) and to a 
lesser extent, to Central Asia (19%; range: 8%-25%)13. 
Opiate seizures continued to increase along the extended 
Balkan route in 2007, accounting for 94% of all seizures 
of Afghan opiates. Seizures along the other route, the 
Silk route (or North route) have continued to decline, 
reaching 9% in 2007. 
Afghan opiates enter the Islamic Republic of Iran either 
directly from Afghanistan or via Pakistan. 
The frequency of Turkey being mentioned by other 
European countries as a ‘country of origin’ for the heroin 
found on their markets has declined in recent years, 
13 UNODC, Afghanistan Opium Survey 2008, October 2008. 
reflecting decreasing heroin manufacturing levels in 
Turkey. Nonetheless, Turkey remains the key transit 
country for heroin produced in South-West Asia and 
consumed in Europe, in spite of alternative trafficking 
routes emerging in recent years. According to Turkish 
authorities, 80% of the heroin illegally imported into 
Turkey was from Afghanistan; the remaining 20% is 
believed to have originated in Iran. 
Once in Turkey, heroin is smuggled from eastern Turkey 
to Istanbul towards Bulgaria for subsequent transport to 
Serbia and Romania for shipments to various countries 
in Western Europe. Heroin and morphine seizures made 
by the Bulgarian authorities rose by 66% in 2007. 
According to Bulgarian authorities, most of the heroin 
seized in 2007 was destined for Croatia and Germany. 
According to information from the Romanian authori-
ties major destination countries were the  Netherlands 
and the United Kingdom.14 
Another transit country for heroin leaving Bulgaria is 
the Former Yugoslav Republic of Macedonia. From 
there, heroin is either sent to Serbia for subsequent 
deliveries along the Balkan route (Bosnia-Herzegovina, 
Croatia, Slovenia) and Western Europe, or to Albania 
for subsequent shipment to Italy. In Italy, heroin coming 
from Albania and Turkey is destined for the domestic 
market (45%) and for re-export, mainly to Germany 
(35%).15 
Most of the heroin shipments to Germany still arrive via 
the Balkan countries and Austria. The main destination 
of heroin seized in Germany is the Netherlands (78% in 
2007). Once in the Netherlands the heroin is typically 
re-exported to the United Kingdom, France, Germany 
and other EU countries. Most of the heroin seized in 
France in 2007 had transited Turkey and the Netherlands 
and was on the way to the UK (50%) or to Spain (15%); 
about a quarter was for domestic consumption.16     
There have been reports that heroin intended for West-
ern Europe was also trafficked through Ukraine via 
Turkey and the Islamic Republic of Iran, with main 
destinations being the UK, Poland and Germany. 17
A number of more direct routes from South-West Asia 
to Europe also exist, mainly via Pakistan as well as via 
the Middle East, Eastern and Western Africa.
14 UNODC, Annual Reports Questionnaire Data for 2007.
15 UNODC, Annual Reports Questionnaire Data for 2007.
16 UNODC, Annual Reports Questionnaire Data for 2007.
17 The Ukraine reported that 45% of heroin seized came via Turkey and 
32% via the Islamic Republic of Iran and that 46% were intended for 
the UK, 31% for Poland and 23% for Germany. Source: UNODC, 
Annual Reports Questionnaire Data for 2007.
Opiate* seizures along the Balkan Fig. 10: 
Route and along the Silk Route,  
1998-2007
*  For this calculation it is assumed that 10 kg of opium are 
equivalent to 1 kg of morphine and 1 kg of heroin.  
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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USA: Heroin retail and wholesale prices, 1990-2007, US$/gramFig. 11: 
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Global illicit supply of opiates, 1997-2007Fig. 14: 
*Opiates are defined as heroin, morphine and opium (10:1) expressed in heroin equivalents.
0702-7991 *:AISA -DETPECRETNI SETAIPO7002 - 7991 *:DLROW -DETPECRETNI SETAIPO
OPIATES INTERCEPTED- AMERICAS:* 1997-2007 OPIATES INTERCEPTED- EUROPE:* 1997-2007
7002 - 7991 *:AINAECO -DETPECRETNI SETAIPO7002 - 7991 *:ACIRFA -DETPECRETNI SETAIPO
*Opiates are defined as heroin, morphine and opium (10:1) expressed in heroin equivalents.
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Global seizures of opium, 1997-2007Fig. 15: 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Metric Tons 196      179      239      213     106     96       133     212     342      384      510       
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Global seizures of heroin(a) and morphine(b), 1997-2007Fig. 16: 
(a) Seizures as reported (street purity).
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Metric Tons 54        56       60        81         66         74        98         100       91        103      92        
(a) Seizures as reported (street purity)
(b) 1 kg of morphine is assumed to be equivalent to 1 kg of heroin.
(c )  Data refer to England and Wales only.
(b) 1 kg of morphine is assumed to be equilveant to 1 kg of heroin.
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Interpretation of seizure data
The quantity of illicit drugs seized in a given year may be 
influenced by two main factors, namely the available 
supply of the drug in the illicit market and the effective-
ness of interdiction efforts by law enforcement agencies.
To measure supply, it is useful to have other indicators 
than seizure quantities. If these are obtained independ-
ently, they can help to interpret the market of illicit 
drugs and the relationship between supply and seizures. 
Price and purity are among the key factors that can help 
to better interpret trends in seizures. Trends in prices 
measure the changes in the market and can be a sign of 
changes in supply. For example, an increasing trend of 
seizures together with a decreasing trend in prices sug-
gest a real increase in supply. An increasing trend in 
seizures with increasing price levels suggests an improve-
ment in law enforcement activities. Information on 
purity is also important to interpret data on seizures. 
Very often the market reacts to a decrease of supply by 
diminishing the pure con-
tent of the drug. Increases 
or decreases of seizures in 
terms of weight or unit 
may not be sufficient to 
measure actual changes 
occurring in the market.
In many countries, only 
seizure data are available 
to estimate a trend in the 
availability of illicit drugs. 
How much seizure trends 
can help to understand 
the availability of drugs is 
illustrated in the following 
example, where trends in 
opium seizures and pro-
duction (as a proxy of 
supply) are compared at 
the global level. Interpret-
ing seizure data on short-term changes or in one single 
country could be meaningless. Looking at long-term 
changes on a global scale provides a more accurate pic-
ture. 
In the figure, the growth of opium production is pre-
sented together with growth of global seizures of opium, 
heroin and morphine. If it is assumed that both seizures 
and opium production are indicators of the supply of 
opiates, it is expected that seizures and production follow 
the same pattern. Indeed it can be noted that seizures of 
opium and morphine follow the same trend as produc-
tion, but this is not true for heroin. Heroin seizures do 
not show the same drastic decline that affected produc-
tion in 2001. The sustained high levels of heroin seizures 
in 2001, despite the decrease of production, may partly 
be attributed to intensified law enforcement efforts 
(notably in China and Tajikistan1). Stock-piling could 
also be a factor that can explain this trend. Opium pro-
duction may also not be a good indicator of supply. In 
fact, heroin seizures may arguably be a better indicator 
of heroin supply than opium production, especially for 
a consumer market that is removed from the production 
basin around Afghanistan, such as West and Central 
Europe.  
Supply and law enforcement activities can not be sepa-
rated, and assuming trends in supply solely on the basis 
of data on seizures can sometimes be misleading. This 
can also be seen by looking at the growth of opium sei-
zures between 2005-2007. Although the trend is similar 
to opium production, the more rapid increase of seizures 
compared to production measures not only an increase 
in supply but most probably also an increased level of 
law enforcement activities.  
It is easy to compare levels and changes of seizures and 
production to understand how much information sei-
zures can give on the increase or decrease of supply. 
However, this kind of analysis is not always possible, and 
in many situations, seizure totals are the best available 
indicators of supply. When information on seizures is 
supplemented with information on price, purity and 
consumption, more accurate conclusions can be made 
about the supply of illicit drugs. When only seizure data 
are used, there is a risk of overestimating or underesti-
mating real changes in supply.  
1 UNODC, Global Illicit Drug Trends 2003.
Growth of opium production and opiate seizures, relative to 1997
Note: All quantities are expressed relative to 1997. Thus, for example, a value of 2.5 indicates 
that the quantity grew 2.5 times since 1997.
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In 2007 UNODC estimates that the total number of 
opiates users at the global level is between 15.2-21.1 
million people. More than half of the world’s opiates-
using population are thought to live in Asia. The highest 
levels of use (in terms of the proportion of the popula-
tion aged 15-64 years) are found along the main drug 
trafficking routes out of Afghanistan. 
This year, significant revisions were made to the approach 
taken in making global and regional estimates of the 
number of people who use drugs. The new estimates 
reflect the uncertainties surrounding these data (which 
exist due to data gaps and quality) and are presented in 
ranges rather than absolute numbers. Because of this 
revision, previous point estimates are not comparable to 
the current ones. 
Region/subregion
Estimated  
number of 
users (lower)
Estimated  
number of users 
(upper)
Percent of 
population 
aged 15-64 
(lower)
Percent of popula-
tion aged 15-64 
(upper)
Africa
North Africa
West and Central Africa
Eastern Africa
Southern Africa
1,000,000
120,000
550,000
100,000
230,000
2,780,000
490,000
650,000
1,330,000
310,000
0.2
0.3
0.3
0.1
0.2
0.5
0.4
0.4
1.0
0.3
Americas
North America
Central America
The Caribbean
South America
2,190,000
1,310,000
20,000
60,000
800,000
2,320,000
1,360,000
30,000
90,000
840,000
0.4
0.4
0.1
0.2
0.3
0.4
0.5
0.1
0.3
0.3
Asia
East/South-East Asia
South Asia
Central Asia
Near and Middle East
8,440,000
2,800,000
3,620,000
340,000
1,680,000
11,890,000
4,970,000
3,660,000
340,000
2,910,000
0.3
0.2
0.4
0.7
0.7
0.5
0.3
0.4
0.7
1.2
Europe
Western/Central Europe
East/South-East Europe
3,440,000
1,230,000
2,210,000
4,050,000
1,520,000
2,535,000
0.6
0.5
0.8
0.7
0.6
0.9
Oceania 90,000 90,000 0.4 0.4
Global 15,160,000 21,130,000 0.3 0.5
Estimated number of people who used opiates at least once in the past year and  Table 3: 
proporton of population aged 15-64, by region, 2007
Note: 2007 estimates cannot be compared to previous UNODC estimates 
Source: UNODC
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Opiate consumption may be falling in East and 
South-East Asia 
In East and South-East Asia, it was estimated that 2.8-
5.0 million persons aged 15-64 years used opiates in the 
past year. Use in China has been estimated at around 
0.19-0.31% (1.8 to 2.9 million persons).1 Higher levels 
have been reported in opium cultivation areas, including 
1.1% in the Shan State and Kachin (Myanmar).2 
Most countries of East and South-East Asia reported 
recent declines in opiate use, reflecting declining opium 
production in Myanmar and the Lao People’s Demo-
cratic Republic. Heroin was still reported as the main 
problem drug in China (Hong Kong and Macao only), 
Indonesia, Malaysia and Myanmar, although reports 
suggested that heroin use may also be declining there. 
Opium use in northern Lao PDR is estimated to have 
declined from 0.6% (2006) to 0.4% (2008)3. In both 
Lao PDR and Myanmar, opium producing villages have 
much higher consumption than non-opium producing 
villages.
1 Estimate derived from Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, 
Poundstone K, et al. “Estimating the number of people at risk for 
and living with HIV in China in 2005: methods and results; Sex 
Transmitted Infections, June 2006, Vol. 82 Suppl 3, pp. iii 87-91, 
reported in: Mathers B, Degenhardt L, Phillips B, Wiessing L, Hick-
man M, Strathdee S, et al. Global epidemiology of injecting drug use 
and HIV among people who inject drugs: a systematic review. The 
Lancet 2008;372:1733-1745.
2 2008 UNODC Opium and Poppy Cultivation Report, South-East 
Asia. (December 2008)
3 Ibid.
Opiates remain a prominent issue in Central and 
South West Asia
Opiate use remains the most prominent illicit drug prob-
lem in this region. Population surveys suggested that 
1.4% used opiates in the past year in Afghanistan (in 
2005), and 2.8% in the Islamic Republic of Iran (has an 
estimated 0.7 to 1.6 million so-called “drug addicts”).4 
In Pakistan, injecting drug use is reportedly increasing;5 
one study estimated 630,000 opiate users in Pakistan, 
equivalent to 0.7% of those aged 15-64, around 77% of 
whom were heroin users.6 
In the Central Asia7 and the Caucasus subregion, opiate 
use is also thought to be above estimated global average 
levels, particularly in Kazakhstan (1%),8 Kyrgyzstan 
(0.8%)9 and Uzbekistan (0.8%).10 Estimates for Tajiki-
stan are slightly lower (0.5%). The HIV epidemic con-
tinues among primarily opiate-injecting drug users in the 
4 Drug Control Headquarters of the Islamic Republic of Iran, Policies, 
Achievements, Ongoing Programs and Future Plans, Tehran 2007.
5 UNODC, Global Assessment Programme on Drug Use, Ministry 
of Narcotics Control of the Government of Pakistan, Anti-Narcotics 
Force of the Government of Pakistan. Problem Drug Use in Pakistan, 
Results from the year 2006 National Assessment. Tashkent, 2007.
6 UNODC and the Paris Pact Initiative, Illicit Drug Trends in Paki-
stan, April 2008. UNODC, Global Assessment Programme on Drug 
Use, Ministry of Narcotics Control of the Government of Pakistan, 
Anti-Narcotics Force of the Government of Pakistan. Problem Drug 
Use in Pakistan, Results from the year 2006 National Assessment. 
Tashkent, 2007.
7 UNODC, HIV/AIDS and injecting drug use in Central Asia: From 
evidence to action, 2007.
8 Ibid.
9 UNODC, HIV/AIDS and Injecting Drug Use in Central Asia: from 
Evidence to Action, Kyrgyzstan Country Report 2007
10 UNODC, HIV/AIDS and Injecting Drug Use in Central Asia: from 
Evidence to Action, Uzbekistan Country Report 2007. 
Opiate use trends as perceived by experts of developed (OECD) and developing (non-OECD) Fig. 17: 
countries, 1998-2007 (baseline: 1998 = 100)
Sources: UNODC, Annual Reports Questionnaire Data, UNODC Field Offices, UNODC’s Drug Use Information  
Network for Asia and the Pacific (DAINAP).
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region, particularly marked across Uzbekistan,11 Tajiki-
stan12 and Kyrgyzstan.13 This is thought to be driven by 
the countries’ proximity to major trafficking routes out 
of Afghanistan. 
South Asia
India holds the largest opiate-using population in the 
subregion, estimated at around 3.2 million persons (esti-
mated from a study conducted in the year 2000). There 
are few data on the size of opiate-using populations in 
this region; the most recent population survey - of 
Indian men - was conducted in 2000. 
Some information on drug use has been obtained from 
samples of illicit drug users in countries across this region. 
These studies have suggested that heroin use is common 
among illicit drug users in Bangladesh14 and India,15 and 
buprenorphine injection16 has been identified as a sig-
nificant issue among Indian and Bangladeshi drug users. 
In Sri Lanka, in contrast, heroin smoking is more 
common – injection appears to rarely occur. 
11 UNODC, HIV/AIDS and Injecting Drug Use in Central Asia: from 
Evidence to Action, Uzbekistan Country Report 2007. 
12 UNODC, HIV/AIDS and Injecting Drug Use in Central Asia: from 
Evidence to Action, Tajikistan Country Report 2007
13 UNODC, HIV/AIDS and Injecting Drug Use in Central Asia: from 
Evidence to Action, Kyrgyzstan Country Report 2007
14 UNODC Regional Office for South Asia. (2008). Rapid Situation 
and Response Assessment of Drugs and HIV in Bangladesh, Bhutan, 
India, Nepal and Sri Lanka: A Regional Report.
15 Degenhardt L, Larance B, Mathers B, Azim T, Kamarulzaman A, 
Mattick RP, on behalf of the Reference Group to the United Nations 
on HIV and injecting drug use. Benefits and risks of pharmaceutical 
opiates: Essential treatment and diverted medication. A global review 
of availability, extra-medical use, injection and the association with 
HIV. Sydney: University of New South Wales, 2008.
16  It is important to note that large scale diversion of buprenorphine is 
at the factory/warehouse level (rather than diversion from patients or 
medical practitioners).
Near and Middle East: heroin use may be increasing 
but data are limited
In countries with available data in this region, heroin use 
is reported to have increased, with decreasing age of 
onset and increasing demand for treatment. Many coun-
tries, however, still lack essential capacity to collect and 
analyse data on drug use and drug treatment demand. 
There is a need to improve data in this region. 
Europe holds the second largest population of 
opiate users; trends differ between western and east-
ern countries 
Europe has an estimated 3.4-4.0 million opiate users 
(around 0.6-0.7% of the population aged 15-64): 
between 1.23-1.52 million estimated consumers in West 
and Central Europe, and between 2.21-2.53 million 
consumers (0.8-0.9%) in Eastern and South Eastern 
Europe. This region is the world’s second largest opiate 
market in terms of quantities consumed, and the largest 
in economic terms. 
The major populations of users in Western Europe are 
estimated to be in the United Kingdom (between 404-
434,000 persons), Italy (305,000), France (171-205,000), 
Germany (76-161,000) and Spain (61-121,000).17 
According to expert perceptions, use of opiates remained 
stable or declined in this subregion. Data from the past 
decade similarly suggest stable levels of use, although 
some countries have reported increases in fatal overdoses 
and in first treatment entrants with heroin as the pri-
mary drug problem in recent years. 
17 All of these estimates have been derived from estimates of the number 
of problem drug users because household surveys are not considered 
to provide good estimates on the number of heroin and other opiate 
users. 
Expert perception of changing opiate use, by region, 2007Table 4: 
Sources: UNODC, Annual Reports Questionnaire data.* Identifies increases/ decreases ranging from either some to strong, 
unweighted by population.
Region
Member 
States 
responding
Use 
problem 
increased*
Percent 
use  
problem 
increased
Use 
 problem 
stable
Percent 
use  
problem 
stable
Use 
problem 
decreased*
Percent 
use 
 problem 
decreased
Africa 17 9 53% 6 35% 2 12%
Americas 12 7 58% 3 25% 2 17%
Asia 27 14 52% 4 15% 9 33%
Europe 31 8 26% 15 48% 8 26%
Oceania 0 0  0  0  
Global 87 38 44% 28 32% 21 24%
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The Russian Federation has the largest opiate-using pop-
ulation in Eastern Europe. Although estimates of the 
number vary substantially18, some estimate there are 
1.68 million opiate users in the country (1.6% of the 
population aged 15-64).19 The second largest opiate 
using population in Eastern Europe is the Ukraine with 
between 323-423,000 opiate users (1-1.3%). 
In 2008, perceived increases in opiate use were noted in 
Albania, Belarus, Croatia, and the Republic of Moldova. 
Specialised studies have estimated that injecting drug 
use is prevalent in many eastern European countries, 
and HIV is common among people who inject drugs.20 
This is particularly the case in the Russian Federation, 
the Ukraine, and Belarus, and there are reasons to be 
concerned about increasing problems in many other 
countries in the region where injecting is also occur-
ring.21
18 This also reflects major differences on the estimates of total drug use 
in the Russian Federation. A review of estimates of the total number 
of drug users in the Russian Federation showed a range from 1.5 mil-
lion to 6 million people (UNODC, Illicit Drug Trends in the Russian 
Federation, 2005. UNODC and the Paris Pact Initiative, Illicit Drug 
Trends in the Russian Federation, April 2008.) 
19 The new estimate is based on registered drug users and a new treat-
ment multiplier. 350,267 drug dependent patients were registered in 
2006. Of these, 89% were opiate users (UNODC and the Paris Pact 
Initiative, Illicit Drug Trends in the Russian Federation, April 2008). 
The new national-level treatment multiplier is 5.3 (United Nations 
Office on Drugs and Crime, National Addiction Centre of the Rus-
sian Federation, Dynamics of Drug-Related Disorders in the Russian 
Federation, 2007).
20  UNODC, Global Assessment Programme on Drug Use (GAP), National 
Addiction Centre of the Russian Federation. Koshkina, E.A. (2007) 
Dynamics of Drug-Related Disorders in the Russian Federation (2008). 
Mathers B, Degenhardt L, Phillips B, Wiessing L, Hickman M, 
Strathdee S, et al. Ibid.
21 Mathers B, Degenhardt L, Phillips B, Wiessing L, Hickman M, 
Strathdee S, et al. Ibid.
Opioid consumption in the Americas: heroin use 
may be stable, but other opiate use is a significant 
issue 
The largest heroin using population in this region is 
found in the USA, with one study estimating approxi-
mately 1.2 million heroin users (0.6% of the population 
aged 15-64;22 derived from a study of “problem drug 
users” in 2000). The  largest opioid using population in 
this region is also, by far, in the USA, with an estimated 
5.2 million persons in 2007 reporting using prescription 
pain relievers non-medically (a level that has remained 
stable since 2002).23 This reflects a very well-docu-
mented problem across the USA of inappropriate pre-
scribing and use of pharmaceutical opiates (particularly 
22 ONDCP, 2000.
23 SAMHSA, Results from the 2007 National Survey on Drug Use and 
Health, National Findings, (Rockville, Maryland, 2008).   
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oxycodone), leading to a new cohort of opiate-depend-
ent persons across the country. Treatment admissions 
and poisoning deaths continue to increase.
The largest population of opioid users in South America 
is found in Brazil, with some 635,000 opioid users 
(0.5% of those aged 12-65). Most use synthetic opioids 
rather than heroin (less than 0.05%). Experts reported a 
stable trend of opioid use in multiple countries in the 
Americas, but rising levels of opioid use were reported 
in Mexico, Venezuela (Bolivarian Republic of ) and 
Argentina. 
Heroin use in Oceania appears stable 
Data from the Oceania region reflect only Australia and 
New Zealand, with no reports from the numerous island 
nations. Data from drug monitoring systems in Aus-
tralia and New Zealand suggest stable levels of use, with 
some 90,000 opiates users in the Oceania region. In 
Australia, these remain much lower than those seen in 
the late 1990s prior to the so-called Australian “heroin 
shortage”, though there are indications that injecting 
drug users are increasingly injecting other opioids such 
as morphine.24
Heroin use may be rising in Africa 
There may be between 1.00-2.78 million people using 
opiates in Africa – the wide range of this estimate reflects 
the uncertainty in the numbers. Comparatively high 
levels have been reported in Mauritius and Egypt25. 
24 E. Black, A. Roxburgh, L. Degenhardt, R. Bruno, G. Campbell, B. de 
Graaff, et al. Australian Drug Trends 2007: Findings from the Illicit 
Drug Reporting System (IDRS). Australian Drug Trends Series No. 
1 National Drug and Alcohol Research Centre, University of New 
South Wales (Sydney, 2008).
25 Ghaz, I. National Study of Addiction, Prevalence of the use of Drugs 
Almost all opiate consumption is heroin, which is the 
primary drug among problematic drug users in coun-
tries such as Kenya, Mauritius, Nigeria, Tanzania and 
Zambia.26,27,28 
Reported heroin use trends suggest that heroin con-
sumption continues to rise in eastern and southern 
Africa and some western African countries. This reflects 
the increasing role of African countries as heroin transits 
from Afghanistan to Europe. Opiates are the second 
most common drug for treatment; greater opiate treat-
ment demand exists in the eastern and southern parts of 
the continent. 
Unfortunately, few countries of west and central Africa 
report drug use trends, and there are no accurate preva-
lence data. Data in Africa therefore primarily reflect 
countries in northern and southern Africa. South Africa 
is the only country with a drug use surveillance system 
(the South African Community Epidemiology Network 
on Drug Use (SACENDU). There is a continuing need 
for technical assistance in the region in order to build 
sustainable, cost-effective drug monitoring capacity.
and Alcohol in Egypt. (Cairo, 2007)
26 Abdool, R., Sulliman, F.T., Dhannoo, M.I. The injecting drug use 
and HIV/AIDS nexus in the Republic of Mauritius, African Journal 
of Drug & Alcohol Studies, 5(2), 2006
27 Deveau, C., Levine, B., Beckerleg, S. Heroin use in Kenya and find-
ings from a community based outreach programme to reduce the 
spread of HIV/AIDS, African Journal of Drug & Alcohol Studies, 
5(2), 2006
28 Timpson, S., McCurdy, S.A., Leshabari, M.T., Kilonzo, G.P., Atkin-
son, J., Msami, A. & Williams, M.L. Substance use, HIV risk and 
HIV/AIDS in Tanzania, African Journal of Drug & Alcohol Studies, 
5(2), 2006
Percentage of all treatment admissions in South Africa for heroin, 1996-2008Fig. 21: 
Unweighted average of treatment (including alcohol) in 6 provinces. Source: SACENDU, “Monitoring Alcohol & Drug Use Trends in 
South Africa, July 1996 - June 2007”, Research Brief, Vol. 10 (2), 2007.
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Injecting drug use and HIV
What is the extent of injecting drug use around the world? 
Injecting drug use is well established in every region of the world and appears to be an emerging phenomenon in 
many countries where it has not been previously reported1. By 2008, injecting drug use had been reported in 148 
countries and territories which together account for 95% of the world’s population. 
Estimates of the prevalence of injecting drug use were available for only 61 countries around the world; these coun-
tries make up 77% of the world’s population. The prevalence of injecting drug use varies consider ably, both between 
and within countries. Observed country-level prevalence of injecting drug use ranges from 0.02% in India and 
Cambodia to Georgia with 4.19% and Azerbaijan with 5.21%.
It is estimated that between 11–21 million people worldwide inject drugs. China, the USA, the Russian Federation 
and Brazil are estimated to have the largest populations of injecting drug users (IDUs) and together account for 45% 
of the total estimated worldwide population of IDUs. 
What is the extent of HIV among people who inject drugs? 
Injecting drug use is responsible for an increasing proportion of HIV infections in many parts of the world, 
including countries in Eastern Europe, South America and East and South-East Asia. Investment in compre-
hensive public-health interventions is required to address this.
HIV infection among people who inject drugs has been reported in 120 countries, and the prevalence of HIV 
among IDUs varies dramatically. Midpoint HIV prevalence is reported to be between 20 and 40% in five 
countries: Spain (39.7%); Russian Federation (37.2%); Viet Nam (33.9%); Cambodia (22.8%) and Libyan 
Arab Jamahiriya (22.0%); and is greater than 40% in a further nine: Estonia (72.1%); Argentina (49.7%); 
Brazil (48.0%); Kenya (42.9%); Myanmar (42.6%); Thailand (42.5%); Indonesia (42.5%); Ukraine (41.8%) 
and Nepal (41.4%). 
HIV prevalence rates among IDUs also vary significantly within countries. For example, in China, reported 
HIV infections are concen trated within seven of the country’s 22 provinces. Moreover, in Russia, the reported 
prevalence rates varied from 0.3% in Pskov, 12.4% in Moscow, 32% in St. Petersburg to 74% in Biysk. 
It is estimated that between 0.8 and 6.6 million people who inject drugs worldwide are infected with HIV. 
Regions with the largest numbers and highest concentration of HIV-posi tive IDUs include Eastern Europe, 
East and South-East Asia, and Latin America. The prevalence of HIV is higher than 40% in many national 
and subnational injecting drug user populations in these regions. 
Outside of sub-Saharan Africa injecting drug users make up a sizeable proportion of the total number of people 
living with HIV. In Eastern Europe and Central Asia, more than half of those living with HIV are IDUs.
The dynamics of the spread of HIV infection are notable. A decade ago, HIV was not identified among people 
who inject drugs in Estonia; by contrast, a more recent estimate now suggests that the prevalence of HIV infec-
tion has reached 72% in one sample of injecting drug users. In contrast, Australia and New Zealand have 
maintained very low levels of HIV infection (1.09% and 0.73% respectively) despite a higher prevalence of 
injecting drug use than some other countries. This difference has been attributed to geographic isolation, as 
well as the swift introduction of needle and syringe programmes and the expansion of opiate substitution treat-
ment programmes after HIV infection was first documented in 1984. 
1  This information was compiled, reviewed and published by the Reference Group to the United Nations on HIV and injecting drug 
use and published in The Lancet in September 2008. The Reference Group was established for the purpose of providing independent 
technical advice on HIV and injecting drug use to the United Nations Office on Drugs and Crime (UNODC), World Health Organization 
(WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) Secretariat and relevant co-sponsors. The Reference Group cur-
rently comprises 24 experts from 20 countries, and includes clinicians, researchers in epidemiology and policy, and injecting drug user 
representatives. Further information is available at: www.iduRefGroup.com 
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*These numbers are extremely tenuous as they are based on very few countries in the region
Data on injecting drug use: challenges and limitations 
Currently only limited data exist on the prevalence of injecting drug use around the world and the quality of the 
available data is generally poor. The inadequacy of the available data makes it impossible to determine with any 
certainty how the extent of injecting drug use globally has changed over time
A lack of consistency in the definition of injecting drug use in the literature and different datasets makes reliable 
comparison between countries, and in some cases even within countries, impossible. 
Injecting drug use is an illegal, stigmatised behaviour and con sequently injecting drug users are often referred to as 
a “hidden population.” It is difficult to measure the extent of this behaviour. Population surveys tend to underesti-
mate its prevalence and indirect methods can also be uncertain.
 Collecting the data is technically challenging, particularly for developing countries. However, data from many 
higher income countries is also inadequate. For example, the most recent na tional estimates of injecting drug use 
for eight Western European countries were from the year 2000 or earlier. In order to plan and implement successful 
interventions to address injecting drug use and HIV, it is critical that consistent, timely data on the extent of inject-
ing drug use and HIV among IDUs is collected. 
Estimated number of 
people who inject 
drugs 
(range)
Estimated 
midpoint 
prevalence 
of injecting 
drug use
Estimated number of 
people who inject 
drugs and who are 
HIV positive 
(range)
Estimated 
midpoint 
prevalence 
of HIV 
among 
people who 
inject drugs
Eastern Europe
3,476,500
(2,540,000-4,543,500)
1.50%
940,000
(18,500-2,422,000)
27.04%
Western Europe
1,044,000
(816,000-1,299,000)
0.37%
114,000
(39,000-210,500)
10.90%
East and South-East 
Asia
3,957,500
(3,043,500-4,913,000)
0.27%
661,000
(313,000-1,251,500)
16.70%
South Asia
569,500
(434,000-726,500)
0.06%
74,500
(34,500-135,500)
13.08%
Central Asia
247,500
(182,500-321,000)
0.64%
29,000
(16,500-47,000)
11.81%
Caribbean
186,000
(137,500-241,500)
0.73%
24,000
(6,000-52,500)
12.90%
Latin America
2,018,000
(1,508,000-2,597,500)
0.59%
580,500
(181,500-1,175,500)
28.77%
Canada and USA
2,270,500
(1,604,500-3,140,000)
0.99%
347,000
(127,000-709,000)
15.29%
Pacific Island States 
and Territories
19,500
(14,500-25,000)
0.36%
500
(<250-500)
1.37%
Australia and New 
Zealand
173,500
(105,000-236,500)
1.03%
2,500
(500-6,000)
1.51%
Middle East and North 
Africa
121,000
(89,000-156,500)
0.05%
3,500
(1,500-6,500)
2.94%
Sub-Saharan Africa*
1,778,500
(534,500-3,022,500)
0.43%
221,000
(26,000-572,000)
12.43%
Extrapolated global 
estimates
15,861,500
(11,008,500-21,222,000)
0.37%
2,997,500
(764,000-6,589,000)
18.90%
Regional and global estimates of prevalence and number of people who inject drugs and  Table 5: 
the prevalence and number who may be HIV positive, 2007
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Cutting agents for heroin in Afghanistan 
Through improved forensic capacities and facilities, the forensic laboratory of the Counter Narcotics Police of 
Afghanistan (CNPA) was able to identify several cutting agents typically used for mixing with heroin.1 The samples 
were seized during law enforcement activities in 2008. The chemicals identified include caffeine, chloroquine, phe-
nolphthalein and paracetamol. 
Users who smoke or inhale heroin draw some practical benefits if it is mixed with a certain amount of caffeine, as 
this causes the heroin to vaporize at a lower temperature. 
Chloroquine, a well-known anti-malarial drug, has been used as a cutting agent in heroin for many years, though it 
was not previously known to be used in Afghanistan. Chloroquine does not alter the effects of heroin or influence 
the way it can be consumed. Its widespread availability, low price, colour and crystalline structure are thought to be 
some of the reasons for its use. Given the close resemblance in appearance and consistency of chloroquine with some 
seizures of what is known in South-West Asia as “crystal heroin”, one could also speculate that the chloroquine was 
marketed on its own, as fake heroin.
Phenolphthalein is used as an acid or base indicator. It has also been used as a laxative for more than a century, but 
has now been removed from the market because of concerns over carcinogenicity. It has been reported as a cutting 
agent for heroin in the past2 but the reasons for its use are not well understood. 
Paracetamol is a popular over-the-counter painkiller. It is easy to purchase and relatively cheap. Its mild analgesic 
properties and bitter taste may disguise a poorer quality heroin. The use of paracetamol as a cutting agent for heroin 
is well documented from many regions and countries. 
The reason for adding specific, pharmacologically active substances (so-called adulterants) to heroin remains an area 
of speculation that can only be partly explained by the pharmacological properties of the substances concerned. 
However, the findings of the CNPA laboratory suggest that cutting of heroin takes place at source and that heroin 
produced in Afghanistan may be customized for different markets and consumer groups.
The findings are also a reminder that there is a frequently neglected market associated with the illicit drug industry: 
the market in cutting agents. This market is lucrative because cutting agents are legal and their trade carries low risk. 
The increased awareness of the potential value for drug enforcement of understanding the trade in these substances 
is very recent.3
1  http://www.unodc.org/pdf/scientific/LIB%20IV-2008_Kabul-.pdf
2  Chaudron-Thozet, H., Girard, J., and David, J.J. (1992), Analysis of heroin seized in France, Bulletin on Narcotics, Vol.1, 29-33.
3  Daly, M. (2008), Police target ‘bash’ industry, DrugLink, September/October 2008, 3.
“Crystal heroin” Chloroquine

1.2 Coca / cocaine market
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1.2.1 Summary trend overview
 
In 2008, a significant decrease in Colombia, the world’s 
largest cultivator of coca bush, brought the total area 
under coca cultivation down by some 8% to 167,600 
ha. Total cultivation is close to the average level since 
2002, and well below the levels reached in the 1990s. 
Similarly, the estimated global cocaine production also 
decreased in 2008, due to a strong reduction in Colom-
bia. The Plurinational State of Bolivia and Peru both 
registered small increases in cultivation and produc-
tion. 
Compared to the record high in 2005, cocaine seizures 
decreased in 2007. The Americas account for the vast 
majority of the world’s cocaine seizures, although a sig-
nificant decline in trafficking towards North America, 
the world's largest cocaine consumer market, was 
reported in 2008. This decline was reflected in rapidly 
rising prices and falling purity levels. 
North America also reported significant declines in 
cocaine use, notably from the USA. Following strong 
increases in recent years, a number of surveys in West 
European countries – including Spain - showed the first 
signs of a stabilization in 2008, whereas cocaine use still 
appears to be increasing in South America. The total 
number of people who used cocaine at least once in 
2007 worldwide is estimated to range between 16 and 
21 million. 
1.2.2 Production
Cultivation
In 2008, the total area under coca cultivation decreased 
by 8% due to a significant reduction in Colombia 
(-18%), which was not offset by small increases in the 
Plurinational State of Bolivia (6%) and Peru (4%). The 
total area under coca cultivation decreased to 167,600 
ha, which is well below the level reached in the 1990s. 
In spite of this decrease, Colombia remained the world’s 
largest coca bush-cultivating country with 81,000 ha, 
followed by Peru (56,100 ha) and Bolivia (30,500 ha). 
Most of the decrease of 18,000 ha in Colombia hap-
pened in the regions of Meta-Guaviare and Putumayo-
Caquetá. However, a significant increase was observed in 
the Pacific region as well as in some smaller cultivation 
regions. 
In 2008, the area under coca cultivation in Peru increased 
by 4% to 56,100 ha, the third, albeit relatively small, 
consecutive yearly increase. Peru remains the world’s 
second largest coca bush-cultivating country. 
The area under coca cultivation in the Plurinational 
State of Bolivia in 2008 increased by 6% to 30,500. Like 
in Peru, this was the third consecutive yearly increase. 
An expansion of the area under coca cultivation was 
observed in both large cultivation regions, the Yungas of 
La Paz and Chapare. 
Although sizeable coca cultivation does not exist outside 
Bolivia, Peru and Colombia, eradication reports from 
Governments and media reports indicate that small-
scale coca cultivation took place in other countries in the 
region in 2008.
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Global illicit cultivation of coca bush and production of coca leaf and cocaine, 1994-2008Table 6: 
(a) Potentially harvestable, after eradication.          
(b) Sources: 1994-2002: CICAD and US Department of State, International Narcotics Control Strategy Report. For the region Yungas of La Paz since 
2002, for all regions since 2003: National Illicit Crop Monitoring System supported by UNODC. Cocaine production: before 2003, see cultivation. 
Since 2003, own calculations, partly based on UNODC yield coca leaf yield surveys. Figures for 2004 and 2005 were revised in 2007 based on new 
information on coca leaf yield in the Yungas of La Paz.
(c) Sources: 1994-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; since 1999: National Illicit Crop 
Monitoring System supported by UNODC. 
(d) Sources: 1994-1999: CICAD and US Department of State, International Narcotics Control Strategy Report; since 2000: National Illicit Crop 
Monitoring System supported by UNODC. 
(e) Refers to the potential dry coca leaf production available for cocaine production, i. e. after deducting the amount, which Governments report as being 
used for traditional or other purposes allowed under national law. In the absence of a standard definition of "dry coca leaf" and given considerable 
differences in the processing of the fresh coca leaf harvested, the figures may not always be comparable across countries.
(f ) Since 2005, potential sun-dried coca leaf production available for cocaine production, estimated by the National Illicit Crop Monitoring System 
supported by UNODC. This figure does not include the estimated amount of coca leaf produced on 12,000 ha in the Yungas of La Paz where coca 
cultivation is authorized under national law.       
(g) Sources: 1994-2002: CICAD and US Department of State, International Narcotics Control Strategy Report. Since 2003, potential coca leaf produc-
tion available for cocaine production estimated by the National Illicit Crop Monitoring System supported by UNODC. Figures refer to oven-dried 
coca leaf equivalents.            
(h) Since 2004, fresh coca leaf production figures are available based on coca leaf yield studies done by UNODC and the Government of Colombia. 
Similar to potential cocaine production, fresh coca leaf production in Colombia is calculated based on two-year area averages.  
(i)  Since 2003, potential sun-dried coca leaf production available for cocaine production, estimated by the National Illicit Crop Monitoring System 
supported by UNODC. For the calculation of coca leaf available for cocaine production, 9,000 mt of sun-dried coca leaf were deducted, which, 
according to Government sources, is the amount used for traditional purposes.
(j)  Amounts of cocaine that could be manufactured from locally produced coca leaf (due to imports and exports of coca derivatives, actual amounts of 
cocaine manufactured in a country can differ).
(k) Since 2002, cocaine production is calculated based on the average area under coca cultivation of the reporting year and the previous year. This is 
thought to be closer to the actual amount produced than a figure solely based on the year-end cultivation. Colombian cocaine production estimates 
for 2004 and later are based on new research and cannot be directly compared with previous years. For the calculation of the 2008 cocaine produc-
tion, new information on coca leaf yield available for some regions was used.
(l)  Figures from 2003 to 2005 were revised in 2007 based on updated information available on the amount of coca leaf necessary to produce one 
kilogram of cocaine HCl.           
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
CULTIVATION OF COCA BUSH IN HECTARES (a)
  Bolivia (b) 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 21,600 23,600 27,700 25,400 27,500 28,900 30,500
  Colombia (c) 44,700 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000 80,000 86,000 78,000 99,000 81,000
  Peru (d) 108,600 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200 50,300 48,200 51,400 53,700 56,100
Total 201,400 214,800 209,700 194,000 190,800 220,600 221,300 210,900 170,300 153,800 158,000 159,600 156,900 181,600 167,600
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS (e)
  Bolivia (f) 89,800 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 27,800 38,000 28,200 33,200 36,400 39,400
  Colombia (g) 67,500 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 186,050 164,280 164,280 154,130 154,000 116,900
Colombia (fresh 
coca leaf)  (h)
552,800 555,400 528,300 525,300  389,600
  Peru (i) 165,300 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 72,800 101,000 97,000 105,100 107,800 113,300
POTENTIAL MANUFACTURE OF COCAINE IN METRIC TONS (j)
  Bolivia (b) 255 240 215 200 150 70 43 60 60 79 98 80 94 104 113
  Colombia (k) 201 230 300 350 435 680 695 617 580 550 640 640 610 600 430
  Peru (l) 435 460 435 325 240 175 141 150 160 230 270 260 280 290 302
Total 891 930 950 875 825 925 879 827 800 859 1,008 980 984 994 845
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Production
In 2008, the global potential cocaine production 
decreased by 15%, from 994 mt in 2007 to 845 mt in 
2008. This is the lowest amount in the period 2004-
2008, for which directly comparable figures are availa-
ble. The decrease is due to a strong reduction in cocaine 
production in Colombia (28%), which was not leveled 
out by production increases in Bolivia and Peru. Colom-
bia remained the world’s largest producer of cocaine 
(51%) followed by Peru (36%) and Bolivia (13%). 
Farm-gate prices 
Sun-dried coca leaf
Farm-gate prices for sun-dried coca leaf increased in 
both the Plurinational State of Bolivia and Peru. As in 
the past years, in Bolivia, coca leaf prices were consider-
ably higher than in neighbouring Peru. The prices 
reached levels of over US$ 6.0/kg in the Chapare region, 
a level last reached in 2002. In Peru, the simple average 
farm-gate price of sun-dried coca leaf traded outside the 
Government-controlled market was US$ 3.4/kg, over 
one third more than in 2007, compared to just US$ 1.7/
kg for coca leaf traded under Government control. 
Global coca bush cultivation (ha), 1994-2008Fig. 22: 
Global cocaine production (mt), 1994-2008Fig. 23: 
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1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Bolivia manual 1,100 5,493 7,512 7,000 11,620 15,353 7,653 9,395 11,839 10,089 8,437 6,073 5,070 6,269 5,484
Colombia
manual 1,033 1,487 4,057 2,262 3,126 1,046 3,495 1,745 2,762 4,219 6,234 31,980 43,051 66,805 95,634
aerial 
spraying 3,871 23,915 18,519 41,861 66,029 43,112 58,073 94,153 130,364 132,817 136,552 138,775 172,026 153,134 133,496
Peru manual 1,259 3,462 7,834 14,733 6,208 6,436 7,134 11,312 10,399 12,237 12,688 12,072 10,143
Ecuador manual 4 18 9 36 10
Venezuela manual 44 181 18 0 0 0 38 47 0 0 118 40 0 0 0
Reported eradication of coca bush (ha), 1994-2008Table 7: 
Sources: Bolivia (Plurinational State of)/Colombia/Peru/Venezuela (Bolivarian Republic of): as reported by the respective Government. 
Ecuador: Comisión Interamericana para el Control del Abuso de Drogas (CICAD); US Department of State: International Narcotics 
Control Strategy Report.
Annual coca bush cultivation and cocaine production in main producing countries,  Fig. 24: 
1994-2008
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For detailed source information, see Table: Global illicit cultivation of coca bush and production of coca leaf and cocaine.  
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Fresh leaf
In Colombia, coca leaf is traded as fresh leaf, and the 
average per kilo price of fresh coca leaf decreased from 
COP 2,400,000/kg or US$ 1.2/kg in 2007 to COP 
2,200,000/kg or US$ 1.1/kg in 2008. Converted into 
sun-dried coca leaf equivalents this would correspond to 
US$ 2.6/kg. 
Coca paste and cocaine
Prices for coca paste and cocaine in different countries 
may not be directly comparable as little is known about 
their quality and composition. In Peru, the average 
farm-gate price of coca paste increased by 21% from 
US$ 600/kg in 2007 to US$ 723/kg in 2008. In Colom-
bia, however, coca paste prices decreased in Colombian 
peso terms by 4% but increased slightly (by 2%) in US$ 
terms, from US$ 943/kg to US$ 963/kg as the Colom-
bian peso gained strength against the US dollar. Whole-
sale prices for cocaine HCl increased in both Colombia 
(7%, in main cities) and Peru (10%, in producing 
regions) in US dollar terms. 
As the availability of farm-gate prices differs from region 
to region and over the course of a year, small changes 
should be interpreted with caution.
Clandestine laboratories and precursors
In 2007, Governments reported the detection of 7,225 
clandestine coca processing laboratories, compared to 
7,060 laboratories reported for 2006.1 Over 99% of the 
coca processing laboratories were located in the three 
coca cultivating countries. Bolivia and Peru also destroyed 
large numbers of coca maceration pits, which are typi-
1 The 2006 figure was updated from originally 6,390 laboratories 
based on additional reports received from Governments.
cally found in coca cultivation regions to produce coca 
paste.2 In 2007, a small number of cocaine laboratories 
was reported from other Latin American countries such 
as Chile (5), Ecuador (1) and Mexico (1). In previous 
years, similarly small numbers of laboratories were 
reported from countries such as Argentina, Brazil and 
the Bolivarian Republic of Venezuela. Outside Latin 
America, the highest number of laboratories detected 
was reported by Spain (18), followed by the USA (3).
Potassium permanganate is believed to be essential for 
cocaine manufacturing and large amounts are required 
each year in coca producing countries. In 2007, 15 
countries reported seizures of potassium permanganate 
totaling 153.3 mt, of which Colombia seized 144 mt. 
The Colombian authorities also dismantled 4 clandes-
tine potassium permanganate laboratories, from which 
they seized almost 45 mt of substance, which may sug-
gest that it is becoming more difficult to import or 
divert potassium permanganate from the licit to the 
illicit market. Peru reported the seizure of 1,5 mt of 
potassium permanganate in 2007. The large amount of 
seizures and the detection of potassium permanganate 
laboratories in coca producing countries may indicate 
that traffickers have found ways to circumvent interna-
tional control mechanisms, for example, by diverting 
potassium permanganate from domestic trade, by smug-
gling or by clandestine manufacturing.3 
2 An extract of the leaves of the coca bush. Purification of coca paste 
yields cocaine.
3 International Narcotics Control Board, E/INCB/2008/4.
Monthly prices for coca paste in Peru and Colombia, 2002-2008Fig. 25: 
Sources: National monitoring system in Colombia and Peru supported by UNODC.
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Global cocaine seizures fell in 2006 but 
remained largely unchanged in 2007 
Global seizures of cocaine base, salts and crack cocaine 
(reported at street purity levels) fell slightly from the 
record high of 750 mt in 2005 to 711 mt in 2007, a 
decrease of some 5%. This was similar to the level in 
2006 (693 mt), thus halting the strong upward trend 
reported in recent years. Nonetheless, cocaine seizures in 
2007 were twice as high as in 2000 (344 mt). The strong 
increases in cocaine seizures were not triggered by an 
increase in production. It can, however, be explained by 
a strengthened commitment to fight the trafficking of 
cocaine, particularly in the region where it is produced. 
The share of South America, Central America and the 
Caribbean in total cocaine seizures rose from 32% in 
1989 to 60% in 2007. 
The global cocaine interception rate remains high 
In 2007, the global cocaine interception rate1 was above 
the 40% benchmark for the third year in a row. It was 
calculated at 41.5% for the year 2007,2 that is, practi-
cally the same as in 2006 and 2005 (around 42%). The 
interception rate was 23% in 1990 and 29% in 1998. 
1 Calculated as the rate of total seizures over the total production.
2 The global interception rate of 41.5% was calculated on the basis of 
a global cocaine production of 994 mt in 2007 and global seizures of 
711 mt at street purity. Given a global average cocaine purity of 58% 
in 2007 (as reported in the ARQ) this is equivalent to pure cocaine 
seizures of some 412 mt (or 41.5% of global cocaine production). 
There is a potential problem of double counting sei-
zures, particularly when more than one law enforcement 
agency is involved3 (for example, customs and police in 
the same country, or police/customs from different 
countries). Considering this potential double counting, 
the ‘actual’ interception rate could be lower than the one 
reported above.
Cocaine seizures remain concentrated in  
the Americas and, to a lesser extent, in Europe 
In 2007, most of the cocaine was again intercepted in 
the Americas (88%), followed by Europe (11%). 
South America accounted for 323 mt (45%) of global 
cocaine seizures in 2007. More than 60% of seizures in 
South America were reported by Colombia. Large sei-
zures in this region were also reported by the Bolivarian 
Republic of Venezuela (32 mt) and Ecuador (25 mt). 
Substantive cocaine seizures in South America were also 
made by the Plurinational State of Bolivia (18 mt), 
Brazil (17 mt), Peru (14 mt), Chile (11 mt) and Argen-
tina (8 mt). Seizures increased in Bolivia but declined in 
Peru. Overall cocaine seizures in the Southern Cone 
countries (Argentina, Chile, Brazil, Paraguay and Uru-
guay) rose from 10 mt in 2000 to 38 mt in 2007. This 
reflects the growing importance of these countries for 
cocaine trafficking to satisfy domestic demand and to 
re-export cocaine to various overseas destinations in 
Europe, Africa and the Pacific region.
Central America and the Caribbean, two major cocaine 
transit regions, accounted for 15% of global seizures. 
The vast majority of seizures in 2007 was reported by 
Central American countries (97 mt) while seizures in the 
Caribbean subregion (7 mt) continued to decline.
North America reported 28% of global cocaine seizures 
(199 mt). The largest seizures were reported from the 
USA (148 mt), followed by Mexico (48 mt).
Europe reported 11% of global cocaine seizures; 99% by 
countries in West and Central Europe. Spain reported the 
largest seizures in Europe (38 mt). The rest of the world 
reported only 1 % of global cocaine seizures in 2007. 
3 The risk of double counting seizures has increased in recent years 
due to the increased cooperation in fighting cocaine trafficking across 
countries and law enforcement agencies.
Global cocaine seizures, 1987-2007Fig. 28: 
* including Caribbean and Central America 
Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
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Declining trafficking of cocaine towards North 
America, the world’s largest cocaine market
Cocaine trafficked to North America typically originates 
in Colombia and reaches the USA through Mexico, 
either directly by speed boats or via countries such as the 
Bolivarian Republic of Venezuela, Ecuador and Panama. 
Most of the cocaine (close to 70%) is estimated to be 
transported via the Eastern-Pacific route towards Mexico 
and some 20% via the Western Caribbean route.4 
North America, notably the USA, reported some of the 
most striking declines of cocaine trafficking in 2007. 
This trend became even more pronounced in 2008. On 
average, federal US seizures fell from more than 13 mt 
per quarter in 2006 to less than 10 mt per quarter over 
the first six months of 2008. A strong decline of 40% 
was observed at the US-Mexican border.5 
In parallel, Mexico saw a major decline of cocaine sei-
zures from 48 mt in 2007 to 19 mt in 2008; a reduction 
of some 60%. Both Mexico and the US reported that 
this decline was linked to a strong decrease in cocaine 
trafficking.6 There are no indications that the reductions 
are related to less enforcement efforts.7
A number of indicators showed that cocaine availability 
decreased in the USA in 2007 and 2008.8 For one, law 
enforcement agencies and interagency analysis coordi-
nated by the National Drug Intelligence Center indi-
cated that the large US cocaine markets experienced a 
substantial cocaine shortage in 20079 and during the the 
first quarter of 2008. Secondly, the number of emer-
gency department visits related to cocaine abuse declined 
in the great majority of the cities in the first quarter of 
2008, compared to 2006.10 Thirdly, the workplace test-
ing results revealed a strong decline in the use of cocaine 
in 2008.11 Finally, the ‘Monitoring the Future’ high 
4 National Drug Intelligence Center, National Drug Threat Assessment 
2009, December 2008.
5 Ibid. 
6 UNODC, Annual Reports Questionnaire Data.
7 The Mexican Government substantially increased supports for its 
security forces and the justice sector in 2008. This resulted, inter 
alia, in the arrest of a number of drug kingpins of the various Mexi-
can drug cartels (Source: US State Department, 2009 International 
Narcotics Control Strategy Report, March 2009). Increased efforts were 
also reported by the United States which continuously increased its 
federal drug control budget for domestic law enforcement over the 
2000-2008 period from $2 bn to $3.8 bn and for interdiction from 
$1.9 bn to $3.2 bn; the overall federal drug control budget rose from 
$9.6 to $13.7 bn. (Source: ONDCP, National Drug Control Strategy 
FY 2009 Budget Summary). 
8 Cocaine shortages were most evident in the Great Lakes, New Eng-
land and the Mid-Atlantic regions, as well as in the cities of Atlanta, 
Los Angeles, Phoenix and San Francisco.
9 ONDCP, National Drug Control Strategy, 2008 Annual Report, Febru-
ary 2008. 
10 National Drug Intelligence Centre, National Drug Threat Assessment 
2009, December 2008.
11  Ibid. 
school surveys found an ongoing decline of perceived 
cocaine availability after 2006; the decline became more 
pronounced in 2008.12
The most striking data indicating a shortage of cocaine 
in the US market relate to the changes in cocaine prices 
and purity in 2008. While street prices increased, purity 
decreased. The purity of cocaine declined from an aver-
age of 69.7% in the fourth quarter of 2006 to 43.9% in 
the fourth quarter of 2008. As a result, the average 
purity-adjusted prices (retail and wholesale) more than 
doubled, from an average of US$89 per gram in the 
fourth quarter of 2006 to US$200 in the fourth quarter 
of 2008. This is the sharpest increase seen in the USA in 
recent years. 
The flow of cocaine towards Europe may have 
started to decline
In 2007, European cocaine seizures declined by some 
35%, from 121 to 79 mt, the lowest total since 2004. 
Individual drug seizures reported by European countries 
suggest that the downward trend may have continued in 
2008. 
The decline in 2007 was primarily due to lower seizure 
totals reported by Portugal, Spain and France and, to a 
lesser extent, by lower totals in Belgium, Sweden, Italy, 
the Netherlands, Iceland and Finland. Overall, 15 Euro-
pean countries recorded declining levels of cocaine sei-
zures in 2007. 
At the same time, 27 countries reported higher levels of 
cocaine seizures compared to the year before, mostly 
smaller countries and/or countries of Central, Eastern 
and South-Eastern Europe. This suggests that cocaine 
12  NIDA, Monitoring the Future – 2008 Data from In-School Surveys of 
8th- 10th- and 12th-Grade Students. 
Availability of cocaine reported by US Fig. 29: 
high school students,* 1998-2008 
*unweighted average of 8th, 10th and 12th grade students 
reporting that it is ‘fairly easy’ or ‘very easy’ to obtain cocaine. 
Source: NIDA, Monitoring the Future 
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trafficking is spreading in geographical terms as new 
routes are being explored, even though the overall traf-
ficked volumes towards Europe seem to have declined. 
The most frequently mentioned country of origin of the 
cocaine trafficked to Europe is Colombia (48% of coun-
tries reported Colombia as the source country for their 
seizures), followed by Peru (30% of countries) and the 
Plurinational State of Bolivia (18% of countries). The 
most frequently reported transit countries were the Boli-
varian Republic of Venezuela and Ecuador. In addition, 
the Dominican Republic, Brazil, Argentina and Chile were 
mentioned, as well as some Western African countries. 
According to UNODC’s individual drug seizures data-
base the most important cocaine transit country in 2007 
in volume terms was the Bolivarian Republic of Venezuela 
(40%). If the origin of the individual cocaine seizure cases 
is analyzed - as opposed to seizures in volume terms - the 
most important cocaine transit countries for Europe in 
2007 were the Dominican Republic (11%), Argentina 
(9%) and Brazil (8%). African countries accounted for 
32% of the total, but this share declined in 2008. 
Cocaine prices increased in Western Europe in 2007, 
both in euro and in dollar terms, suggesting that falling 
cocaine seizures in 2007 were a consequence of lower 
trafficking flows. Retail prices rose from on average 
US$82 per gram in 2006 to US$92 per gram in 2007. 
Retail prices in dollar terms were at their highest level 
since 1998 (in euro terms since 2002). However, the 
increase was less pronounced once inflation – as meas-
ured by the consumer price index – was taken into 
account.
Average wholesale prices rose from some US$47 per 
gram in 2006 to US$56 per gram in 2007. Once infla-
tion is considered, the wholesale prices of 2007 (in euro) 
were at their highest level since 1997. 
Drug price changes can be misleading unless additional 
information on changes in purity is taken into account. 
Unfortunately, such information is not systematically 
collected, analyzed and reported by most European 
countries. 
One exception is the UK – Europe’s largest cocaine 
market - where information of changes in purity is made 
available on a quarterly basis. The results of forensic 
analyses show that the mean cocaine purity declined in 
the UK from 2006 to the first quarter of 2009, at both 
wholesale retail levels.13 The average cocaine purity in 
13 Customs seizures reflect mainly the import-wholesale level; seizures 
USA, cocaine prices and purity, 2005-2008Fig. 30: 
Source: DEA, System To Retrieve Information on Drug Evidence (STRIDE), April 2009, quoted in ONDCP, “What can Europe learn 
from the US experience of policy-related drugs monitoring?”, presentation to the EMCDDA Conference, “Identifying Europe’s  
Information Needs for Effective Drug Policy”, Lisbon, May 6-8, 2009. 
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police seizures fell from 32% in 2007 to 23% in the first 
quarter of 2009 while the purity of cocaine seized by the 
customs declined from 67% in 2007 to 56% in the first 
quarter of 2009.14 Almost a third of police seizures now 
have purity levels of less than 9%, and in some small-
scale seizures at the retail level, purity levels were as low 
as 4%-5% in the first quarter of 2009. This indicates 
that purity-adjusted cocaine prices in the UK rose, 
despite the stable retail prices.15 
The increased dilution of cocaine within the UK also 
suggests the establishment of large international traffick-
ing activities in cutting agents which are usually legal 
substances when they are not used to adulterate cocaine. 
The Serious Organized Crime Agency (SOCA) seized 
some 15 mt of such cutting agents over the last year, 
which is more than the amount of cocaine seizures 
reported by the UK to UNODC.16 
The cocaine wholesale prices rose over the same period 
from some £30,000 per kg in 2007 to £45,000 per kg 
in the first quarter of 2009 according to data collected 
by SOCA in the UK.
made by the police reflect the domestic wholesale as well as the 
domestic retail level. 
14 Forensic Science Service Data.
15 The purity-adjusted wholesale prices (based on Customs purities) 
increased from around £44,000 per kg of 100% pure cocaine in 
2007 to around £80,000 in the first quarter of 2009, equivalent to 
an increase of some 80%.
16 Frequently found cutting agents for cocaine in the UK are benzocaine 
and lignocaine - normally used to relive pain in the dentistry and 
veterinary fields - which mimic some of the anaesthetic effects of 
cocaine. These are not easily identified by retail customers. (Source: 
Representative of the Serious Organized Crime Agency (SOCA) at 
the conference: "Identifying Europe's information needs for effective 
drug policy", 6-8 May 2009.)
Trafficking of cocaine via Africa, notably Western 
Africa, showed an upward trend until 2007… 
In 2007 total cocaine seizures amounted to 5.5 mt in 
Africa, a more than seven-fold increase since 1998. But 
the cocaine seized in Africa (0.8% of global seizures in 
2007) is still a very modest percentage as compared to the 
likely cocaine trafficking flows affecting the continent. 
Out of 26 African countries reporting their 2007 drug 
seizures to UNODC, 25 reported seizures of cocaine. 
Only two countries reported falling levels of seizures in 
2007, while the remaining 23 reported a rising trend. 
Over the 1998-2002 period, annual cocaine seizures in 
Africa were very limited and concentrated in Southern 
Africa. After 2003, cocaine seizures increased sharply and 
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concentrated mostly in Western Africa, reflecting the 
rising importance of this region for transit of cocaine. 
In 2007, 83% of total seizures of cocaine in Africa were 
reported in West and Central Africa, 12% in Southern 
Africa, 5% in Northern Africa and 0.3% in Eastern 
Africa. The largest seizures in 2007 were reported by 
Senegal (2.5 mt). The cocaine found in Africa originated 
mainly in Colombia and Peru and frequently transited 
through Brazil. There is, however, significant trafficking 
of cocaine across the continent. The main African transit 
countries in 2007 (in terms of cocaine seized in other 
African countries) were Cape Verde, Guinea, Mali, Guin-
ea-Bissau, Ghana, Benin, Togo, Gambia and Nigeria, all 
in West Africa.  
….but the importance of Africa as a cocaine transit 
region appears to have declined in 2008 and in the 
first quarter of 2009 
According to UNODC’s individual drug seizure data-
base, in 2008, there has been a substantive decline in the 
percentage of seizures transiting Africa, from 28% in 
2007 to 7% in 2008. The decline can also be seen in the 
number of seizures. No large seizures which can be 
traced back to Africa have been reported to UNODC in 
the first quarter of 2009. In 2008 there was a strong 
decline in European seizures with Africa as the source, as 
well as a general decline of European seizures. 
Other sources seem to confirm the downward trend 
after 2007. From 1990 to 2007, there was a large increase 
in the share of cocaine couriers from Africa detected in 
17 Cocaine seizures reported in 2006 and 2007 are not comparable. 
2006 data included one major seizure of more than 14 mt which – 
after follow-up analysis it appeared that no psychoactive ingredients 
could be identified. Excluding the 14 ton seizure, total African sei-
zures appear to have markedly increased in 2007.
European airports. While in 2007, 28% of cocaine cou-
riers were African, in 2008, this share decreased to 
17%.18 
Signs of stabilization in Oceania in 2008 
Though cocaine seizures in the Oceania region are still 
very small (0.6 mt or 0.1% of global seizures in 2007), 
they showed a clear upward trend after 2005. Australia 
accounted for more than 99% of the cocaine seizures 
made in the Oceania region in 2007.19 
The expansion of cocaine supply and the resulting 
downward trend in cocaine prices noted in 2006/07, 
however, does not seem to have continued in 2008. The 
Australian Customs Services reported seizures of 0.6 mt 
in both 2006/07 and 2007/08. Moreover, cocaine avail-
ability as well as cocaine prices remained basically stable 
in 2008 according to information collected from a panel 
of injecting drug users and other key informants in Aus-
tralia. 20
Cocaine seizures are still limited in Asia, in spite of 
some subregional increases 
Cocaine seizures reported to UNODC from Asia 
amounted to 400 kg in 2007, equivalent to 0.06% of 
global seizures. The largest cocaine seizures in Asia were 
reported from Hong Kong, China (200 kg in 2007, up 
from 15 kg in 2006), followed by the Syrian Arab 
Republic (77 kg in 2007, up from 2 kg in 2006). Other 
18 UNODC, Transnational trafficking and the rule of law in West Africa: 
A threat assessment. Vienna: UNODC, 2009 (forthcoming).
19 Australian Crime Commission, Illicit Drug Data Report 2006-07, 
revised edition, March 2009. 
20 National Drug and Alcohol Research Centre (NDARC), Australian 
Drug Trends 2008 – Findings from the Illicit Drug Reporting System 
(IDRS), Sydney 2009.
Cocaine seizures in Africa, 1998-2007Fig. 35: 17 
Sources: UNODC, Annual Reports Questionnaire Data.
Proportion of cocaine seized in Europe Fig. 36: 
that transited Africa, 2005-2008
Source: UNODC, Individual Drug Seizures Database
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countries and territories reporting cocaine seizures in 
Asia included - in order of importance - Israel, Japan, 
Thailand, Malaysia, the Islamic Republic of Iran, India, 
Jordan, Pakistan, Lebanon, Taiwan Province of China, 
Kazakhstan, Indonesia, Armenia, the Palestinian Terri-
tory, the Republic of Korea, the Philippines and Geor-
gia. 
Out of the 43 Asian countries and territories that 
reported drug seizures to UNODC in 2007, 19 reported 
seizures of cocaine. No cocaine seizures were reported by 
the People’s Republic of China (excluding Hong Kong) 
in 2007. However some 530 kg of cocaine were, seized 
in one single case in June 2008 in Guangzhou.21
The largest increase of cocaine seizures in 2007 was 
reported by the countries of the Near and Middle East 
(from 72 kg in 2006 to 141 kg in 2007).
 
21 US State Department, 2009 International Narcotics Control Strategy 
Report, March 2009. 
Share of detected cocaine couriers whose ﬂight originated in West AfricaFig. 37: 
Source: UNODC, Transnational trafficking and the rule of law in West Africa: A threat assessment. Vienna: UNODC, 2009 
(forthcoming).
Cocaine seizures in the Oceania  Fig. 38: 
region, 2002-2007 
Source: UNODC, Annual Reports Questionnaire Data. 
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Global illicit supply of cocaine, 1997-2007Fig. 39: 
(a) Seizures as reported (street purity).
(b) Seizures as reported (street purity)
(c)  Data refer to England and Wales only.
(b) Includes cocaine HCl, cocaine base, crack cocaine, and other cocaine types.
(a) Includes cocaine HCl, cocaine base, crack cocaine, and other cocaine types.
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Global seizures of cocaine, 1997-2007Fig. 40: 
7002 - 7991 :AISA - DETPECRETNI ENIACOC7002 - 7991 :DLROW - DETPECRETNI ENIACOC
COCAINE INTERCEPTED - AMERICAS: 1997-2007 COCAINE INTERCEPTED - EUROPE: 1997-2007
COCAINE INTERCEPTED - AFRICA: 1997-2007 COCAINE INTERCEPTED - OCEANIA: 1997-2007
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ric
 to
n 
eq
ui
va
le
nt
s
0
100
200
300
400
500
600
700
800
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ri
c 
to
n
 e
q
u
iv
al
en
ts
0
100
200
300
400
500
600
700
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ri
c 
to
n
 e
q
u
iv
al
en
ts
0
20
40
60
80
100
120
140
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ri
c 
to
n
 e
q
u
iv
al
en
ts
0
1
2
3
4
5
6
7
8
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ri
c 
to
n
 e
q
u
iv
al
en
ts
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
M
et
ri
c 
to
n
 e
q
u
iv
al
en
ts
78
World Drug Report 2009 
USA: Cocaine retail and whole sale prices, 1990-2008 (US$/gram)Fig. 41: 
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In 2007, UNODC estimates that the annual prevalence 
of cocaine use worldwide ranges from 15.6 to 20.8 mil-
lion people, equivalent to 0.4% to 0.5% of the popula-
tion aged 15-64. The new estimates – like those reported 
for previous years - suggest that the largest market is still 
North America, followed by West and Central Europe 
and South America.   
This year, significant revisions were made to the approach 
taken in making global and regional estimates of the 
number of people who use drugs. The new estimates 
reflect the uncertainties surrounding these data (which 
exist due to data gaps and quality) and are being pre-
sented in ranges rather than absolute numbers. Because 
of this revision, previous point estimates are not compa-
rable to the current ones. 
 
Cocaine use is falling strongly in North America
Significant declines in cocaine use were reported in 
North America, notably from the USA, which in abso-
lute numbers is still the world’s largest cocaine market. 
Cocaine was used at least once in the last year by some 
5.8 million people in the USA in 2007, equivalent to an 
annual prevalence rate of 2.8% of the population aged 
15-64. The monthly prevalence rate (use at least once in 
* The estimates for Africa and its subregions are the most problematic 
because of the lack of data for most countries. This is reflected in the 
wide ranges calculated. The problem is particularly acute for Eastern 
Africa where the is an almost total lack of data.
Estimated number of people who used cocaine at least once in the past year and  Table 8: 
proporton of population aged 15-64, by region, 2007
Region/subregion
Estimated  
number of users 
annually (lower)
Estimated  
number of users 
annually (upper)
Percent of  
population aged 
15-64 (lower)
Percent of  
population aged 
15-64 (upper)
Africa*
 North Africa
 West and Central Africa
 Eastern Africa
 Southern Africa
1,150,000
30,000
750,000
3,640,000
50,000
1,320,000
0.2
0.0
0.4
0.7
0.0
0.8
Subregional estimate cannot be calculated
300,000 820,000 0.3 0.8
Americas
 North America
 Central America
 The Caribbean
 South America
9,410,000
6,870,000
120,000
170,000
2,250,000
9,570,000
6,870,000
140,000
250,000
2,310,000
1.6
2.3
0.5
0.7
0.9
1.6
2.3
0.6
1.0
0.9
Asia
 East/South-East Asia
 South Asia
 Central Asia
 Near and Middle East
400,000
310,000
2,560,000
990,000
< 0.1
< 0.1
0.1
0.1
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Europe
 Western/Central Europe
 East/South-East Europe
4,330,000
3,870,000
460,000
4,600,000
3,880,000
720,000
0.8
1.4
0.2
0.8
1.4
0.3
Oceania 340,000 390,000 1.5 1.7
Global 15,630,000 20,760,000 0.4 0.5
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the month prior to the survey) was 0.8% of the popula-
tion age 12 and above in 2007, down from 1.0% in 
2006.  
This decline in the use of cocaine is confirmed by the 
results of drug tests among the general US workforce. 
The proportion of the workforce testing positive dropped 
from 0.91% in 1998 to 0.72% in 2006 and 0.41% in 
2008, equivalent to a decline by more than 50% over 
the last decade.1 The annual declines accelerated, from 
-3% in 2006 to -19% in 2007 and -29% in 2008. Posi-
tive tests for cocaine typically result from cocaine con-
sumption a few days prior to drug testing.2 Data show 
that most of the decline took place during the last two 
years. 
Declines in cocaine use were also noticed in school sur-
veys conducted in Ontario, Canada. The school surveys 
showed a decline in the annual prevalence of cocaine use 
of around 35% between 2003 and 2007. The perceived 
availability of cocaine dropped strongly between 2003 
and 2007 and is now lower than in the late 1980s.
Following several years of increase, the Mexican author-
ities also reported cocaine use to have declined among 
the general population in 2007 as compared to the prev 
ious year. Overall cocaine use is,  nonetheless, still higher 
than a decade ago. Preliminary results of a national 
1 The data have been generated by Quest Diagnotics, based on more 
than 8.5 million drug tests every year, and are regularly reported by 
the US Office on National Drug Control Policy (ONDCP). 
2 Cocaine positive result in urine tests are normally obtained for ‘infre-
quent users’ 12-48 hours after having consumed cocaine and for ‘frequent 
users’ the period extends to 1-4 days . For ‘chronic users’, in contrast, the 
substance can be detected up to several weeks after they had last used it. 
(Source: United Nations International Drug Control Programme, “A 
summary of commercially available products and their applications: 
guidance for the selection of suitable products, Part I, Biological Spec-
imens”, Scientific and Technical Notes, SCITEC/18, Dec. 2001, p. 6.)
household survey, conducted in 2008, suggest that life-
time prevalence of cocaine use rose from 1.5% in 19983 
to 2.5% of the population aged 12-65 in 20084. Such 
levels are, however, still significantly lower than lifetime 
prevalence of cocaine use in the USA (17.8% of the 
population aged 15-65 in 2007) or in Canada (10.6% 
among the population aged 15 and above in 2004). 
In several West and Central European countries, use 
is stabilizing 
Following strong increases in recent years, a number of 
surveys in West European countries showed first signs of 
a stabilization. The largest cocaine markets in Europe – 
Spain, England and Wales, Italy, and Germany – have 
begun to stabilize.
Spain, which has had the highest cocaine prevalence 
rates in Europe for the last decade and even higher rates 
than the USA in recent years, stabilized at an annual 
prevalence rate of 3% of the population aged 15-65 
between 2005 and 2008.  This is equivalent to some 
910,000 cocaine users. Annual prevalence of  cocaine 
use among secondary school students fell from a peak of 
7.2% in 2004 to 4.1% in 2006, the lowest such rate 
since the late 1990s.5 
Cocaine use in England and Wales showed strong 
increases from the mid-1990s to 2007. Data for 2008, 
3 Secretaria de Salud, El Consumo de Drogas en México, Mexico Salud-
2000.
4 Monica Arriola, “Encuesta Nacional de Adicciones 2008”, La Chro-
nia de Hoy, 23 Sept. 2008.
5 Ministerio de Sanidad y Consumo, 2007 National Report to the 
EMCDDA by the Reitox National Focal Point, “Spain” New Devel-
opment, Trends and in-depth information on selected issues, http://
www.emcdda.europa.eu/attachements.cfm/att_61190_EN_
NR2007Spain.pdf
US national workforce: percentage testing positive for cocaine, 2000-2008 Fig. 44: 
Source: Quest Diagnostics, “Quest Diagnostics Drug Testing Index” (June 2008), quoted in ONDCP, Making the Drug Problem 
Smaller, 2001-2008, January 2009.
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however, suggest a stabilization or even a small decline 
with annual prevalence of cocaine use falling from a 
peak of 2.6% of the population aged 16-59 in 2006/07 
to 2.3% in 2008. This corresponds to a total of 860,000 
persons estimated to have used cocaine in England and 
Wales in 2007/08. Including Scotland and Northern 
Ireland, the United Kingdom is estimated to have about 
1 million cocaine users. The UK thus continues to be 
– in absolute numbers – Europe’s largest cocaine market, 
with its second highest cocaine use prevalence rate.     
Europe’s third largest cocaine market is Italy with around 
850,000 cocaine users. Similar to Spain, and England 
and Wales, data for Italy showed a stabilization of cocaine 
use over the 2005-08 period, following massive increases 
in previous years. The annual prevalence rate of cocaine 
use remained at 2.2% of the population aged 15-64 in 
2008, the same level as in 2005.   
The cocaine market in Germany, Europe’s fourth largest 
(in absolute numbers), also stopped growing. Cocaine 
use among the general population aged 18-59 declined 
from 1.0% in 2003 to 0.6% in 2006. Including crack 
cocaine, the prevalence rate amounted to 0.7% in 2006,6 
equivalent to some 380,000 persons. The decline in 
prevalence rates in Germany is also reflected in falling 
numbers of new cocaine users identified by law enforce-
ment each year. This number declined some  30% over 
the last decade. Household surveys also showed a stabi-
lization of cocaine use in Austria over the 2004 to 2008 
period.
A stabilization in cocaine use in 2007 was reported in 
Switzerland and the Netherlands. The Baltic countries 
(Estonia, Latvia and Lithuania) as well as some countries 
6 DBDD, 2007 National Report to the EMCDDA by the REITOX 
National Focal Point Germany. 
in Central Europe (Poland and Hungary) similarly 
reported a stabilization in 2007. Household surveys sug-
gest that cocaine use may have even declined in recent 
years in both Poland (from 0.5% in 2002 to 0.2% in 
2006) and Hungary (from 0.7% in 2001 to 0.2% in 
2007).  
Use still rising in some European countries
In contrast, a number of countries continued to show 
increases in cocaine use. France, Europe’s fifth largest 
cocaine market, reported an increase of cocaine use in 
2007, in addition to the Czech Republic, Ireland, Slova-
kia and Ukraine. Cocaine use also increased in Portugal 
Spain, England & Wales, Italy, Germany and annual prevalence of cocaine use in % of youth Fig. 45: 
and adult populationa
a Spain in % of population aged 15-64; England and Wales in % of population aged 16-59; Italy: 2001 in % of population aged 15-44, in 2003 15-54, 
2005 and 2008 15-64, Germany: in % of population aged 18-59, 1995-2003; in % of population aged 18-64 in  2006; Austria: in % of population 
15-64. Sources: UNODC, Annual Reports Questionnaire data; EMCDDA, Statistical Bulletin; Ludwig Boltzmanninstitut, “Österreichweite Repräsentativer-
hebung zu Substanzgebrauch – Erhebung 2008” (Draft), Vienna 2009”. 
Hungary and Poland: annual preva-Fig. 46: 
lence of cocaine use, 2001-2007
Source: UNODC, Annual Reports Questionnaire data.
* annual prevalence in % pop. age 18-59; ** in % of pop. age 15-64
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over the 2001-2007 period, from 0.3% to 0.6%, reflect-
ing the growing importance of Portugal as a cocaine 
transit country between South America, Western Africa 
and continental Europe in the last few years. Cocaine 
use in Ireland increased from 1.1% in 2003 to 1.7% in 
2007 among the population aged 15-64. This increasing 
trend reverses the previously seen decrease (see figure).
Expert perceptions in the Nordic countries indicated 
that cocaine use continued to increase among the gen-
eral population. The annual prevalence of cocaine use in 
Finland increased from 0.2% (of the population aged 
15-64) in 20007 to 0.5% in 20068. Cocaine use also 
appears to be increasing in a number of countries in 
South-East Europe, as reflected in school survey data 
from the European School Survey Project on Alcohol 
and Other Drugs (ESPAD), conducted under the aus-
pices of the Council of Europe.9
7 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Statistical Bulletin 2007: Last year prevalence of drug 
use among all adults (aged 15 to 64 years old) in nationwide surveys 
among the general population. http://www.emcdda.europa.eu/stats07/
gpstab03
8 EMCDDA, Country overview: Finland – Key statistics on the drug 
situation in Finland. http://www.emcdda.europa.eu/publications/
country-overviews/fi/data-sheet#fn_one
9 In total, 35 European countries and territories participated in the 
2007 ESPAD survey. In addition, the reports also provided data from 
Spain even though Spain had not formally participated in the ESPAD 
process
Several South American countries continue  
to show increases 
In contrast to the decline in North America and the 
stabilization in Europe, cocaine use in South America 
still appears to be increasing. Increases in cocaine use in 
2007 were reported by Venezuela (Bolivarian Republic 
of ), Ecuador, Brazil, Argentina, Uruguay as well as 
countries in Central America (Guatemala and Hondu-
ras) and the Caribbean (Jamaica and Haiti). A stable or 
slightly decreasing level of cocaine use was seen in  Chile, 
Peru, Paraguay and Costa Rica.
A study by UNODC and the Comisión Interamericana 
para el Control del Abuso de Drogas (CICAD)10 shows 
that the highest prevalence rate in South America was 
reported by Argentina. The annual prevalence of cocaine 
use for 2006/07 was 2.6% of the population aged 12-65, 
up from 1.9% in 1999. Argentina also constitutes the 
second largest cocaine market in South America in abso-
lute numbers (some 660,000 persons) after Brazil (some 
890,000 persons or 0.7% of the population aged 12-65; 
up from 0.4% in 2001). 
For some countries, results from the UNODC/CICAD 
study differed from other household surveys conducted 
in these countries. This variance can usually be explained 
by differences in the sampled populations (age group, 
urban/rural, etc.). 
Poly drug use further complicates the comparison of 
annual prevalence data.  Annual prevalence of all cocaine 
use (as reported to UNODC in the ARQ) does not take 
into account poly drug use and cannot be calculated 
simply by adding prevalence rates for cocaine HCL and 
cocaine base found in the UNODC/CICAD study.
In contrast to the upward trend found in most South 
American countries, cocaine use in Chile has been grad-
ually declining over the last few years. Annual prevalence 
of all cocaine use fell slightly, from 1.8% in 2000 to 
1.5% of the population aged 12-64 in  2006. This is 
equivalent to 1.7% of the population aged 15-64 (as 
reported to UNODC in the ARQ for the year 2007), or 
190,000 persons. Results from school surveys in Chile 
also confirm a slight downward trend of cocaine HCl 
use in recent years, as the annual prevalence among high 
school students fell slightly between 2001 and 2007. 
Drug use levels in Uruguay have clearly shown an 
upward trend in recent years. Annual prevalence of 
cocaine use rose from 0.2% in 2001 to 1.4% among the 
population aged 12-65  in 2007.
10 Naciones Unidas Oficina contra la Droga y el Delito (UNODC) 
y Comisión Interamericana para el Control del Abuso de Drogas 
(CICAD), Elementos orientadores para las Políticas Públicas sobre 
Drogas en la Subregión, Lima 2008. 
Ireland: annual prevalence of cocaine Fig. 47: 
use among the general population 
aged 15-64, 1998-2007
Source: EMCDDA, Statistical Bulletin 2008: Last year preva-
lence of drug use among all adults (aged 15 to 64 years old) 
in nationwide surveys among the general population. http://
www.emcdda.europa.eu/stats08/gpstab03
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The levels of cocaine HCl use for Bolivia (0.7%),  Peru 
(0.3%) and Ecuador (0.1%) found in the UNODC/
CICAD study are much lower than for Argentina, Uru-
guay and Chile.  In addition to the use of cocaine HCL, 
the study showed that ‘pasta base’ (cocaine base),  is 
frequently being consumed in South America. The high-
est annual prevalence rates of cocaine base were reported 
by Chile (0.6%) followed by Argentina (0.5%) and Peru 
(0.4%).     
Use rising around emerging cocaine transit  
countries in Africa...  
Data on cocaine use in Africa is mostly based on the 
perceptions of country experts rather than surveys. These 
data show that some African countries, notably in West-
ern and Southern Africa, are experiencing rising levels of 
cocaine use. Unfortunately, most countries in these 
regions still do not have proper monitoring systems that 
could validate the expert perceptions. 
South Africa is one of the few countries which has some 
data to substantiate expert perceptions. Treatment data 
for South Africa show a strong increase of cocaine related 
treatment (incl. alcohol) over the 1998-2008 period, 
from a proportion of around 5% of  treatment demand 
in 1998 to 9% of total treatment demand over the first 
two quarters of  2008.  Data show that treatment 
demand for cocaine (incl. alcohol) is responsible for 
Annual prevalence of cocaine use in six South American countries, 2006/07 in % of  Fig. 48: 
population aged 15-64, 
Source: Naciones Unidas Oficina contra la Droga y el Delito (UNODC) y Comisión Interamericana para el Control del Abuso de 
Drogas (CICAD), Elementos orientadores para las Políticas Públicas sobre Drogas en la Subregión, Lima 2008. 
Uruguay: cocaine use among the population aged 12-65*, 1998-2007 Fig. 49: 
* Age group 15-65 for survey in 1994; age group 12-64 in 1998 and in 2001; and age group 12-65 in 2007.  
Sources: Observatorio Uruguay de Drogas (OUD), Encuesta Nacional en Hogares sobre Consumo de Drogas 2007 and Secretaria 
Nacional de Drogas y Junta Nacional de Drogas, Encuesta Nacional de Prevalencia del Consumo de Drogas 2001.
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some 10% of all drug treatment in South Africa. If alco-
hol is excluded, treatment demand for cocaine is already 
responsible for more than 15% of all drug treatment in 
South Africa – a higher proportion than in Europe.
…as well as in the Oceania region
In contrast to the decline of cocaine use in North Amer-
ica and  signs of a stabilization in Europe, cocaine use 
appears to be growing in the Oceania region. 
Annual prevalence of cocaine use among the population 
age 14 and above grew in Australia from 1.0% in 2004 
to 1.6% in 2007 (1.9% among those aged 15-64 years). 
Annual prevalence is thus now slightly above the West 
and Central European average (1.4%). The upward 
trend over the 2004-2007 period reversed the previous 
downward trend observed over the 1998-2004 period. 
The upward trend over the 2003-2007 period is also 
reflected in the data collected by the Australian Institute 
for Criminology for the ongoing Drug Use Monitoring in 
Australia (DUMA) project where arrested people at 
selected police stations across Australia are regularly 
tested for drug abuse. The unweighted average of the 
results showed an increase in the number of people test-
ing positive for cocaine from 0.5% in 2003 to 2.1% in 
2007. 
Cocaine use in New Zealand also more than doubled 
between 2003 and 2006. In both Australia and New 
Zealand cocaine prevalence is now higher than in 
1998.
South Africa: cocaine as primary drug of abuse in treatment demand*, 1996-2008Fig. 50: 
* unweighted average of treatment (incl. alcohol) in 7 provinces. 
Source: SACENDU, “Monitoring Alcohol & Drug Abuse Trends in South Africa, July 1996-June 2008”, Research Brief, Vol. 11 (2), 2008
Australia: annual prevalence of  Fig. 51: 
cocaine use among the population  
age 14 and above, 1993-2007
Source: Australian Institute of Health and Welfare, 2007 
National Drug StrategyHousehold Survey, April 2008.
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Joint UNODC-WHO Programme 
on Drug Dependence Treatment  
and Care 
The Joint UNODC-WHO Programme on Drug Depend-
ence Treatment and Care is a milestone in the develop-
ment of a comprehensive, integrated health-based approach 
to drug policy that can reduce demand for illicit sub-
stances, relieve suffering and decrease drug-related harm to 
individuals, families, communities and societies. 
The initiative sends a strong message to policymakers 
regarding the need to develop services that address drug use 
disorders in a pragmatic, science-based and humanitarian 
way, replacing stigma and discrimination with knowledge, 
care, recovery opportunities and reintegration.
The programme is based on a global collaborative effort, 
under the leadership of UNODC and WHO. The col-
laboration will include governments, health profession-
als, nongovernmental organizations (NGOs) and funding 
agencies committed to increasing the coverage of essential 
services for drug dependence treatment and care. 
Why UNODC and WHO together? 
UNODC and WHO both have constitutional mandates 
to address issues presented by drug use and dependence. 
Moreover, taking into account the health, socioeconomic 
and security implications of drug use and related disor-
ders, the two agencies are uniquely positioned to lead this 
initiative. In particular, it will open a dialogue with 
Member States and involve a varied group of government 
ministries such as those for health and welfare, as well as 
the criminal justice system and other relevant sectors.  
Objectives:
Promoting and supporting worldwide (with a par- s
ticular focus on low- and middle-income countries) 
evidence-based policies, strategies and interventions 
that are based on a public health and human rights 
approach, in order to reduce drug use and the health 
and social burden it causes.
Recognizing drug dependence as a preventable and  s
treatable multi-factorial health disorder; and recog-
nizing the social advantages of investing in treatment: 
lowering health-related costs, improving security and 
contributing to social cohesion. 
Bringing drug dependence treatment into the main- s
stream health care and social welfare system, without 
discrimination.
Promoting investment in comprehensive and re- s
sults-oriented programmes for drug dependence 
treatment and care, particularly community-based 
interventions. 
The Joint Programme: 
 Leads a global collaborative eﬀort for improving 1. 
coverage and quality of treatment and care services 
for drug use disorders in low- and middle-income 
countries.
 Promotes the development of comprehensive and 2. 
integrated treatment systems that are able to deliver 
a continuum of care for drug users and link services 
at municipal and national levels.
 Maps population needs, legislative frameworks and 3. 
available services and programmes for drug depend-
ence treatment and care. 
 Supports policy and legislation revision to achieve 4. 
balance in drug policy and to support humane and 
eﬀective drug prevention, treatment and care.
 Develops low-cost outreach treatment and care ser-5. 
vices, and increases access in rural and remote areas.
 Places prevention, treatment and care of drug use 6. 
disorders into the mainstream health care system, 
linking with NGOs and ensuring full coordination 
with the health care system, as part of an integrated 
continuum of care. 
 Provides alternative measures to imprisonment for 7. 
dependent drug users where appropriate and, where 
this is not possible, provision of drug-dependence 
treatment in prison settings.
 Supports universities at the national level to promote 8. 
research and training curricula on drug dependence 
treatment and care.
 Provides and supports training programmes for pro-9. 
fessionals involved in the provision of treatment and 
care for drug users, including those whose profes-
sional primary focus is not in that area.
Develops international recommendations, guide-10. 
lines and standards aiming at the knowledge transfer 
from research to practice and supports adaptation 
and implementation at country level.
Supports regional networks of quality service pro-11. 
viders, working on drug dependence treatment, so-
cial support services and HIV/AIDS prevention and 
care.
Seeks to assist the development of drug treatment 12. 
monitoring systems in countries, in ways that will 
facilitate not only a greater understanding of the 
drug situation within countries, but also between 
countries, for a better understanding of regional and 
global trends.
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1.3.1 Summary trend overview
UNODC estimates that between 200,000-641,800 ha 
were used for outdoor cannabis cultivation in 2008. 
There are high levels of uncertainty in cultivation esti-
mates as cannabis can be grown - indoors or outdoors - 
in most countries in the world. Therefore, it is not 
possible to produce more precise data, as is done for 
opiates and cocaine. The total cannabis herb production 
is estimated to range from 13,300-66,100 mt, and for 
cannabis resin, the estimated production range is 2,200-
9,900 mt.
Total cannabis herb seizures increased somewhat in 2007 
to reach a total of 5,600 mt. As in 2006, the majority of 
cannabis herb seizures in 2007 were reported from 
Mexico and the USA. Cannabis resin seizures also 
increased to some 1,300 mt, with most seizures reported 
by countries in West and Central Europe. Resin seizures 
increased by more than one third in this subregion, 
compared to 2006. 
UNODC estimates that between 143 and 190 million 
persons globally used cannabis at least once in 2007. 
Cannabis use seems to be increasing in several countries 
in Latin America and Africa, whereas in the established 
markets of North America and Western Europe, there 
are signs from recent studies that the levels of use are 
declining, particularly among young people.
1.3.2 Production
The total estimated area for outdoor production of can-
nabis in 2008 ranges from 200,000-641,800 ha. The 
total cannabis herb production is estimated to range 
from 13,300-66,100 mt and the production of cannabis 
resin from 2,200-9,900 mt. Due to high levels of uncer-
tainty in estimating cultivation, it is not possible to 
produce more precise data, as is done for opiates and 
coca/cocaine. 
This chapter shows the information that is available and 
gives an indication of the extent of global cannabis cul-
tivation and production. Minimum and maximum 
levels of production and cultivation are explored by 
applying four methods. One method is based on reported 
cultivation and production, the second is based on sei-
zures of cannabis, and the third and fourth method are 
based on user prevalence rates.
Availability of data 
The cannabis market is the largest illicit drug market in 
terms of global spread of cultivation, volume of produc-
tion and number of consumers. Unfortunately, the dom-
inance of cannabis in the drug market is not reflected in 
the availability of reliable data. The information available 
on cannabis cultivation and production is fragmented, 
non-standardized and not always based on scientific 
research. This complicates the estimation of total global 
production. 
A major source of information for cultivation and pro-
duction are the responses to the Annual Report Ques-
tionnaires (ARQ). The ARQ asks for figures on the 
extent of cultivation, production and yield. Data on 
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Global cannabis herb and  
resin production estimates
Cannabis herb and resin production can be estimated 
from the supply and from the demand side. An estimate 
from the supply side can be based on reported seizures 
or by estimating the total area of cultivation and produc-
tion per hectare, based on the figures provided by a 
limited number of countries. For the latter, most coun-
tries do not have a national figure for cultivation and do 
not have the capacity to generate an estimate. The table 
summarizes the most recent data available for some of 
the main producing countries as reported in the ARQs 
and other sources. The figures given in the table are in 
herbal equivalents, and the total shows a range of herbal 
production of some 88,000-110,000 mt. This does not 
include important producing countries like Afghanistan,3 
Democratic Republic of the Congo, Ghana, Jamaica, 
Nigeria and Pakistan, and should therefore be considered 
as an absolute minimum figure of global production.
These figures are given in herbal equivalent volumes, and 
are therefore not comparable with the figures calculated in 
the 2008 WDR. They cannot be used to describe trends.
Another way to estimate cannabis production is to use 
data on seizures reported in the ARQs and multiply 
3 UNODC was not able to provide relieable estimates for cannabis 
cultivation in Afghanistan during the Opium Poppy Survey 2008.
4 Annual Reports Questionnaires, 2007.
5 Official Government communication 26/02/2009, in Lutte antid-
rogue - Synthese 2008, Min of Interior. Herbal production, which 
was calculated from the reported resin production of 877 mt, refers to 
gross cannabis production and is not necessarily directly comparable 
to herbal production of other countries.
6 Secretaria Nacional Antidrogas (SENAD), 2008.
7 US Department of State, International Narcotics Control Strategy 
Report (INCSR), 2009.
them by an estimated rate of interdiction. Cannabis sei-
zures are reported as herb, plants or resin. The interception 
rate for herbal cannabis and cannabis plants is estimated 
to range between 10-20%, whereas the interception rate 
for resin is likely to be a bit higher, at least 17% (Bulletin 
on Narcotics, 2006). These interception rates were com-
bined with conversion rates for resin and plants to calcu-
late the total production range of each drug.
The third way to estimate production is based on the 
demand for cannabis from the calculated number of 
cannabis users and the average use per year. This pro-
vides the amount of herbal and resin cannabis produc-
tion required to satisfy global demand. The estimates for 
average use per year has a high variability depending on 
the users’ habits, the method of consumption and the 
quality of cannabis products. The literature mentions 
average use estimates between 60-200 g per year, with-
out making a distinction between cannabis resin and 
herbal cannabis. These levels of use give a demand 
volume of 9,000-51,000 mt. About 10-17% of the use 
is estimated to be consumed as cannabis resin. Applying 
these factors and adding the amount of cannabis herb, 
cannabis plants (in herbal equivalents) and resin, respec-
tively, gives a required production volume of some 
13,300-52,400 mt of cannabis herb and 2,200-9,900 
mt of cannabis resin.   
8 Annual Survey reports Cannabis, Opium Poppy and Ephedra, 1998 
and 1999. UNDCP. Includes areas of wild growth. 
9 INCSR 2009; expert opinion; some top-end estimates are that 
20,000-30,000 hectares of arable land are used to grow cannabis.
10 Bulletin on Narcotics 2006.
11 UNODC, calculated with the number of eradicated plants, using 
the method applied by the US National Drug Intelligence Center, 
2007.
12 Public Safety Canada, 2009. http://www.publicsafety.gc.ca/prg/le/
oc/_fl/us-canadian-report-drugs-eng.pdf.
13 Van der Heijden, 2003. De Nederlandse Drugsmarkt. Korps landeli-
jke politiediensten, Dienst Nationale Recherche Informatie.
Available information on cannabis production in the major producing countries 2008Table 9: 4
Country Cultivated area (ha) Eradicated area (ha)
Harvestable area 
(ha)
Herbal production 
(mt)
Morocco 60,0005 60,0005 43,8505
Mexico 21,357
4 (2007)
18,5624 (2008) 8,900 (2007)
7 27,8064 (2007)
15,8007 (2008)
Paraguay 6,0006 1,6934 (2007) 6,0006 16,5006
Kazakhstan (1999) 124,000-329,6278 3,000-6,0007
South Africa 1,500-2,0009 1,500-2,0009
Colombia (2006) 5,00010 4,00010
USA
6.6 million outdoor 
plants / 430 000 
indoor plants7
3,149-7,34911
Canada 1,399-3,49812
Netherlands 851,510 plants7 36-99
13
6257
Lebanon 3,5007 3,5007
 Total 200,000-406,000 87,734-109,628
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Instead of using a simple average for all users, according 
to a typology reported in the Bulletin on Narcotics (2006), 
users can be differentiated and classed as casual users, 
regular users, daily users and chronic users. Casual users 
(45%) are people who share cannabis cigarettes an aver-
age of four times per year (0.6 grams/year). Regular users 
(41%) use more advanced inhaling techniques with 
higher frequency, on average 100 times per year (15 g/
year). Daily users (9%) use one to four cannabis ciga-
rettes per day (320 g/year) and chronic users (4%) who 
reach ten cigarettes per day (1,825 g/year). 
Applying these user rates and the same conversion factors 
as in the former estimation method (proportion of can-
nabis resin use and conversion rate) give a total of can-
nabis used for consumption which ranges between 
20,000-33,200 mt of cannabis herb and 3,000-6,300 mt 
of cannabis resin. 
The calculated estimates, using the four different meth-
ods, indicate the large range of uncertainties in estimat-
ing the worldwide cannabis herb and resin production. 
A final range can be constructed by considering the dif-
ferent estimates. The final global production figure can 
Estimated volume of cannabis herb and resin based on seizure dataTable 10: 
Sources: *2009 WDR and **Bulletin on Narcotics 2006.
Total cannabis demand, based on average user consumptionTable 11: 
Sources: *Van der Heijden, 2003. De Nederlandse Drugsmarkt. Korps landelijke politiediensten, Dienst Nationale Recherche  
Informatie and **2008 WDR; neither source differentiates between cannabis resin and herbal use.
Estimated global production of cannabis herb and resin, based on average user  Table 12: 
consumption
Source: *Based on the proportion of seizures. 17% of the seizures were cannabis resin, however this is most probably an overestima-
tion of the proportion of use since resin is more trafficked abroad and has higher chances of being seized. The lower proportion is 
assumed to be 10%.** In herbal equivalents, applying a factor of 0.1 and 0.2 to plant seizures for the low/high estimates, respectively.
Interception rate** Conversion rate Production (mt)
Seizures* (mt) Low High Low High Low High
Cannabis herb 5,557 0.1 0.2 - - 28,025 56,050 
Cannabis plants 5,020 0.1 0.2 0.1 0.2 2,510 10,040
Total cannabis herb 30,535 66,090 
Total cannabis resin 1,296 0.17 0.2 - - 6,480 7,624
Number of users 15-64 year Average use (kg/user/year) Calculated use (mt)
Low High Low* High** Low High
Africa 29,545,844 120,459,807 0.06 0.2 1,773 24,092
Asia 40,912,205 59,464,983 0.06 0.2 2,455 11,893
Europe 28,888,570 29,660,039 0.06 0.2 1,733 5,932
North America 31,262,302 31,262,302 0.06 0.2 1,876 6,252
Oceania 2,455,307 2,572,840 0.06 0.2 147 515
South America 10,457,999 11,083,110 0.06 0.2 627 2,217
Global total 143,522,228 254,503,082 0.06 0.2 8,611 50,901
Use (mt)
Correction factor for propor-
tion of cannabis resin use*
Calculated cannabis 
production (mt)
Low High Low High Low High
Total cannabis use 8,611 50,901     
Cannabis herb use   83% 90% 7,147 45,811 
Cannabis herb/plant seizures**     6,107 6,609 
Total cannabis herb production     13,254 52,420 
Cannabis resin use   10% 17% 861 8,653 
Cannabis resin seizures     1,296 1,296 
Total cannabis resin production     2,157 9,949 
93
1. Trends in the world drug markets Cannabis market
vary from 13,300-66,100 mt of cannabis herb and 
2,200-9,900 mt of cannabis resin.  
To convert these figures into cultivation area, a distinc-
tion should be made between indoor and outdoor culti-
vation, since acreage for indoor cultivation is not a very 
meaningful unit. Indoor cultivation is not area restricted 
due to the potential use of several floors in one building 
and the large number of harvests per year.14 Outdoor 
cannabis yields can also vary largely, for example, due to 
climate variances and the use of irrigation, but these 
yields probably have a smaller range.15 Assuming aver-
14 Indoor crops can have up to 6 harvests per year, with a yield of 5,000 
kg/ha confirmed by several sources. This makes indoor cropping 
15-30 times more productive than outdoor crops (Bulletin on Narcot-
ics, 2006).
15 Yields vary from 5 kg/ha to 40,000 kg/ha, reflecting ranges between 
wild cannabis and hydroponically grown cannabis. The median can-
nabis yield was 770 kg/ha. Typical yield for outdoor cannabis varies 
age outdoor yields for herb from 470-1,200 kg/ha (2008 
WDR) and assuming that 80-95% of the total produc-
tion takes place outside, gives a range of cultivated area 
varying broadly between 25,800-641,800 ha. For can-
nabis resin, yield per hectare could be derived from 
surveys in Morocco and Afghanistan. The average yield 
in Morocco, where most cannabis is grown on rain-fed 
land, was used for the lower estimate, and the yield from 
Afghanistan, where most cannabis is grown on irrigated 
land, for the higher estimate.16  
between 470 kg/ha without irrigation to 5,000 kg/ha in well-tended 
gardens, with figures around 2,000 kg/ha typical for the situation in 
the USA (as identified through the analysis of data from court cases), 
and levels around 1,000 kg/ha typical for developing countries. In 
contrast, hydroponically grown cannabis were found to reach typical 
yield levels from 15,000-30,000 kg/ha. (WDR 2008).
16 Sources: UNODC/Govt. of Morocco: Enquête sur le cannabis, 2004 
and 2005. The lower average resin yield of the two years 2004 and 
2005 was taken for the lower estimate. Afghanistan: UNODC/Min. 
Calculation of the volume of cannabis demand, based on amounts of use by user typologyTable 13: 
* weighted average
Typology % of users Use (gram/year) Min demand (mt) Max demand (mt)
Casual 45 0.6 39 69
Regular 41 15 888 1,575
Daily 9 320 4,306 7,635
Chronic 4 1,825 11,459 20,320
Total 100 172* 16,692 29,599
Estimated volume of cannabis herb and resin demand, based on amounts of use by  Table 14: 
user typology
* Based on the proportion of seizures. 17% of the seizures were cannabis resin, however this is most probably an overestimation of the proportion of 
use since resin is more trafficked abroad and has higher chances of being seized. The lower proportion is assumed to be 10%. ** In herbal equivalents, 
applying a factor of 0.1 and 0.2 to plant seizures for the low/high estimates, respectively.
Calculated use of cannabis*
Low High
Cannabis herb 13,854 26,639 
Cannabis herb/plant seizures* 6,107 6,609 
Total cannabis herb production 19,961 33,248 
Cannabis resin 1,669 5,032 
Cannabis resin seizures 1,296 1,296 
Total cannabis resin production 2,965 6,328 
Summary of cannabis herb and resin production estimatesTable 15: 
Cannabis herb (mt) Cannabis resin (mt)
Method Minimum Maximum Minimum Maximum
Seizure based calculation 30,535 66,090 6,480 7,624 
User based calculation –  
average use total population 13,254 52,420 2,157 9,949 
User based calculation –  
average use by user type 19,961 33,248 2,965 6,328 
Ranges 13,254 66,090 2,157 9,949
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Since the cultivation area in Morocco alone ranged from 
60,000-130,000 ha in the period of 2004-2008, it is 
better to use the sum of the known cultivated areas as an 
absolute minimum, which is 200,000 ha. Thus, the 
estimated area under cannabis cultivation ranges from 
of Counter Narcotics (2008): Baseline information on cannabis cul-
tivation. The median of 81 farmer responses was used for the higher 
estimate.
about 200,000-641,800 ha. Outdoor cultivation can 
also give several harvests in one year17 but this has not 
been taken into account here, which makes the calcu-
lated area an absolute maximum for the calculated pro-
duction.
17 Especially at lower-latitude locations, where temperature and day 
length are less restricting.
Ranges of global estimates of cannabis herb production by methodologyFig. 52: 
Estimation of outdoor cultivation area from the calculated production rangeTable 16: 
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Ranges of global estimates of cannabis resin production by methodologyFig. 53: 
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Production range (mt)
Proportion of out-
door cultivation
Average outdoor 
yield kg/ha*
Cultivation area (ha)
Low High Low High Low High Low High
Cannabis herb 13,254 66,090 80% 95% 470 1,200 8,836 133,586 
Cannabis resin 2,157 7,624 - - 15 125 17,256 508,235 
Total       (25,757) 200,000 641,821 
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Trends by country 
Since few countries report the extent of their own can-
nabis production, it is difficult to analyze any global 
trends from these data. However, there are more reports 
on the origin of cannabis in the market of each country. 
UNODC collects data on countries of origin of annual 
and individual seizures through the ARQ and a ques-
tionnaire on individual seizures. This information pro-
vides some indication of the trends in the main 
producing countries. The table below shows the main 
source countries of cannabis herb. The Netherlands, 
South Africa, Albania, Jamaica and Paraguay have been 
seen as principal producers of cannabis herb for about 
25% of the cannabis herb market, because seized can-
nabis originated there. In 2005-2007, Colombia and 
Nigeria were added to the list. However, almost 76% of 
the entries refer to source countries which are mentioned 
less than 10 times in a 3-year period. There are only 
insignificant changes between the two time periods.   
Cannabis resin production
The picture for cannabis resin is clearer because the 
production of resin is concentrated in relatively few 
countries and it is trafficked across borders more often. 
Morocco is known to be the world’s main source of can-
nabis resin. The Government of Morocco reported fur-
ther reduction of the cannabis production in 2008, 
reporting 60,000 hectares in production after eradica-
tion, following a decrease observed in the 2005 survey 
by the Government of Morocco and UNODC. This 
decline is, however, not reflected in the data reported by 
countries on the origin of their seized cannabis resin. 
Both in the ARQs and in the Individual Seizure Data-
base, Morocco continues to be the principal supplier of 
resin in the world. In the ARQs, the proportion report-
edly of Moroccan origin has increased in the period 
2005-2007, compared to 2001-2004. 
Afghanistan is the second most prominent cannabis 
resin producer, with a small increase in the figures from 
the annual seizures. Nine per cent of source countries in 
2005-2007 pointed to Afghanistan, compared to 6% in 
2001-2004. Another indication of the importance of 
Afghanistan as a cannabis producer is the report of a 
very large seizure in 2008, amounting to some 237 mt 
in one stockpile.18 Although there is no reliable figure 
available for cannabis cultivation in Afghanistan in 
2008, experts believe that the extent of cannabis produc-
tion is approaching the cultivation area of Morocco with 
steadily increasing production due to the relatively 
higher prices for cannabis products, compared to opium. 
At the end of 2008, UNODC performed a baseline 
study on cannabis cultivation in Afghanistan and identi-
fied 20 out of 34 provinces with substantial cannabis 
cultivation. A first cannabis survey is being planned by 
the Afghanistan Ministry of Counter Narcotics and 
UNODC in 2009.
India and Nepal are also identified as source countries 
(4%). Some CIS countries are increasingly (6%) men-
tioned as a source for cannabis resin, mainly due to new 
reports from Azerbaijan, in addition to reports from 
Ukraine, the Republic of Moldova, the Russian Federa-
tion and Armenia. Pakistan continues to be an impor-
tant source according to both annual and individual 
seizure information. The Central Asian countries, mainly 
Kazakhstan and Kyrgyzstan, are only mentioned as 
sources in the annual seizures. The main production area 
in Central Asia is the Chu Valley in Kazakhstan where 
cannabis - for both herb and resin production - grows 
on extensive wild and cultivated areas, estimated to total 
more than 300,000 ha.
18 ISAF, 2008, http://www.nato.int/isaf/docu/pressreleases/2008/06-
june/pr080611-246.html.
Main source countries of cannabis herb according to reported seizures in the ARQs,  Table 17: 
2005-2007 and 2002-2004
Source: UNODC Annual Reports Questionnaire data.
Source country 2005-2007 2002-2004
Number of mentions 
as a source country
Proportion (%) of all 
reporting countries*
Number of mentions 
as a source country
Proportion (%) of all 
reporting countries*
Netherlands 38 8% 36 8%
South Africa 15 3% 14 3%
Albania 14 3% 20 4%
Jamaica 12 3% 14 3%
Colombia 11 2% 7 1%
Paraguay 10 2% 12 3%
Nigeria 10 2% 7 1%
Others 1 to 9 times 76% 1 to 9 times 77%
Total 458 100% 485 100%
* Cumulative reporting for three years. Countries may report more than once.
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Algeria and the Islamic Republic of Iran have recently 
emerged as a significant source country for individual 
seizures. Iran is also mentioned as a source by 3% of the 
annual seizures as reported in the ARQ. It might be an 
indication of Iran being increasingly used as a transit 
country.   
The Netherlands is mentioned as a country of origin for 
resin, but it is not clear to what extent the cannabis resin 
actually originates there. Although the Netherlands is an 
important producer of cannabis herb, available informa-
tion suggests that resin production is limited. The same 
might be true for other Western European countries 
such as France, Germany and Belgium that are men-
tioned in the annual seizures, but it is not clear to what 
extent they are transit countries.
Albania’s importance as an exporter of cannabis in gen-
eral and specifically of resin seems to have diminished. 
Only 3% of the countries mention Albania as an exporter 
and it seems to be cultivating mostly for local/regional 
use.19 Seizures of herbal cannabis from Albania have 
become very rare in the last five years.20  
Lebanon continues to be a source country in the Middle 
East. Production in Lebanon has declined drastically 
compared to the early 1990s, but farmers appear to be 
resuming cannabis cultivation. 
Overall production and consumption of cannabis resin 
in the Americas are limited. The most important resin 
producer in the region is Jamaica (3% of annual sei-
zures). Paraguay is also mentioned in 2% of the cases but 
is more important as a cannabis herb producer. The 
cultivation area in Paraguay is estimated at 6,000 ha.21 
19 INCSR 2009.
20 World Customs Organization, Customs and Drugs Report 2007.
21 Secretaria Nacional Antidrogas (SENAD), 2008
UNODC has had consultations with relevant Govern-
ment institutions to conduct a survey in Paraguay to 
collect more precise information.22
22 The Government of Brazil has also been involved in the consultations 
as Brazil is likely to fund the survey.
Main source countries of cannabis resin seizures according to the Individual Seizure  Table 18: 
Database in the period 2005-2007 and 2002-2004
Source: UNODC, Individual Seizure Database.
Source  
country
2005-2007 Source 
country
2002-2004
No. of seizures Quantity (kg) No. of seizures Quantity (kg)
Morocco 811 440,747 Morocco 1,243 468,727
Afghanistan 1,083 144,387 Afghanistan 1,113 172,565
Spain 853 19,226 Pakistan 22 16,400
Pakistan 10 2,825 Spain 84 16,072
Netherlands 27 2,615 Netherlands 20 9,047
Portugal 1 2,449 Portugal 2 7,207
France 3 2,135 France 7 2,216
Germany 5 591 Belgium 9 1,764
Algeria 16 455 South Africa 6 926
Iran (I.R. of) 13 450 Germany 6 771
Main source countries of cannabis  Fig. 54: 
resin according to the ARQs in the  
period 2005-2007 and 2002-2004*
*Number of times that countries were identified as source countries, 
represented as proportion of countries reporting. 
Source: UNODC, Annual Reports Questionnaire data.
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Why does cannabis potency matter? 
Cannabis products dominate the world’s illicit drug market. 
The term cannabis, however, refers to different types of 
preparations derived from the plant Cannabis sativa, which 
all contain chemical substances called cannabinoids. The 
most psychoactive of these substances is Δ-9-
tetrahydrocannabinol (THC). The amount of THC in a 
cannabis sample is generally used as a measure of “cannabis 
potency”. In recent years, several claims of increased can-
nabis potency have been made. 
One driving force behind the interest in cannabis potency 
is the possible link to mental health problems.1 It is 
thought that high potency cannabis may have the poten-
tial to be more harmful.2 Also significant may be the ratio 
between THC and cannabidiol (CBD), another cannabi-
noid believed to moderate the effect of THC. Consider-
ing the large population of cannabis users worldwide, it is 
important that the link between mental health problems 
and cannabis potency is understood. 
What do we know about trends  
in cannabis potency?
A number of studies have been carried out to assess poten-
tial changes in potency over time. One of the most compre-
hensive was conducted in 2004 by the European 
Monitoring Centre on Drugs and Drug Addiction 
(EMCDDA) and concluded that that a modest increase in 
aggregate cannabis potency had occurred, possibly related 
to the use of intensive indoor cultivation methods. The 
authors noted that THC content nonetheless varied wide-
ly.3 While the United Kingdom Home Office study in 
20084 found little change: from a median potency of sin-
semilla cannabis of 14% among samples in 2004/5 com-
pared to 15% in 2008, long-term increases have been 
reported in the United States5 with an average potency of 
10% in 2008. 
Multiple methodological issues have been raised, which 
impact on our capacity to generate comparable data and 
infer trends.6 Important variables to be considered include 
the phytochemistry;7 type of cannabis product; cultivation 
method; sampling; and stability. As detailed below, each of 
these can affect the potency estimates. Only through 
examining these factors can we have a more systematic, 
1 Ashton CA, Pharmacology and effects of cannabis, a brief review. 
British journal of Psychiatry 2001; 178:101-6.
2 Smith H, High potency cannabis; the forgotten variable. Addiction 
2005; 100: 1558-60.
3 EMCDDA, An overview of cannabis potency in Europe. 2004.
4 Hardwick S and King L. Home Office Cannabis Potency Study 
2008.
5 Office of National Drug Control Policy, Press Release  May 14, 
2009. 
6 McLaren J, Swift W, Dillon P and Allsop S. Addiction 2008; 103: 
1100-09.
7 Phytochemistry refers to the chemical composition of plants. 
scientific and comparable assessment of cannabis potency 
between places and over time.8
Plant part used:  The secretion of THC is most abundant 
in the flowering heads and surrounding leaves. The 
amount of resin secreted is influenced by environmental 
conditions during growth (light, temperature and humid-
ity), sex of the plant, and time of harvest. The THC 
content varies between parts of the plant: from 10-12 % 
in flowers, 1-2 % in leaves, 0.1-0.3 % in stalks, to less 
than 0.03 % in the roots. 
Product type: There are three main types of cannabis 
products: herb (marijuana), resin (hashish) and oil (hash 
oil). Cannabis herb comprises the dried and crushed flow-
er-heads and surrounding leaves. It  often contains up to 
5% THC. Sinsemilla, derived from the unfertilized female 
plant, can be much more potent, however. Cannabis resin 
can contain up to 20% THC. The most potent form of 
cannabis, however, is cannabis oil, derived from the con-
centrated resin extract. It may contain more than 60% 
THC. The increase in market share of a particular prod-
uct type can influence the reported average potency 
values. For example, the reported rise in the average THC 
content to 10% in seized samples in 2008 by the United 
States Office of National Drug Control Policy is associ-
ated with a market share of 40% for high potency can-
nabis (presumably indoor-grown).9
Cultivation methods: The cannabis plant grows in a variety 
of climates. The amount and quality of resin produced 
depends on the temperature, humidity, light and soil acid-
ity/alkalinity. Outdoor-produced herbal cannabis, therefore, 
shows considerable variation in potency. Intensive indoor 
cultivation of female plants and clones, under artificial light, 
often without soil (hydroponic cultivation), and optimised 
cultivation conditions, produces cannabis of a consistently 
higher potency.
Sampling: Most data on cannabis potency are derived from 
the analysis of seized samples. This means that these samples 
need to be representative of the entire seizure so that infer-
ences and extrapolations can be made. 
Stability: THC is converted to cannabinol on exposure 
to air and light. This process reduces the THC concentra-
tion, especially in old samples which have not been stored 
under suitable conditions (such as a dark, cool place). It 
is believed that claims of increases in potency of cannabis 
preparations confiscated over a period of 18 years in the 
United States10 may have been affected by the stability of 
THC in old samples. 
8 Hunt N, Lenton S, and Witton J, Cannabis and mental health: 
Responses to the Emerging Evidence. Beckley Foundation Report, 
2006: No 8.
9 Office of National Drug Control Policy, Press Release  May 14, 
2009. 
10 ElSohly MA et al. Potency trends of delta-9-THC and other can-
nabinoids in confiscated marijuana from 1980-1997. Journal of 
Forensic Science 2000; 45:24-30
1.3.3 Trafficking
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Seizures of cannabis herb and resin
Global seizures of both cannabis herb and resin increased 
in 2007. Seizures of cannabis herb amounted to 5,600 
mt, whereas for resin, the total was some 1,300 mt. An 
overwhelming proportion of all cannabis herb seizures 
was made in the Americas (82%), mainly in Mexico and 
the USA, which together accounted for almost two 
thirds of global herb seizures. Most of the global increase 
in cannabis resin seizures was due to a strong increase in 
West and Central Europe, where seizures were up 33% 
compared to 2006.
The two main cannabis products, cannabis herb (also 
known as marijuana), and cannabis resin  (commonly 
marketed under the name hashish), are considerably dif-
ferent in several aspects. The production areas for can-
nabis resin are much more limited in geographic terms 
than those of cannabis herb. Moreover, consumption of 
cannabis resin is concentrated in, although not limited 
to, West and Central Europe, while the use of cannabis 
herb is widespread. Thus, quite different regional and 
international trafficking and seizure patterns become 
apparent when comparing cannabis herb and resin. A 
specific feature of cannabis herb is that sizable amounts 
are thought to be produced in the countries of con-
sumption. This is likely to lower the probability of can-
nabis being seized by customs and border authorities, 
which in many countries contribute heavily to the over-
all amount of drugs seized. In spite of this, a much 
higher number of countries and territories reported sei-
zures of cannabis herb (165) to UNODC in the period 
2005-2007 than cannabis resin (120), which can be 
taken as an indication of its wider use and its broader 
geographical spread.
Cannabis herb seizures amounted to 5,605 mt in 2007, 
whereas resin seizures amounted to 1,300 mt. Both herb 
and resin seizures were higher in 2007 than in 2006 and 
2005. However, comparing total seizures during this 
period, the total is still lower than in 2002-2004, when 
global seizures of cannabis reached record highs. Small 
quantities of cannabis oil were also seized in 2007 
(equivalent to 418 kg). 
The majority of cannabis herb seizures in 2007 were 
reported from Mexico (39% of the world total), fol-
lowed by the USA (26%), Bolivia (Plurinational State 
of ) (8%), Nigeria (4%), Morocco (4%), Colombia (3%) 
and Paraguay (3%). South Africa and Malawi, which 
had ranked third and fourth in 2006 after the USA and 
Mexico, reported much lower seizures in 2007.  
Most seizures of cannabis resin, on the other hand, were 
made by Spain (50%), followed by Morocco (9%), Iran 
(Islamic Republic of ) (7%), Pakistan (8%), Afghanistan 
(6%), Belgium (5%), Portugal (3%) and France (3%). 
176 countries and territories reported cannabis seizures 
(both herb and resin) to UNODC in the period 2005-
2007. 
Most cannabis herb seizures are reported  
by North America
In contrast to other drugs, trafficking in cannabis herb 
continues to be mostly intraregional. In 2007, an over-
whelming proportion of all cannabis herb seizures was 
made in the Americas (82%), mainly in Mexico (2,177 
mt) and the USA (1,447 mt), which together accounted 
for almost two thirds of global herb seizures. Cannabis 
herb seizures increased both in the USA and Mexico in 
2007 compared to the previous year. 
South America including Central America and the 
Caribbean accounted for 17% of global cannabis herb 
seizures. The largest seizures were made in Bolivia 
(Plurinational State of ) (424 mt), which reported over 
Cannabis herb and resin seizures (mt), Fig. 55: 
1985-2007
Source: UNODC, Annual Reports Questionnaire / DELTA
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three times more cannabis herb seizures than in 2006, 
followed by Colombia (183 mt), Paraguay (172 mt), 
Argentina (75 mt) and Venezuela (Bolivarian Republic 
of ) (25 mt). In the period 2005-2007, Paraguay was 
mentioned as the source of cannabis herb seized in 
South America more often than other countries in the 
region. However, many other countries were mentioned 
as well, including Bolivia, Brazil, Colombia and Peru. 
Paraguay was also reported several times as the source of 
cannabis resin. 
Large seizures were also made in Africa, accounting for 
11% of global cannabis herb seizures. In 2007, more 
seizures were made in Morocco, several West African 
countries and Kenya. Less seizures were reported from 
Egypt, Malawi and South Africa, which resulted in an 
overall decline in herb seizures for Africa as a region 
compared to one year earlier. 
The largest cannabis herb seizures made in Asia – which 
accounted for 4 % of all seizures in 2007 – were reported 
by India (108 mt), followed by Indonesia (32 mt), Kaza-
khstan (22 mt), Thailand (15 mt) and Nepal (8 mt). 
Cannabis herb seizures in Europe – representing 3% of 
the world total in 2007 – increased slightly but remained 
well below the seizure levels reached between 1997 and 
2004. As in 2006, the largest seizures were reported by 
the Russian Federation (27 mt), Turkey (26 mt) and the 
United Kingdom (20 mt).1 Europe is the only region 
which also “imports” significant amounts of cannabis 
herb from other regions. 
Oceania reported only a small fraction of global seizures 
in 2007 (2.7 mt), most of which was reported by Aus-
tralia (2.4 mt). 
Main cannabis resin trafficking routes run from 
Morocco and South-West Asia to West and Central 
Europe
In 2007, global cannabis resin seizures increased by 29% 
and accounted for 1,296 mt, which was higher than in 
most years since 1985 with the exception of 2003 and 
2004. A large number of countries reported resin sei-
zures in the period 2003-2007 though this was smaller 
than the number of countries reporting seizures of can-
nabis herb. Trafficking patterns seem to follow the estab-
lished routes from the two main resin production areas 
in Morocco and South-West Asia to the main consump-
tion areas in West and Central Europe. As the consump-
tion of cannabis resin is mainly concentrated in West 
and Central Europe, trafficking to other regions, as 
reflected in seizures, took place at a far lower level. 
1  Data refer to England and Wales only. 
Most seizures of cannabis resin reported by  
countries of West and Central Europe
Most of the global increase in cannabis resin seizures was 
due to a 33% increase in West and Central Europe, 
compared to 2006. In 2007, 849 mt - two thirds of global 
cannabis resin seizures - were made in West and Central 
Europe. Cannabis resin seized in Europe continued to 
originate mainly from Morocco. Spain accounted for 
50% of global resin seizures, and for 77% of seizures in 
the West and Central Europe subregion. In 2007, resin 
seizures in Spain increased by 42% compared to the 
previous year, and in Morocco, the increase was 33%. 
Despite an increase in cannabis resin seizures in Europe, 
the amounts seized in 2006 and 2007 were still lower 
than those reported in 2003 and 2004. 
Morocco accounted for most cannabis seizures made in 
Africa (118 mt), followed by Algeria (17 mt) and Egypt 
(6 mt), both of which also reported higher seizures than 
in 2006. While most cannabis resin produced in 
Morocco is destined for Europe, trafficking also takes 
place to or via North African and sub-Saharan coun-
tries. 
In 2007, as in the year before, South West Asia reported 
the second highest cannabis seizures worldwide, repre-
senting 22% of the global total. Most seizures in the 
region were made by Pakistan (8% of global seizures or 
110 mt), followed by Iran (Islamic Republic of ) (7% or 
90 mt) and Afghanistan (6% or 84 mt). Cannabis resin 
seizures more than doubled in Iran and Afghanistan, 
while they remained at about the same level in Pakistan. 
The strong increase in cannabis resin seizures in this 
subregion confirms its role as an important cannabis 
resin producer. A rapid assessment of cannabis con-
ducted by UNODC in 2008 confirmed the existence of 
cannabis cultivation for resin production in most prov-
inces in Afghanistan. 
Most of the cannabis resin produced in the region is 
trafficked towards Europe. However, reports confirm 
that some cannabis resin originating in South-West Asia 
also reached other Asian as well as North American 
countries. 
South Asia reported about 6 mt or 0.5% of global sei-
zures in 2007. India (3.8 mt) and Nepal (2.1 mt) con-
tinued to report the majority of cannabis resin seizures 
made in the region. Both countries are considered to be 
cannabis resin producers. 
100
World Drug Report 2009 
Global seizures of cannabis herb, 1997-2007Fig. 56: 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Metric tons 3,105   2,998  4,043    4,680    4,759    4,801    5,941    7,154    4,671    5,247   5,605    
(a)  Data refer to England and Wales only.
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Global seizures of cannabis herb, 1997-2007Fig. 57: 
CANNABIS HERB INTERCEPTED - WORLD: 1997 - 2007 CANNABIS HERB INTERCEPTED - ASIA: 1997 - 2007
CANNABIS HERB INTERCEPTED - AMERICAS: 1997 - 2007 CANNABIS HERB INTERCEPTED - EUROPE: 1997 - 2007
CANNABIS HERB INTERCEPTED - AFRICA: 1997 - 2007 CANNABIS HERB INTERCEPTED - OCEANIA: 1997 - 2007
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Global seizures of cannabis resin, 1997-2007Fig. 58: 
Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Metric tons 819      899      902      1,052   943    1,090 1,394 1,474 1,272   1,003   1,296 
(a)  Data refer to England and Wales only.
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Global seizures of cannabis resin, 1997-2007Fig. 59: 
CANNABIS RESIN INTERCEPTED - WORLD: 1997 - 2007 CANNABIS RESIN INTERCEPTED - ASIA: 1997 - 2007
CANNABIS RESIN INTERCEPTED - AMERICAS: 1997 - 2007 CANNABIS RESIN INTERCEPTED - EUROPE: 1997 - 2007
CANNABIS RESIN INTERCEPTED - AFRICA: 1997 - 2007 CANNABIS RESIN INTERCEPTED - OCEANIA: 1997 - 2007
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The global number of cannabis users is estimated to 
range from some 142.6-190.3 million persons, equiva-
lent to a range from 3.3 to 4.4% of the population aged 
15-64 who used cannabis at least once in 2007. 
This year, significant revisions were made to the approach 
taken in making global and regional estimates of the 
number of people who use drugs. The new estimates 
reflect the uncertainties surrounding these data (which 
exist due to data gaps and quality) and are presented in 
ranges rather than absolute numbers. Because of this 
revision, previous point estimates are not comparable to 
the current ones.
Estimated number of people who used cannabis at least once in the past year and  Table 19: 
proporton of population aged 15-64, by region, 2007
Region/subregion
Estimated number 
of users annually 
(lower)
Estimated number 
of users annually 
(upper)
As percent of 
population 
aged 15-64 
(lower)
As percent of 
population 
aged 15-64 
(upper)
Africa
 North Africa
 West and Central Africa
 Eastern Africa
 Southern Africa
28,850,000
3,670,000
16,110,000
4,490,000
4,570,000
56,390,000
9,320,000
27,080,000
9,030,000
10,950,000
5.4
3.0
9.3
3.4
4.3
10.5
7.6
15.6
6.9
10.2
Americas
 North America
 Central America
 The Caribbean
 South America
41,450,000
31,260,000
580,000
1,110,000
8,500,000
42,080,000
31,260,000
580,000
1,730,000
8,510,000
7.0
10.5
2.4
4.3
3.4
7.1
10.5
2.4
6.7
3.4
Asia
 East/South-East Asia
 South Asia
 Central Asia
 Near and Middle East
40,930,000
4,110,000
27,490,000
1,890,000
7,440,000
59,570,000
19,860,000
27,490,000
2,020,000
10,200,000
1.6
0.3
3.2
3.8
3.1
2.3
1.3
3.2
4.1
4.3
Europe
 Western/Central Europe
 East/South-East Europe
28,890,000
20,810,000
8,080,000
29,660,000
20,940,000
8,720,000
5.2
7.7
2.9
5.4
7.7
3.1
Oceania 2,460,000 2,570,000 11.0 11.5
Global 142,580,000 190,270,000 3.3 4.4
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Use stabilizing or declining in North America 
Cannabis use declined in North America over the last 
decade. In 2007/08 it seems to have stabilized at the 
lower levels. 
Drug tests, which are regularly conducted among the 
US workforce, found a decline in the proportion of 
positive cannabis tests among the general US workforce 
from 3.4% in 1997 to 2.3% in 2007, equivalent to a 
decline of 31% over the last decade. The figures suggest 
that the USA may be heading towards a stabilization of 
cannabis use at around 2%. In 2008 2.1% of the work-
force tested positiv for cannabis.   
The decrease can also be observed in the total popula-
tion using household data. Over the 2002-2007 period 
the annual prevalence of cannabis use declined gradually, 
from 11% of the population aged 12 and above in 2002 
to 10.1% in 2007. 
The last national Canadian Addiction Survey (CAS), 
conducted in 2004, found a prevalence rate of 14.1% 
among the population aged 15 and above1 - thus exceed-
ing the prevalence of cannabis use in the USA. The 
highest levels of cannabis use were reported in the 
1 Health Canada, Canadian Addiction Survey (CAS), Detailed Report, 
March 2005. 
province of British Columbia, located at the Pacific 
coast (16.8%). Though data show that the differences 
across provinces in Canada or across states in the USA 
are not negligible, it should be pointed out that the 
Estimates of cannabis use for the People’s Republic of China  
A number of indirect indicators, including seizures, arrest data and treatment data, suggest that cannabis use in the 
People’s Republic of China is significantly lower than in other East and South-East Asian countries. China has so 
far, however, not undertaken any national household survey of illicit drug use. No national estimate of cannabis use 
exists.
One World Health Organization (WHO) school survey, conducted in 2003 in four cities, assessed drug use. It found 
lifetime prevalence rates of drug use among 13-15 year old pupils ranging from 0.9% in Beijing to 2.5% in 
Hangzhou (eastern China). The unweighted average of the four cities was 1.75%. 
In comparison, the lifetime prevalence of drug use among 13-15 year old pupils in Thailand in 2008 was 6.1%. A 
2007 Thai household survey found an annual prevalence of cannabis use of 1.2% among the general population 
(aged 12-65). In the Philippines, data from a 2003 WHO school survey among 13-15 year old students (life-time 
prevalence of 6.7%) was similarly far higher than a recent household survey estimate (annual prevalence of around 
0.8% in 2008).
In the regional estimate calculated for cannabis use, all countries with no national data available, including China, 
were assigned the range from other countries in the region. This means that there was a wide range applied from 
existing national prevalence estimates, namely from 0.23% to 1.34% 
UNODC has not applied the school data estimate for China to make an estimate for 15-64 year olds across the 
country, because it was based on only four cities that do not necessarily reflect the national picture of cannabis use. 
This means that the regional and global range of estimated cannabis users is very large, because of the sheer size of 
China’s population. However, using such an estimate would reduce the range of uncertainty in the estimates for Asia 
by 25%. This highlights the great importance that estimates of the level of drug use in the world’s populous countries 
(and in this case, their absence) has upon our confidence in global figures.
USA: annual prevalence of cannabis Fig. 60: 
use, 2002-2007 
Source: SAMHSA, Results from the 2007 National Survey on 
Drug Use and Health, National findings, Rockville, Maryland, 
2008.
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differences are far less pronounced than, for instance, 
across countries in Europe or South America.  
A significant decline in cannabis use over the last few 
years was found among high school students in North 
America. Cannabis use among 8th-12th graders in the 
USA fell by 21% between 1998 and 2008. A decline in 
cannabis use over the last decade was also reported 
among high-school students in the province of Ontario, 
Canada. 
Increases reported  in Latin America   
In contrast to the declining trend in North America, 
increases in cannabis use have been  reported in coun-
tries in Latin America and the Caribbean in recent years, 
notably  in 2007. Eleven  countries reported rising levels 
of cannabis use in 2007, up from seven in 2005. Seven 
countries saw a stable trend, but not a single country 
reported a decline in 2007. The increase across the 
region was also identified by the Latin American Epide-
miological Network (REDLA).2
Despite the increasing trend, cannabis use levels are still 
significantly lower in South America than in North 
America, as reflected in data collected in school surveys 
and household surveys. 
Comparative household surveys among the general pop-
ulation were conducted in six South American states in 
2006/07 by UNODC and the Inter-American Drug 
Abuse Control Commission (CICAD). These identified 
the highest levels of cannabis use in Chile, followed by 
Argentina and Uruguay.  Far lower levels were reported 
in Peru and Ecuador. 
In Argentina, the 2006 household survey showed an 
2 CICAD Observer, “REDLA Network Identified Worrisome Trends 
in Drug Use across Latin America”, June 2008,  http://www.cicad.
oas.org/oid/NEW/Information/Observer/08_01/REDLA.asp
increase in the annual prevalence rate from 3.7% in 
1999 to 6.9% in 2006, among the population aged 
12-65. Moreover, studies among high school students in 
Argentina (aged 13-17) showed an increase in the annual 
prevalence rate of cannabis use from 3.5% in 2001 to 
8.1% in 2007.  
A clear upward trend is also reflected in data from neigh-
bouring Uruguay. Following moderate use rates in the 
1990s, the annual prevalence of cannabis use rose quad-
rupled, from 1.3% among the population aged 15-65 in 
2001 to 5.3% in 2007.   
An increase in cannabis use was also reported in Brazil, 
the largest country in South America. The annual prev-
alence of cannabis use more than doubled, from 1% in 
2001 to 2.6% in 20053 and – according to the Brazilian 
authorities it appears to have continued rising in subse-
quent years. 
Strong increases in cannabis use were also reported in 
Chile. The annual prevalence of cannabis use  rose from 
3.7% in 1994 to 7.5% in 2006.
3 CEBRID, Il Levantamento Domiciliar sobre o Uso de Drogas Psi-
cotrópicas no Basil: Estudo Envolvendo as 108 Maiores Cidades 
do Pais, 2005, Sao Paolo 2006 and CEBRID,  Il Levantamento 
Domiciliar sobre o Use de Drogas Psicotrópicas no Basil: Estudo 
Envolvendo as 107 Maiores Cidades do País, Sao Paolo 2002.
Cannabis use in selected South  Fig. 61: 
American countries in 2006/07*
Source: UNODC and CICAD, Elementos orientadores par alas 
Políticas Públicas sobre Drogas en la Subregión, Lima 2008. 
Uruguay: annual prevalence of  Fig. 62: 
cannabis use among the population 
aged 15-65, 1994-2007
Sources: Observatorio Uruguay de Drogas (OUD), Encuesta 
Nacional en Hogares sobre Consumo de Drogas 2007 and 
Secretaria Nacional de Drogas y Junta Nacional de Drogas,  
Encuesta Nacional de Prevalencia del Consumo de Drogas 
2001. 
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Cannabis use is increasing in Africa 
From a total of 21 African countries reporting cannabis 
use trends for 2007, 7 countries saw use levels rising and 
4 countries reported a decline. The rest were stable. 
These data suggest that overall cannabis use continued 
to rise in Africa in 2007. The increase, however, may be 
losing momentum. While 7 African countries saw an 
increase in cannabis use in 2007, the comparable num-
bers were 12 in 2006 and 18 in 2004. 
The only systematic monitoring of drug use in Africa is 
taking place in South Africa, based on treatment demand. 
Data for South Africa suggest that treatment demand for 
cannabis use increased over the first two quarters of 
2008. Including alcohol, cannabis accounted for 23.5% 
of substance abuse-related treatment demand in South 
Africa during this period. 
In many European countries, use is stabilizing  
or declining  
In contrast, cannabis use in Europe has stabilized or 
shown a downward trend in a number of countries. 
Increased prevention efforts and the spread of knowledge 
on the health risks, partly related to the emergence of 
high-potency cannabis, seems to have contributed to the 
stabilization or downward trend. Some of the stabiliza-
tion/decline may be linked to decreases of cannabis resin 
production in Morocco, Europe’s main source country 
of hashish, though such supply reductions seem to have 
been partly offset by rising levels of cannabis herb pro-
duction within Europe. 
In the UK, which used to be Europe’s largest cannabis 
market, a clear downward trend has been observed in 
recent years. In England and Wales cannabis  use fell 
from a prevalence rate of 10.9% among the population 
aged 16-59 in 2002/03 to 7.4% in 2007/08. The decline 
among youth started several years before the decline 
among the general population. In fact, annual preva-
lence of cannabis use among people aged 16-24 fell from 
28.2% in 1998 to 17.9% in 2007/08, a decline of 37% 
over the last decade. The overall prevalence estimate for 
the United Kingdom as a whole would be around 8.1%, 
equivalent to some 3.2 million persons. 
In Spain, an important cannabis market due to its stra-
tegic location close to the main cannabis resin produc-
tion centers of  Morocco, household survey data showed 
a moderate decline, from a peak of 11.3% of the popula-
tion aged 15-64 in 2003 to 10.1% in 2007. Data sug-
gest that the strong upward trend over the 1993-2003 
period has thus started being reversed. The total number 
of cannabis users in Spain is now estimated at around 3 
million persons.   
South Africa: cannabis as primary drug of abuse in treatment demand*, 1996-2008Fig. 63: 
* unweighted average of treatment (incl. alcohol) in 7 provinces. 
Source: SACENDU, “Monitoring Alcohol & Drug Abuse Trends in South Africa, July 1996 – June 2008”, Research Brief, Vol. 11 (2), 2008.
Spain: annual prevalence of cannabis Fig. 64: 
use among the population aged 15-64
Source: Delegación del Gobierno para el Plan Nacional Sobre 
Drogas, “Informe de la Encuesta Domiciliaria sobre Alcohol y 
Drogas en España (Edades) 2007/08”, October 2008.
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A similar trend of rising cannabis use in the 1990s fol-
lowed by some decline in recent years can be also noticed 
in recent household surveys from a number of other 
European countries. 
Cannabis use seems to have remained stable in the Neth-
erlands, one of the key cannabis production and redis-
tribution centres in Europe. Available household survey 
data, however, only reflect the situation over the first few 
years of the new millennium (5.5% in 2001 and 5.4% 
in 2005). Despite this stabilization, treatment demand 
related to cannabis abuse increased strongly between 
2000 and 2005, possibly reflecting the emergence and 
spread of higher-potency cannabis on the market. The 
number of (outpatient) addiction care clients with pri-
mary cannabis problems rose by more than 75% between 
2000 and 2005.4 The average THC content of domesti-
cally grown Dutch marijuana almost doubled, from 
8.6% in 2000 to 16% in 2007. 
Following increases in the 1990s, cannabis use levels also 
remained quite stable in some of the new Central Euro-
pean EU member states, including Poland (2.8% in 
2002; 2.7% in 2006), the Czech Republic (10.9% in 
2002; 9.3% in 2004) and Slovakia (7.2% in 2000; 6.9% 
in 2006). 
4 Trimbos Instituut,  The Netherlands National Drug Monitor, Annual 
Report 2007,  Utrecht 2008. 
... although use is increasing in some  
European countries
In contrast, cannabis use appears to have increased in 
some of the countries at the geographical fringes of 
Europe such as Ireland, Portugal, Bulgaria, Latvia and 
Finland. However, some of these increases were small 
and not statistically significant. 
The situation is different for Italy, where the cannabis 
prevalence rates more than doubled in recent years 
(7.1% in 2003; 14.6% in 2007). Italy has evolved as 
Europe’s single largest cannabis market, with some 5.7 
million users in 2007, out of a total of about 30 million 
users in Europe. This reflected, inter alia, widespread 
availability of cannabis herb from Albania and the Neth-
erlands, and rising domestic production in southern 
Italy. In contrast to many other European countries, the 
average cannabis potency has remained stable in Italy, 
fluctuating at around 6%, which is a low level by Euro-
pean standards. This may explain that the negative con-
sequences of cannabis consumption, found in many 
other European countries, may have been less obvious in 
Italy. 
Despite of the increases in cannabis use in Italy, overall 
cannabis use in Europe remained basically stable.
England & Wales, France, Denmark, Germany, Austria, Hungary and Sweden:  Fig. 65: 
annual prevalence of cannabis use in % of the young and adult populationa
a England and Wales in % of population aged 16-59; France: in % of population aged 15-64; Germany: in % of population aged 18-59, 1995-2003; 
in % of population aged 18-64 in  2006; Denmark: in % of population aged 16+ in 1990 and in % of population aged 16-64 in 2005; Austria: in % 
of population 15-65. * UNODC estimate for Austria for 1984 extrapolated from results of a national study in 1984 among 15-40 year olds; UNODC  
estimate for 2002 based on several local studies conducted  around  2002, reported in  UNODC’s 2004 World Drug Report.  
Sources: UNODC, Annual Reports Questionnaire data; EMCDDA, Statistical Bulletin; Ludwig Boltzmanninstitut, “Österreichweite Repräsentativerhebung 
zu Substanzgebrauch – Erhebung 2008” (Draft), Vienna 2009”. 
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Cannabis use  declined in the Oceania region 
The downward trend of cannabis use in the Oceania 
region continued. The annual prevalence rate of canna-
bis use in Australia fell by almost one fifth to 9.1% of 
the population aged 14 and above between 2004 and 
2007. The decline was strongest among the 14-19-year-
olds, falling by 28%, indicating that prevention activi-
ties in schools may have played a key role in lowering 
cannabis use. 
Household survey data for New Zealand also showed a 
decline of cannabis use in recent years, though this was 
less pronounced than in Australia. The annual preva-
lence of cannabis use fell from 20.4% among the popu-
lation aged 15-45 in 2003 to 17.9% in 2007, a decline 
of 12%.
Cannabis use appears to be rising in Asia 
According to expert opinion, expressed by the national 
drug authorities reporting to UNODC, cannabis use 
appears to be rising in Asia. However, most countries in 
this  region do not have effective drug abuse monitoring 
systems which means that no recent cannabis prevalence 
data exist. Trends from Asia - largely based on expert 
perceptions - must thus be treated with caution.
The number of Asian countries reporting an increase in 
cannabis consumption rose from 9 in 2005 to 13 in 
2007. Increases in 2007 were reported by Azerbaijan, the 
People's Republic of China, Indonesia, the Islamic Repub-
lic of Iran, Kazakhstan, Lebanon, Mongolia, Myanmar, 
Oman, the Philippines, Sri Lanka, Tajikistan and Uzbeki-
stan. Six countries/territories reported a decline, whereas 
11 reported stable levels of cannabis use in 2007.
Australia: annual prevalence of  Fig. 67: 
cannabis use among the population 
aged 14 and above, 1998-2007
Source: Australian Institute of Health and Welfare, 2007 
National Drug Strategy Household Survey, April 2008. 
Bulgaria, Portugal, Finland, Latvia, Ireland and Italy: annual prevalence of cannabis use  Fig. 66: 
in % of the young and adult populationa
a in  % of population aged 15-64 for Bulgaria, Portugal, Finland, Latvia, Ireland; data for Italy refer to the age group 15-44 in 2001; 15-54 in 2003 and 
15-64 in 2005 and 2007. 
Sources: UNODC, Annual Reports Questionnaire data, EMCDDA, Statistical Bulletin,  Presidenza del Consiglio dei Ministri, Relazione 
sullo Stato delle Tossicodipendenze in Italia, Anno 2007, Rome 2008. 
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1.4 Amphetamine-type stimulants market
1.4.1 Summary trend overview
In  2007, UNODC estimates that between 230 and 
640mt of amphetamines-group1 stimulants were manu-
factured. Ecstasy-group2 production was between 72 and 
137 mt. As amphetamine-type stimulants (ATS) can be 
produced virtually anywhere at relatively low cost, the 
locations of production are changing rapidly. Moreover, 
organized criminal groups are increasing the size and 
sophistication of manufacturing operations.
A record level of nearly 52 mt of ATS was seized world-
wide in 2007. The amphetamines-group dominates ATS 
seizures, but there was also a marked increase in ecstasy-
group seizures in 2007. Trafficking in ATS substances is 
most commonly intraregional, but precursor chemicals 
from which ATS materials are made are trafficked 
throughout the world. 
Clear regional distinctions can be seen in ATS use pat-
terns. In East and South-East Asia, users primarily con-
sume methamphetamine. In the Near and Middle East, 
tablets sold as Captagon often contain amphetamine, 
and are used throughout the region. In Europe, users 
primarily consume amphetamine. Worldwide, between 
16 and 51 million people aged 15-64 used ampheta-
mines-group substances at least once in 2007, whereas 
the number who used ecstasy-group drugs is estimated 
at between 12 and 24 million worldwide. 
1 The amphetamines-group substances include predominately metham-
phetamine and amphetamine, but also non-specified amphetamines 
(for example, tablets sold as Captagon, methcathinone, fenetylline, 
methylphenidate and others). 
2 The ecstasy-group substances include predominately MDMA, MDA 
and MDEA/MDE. However, limited forensic capacity often leads to 
confusion about the actual content of tablets believed to be “ecstasy” 
(MDMA).
1.4.2 Production
Global amphetamine-group manufacture estimated 
between 230 and 640 mt; ecstasy 72 and 137 mt
Clandestine ATS manufacture can, and does, occur nearly 
everywhere. The output, however, can only be indirectly 
estimated, using information on use of ATS around the 
world and/or information about seizures. In the 2009 
World Drug Report the estimates are based on the number 
of users and their yearly average consumption.3 
UNODC estimates that in 2007, amphetamines-group 
manufacture amounted to between 230 and 640 metric 
tons. Ecstasy-group manufacture was estimated at 
between 72 and 137 mt. Due to the revised methodol-
ogy, estimates are not comparable with previous reports. 
Based on these estimates and reported seizures, the 
global interception range is estimated to range between 
7% to 19% for amphetamines-group and from 6% to 
12% for ecstasy.4 Interception rates for regions, subre-
gions, and individual Member States vary considerably 
more than the global rates. 
3 Previously, UNODC utilized a multiple component model to trian-
gulate ATS manufacture based on three sub-components: (i) global 
seizures of ATS end-products (drug seizures), (ii) seizures of ATS-re-
lated chemical precursor seizures, and (iii) ATS consumption (preva-
lence rates). See Ecstasy and Amphetamines - A Global Survey 2003. 
4 Similar orders of magnitude were identified in a study of interception 
rates in New Zealand (2%-7% for amphetamines-group substances 
and 5%-17% for ecstasy-group substances). See Wilkins, C., Reilly, 
J., Rose, E., Roy, D., Pledger, M., & Lee, A. (2004). The Socio-
Economic Impact of Amphetamine Type Stimulants in New Zealand. 
Centre for Social and Health Outcomes Research and Evaluation 
(Auckland).
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availability of inexpensive precursor chemicals. These 
were concentrated in North America (particularly the 
USA), and to a lesser extent Oceania, and Central and 
Eastern Europe. Methamphetamine laboratories are also 
increasingly found in large industrial-sized operations 
run by large criminal organizations, particularly in East 
and South-East Asia and North America, although sig-
nificant operations recently emerged in South Asia.
Amphetamine and ecstasy (MDMA) operations tend to 
be fewer in numbers, but have more sophisticated oper-
ations. They require more specialized equipment, pre-
cursor chemicals and more sophisticated skills. 
Amphetamine operations are reported from all of 
Europe, with the notable exception of the Czech Repub-
lic and neighbouring countries.8 Ecstasy-group manu-
facture appears relatively stable, with a significant albeit 
declining proportion of the world’s manufacture con-
tinuing to occur in Europe (West and Central subre-
gions). Outside Europe, significant manufacture of 
ecstasy now occurs in North America, Oceania, and East 
and South-East Asia, as operations have shifted closer to 
those consumer markets. 
USA laboratory count drops; driving global decline
The majority of global ATS laboratories are metham-
phetamine laboratories reported from North America. 
8 One notable exception to this is methamphetamine (Pervitin) manu-
facture located in the Czech Republic and Slovakia, and to a lesser 
degree in neighbouring countries.
ATS laboratories (all sizes) reported to UNODC, by type, 1998-2007Fig. 68: 
Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
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Despite the declining incidents, US laboratories still 
amount to 82% of the total reported in 2007. The count 
of laboratories alone does not provide accurate informa-
tion on the size of manufacturing given that the scale of 
operation may differ between laboratories.9
The most commonly used ATS chemical precursors fall 
under international control, and their seizures–reported 
to the International Narcotics Control Board (INCB)
ααcan provide some limited indications about manu-
facturing trends. Seizures of ATS-related precursor 
chemicals under international control were 45 mt in 
2007,10 which is an increase from 2006, but still a low 
level in a 10-year perspective.11 Global seizures of ATS 
precursors in 2007 included: 
Amphetamines-group  s
  Methamphetamine  
  - 25.3 mt of pseudoephedrine and 22.1 mt  
  of ephedrine, suﬃcient to manufacture 
  some 31.7mt of methamphetamine. 
  Amphetamine  
  - 1.2 mt norephedrine, suﬃcient to   
  manufacture 770 kg of amphetamine; 
  - 834 litres (l) of P-2-P,12 suﬃcient   
9 As yet, there are no internationally accepted forensic reporting stand-
ards for clandestine laboratory operations, their chemical precursors, 
synthesis routes, drugs produced, and manufacture capacity (such 
as frequency of cycle, amount of output, and purity levels), thus 
limiting the overall analytical value of simple counts of laboratory 
incidents.
10 Expressed in ATS drug weight equivalents.
11 International Narcotics Control Board (2009), Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, 2008. (United Nations publication Sales No. 
E.09.XI.4) and prior years. 
12 P-2-P (1-phenyl-2-propanone) also known as benzyl methyl ketone 
(BMK), is typically used in the manufacture of amphetamine com-
monly in Europe but can be also used for the manufacture of meth-
  to manufacture 417 kg of amphetamine; and 
  - small amounts (159 kg) of phenylacetic  
  acid,13 suﬃcient to manufac ture some 40 kg  
  of amphetamine.   
Ecstasy-group   s
  MDMA (and its analogues)  
  - 45,986 l of safrole, sufficient to   
  manufacture 9.7 mt of MDMA;   
  - 2,297 l of 3,4-MDP-2-P14,  
  sufficient to manufacture 1.8 mt of MDMA;  
  - 2 mt of piperonal which could be   
  converted into 760 kg of MDMA; and  
  - 225 l of isosafrole used in the 
  manufacture of MDMA.
ATS producers adapt to evade law enforcement
There are signs that criminal organizations are adapting 
their manufacturing operations to avoid control by: 1) 
utilizing precursor chemicals not under international 
control; 2) moving manufacturing operations to more 
vulnerable locations; and 3) shifting precursor chemicals 
and drug trafficking routes to new locations to avoid 
detection.15
Evidence points to increased frequency of manufactur-
ing ATS using uncontrolled precursors, most notably 
tableted pharmaceutical preparations16 containing 
amphetamine, a process more commonly seen in North America and 
to a lesser degree in Oceania. 
13 Phenylacetic acid is used in illicit manufacture to synthesize the 
amphetamines-group precursor P-2-P and is therefore a ‘pre-precur-
sor.’
14 Also known as PMK (piperonyl methyl ketone).
15 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
16 Pharmaceutical preparations are drugs intended for human or veteri-
Reported seizures of ATS precursors, expressed in metric ton ATS equivalents, 1998-2007Fig. 70: 
Source: UNODC calculations based on INCB data and conversion factors. (INCB, Precursors and chemicals frequently used in the illicit 
manufacture of narcotic drugs and psychotropic substances, 2008 (March 2009, and previous years) and UNODC, Annual Reports 
Questionnaire Data / DELTA).
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pseudo/ephedrine17 and P-2-P based processes in the 
manufacture of methamphetamine.18 Tableted pharma-
ceutical preparations containing pseudo/ephedrine do 
not fall under the same international controls as bulk 
chemicals containing the identical chemicals, and there-
fore are more easily accessible.19
Besides benzaldehyde, a growing number of other 
emerging substitute precursor chemicals have been 
recently identified related to methamphetamine20 syn-
thesis including: α-phenylacetoacetonitrile (converts 
easily into P-2-P), and methyl phenylacetate, ethyl phe-
nylacetate, amyl phenylacetate and isobutyl phenylace-
tate (which can all be converted into phenylacetic 
acid).
nary use, presented in their finished dosage form (for example, pills 
and tablets). Over-the-counter cold medicines in pill form or bulk 
precursors tableted into pill form would be classified as pharmaceuti-
cal preparations and are increasingly used in clandestine manufac-
ture. 
17 The term pseudo/ephedrine refers to both or either ephedrine or 
pseudoephedrine.
18 International Narcotics Control Board, Trafficking in Pharmaceutical 
Preparations for the Illicit Manufacture of ATS, presented at the 52nd 
Commission on Narcotic Drugs (March 17, 2009, Vienna).
19 In January 2009, Mexican authorities reportedly seized more than 8 
million pseudoephedrine tablets (equivalent to 3 mt) aboard a ship 
which embarked from South Korea. (Guadalajara Reporter, Police 
seize eight million illegal pills in Manzanillo, 31 January, 2009.)
20 Amphetamines-group substances synthesized via P-2-P can result in 
either amphetamine or methamphetamine, but outside of Europe 
they more commonly result in methamphetamine.
ATS manufacture is rapidly spreading to vulnerable 
locations  
As awareness, restrictions and enforcement against ATS 
manufacture increase in known problem areas, manufac-
ture has expanded into vulnerable nearby countries. For 
example, from the USA manufacture shifted south to 
Mexico. As Mexico responded with strong counter-
methamphetamine initiatives manufacturing activities 
moved south to Latin America, including Argentina, 
Guatemala, Honduras, and Peru. Similar shifts may also 
be occurring in South Asia where India and Sri Lanka 
reported their first operational methamphetamine labo-
ratories in 2008, and reported seized manufacturing 
equipment and chemicals in 2007.21
Trafficking routes are increasingly shifting into places 
that lack the stability, enforcement and forensics infra-
structure to detect movement of both precursor chemi-
cals and finished products. 22 
Methamphetamine manufacture shifts rapidly
North America, which accounts for most of the reported 
methamphetamine operations globally, saw a decline in 
2007 (17%). The USA accounts for 82% of the total 
number of methamphetamine laboratories seized in 
2007, a figure which has been in decline since nation-
wide pharmaceutical precursor controls were enacted in 
2005.23 However, preliminary reports for 200824 sug-
gest that manufacture may be rebounding in the USA, 
as illustrated by increases in US clandestine laboratory 
incidents and increased “smurfing” activity.25 
The number of laboratories reported by Mexico and 
Canada remains comparatively small, although the size 
of the laboratories may on average be larger.26 There is 
21 UNODC, Global SMART Update 2009, Volume 1 (March). Since 
2003 India has reported several attempts at methamphetamine-
related manufacture, none of which came to fruition. 
22 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
23 Incidents are defined to include all counts of various types of labs (for 
example, extraction, manufacturing, cutting and packaging), chemi-
cal dumpsites, and drug processing chemical and glassware seizures. 
24 US Department of Justice (2008). National Methamphetamine Threat 
Assessment 2009 (National Drug Intelligence Center, Product No. 
2008-Q0317-006). Johnstown, PA. 
25 Smurfing–unique to methamphetamine manufacture–is a term used 
to describe the emergence of groups who shop multiple pharmacies 
making many small purchases of pharmaceutical precursor chemi-
cals, thereby avoiding sales restrictions and law enforcement atten-
tion. This phenomenon, also known as pill or pharmacy shopping, 
or pseudo-running, and has occurred in other places where over-
the-counter pharmaceuticals used in the manufacture in metham-
phetamine have become restricted (for example, Australia and New 
Zealand).
26 The USA reported 11 large to industrial-sized laboratories in 2007, 
while Mexico and Canada reported 22 and 17 laboratories, respec-
tively. (US Department of Justice (2008). National Methamphetamine 
Threat Assessment 2009 (National Drug Intelligence Center, Product 
No. 2008-Q0317-006). Johnstown, PA., and previous years. None of 
these were identified as small scale laboratories in the ARQ.  
Proportion of methamphetamine back-Fig. 71: 
track investigations involving pharma-
ceutical preparations as the chemical 
precursors for methamphetamine
Source: International Narcotics Control Board, Trafficking in 
Pharmaceutical Preparations for the Illicit Manufacture of ATS, 
presented at the 52nd Commission on Narcotic Drugs (March 
17, 2009, Vienna).
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evidence that Canada-based Asian organized crime 
groups and outlaw motorcycle gangs have significantly 
increased the amount of methamphetamine they manu-
facture and export, for the US market, but also for 
Oceania and East and South-East Asia.27 
Many operations in Mexico were disrupted in 2007 and 
as a result, Mexican-based drug cartels have spread their 
risks by diversifying manufacturing methods28 and 
moved to other countries in Latin America or back to 
the USA.29 
Methamphetamine manufacture is increasing  
in other regions   
Methamphetamine manufacture has also grown consid-
erably outside of the Americas from 46 laboratories 
reported a decade ago to 700 in 2007,30 with the largest 
increase in East and South-East Asia, Oceania, Europe, 
and Southern Africa. Laboratory operations in East and 
27 US Department of Justice. (2008). National Methamphetamine Threat 
Assessment 2009 (National Drug Intelligence Center, Product No. 
2008-Q0317-006). Johnstown, PA; Australian Crime Commission 
(2009). Illicit Drug Data Report 2006–07 (Revised March 2009); 
Recent Illicit Synthetic Drug Smuggling Situation in Japan. Pre-
sented by the Customs and Tariff Bureau, Ministry of Finance, Japan 
at the 18th Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), (September, 2008, Busan, Republic of 
Korea).
28 US Department of Justice. (2008). Changes in Drug Production, Traf-
ficking, and Abuse, Second Half-Year CY2007 (National Drug Intel-
ligence Center). Johnstown, PA; US Department of Justice. (2008). 
Emerging Threat Report, Alternative chemicals sought to produce meth-
amphetamine precursors (Drug Enforcement Administration, DEA 
08035, October 2008). 
29 US Department of Justice (2008). National Methamphetamine Threat 
Assessment 2009 (National Drug Intelligence Center, Product No. 
2008-Q0317-006). Johnstown, PA.
30 The Republic of Moldova, which reports on average 80 metham-
phetamine laboratories annually (2004-2006), failed to report any 
drug manufacturing to UNODC in 2007.
South-East Asia are often significant industrial-sized 
operations, which have grown in sophistication over the 
last few years.31 While manufacture has been reported in 
many countries, operations in China, Myanmar and the 
Philippines account for most of the production.32
China accounts for the majority of reported metham-
phetamine laboratories seized in East and South-East 
Asia. Seventy-five predominately methamphetamine 
laboratories were reported in 2007, an annual increase 
of nearly 50% since 2005. The sophistication and size of 
these operations are significant, as seen when authorities 
in Guangdong seized one of the largest methampheta-
mine laboratories ever discovered, along with 1.7 mt of 
liquefied methamphetamine.33 The increase in Keta-
mine34 manufacture can be seen clearly in the number 
of clandestine laboratories reported (from 17 in 2006 to 
44 in 2007) as demand for the drug increases through-
out the region, particularly in Hong Kong, China.
The source for much of the tableted form of metham-
phetamine (‘yaba’) found in East and South-East Asia 
occurs within Myanmar35, as precursors enter from 
porous borders from India, China and Thailand. 
31 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
32 Information based on 92 mentions of the origin of seized metham-
phetamines. Mentions of Japan as a source country reflects the dif-
ficulty in identifying source countries and transiting countries. Japan 
has reported no clandestine manufacture to UNODC.
33 UNODC, Global SMART Update 2009, Volume 1 (March).
34 Ketamine is a licit pharmaceutical illicitly used as a hallucinogen. 
While it is not an ATS it is increasingly encountered in ATS markets, 
either in connection with the “club-drug” scene, or found knowingly 
or unknowingly as an active ingredient in what is sold on illicit 
markets as ‘ecstasy’. Ketamine is not currently under international 
control.
35 There are indications that high potency crystalline methampheta-
mine is also being manufactured there.
North America methamphetamine laboratories reported (all sizes), 1998-2007Fig. 72: 
Source: UNODC, Annual Reports Questionnaire Data / DELTA
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Manufacture is allegedly controlled by the United Wa 
State Army (UWSA), the Shan State Army-South (SSA-
S)36 and groups in the Kokang Autonomous Region, 
and are increasingly trafficked throughout the Greater 
Mekong Subregion (GMS).37 In 2007, only five tablet-
ing facilities were reported. However, reports from 
neighbouring countries suggest that the number of 
clandestine manufacturing operations is significantly 
higher38 than seizures would suggest.
The Philippines remains a significant source of high 
potency crystalline methamphetamine (‘shabu’) used 
both domestically and exported to locations in East 
and South East Asia and Oceania. Manufacture often 
occurs in industrial-sized laboratories operated by tran-
snational organized crime with most chemists being 
foreign nationals.39 In 2007, a notable increase in the 
seizure of methamphetamine-related manufacturing 
facilities was reported with nine significant laboratories 
(and an additional 13 chemical warehouses) seized, 
increasing in 2008 to 10 laboratories, marking the 
36 UNODC Regional Crime Centre for Asia  and the Pacific. Patterns 
and Trends of amphetamine-type stimulants (ATS) and other drugs 
abused in East Asia and the Pacific 2005. (Bangkok, June 2006); 
UNODC. Amphetamines and Ecstasy: 2008 Global ATS Assessment 
(United Nations publication, Sales No. E.08.XI.12); US Department 
of State, Bureau for International Narcotics and Law Enforcement 
Affairs, International Narcotics Control Strategy Report (Washington 
D.C., 2009).
37 A region encompassing Cambodia, Lao PDR, Myanmar, Thailand, 
Viet Nam, and bordering provinces of south China.
38 Drug situation 1-15 December 2006, presented to UNODC, Thai-
land Office of the Narcotics Control Board (ONCB). 
39 Philippine Country Report, Current Situation and Recent Trends 
in ATS Manufacture and Precursor Diversion.  Joint Meeting of 4th 
Asian Collaborative Group on Local Precursor Control (ACoG) and 
4th International Forum on Control of Precursors for ATS (IFCP) 
12-15 February 2008 Tokyo, Japan.
third consecutive year of increases.40
Transnational criminal organizations shift operations 
to vulnerable areas; size and sophistication increase
Subregional shifts in manufacture to new areas within 
the Greater Mekong Subregion and beyond are occur-
ring as criminal syndicates increasingly exploit new vul-
nerable areas in which to synthesize methamphetamine 
undetected. For example, significant methamphetamine-
related manufacture was first reported in Cambodia in 
2007 and Viet Nam in 2005.41 
Indonesia and Malaysia have reported increasing inci-
dents, size and sophistication of ATS manufacture. 
Operations discovered there are some of the world’s larg-
est and most sophisticated industrial-sized operations to 
date, both requiring an unprecedented level of logistical 
support to fully operate.42 In 2007/08 Indonesian 
authorities reported ketamine findings at several clan-
destine methamphetamine laboratories, raising the pos-
sibility that local manufacture of ketamine may also 
occur as its use increases.43 
40 Country report by the Philippines (UNODC/HONLAP/2009/32/
CRP.6). Thirty-second Meeting of Heads of National Drug Law 
Enforcement Agencies, Asia and the Pacific (February 2009, Bang-
kok).
41 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
42 At the Kulim laboratory—an operation estimated to have a the-
oretical production cycle of 1.4 mt used P-2-P believed to have 
been manufactured from α-phenylacetoacetonitrile, a chemical not 
under international control, to manufacture methamphetamine. 
The National Project Workplan for National Narcotics Board Indo-
nesia: Improving ATS data and information systems, presented at the 
Regional ATS forum (August 2007).
43 Country report by the Indonesia (UNODC/HONLAP/2009/32/
CRP.8). Thirty-second Meeting of Heads of National Drug Law 
Enforcement Agencies, Asia and the Pacific (February 2009, Bang-
kok).
Sources of seized East and South East Fig. 73: 
Asia methamphetamine as mentioned 
by Member States, 2002-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Number of East and South East Asia Fig. 74: 
amphetamines-group laboratories  
(all sizes), 1998-2007
Source: UNODC, Annual Reports Questionnaire Data. 
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Oceania amphetamines-group laboratory seizures 
stable at high levels
Amphetamines-group laboratory seizures in Oceania44 
have remained at high levels for the past several years. 
However, in 2007, there were signs of a moderate 
decrease. Australia reported a total of 328 (an 8% decline 
from the previous year) amphetamines-group and com-
bination ATS-type operations (excluding MDMA only 
operations) and New Zealand reported 190 ampheta-
mines-group laboratories (10% decrease), each predom-
inantly methamphetamine-related.45 
Significant methamphetamine precursors continue to be 
intercepted by customs and law enforcement in both 
countries. In Australia, large quantities of pseudo/ephe-
drine continue to be imported via air cargo.46 In July 
2008, Australian authorities intercepted a single ship-
ment of 850 kg of pseudoephedrine trafficked from 
Thailand.47 Increases were also noted in P-2-P based 
precursors.
New Zealand estimates that as many as 10 million phar-
maceutical precursors tablets containing pseudoephe-
44 Only Australia and New Zealand provide regular reporting of their 
drug situations to UNODC.
45 Note these figures include extraction laboratories/operations for the 
manufacture of methamphetamine. Australian Crime Commission 
(2009). Illicit Drug Data Report 2006–07 (Revised March 2009). 
The figures from Australia include 249 amphetamines-group only 
laboratories and 79 “other” clandestine laboratories, but exclude 
MDMA only laboratories. The “other” category has historically 
included cases/ laboratories containing equipment and chemicals 
associated with making unknown ATS, and were therefore included 
in the broader group. See, Australian Crime Commission (2007). 
Illicit Drug Data Report 2004–05, and previous years.
46 Australian Crime Commission (2009). Illicit Drug Data Report 
2006–07 (Revised March 2009).
47 UNODC, Global SMART Update 2009, Volume 1 (March).
drine are trafficked from China to New Zealand annually. 
The authorities estimate that it could be used to synthe-
size 630 kg of methamphetamine.48 However, most 
clandestine operations detected appear to be using 
domestically diverted pharmaceutical precursors.
There is still a risk that manufacturing could become 
established in other countries in Oceania, as seven of the 
countries are not yet parties to the 1988 United Nations 
Convention Against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances.49
Methamphetamine manufacture in Europe is lim-
ited to Central and Eastern Europe
In Europe, methamphetamine manufacture is largely 
limited to a number of countries in Central Europe and 
East Europe (405 cases in 2007). Compared to 2006, a 
15% decline was noted in total laboratories reported to 
UNODC. However, inconsistencies in reporting makes 
it difficult to compare the figures.50 The majority of 
operations are small scale and the main producing coun-
try is the Czech Republic (96%). In 2007, Poland and 
Portugal  also reported methamphetamine manufac-
ture.51
48 National Drug Intelligence Bureau, Illicit Drug Assessment 2008. Wel-
lington; National Drug Intelligence Bureau, Precursors and Chemicals 
used for Methamphetamine Manufacture in New Zealand. July 2008, 
Wellington.
49 These include Kiribati, the Marshall Islands, Nauru, Palau, Papua 
New Guinea, Solomon Islands and Tuvalu.
50 For example, the Republic of Moldova averaged 80 laboratories per 
year between 2004-06, but did not provide an ARQ in 2007. The 
Russian Federation lists methamphetamine as an end product manu-
factured domestically, however only seizure of amphetamine labora-
tories were reported to UNODC. There are reports of widespread 
small scale manufacture in the Ukraine, but laboratories (7) were last 
officially reported in 1998.
51 Amphetamine-type stimulants in the European Union 1998-2007: 
Oceania amphetamines-group laboratories seized (all sizes), 1998-2007Fig. 75: 
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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The number of Czech Republic methamphetamine 
(Pervitin) laboratories reported in 2007 (388) suggests 
that a possible stabilization–at a high level–may be 
occurring. In this country, the majority of metham-
phetamine synthesis utilizes tableted pharmaceutical 
preparations. This shows in the estimated 82% of 
domestic pharmaceutical sales which were used for illicit 
manufacture.52 New 2009 restrictions limiting the sale 
of pharmaceutical preparations containing pseudoephe-
drine may impact the methamphetamine production in 
the Czech Republic.
There are emerging reports of increased methampheta-
mine manufacture throughout the Baltic countries. 
Poland, known as a source of amphetamine, reported its 
first methamphetamine laboratory in 2007. There are 
also reports of manufacturing of considerable scale in 
Lithuania.
In South Africa, methamphetamine laboratories 
outpace methcathinone
South Africa dismantled 12 clandestine methampheta-
mine (‘tik’) laboratories in 2007, a decline from 2006 
(17). However, for the first time the number of meth-
amphetamine laboratories seized outpaced those of 
methcathinone ( , 10 reported in 2007).53 While 
declining, South Africa legally imports significant 
amounts of licit ephedrine and pseudoephedrine, how-
Europol contribution to the Expert Consultations for the UNGASS 
assessment. Europol (The Hague, July 2007).
52 Havlíček, S. (2008). Pharmacies and Clandestine Production of Meth-
amphetamine in the Czech Republic, presented at the 2008 Global 
Conference on Methamphetamine: Science, Strategy, and Response 
(September 2008, Prague). Czech Chamber of Pharmacists.
53 Methcathinone manufacture represents a group of ATS grouped 
under ‘other synthetic stimulants.’ These 10 laboratories represent 
39% of the total for that category (26) reported in 2007.
ever, little is seized in relation to illicit activities.54 In an 
effort to stem domestic diversion into illicit drug manu-
facture, the Government in April 2008 amended its 
Medicines and Related Substances Act (1965) to include 
pharmaceutical preparations containing pseudo/ephe-
drine. 
54 International Narcotics Control Board (2009). Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, 2008. (United Nations publication Sales No. 
E.09.XI.4); US Department of State, Bureau for International Nar-
cotics and Law Enforcement Affairs, International Narcotics Control 
Strategy Report Volume I Drug and Chemical Control (Washington 
D.C., 2009)
Czech Republic: illicit methamphetamine laboratories and licit tableted pharmaceutical  Fig. 76: 
precursors sales, 1998-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA; Havlíček, S. (2008). Pharmacies and Clandestine Production of Meth-
amphetamine in the Czech Republic, presented at the 2008 Global Conference on Methamphetamine: Science, Strategy, and 
Response (September 2008, Prague). Czech Chamber of Pharmacists.
South Africa: seized methampheta-Fig. 77: 
mine and methcathinone laboratories 
(all sizes), 2002-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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Number of amphetamine laboratories decline;  
locations may be shifting  
After methamphetamine, the largest group of ATS 
manufacture is for combined amphetamine substanc-
es.55 This group of laboratories represents nearly a third 
of the total, with 453 reported in 2007. Operations that 
manufacture only amphetamine declined by 23% to 
118 in 2007. Most of these operations are located in 
Europe (81%) followed by the Americas (17%).
Over the last decade (1998-2007) Europe has reported 
the dismantling of 971 clandestine amphetamine labo-
ratories (72% of the global total). The largest numbers 
of dismantled operations were reported by the Russian 
Federation (61% of the European total), Poland (13%), 
the Netherlands (10%), Germany (4%), the UK (3%), 
Belgium and Bulgaria (2% each). For 2007, the largest 
number of European operations were in the Russian 
Federation (62),56 followed by Poland (13), Belgium (7) 
and Germany and the Netherlands (5 each). 
The low figures reported by Belgium, Netherlands and 
Poland may not be indicative of manufacture capacity. 
Member States in the ARQ often mention these coun-
tries as the source of seized amphetamine.57 
P-2-P is the most common precursor chemical used in 
the illicit manufacture of amphetamine throughout 
Europe, where it accounted for 93% of the global sei-
zures reported to the INCB in 2007.58 However, total 
P-2-P seized in Europe in 2007 amounted to only 773 
litres (l), the lowest levels in the new millennium. Only 
four countries, Germany (243 l), Poland (241 l), the 
Russian Federation (191 l) and Estonia (51 l), reported 
seizures. Small amounts of phenylacetic acid (used to 
make P-2-P) were seized in 2007 by Bulgaria (50 kg) 
and Lithuania (106 kg). 
Organized crime operating in the Netherlands and to a 
lesser extent Belgium still dominate the major manufac-
ture of synthetic drugs. Greater sophistication of opera-
tions has been noted by Europol, as increased laboratory 
sizes, higher capacity tableting machinery and segrega-
tion of the production cycle to safeguard operations 
become more commonplace.59 
55 Many countries do not have the forensic capabilities to differenti-
ate between various types of ATS operations. These counts include 
amphetamine, non-specified amphetamine and those laboratories 
that manufactured multiple products, but exclude clearly identified 
laboratories of methamphetamine, ecstasy (MDMA), and other syn-
thetic (fir example methcathinone) laboratories. 
56 Note figures may also include methamphetamine operations.
57 Information based on 321 mentions on the origin of amphetamine 
seizures between 2002 and 2007.
58 International Narcotics Control Board (2009). Precursors and chemi-
cals frequently used in the illicit manufacture of narcotic drugs and 
psychotropic substances, 2008. (United Nations publication Sales No. 
E.09.XI.4)
59 Europol, Amphetamine-type Stimulants in the European Union 1998-
Bulgaria and to a lesser degree Turkey are believed to be 
the sources for counterfeit pharmaceuticals sold as 
Captagon–believed to contain amphetamine–increas-
ingly reported throughout the Near and Middle East. 
There are several indications that undetected ampheta-
mine manufacture may already be occurring in the Near 
and Middle East.60 
Significant ecstasy manufacture in Europe, North 
America, Oceania, and East and South-East Asia 
Ecstasy-group laboratories totalled 72 in 2007, which is 
higher than 2006, but similar to levels seen in recent 
years. Manufacture in 2007 was reported in just eight 
countries: Australia (19), Indonesia (16), Canada (14), 
USA (12), Netherlands (8), France (1), Mexico (1) and 
Spain (1). Operationally, ecstasy manufacture (predomi-
nately MDMA) is more demanding than the manufac-
ture of new ATS. It requires increased skills, specialized 
equipment, and precursor chemicals. Nearly all MDMA 
operations are large enough to be economically profita-
ble, thus the low number of laboratories may not be a 
sign of low production. 
The most significant development in ecstasy-group 
manufacture has been the shift of operations from West 
and Central Europe to locations closer to consumers 
around the world. 2002/03 marked the period when 
greater numbers of laboratories were seized in regions 
2007. Europol contribution to the Expert Consultations for the 
UNGASS assessment (The Hague, July 2007).
60 For example, Lebanese authorities in 2007 successfully intercepted 
laboratory equipment and precursor chemicals for Captagon manu-
facture smuggled into the country by Bulgarian nationals; in 2007, 
the INCB reported that 75% of licit global trade in the amphetamine 
precursor P-2-P was destined for two countries located in the Near 
and Middle East allowing for a localized source for diversion.
Global amphetamine laboratories  Fig. 78: 
reported to UNODC (all sizes),  
1998-2007
Source:  UNODC, Annual Reports Questionnaire Data / DELTA.
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outside Europe, most notably North America, Oceania, 
and East and South-East Asia. Several instances of Euro-
pean-based criminal expertise (for example, chemists) 
were also observed in these regions.61 
The Netherlands was mentioned most frequently as the 
source country for seized ecstasy (178 mentions or 
38.5%), followed by Belgium (9.5%), Germany (5.2%), 
and the UK (3.2%). Europe overall accounted for 86% 
of all mentions, in spite of significant shifts in manufac-
ture to regions outside Europe.
Precursors for ecstasy-group substances include safrole 
(and safrole-rich oils), isosafrole, piperonal and 3,4-
MDP-2-P, which are all under international control. In 
2007, only one country, Thailand, reported significant 
safrole seizures. Australia (1,907 l), Canada (370 l), and 
the Netherlands (20 l) were the only countries reporting 
3,4-MDP-2-P seizures in 2007. The total of 2,297 l is 
the lowest level in the new millennium. Mexico reported 
a single seizure of 2 mt of piperonal, accounting for 
nearly all seized in 2007.62 While many of these seizures 
point to locations where MDMA manufacture is likely 
significant, their amounts clearly do not reflect the req-
uisite chemicals needed to produce the amount of ecstasy 
consumed annually.
In Australia, there is continued evidence of notable 
domestic manufacture.63 Canada has grown to be the 
most important producer of MDMA for North Amer-
ica, and since 2006, all ecstasy laboratories reported have 
61 Europol (2008). OCTA 2008, EU Organized Crime Threat Assessment 
(The Hague 2008).
62 Mexico reported an MDMA laboratory in 2007, the first such report 
since 2002.
63 Australian Crime Commission (2009). Illicit Drug Data Report 
2006–07 (Revised March 2009).
been large capacity facilities operated principally by 
Asian organized crime groups.64 The number of labora-
tories in the USA appears comparable to other produc-
ers, however, US operations tend to be smaller in nature, 
providing limited amounts for domestic consumption. 
On the other hand operations in West and Central 
Europe tend to be larger and more sophisticated, and 
produce higher quality products trafficked around the 
world. For example, the Netherlands seized two of the 
largest MDMA laboratories ever in 2007. In 2008, Bra-
zil’s Federal Police dismantled the country’s first clandes-
tine MDMA laboratory in the southern state of Paraná, 
again illustrating how ATS manufacture is able to shift 
closer to its consumers.65 
64 US Department of Justice. (2008). National Drug Threat Assessment 
2009 (National Drug Intelligence Center, Product No. 2008-Q0317-
005). Johnstown, PA.
65 Brazil Federal Police, Relatório annual de atividades – 2008. Divisão 
de Controle de Produtos Químicos. Note, the majority of MDMA 
consumed in Brazil is believed to originate in Europe.
Global ecstasy-group laboratories  Fig. 79: 
reported to UNODC (all sizes),  
1998-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Regional ecstasy-group laboratories Fig. 80: 
reported to UNODC, 1998-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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Global ATS seizures increase in 2007, surpassing 
previous records
Global seizures of amphetamine-type stimulants (ATS)1 
have continued to increase, totalling nearly 52 metric 
tons (mt) in 2007, surpassing their 2000 peak by nearly 
3 mt.2 The proportion of Member States that reported 
ATS seizures was 65%, the highest level recorded. The 
countries also reported an increase in average weight 
seized, from 492 kg in 2000 to 555 kg in 2007.3
Trafficking in ATS substances is most commonly intra-
regional – thus crossing fewer international borders – 
because manufacture typically occurs near the consumer 
market. This partially explains the relatively low levels of 
ATS seized compared to cocaine and heroin seizures. 
However, data suggests that interregional trafficking is 
1 Amphetamine-type stimulants (ATS) are a group of substances com-
prised of synthetic stimulants including amphetamine, metham-
phetamine, methcathinone and ecstasy-group substances (MDMA 
and its analogues).
2 To standardize, seizures reported in kilograms, litres and dose/units/
pills/tablets are transformed into kg equivalents: a dose of “ecstasy” 
was assumed to contain on average 100 mg of psychoactive ingredient 
(MDMA); a dose of amphetamine/methamphetamine was assumed 
to contain 30 mg of active ingredient; a litre was assumed to equal a 
kilogram. Until 1999 ‘other hallucinogens’ were included in data for 
the ecstasy-group substances, but the proportion of ecstasy-group in 
the total exceeded 90% for most years.
3 It is important to note that drug and precursor seizure data are sub-
ject to change for a variety of reasons, such as new or late data being 
added or revisions in data already provided by Member States. All 
data reported in trafficking reflect the most up-to-date and accurate 
information available at the time of printing. 
increasing.4 Moreover, the precursor chemicals from 
which ATS materials are manufactured continue to be 
trafficked throughout the world. They are often diverted 
from licit manufacture in South, East and South-East 
Asia.
Amphetamine continues to dominate  
global ATS seizures
The amphetamines-group5 dominates ATS seizures, 
accounting for 85% of all seizures by volume. However, 
2007 saw a dramatic jump in ecstasy-group6 seizures 
(15% of all ATS seized), as significant increases were 
noted in several large markets. In 2006, amphetamine 
seizures were higher than methamphetamine. This trend 
continued in 2007, when amphetamine accounted for 
46% of all ATS seized.
4 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
5 The amphetamines-group substances includes predominately meth-
amphetamine and amphetamine, but also includes non-specified 
amphetamines-group (for example, tablets sold as Captagon, meth-
cathinone, fenetylline, methylphenidate and others), however it 
excludes substances purportedly of the ecstasy-group of substances.
6 The ecstasy-group substances include predominately MDMA, with 
MDA and MDEA/MDE. However, limited forensic capacity by 
Member States often leads to confusion about the actual content of 
tablets believed to be “ecstasy” (MDMA).
Global seizures of amphetamine-type stimulants (ATS), 1990 - 2007Fig. 81: 
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (Brussels, 2008) and previous years.
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1. Trends in the world drug markets Amphetamine-type stimulants market
While drug seizures vary dramatically from year to year, 
clear increases in the amount of amphetamine seized 
began around 2000, with large increases reported in 
2005. These increases are due, in large part, to intercep-
tions of a fake pharmaceutical marketed as Captagon 
(amphetamine) in the Near and Middle East.7 Seizures 
of methamphetamine, until recently the main ATS 
seized in East and South-East Asia and North America, 
have declined somewhat since 2005, and remain at some 
18 mt. 
7  See special Captagon feature in this chapter. 
8 Also know as benzyl methyl ketone (BMK).
The majority of ATS seizures worldwide occur primarily 
in the four subregions with distinct patterns: 
Near and Middle East (29%)–primarily fake Captagon  s
tablets likely containing amphetamine;
East and South-East Asia (23%)  s
–primarily methamphetamine; 
West and Central Europe (22%)–primarily ampheta- s
mine and ecstasy; and
North America (18%)–primarily methamphetamine  s
and ecstasy.
Each of these subregions is also a significant manufac-
turing area. The one exception is the Near and Middle 
East, where no clandestine manufacture has been 
reported. However, undetected amphetamine manufac-
ture may be occurring in the subregion. This is because 
ATS are typically manufactured in the subregion in 
which they are consumed, and because of several indica-
tors of manufacture in the subregion. For example, 
Lebanese authorities in 2007 intercepted laboratory 
equipment and precursor chemicals for Captagon man-
ufacture; 75% of licit global trade in the Captagon 
precursor 1-phenyl-2-propanone (P-2-P)8 in 2007 was 
destined for two countries in the Near and Middle East; 
and intelligence reports support the assertion that ongo-
ing manufacturing has been occurring in the Syrian 
Arab Republic since at least 2006 (although no labora-
tories have been detected to date).9 
9 Lebanon Drug Enforcement Central Bureau, presentation at the 
Working Group Meeting on Captagon Smuggling to the Middle East 
Region, (December 2008, Beirut); Turkish National Police, Depart-
ment Of Anti-Smuggling And Organized Crime (KOM), Annual 
Report 2008. Ministry of the Interior (February 2009, Ankara) and 
previous years. International Narcotics Control Board (2009). Precur-
sors and chemicals frequently used in the illicit manufacture of narcotic 
drugs and psychotropic substances, 2008. (United Nations publication 
Sales No. E.09.XI.4)
ATS seized, by substance type, 2007 Fig. 82: 
(total: 51.6 mt)
Source: UNODC, Annual Report Questionnaire Data/DELTA; 
UNODC Drug Information Network for Asia and the Pacific 
(DAINAP); Government reports; World Customs Organization 
(WCO), Customs and Drugs Report 2007 (June 2008) and pre-
vious years.
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Global ATS seizures, by substance type, 1998-2007Fig. 83: 
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (Brussels, 2008) and previous years
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Ten countries in five distinct subregional markets 
accounted for more than 80% of all ATS seized. The 
most significant ATS seizures are reported from Saudi 
Arabia (27% of all ATS), China and the USA (12% 
each), the Netherlands (10%), Canada, the United 
Kingdom,10 Australia, Indonesia, Thailand and Myan-
mar, all with 5% or less. 
Trafficking in amphetamines-group substances
Decline in seized amphetamines-group substances; 
the Near and Middle East leads in amphetamines-
group seizures
Seizures of amphetamines-group substances (that is, 
amphetamine, methamphetamine and non-specified 
amphetamines) have increased considerably since the 
mid-1990s, and again beginning in 2002. 
10 Figures for the UK include England, Wales, Scotland and Northern 
Ireland 
However 2007 saw a decline of about 2.5 mt over the 
prior year from decreases in the non-specified ampheta-
mines group. The more recent increases have been driven 
primarily by amphetamine in the Near and Middle East, 
Europe and North America, while seizures reported 
from East and South-East Asia–while substantial–have 
been on the decline. In 2007, the Near and Middle East 
accounted for about a third of global seizures (43.2 mt 
total), followed by East/ South East Asia, West and Cen-
tral Europe, and North America. 
Trafficking in amphetamine
Trafficking in fake Captagon (amphetamine)  
in the Near and Middle East dominates global 
amphetamine seizures
The 23.6 metric tons of amphetamine seized in 2007 
Global ATS seizures, by subregion, 1998-2007Fig. 84: 
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (June 2008) and previous years.
Global seizures of the Fig. 85: amphetamines-group substances, by region, 1990 - 2007
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (Brussels, 2008) and previous years.
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1. Trends in the world drug markets Amphetamine-type stimulants market
represents the highest level of seizures ever for this class 
of drug. The Near and Middle East accounted for nearly 
two thirds of all amphetamine seized, followed by 
Europe with just over a third. Saudi Arabia accounted 
for the vast majority. Notable seizures were also reported 
from the Syrian Arab Republic, Jordan and the United 
Arab Emirates (UAE). West and Central Europe 
accounted for 94% of all of Europe’s seizures, led by the 
Netherlands, the United Kingdom and Germany. 
Given the significant increases in the Near and Middle 
East, Europe’s share of global seizures has declined, 
despite an increase in the absolute amounts seized in 
Europe between 2000 and 2007. European seizures 
accounted for 93% of all amphetamine seizures in 2000, 
compared to 36% in 2007. 
The shifts in the Near and Middle East are concentrated 
in several key countries and are largely due to fake Capta-
gon – an ATS product unique to the subregion. In 2007, 
Saudi Arabia seized a record 13.9 mt of fake Captagon, a 
weight near equivalent to all of the UK’s amphetamines-
group seizures since 2000.11 It is likely that the reported 
weight of this significant seizure in Saudi Arabia repre-
sents bulk tablet weight, which includes adulterants and 
binders. Many of the seizures depart from the Syrian 
Arab Republic, travel by road via Jordan and arrive in 
Saudi Arabia. Several other countries in the subregion 
have reported dramatic increases in seizures of these tab-
lets since 2004, including Jordan, Syria, UAE, and 
Yemen, typically via overland routes and often destined 
for Saudi Arabia’s large domestic market. In addition to 
 
11 In March 2009, Saudi Arabia arrested 35 drug traffickers believed 
part of four different drug networks operating across the country, 
along with 3.4 million fake Captagon tablets. Security spokesman of 
Ministry of Interior; Riyadh, Saudi Press Agency 8 March 2009
the increase in reported seizure weight, the number of 
individual Captagon (amphetamine) tablets seized in 
selected countries also showed significant increases during 
the period 1998 to 2007.
Global amphetamine seizures, by region, 1998-2007Fig. 86: 
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Government reports; World Customs Organization (WCO), Customs and Drugs Report 2007 (Brussels, 2008) and previous years.
Regional shifts in proportion of  Fig. 87: 
amphetamine seizures, 2000-2007
Source: UNODC, Annual Report Questionnaire Data/DELTA; 
UNODC Drug Information Network for Asia and the Pacific 
(DAINAP); Government reports; World Customs Organization 
(WCO), Customs and Drugs Report 2007 (June 2008) and pre-
vious years.
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The evolution of Captagon
Captagon® was originally the trade name for a pharmaceu-
tical preparation containing fenetylline, a synthetic stimu-
lant. Today, Captagon accounts for a significant amount of 
seized amphetamine-type stimulants in several countries, 
particularly in the Near and Middle East region. However, 
the drug has experienced a number of transitions since it 
was first developed for paediatric and geriatric use and 
given its trade name in the 1960s
The original Captagon product contained fenetylline, 
which is metabolized in the human body to amphetamine. 
Fenetylline essentially exerts the same effects as ampheta-
mine and misuse of fenetylline started as early as the 1970s. 
Diversion from legitimate trade constituted the main 
source of fenetylline, and as a result of reports of increasing 
misuse, the substance was placed under international con-
trol in 1986. No licit manufacture has been reported since 
1987. 
Similar to what has happened with other ATS that have 
been placed under control, counterfeit or fake products 
started to appear. In the case of Captagon, pharmaceutical 
companies are reported to have been approached to pro-
duce counterfeit Captagon tablets. Subsequently, clandes-
tine operators moved to the production of entirely fake 
products that did not contain any fenetylline but combi-
nations of substances that mimic the effects of the original 
product. Such fake products are today predominant on 
illicit markets. 
Throughout this transition, the original brand name 
Captagon and the original physical appearance of tablets 
has continued to be used in an attempt by illicit manufac-
turers to build on the reputation of the original product.
The primary market for Captagon has traditionally been 
countries in the Near and Middle East, where it is popular 
among the younger, affluent population and where it has 
also enjoyed a reputation as sexual stimulant since the 
beginning of the 1980s.
Today, despite increasing seizures of Captagon, there is still 
a lack of information on its chemical composition. What 
seems to be clear is that while until the early 1990s seized 
Captagon was found to contain fenetylline, there have not 
been any such reports since. The few forensic studies avail-
able from that time suggest that fake Captagon then con-
sisted mainly of combinations of caffeine, ephedrine and 
quinine, usually mixed with sugars such as lactose. 
Amphetamine was also occasionally encountered.1 2 3 
1 Dimova, D. and Dinkov, N. (1994), Psychotropic Substances 
of the Amphetamine-Type Used By Drug Addicts in Bulgaria, 
UNDCP SCITEC Publication Series, SCITEC/10. 
2 Al-Gharably, N. and Al-Obaid, A-R. (1994), Journal of the Forensic 
Science Society (now: Science & Justice), 34 (3), 165-167.
3 Al-Hussaini, SR (1996), Counterfeit Captagon: an analytical study, 
Science & Justice, 36 (3), 139-142.
More recent studies of Captagon seized in Jordan4, Tur-
key5, Serbia6 and Iraq7 demonstrated the presence of 
amphetamine and caffeine in most Captagon tablets ana-
lyzed. Tablets that did not contain amphetamine, con-
tained caffeine, ephedrine and/or a quinine. Fenetylline 
was not identified.
The most recent laboratory data (2008/09) come from an 
analysis of tablets from countries in the Near and Middle 
East mainly as part of a feasibility study initiated by Inter-
pol aimed at assisting countries in that region in the iden-
tification of Captagon manufacturing and trafficking 
trends. The results from a very limited number of tablets 
from Jordan and Yemen confirm published data in that the 
main active ingredient is amphetamine. 8
From the above it is clear that the Captagon market has 
experienced a number of transitions, characteristic for 
many transitions of a legitimate pharmaceutical to an 
entirely clandestine product. The limited forensic data 
available show that Captagon today does not contain any 
fenetylline, but mainly caffeine and a range of other con-
trolled and non-controlled substances. Amphetamine is 
the ATS most typically associated with today’s Captagon. 
The amount of amphetamine found in Captagon, how-
ever, is generally low (below the standard transformation 
ratio of 30mg per dose, used in most calculations to con-
vert tablet seizures into units of weight). 
The presence of many of the other ingredients cannot be 
explained easily based on their pharmacology and that of 
the original drug fenetylline, and remains open to specula-
tion. Synergistic effects, reputation (for example as sexual 
stimulant), or contamination from the production process 
are all possible explanations. 
Regardless of why Captagon tablets nowadays contain such 
a variety of ingredients, their systematic forensic examina-
tion and the collective results, that is, from analysis of the 
physical appearance (tablet design), the chemical composi-
tion (both active ingredients and tableting aids), and the 
impurity profile of the amphetamine, provide a wealth of 
valuable information for drug  intelligence. So far, this tool 
remains heavily underutilized.
4 Alabdalla, M.A. (2005), Chemical characterization of counterfeit 
Captagon tablets seized in Jordan, Forensic Science International, 152, 
185-188.
5 Turkish Drug Report, 2001
6 Nevešćanin, M., et al. (2008), Analysis of amphetamines illegally 
produced in Serbia, Journal of the Serbian Chemical Society, 73 (7), 
691-701.
7 Intelligence alert, Captagon mimic tablets (containing d,l-amphet-
amine, caffeine, theophylline, and other components) in Al Anbar 
province, Iraq, Micogram Bulletin, 42 (3), March 2009; Note: 
Amphetamine calculated as sulfate; diphenhydramine and quinine 
calculated as hydrochlorides.
8 Rainer Dahlenburg, Forensic Expert, Bundeskriminalamt, Ger-
many, personal communication. 
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Trafficking in methamphetamine
Methamphetamine markets are concentrated in East 
and South-East Asia and North America, but more 
countries are reporting seizures
Although the total amount of methamphetamine seized 
in 2007 has decreased in comparison with previous 
years, the increasing number of countries reporting sei-
zures suggest that the market is expanding geographi-
cally. The amount of methamphetamine seized in 2007 
(18.2 mt) represents about half of the amount seized at 
its peak in 2000. In 2007, several countries reported 
methamphetamine seizures to UNODC for the first 
time, including Azerbaijan, Belarus, Bosnia and Herze-
govina and Kyrgyzstan.14 While the amounts reported 
were relatively small, they illustrate the geographical 
spread of methamphetamine.
14 Kyrgyzstan’s seizure was reported in 2008. See UNODC, Global 
SMART Update 2009, Volume 1 (March).
Amphetamine (with non-speciﬁed amphetamines) seized in Europe, 1990-2007Fig. 89: 
Source: UNODC, Annual Reports Questionnaire Data.
Top European Countries (rank ordered) in combined amphetamine and non-speciﬁed  Table 21: 
amphetamine seizures (mt), 1998-2007
Source: UNODC, Annual Reports Questionnaire Data/DELTA
County (Top 10) 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
United Kingdom* 1.81 1.30 2.03 1.85 1.55 1.78 1.49 2.23 1.64 2.07 17.75
Netherlands 1.46 0.85 0.29 0.58 0.48 0.88 0.59 2.03 0.63 2.85 10.64
Belgium 0.45 0.34 0.08 0.08 0.50 0.21 2.54 0.18 0.12 0.48 4.97
Germany 0.31 0.36 0.27 0.26 0.36 0.48 0.56 0.67 0.71 0.81 4.80
Bulgaria 0.00 0.09 0.21 0.06 0.18 0.59 1.46 1.12 0.88 0.12 4.71
Sweden 0.13 0.12 0.10 0.25 0.33 0.33 0.44 0.42 0.42 0.29 2.83
Turkey 0.01 0.04 0.01 0.03 0.26 0.16 0.35 0.27 0.73 0.46 2.32
Poland 0.05 0.05 0.14 0.19 0.16 0.19 0.24 0.46 0.33 0.42 2.25
France 0.20 0.23 0.52 0.06 0.15 0.27 0.08 0.11 0.08 0.31 2.00
Norway 0.21 0.05 0.09 0.09 0.21 0.22 0.23 0.12 0.32 0.39 1.93
Subtotal 4.64 3.43 3.75 3.46 4.18 5.11 7.96 7.60 5.86 8.21 54.20
* England, Wales, Scotland and Northern Ireland. 
Methamphetamine seizures, by  Fig. 90: 
subregion, 2007 (18.2 mt) 
Source: UNODC, Annual Report Questionnaire Data/DELTA; 
UNODC Drug Information Network for Asia and the Pacific 
(DAINAP); Government reports; World Customs Organization 
(WCO), Customs and Drugs Report 2007 (June 2008) and pre-
vious years.
0.7
8.9
0
3
6
9
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007Se
iz
u
re
s 
(i
n
 m
et
ri
c 
to
n
s 
eq
u
iv
al
en
ts
) 
Amphetamine Amphetamine+Non-s pecified Amphetamines Non-s pecified Amphetamines
All others
0.4%
Oceania
1.0%
West & Central 
Europe
2.0%
Near and Middle 
East /South-West 
Asia/ North Africa
0.2%
North America
40.4%
East and South-East 
Asia
56.0%
133
1. Trends in the world drug markets Amphetamine-type stimulants market
The subregions of East and South-East Asia (56%) and 
North America (40%) continue to account for most of 
the world’s seized methamphetamine, with relatively low 
seizures reported elsewhere. Over the last decade, 10 
Member States (or their territories) accounted for more 
than 95% of all reported seizures. 
Over the last decade, several changes have occurred. In 
1998, 10 Member States (or territories) accounted for all 
global seizures of methamphetamine. In 2007, the same 
10 Member States accounted for 95%, suggesting that 
other countries have emerged in the market. Canada 
increased its prominence in 2007, linked to increased 
manufacture and export by organized crime groups. The 
USA saw significant declines in methamphetamine 
seized in 2007. 
Methamphetamine trafficking shifts quickly,  
with devastating effects
The Greater Mekong Subregion (GMS),15 where some 
of the largest single methamphetamine seizures in the 
world have occurred, is central to methamphetamine 
manufacture, trafficking and use. Thailand, the largest 
market in the GMS, significantly increased law enforce-
ment efforts in 2003/04 in response to widespread 
methamphetamine use. As a result, illicit trafficking in 
the GMS has relocated from the Golden Triangle16 into 
neighbouring countries, including Cambodia, Lao Peo-
ple’s Democratic Republic and Viet Nam.
Emerging trends can be more clearly seen when measur-
ing the number of tablets seized, instead of the total 
15 A region encompassing Cambodia, Lao People’s Democratic Repub-
lic, Myanmar, Thailand, Viet Nam, and bordering provinces of south 
China.
16 The Golden Triangle is an area overlapping the borders of Lao PDR, 
Myanmar and Thailand.
weight. In 2004, tableted methamphetamine (yaba) 
seizures began increasing in Cambodia, Lao PDR, and 
Viet Nam, suggesting that trafficking routes shifted to 
the Mekong River. These shifts have accompanied 
increased use in the general population
Trafficking outside the subregion has also increased. 
Historically, trafficking of methamphetamine was intra-
regional, with laboratories manufacturing for the nearby 
domestic market. However, over the last few years, 
organized crime groups have increased their involve-
ment, bringing improved logistics, sophistication and 
production capacity, a more varied product line, and the 
ability to quickly move manufacture to geographic areas 
with weak control regimes.17 Interregional trafficking 
routes have been identified from Myanmar to Bangla-
desh and India; from Hong Kong, China, to Australia, 
Indonesia, Japan and New Zealand; from the Philip-
pines to Australia, Canada, New Zealand, and the USA; 
and from East and South-East Asia into the Islamic 
Republic of Iran, Saudi Arabia and the UAE.
Methamphetamine trafficked from Mexico drops  
in 2007, but may be temporary
Most methamphetamine trafficking in North America 
supplies demand in the USA. Methamphetamine manu-
facture in Mexico, and increasingly Canada, represent 
the bulk of methamphetamine trafficked into the USA. 
Following consistent increases for several years, 2007 
marked the first decline in methamphetamine seized by 
the US authorities along the border with Mexico. This 
trend was reversed however in 2008, with a return to an 
increase in border seizures,18 probably due to increasing 
17 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
18 USA National Drug Intelligence Center, National Methamphetamine 
Top countries (rank ordered) in methamphetamine seizures (mt), 1998-2007Table 22: 
Source: UNODC, Annual Reports Questionnaire Data/DELTA
Top Member 
State/Territory
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
China 1.61 16.06 20.90 4.84 3.19 5.83 2.75 6.76 6.07 6.09 74.10
Thailand 3.01 4.52 10.08 8.34 8.63 6.51 2.12 0.79 0.51 1.29 45.78
USA 0.00 2.64 0.00 2.86 1.11 3.86 5.74 6.24 7.61 4.89 34.94
Taiwan,  
Prov. of China 0.89 1.22 0.84 1.16 1.30 3.98 3.17 1.73 0.20 0.12 14.59
Philippines 0.00 0.94 1.02 1.71 0.91 3.12 3.73 0.10 0.77 0.37 12.68
Mexico 0.00 0.36 0.64 0.40 0.46 0.73 0.95 0.90 0.75 0.92 6.11
Myanmar 0.00 0.89 0.81 0.99 0.42 0.10 0.00 0.39 0.58 0.52 4.70
Japan 0.00 0.00 1.03 0.42 0.44 0.49 0.51 0.13 0.15 0.36 3.53
Indonesia 0.01 0.22 0.01 0.00 0.05 0.02 0.03 0.26 1.24 1.23 3.07
Canada 0.00 0.00 0.02 0.05 0.03 0.02 0.05 0.06 0.06 1.54 1.82
Subtotal 5.52 26.84 35.35 20.76 16.53 24.67 19.04 17.35 17.93 17.34 201.31
Percent of global 
seizures 100.0% 99.7% 98.8% 98.5% 98.5% 96.7% 96.9% 95.9% 95.3% 95.2%
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methamphetamine manufacturing capacity and sophis-
tication in Mexico. Another reason for increases in the 
USA is related to growing ‘smurfing’ activity, where 
criminal groups obtain precursor chemicals used in 
manufacture through small purchases from multiple 
pharmacies, avoiding sales restrictions and law enforce-
ment attention.19 In Mexico, drug cartels also utilize 
non-pseudo/ephedrine based precursor processes and 
have the capacity to shift operations further south to 
other Latin American countries in order to acquire tra-
ditional chemical precursors.
Canada-based organized crime groups’ participation in 
the methamphetamine trade has grown significantly 
since 2003. By 2006, law enforcement intelligence noted 
that Asian organized crime and traditional outlaw 
motorcycle gangs operating in Canada had increased the 
amount of methamphetamine they manufactured and 
exported, primarily into the USA, but also to Oceania 
and East and South-East Asia.20 For example, Australia 
identified that methamphetamine from Canada 
accounted for 83% of total seized imports by weight, 
for Japan the figure was 62%.21 Although only 5% of 
domestically manufactured methamphetamine was 
exported in 2006, by 2007 that figure was 20%.
Threat Assessment 2009.
19 This phenomenon, also known as ‘pill or pharmacy shopping’or 
‘pseudo-running’, is also observed in other countries where over-the-
counter pharmaceuticals used in the manufacture of methampheta-
mine are restricted (for example, Australia and New Zealand).
20 USA National Drug Intelligence Center, National Methamphetamine 
Threat Assessment 2009.
21 Australian Crime Commission (2009). Illicit Drug Data Report 
2006-07 (Revised March 2009); Recent Illicit Synthetic Drug Smug-
gling Situation in Japan. Presented by the Customs and Tariff Bureau, 
Ministry of Finance, Japan at the 18th Anti-Drug Liaison Officials’ 
Meeting for International Cooperation (ADLOMICO), (Pusan, 
Republic of Korea, 2008).
The geographic spread of methamphetamine 
increases
The increased reports of methamphetamine use outside 
East and South-East Asia and North America are also 
reflected in the growing number of countries and terri-
tories reporting seizures. In 2007, only 10% of reporting 
countries outside East and South-East Asia reported 
seizures of methamphetamine. This figure increased to 
25% in 2007. Countries are also reporting larger average 
seizures than in the past. As trafficking routes shift into 
Seized methamphetamine-related tablets, by select country, 2001–2007Fig. 91: 
Source: UNODC, Annual Report Questionnaire Data/DELTA; UNODC Drug Information Network for Asia and the Pacific (DAINAP); 
Viet Nam Country Report from the Joint Meeting of the Fourth Asian Collaborative Group on Local Precursor Control and Fourth 
International Forum on Control of Precursors for ATS Meetings (Tokyo, February 2008).
USA seizures of methamphetamine Fig. 92: 
near the Mexico border versus sei-
zures of large to industrial scale USA 
clandestine methamphetamine manu-
facture, 2001-2008*
Source: USA National Drug Intelligence Center, National Meth-
amphetamine Threat Assessment 2009 (and previous years); 
USA Drug Enforcement Administration, Office of Diversion 
Control. *Data as of November, 2008
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new countries, spillover drug use in the general popula-
tion and subsequent uptake can quickly occur. 
Although the Near and Middle East subregion has a 
well-established amphetamine market (fake Captagon), 
there is increasing evidence that methamphetamine 
(including the crystalline form) is also trafficked there. 
In 2008, the Islamic Republic of Iran reported its largest 
seizure of crystalline methamphetamine (150 kg), 
whereas in 2004, there were no reports of metham-
phetamine. This is consistent with reports of increased 
use.22 Significant seizures have also been reported in 
Saudi Arabia,23 including a 23 kg methamphetamine 
shipment originating in the Syrian Arab Republic.24 
 
22 Drug Control in 2008: Annual report and rapid situation assessment. 
Islamic Republic of Iran, Drug Control Headquarters (Tehran, 
2009).
23 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
24 World Customs Organization (WCO), Annual Customs and Drugs 
Report 2007 (Brussels, 2008).
Islamic Republic of Iran: seizure  Fig. 93: 
of crystalline methamphetamine,  
2004-2008 
Source: Policies Achievements Ongoing Programs and Future 
Plans, Islamic Republic of Iran, Drug Control Headquarters 
(Tehran, 2007); Drug Control in 2008: Annual report and rapid 
situation assessment. Islamic Republic of Iran, Drug Control 
Headquarters (Tehran, 2009); UNODC, Field Office Report 
(2005).
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Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006       2007
Metric ton 
equivalents(b)
15        15        34        44        26        23        37        36        43        46        44              
(a) Amphetamine-group substances are amphetamine, methamphetamine and related non-specified amphetamines (excludes ecstasy-group  substances).
(b) 1 dosage unit is assumed to be equal to 30 mg; 1 litre is assumed to be equal to 1 kg.
(c)  Data refer to England and Wales only.
(d) Total seizures reported by national as well as state and territory law enforcement agencies which may result in double counting.                                      
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SEIZURES OF AMPHETAMINE-GROUP SUBSTANCES (a) in % of world total and 
kg equivalents (b)  HIGHEST RANKING COUNTRIES - 2007
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Interception of amphetamines-group substances, 1997-2007Fig. 95: 
AMPHETAMINES INTERCEPTED - WORLD: 1997-2007 AMPHETAMINES INTERCEPTED - ASIA: 1997-2007
AMPHETAMINES INTERCEPTED - AMERICAS: 1997-2007 AMPHETAMINES INTERCEPTED - EUROPE: 1997-2007
AMPHETAMINES INTERCEPTED - AFRICA: 1997-2007 AMPHETAMINES INTERCEPTED - OCEANIA: 1997-2007
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Trafficking in ecstasy-group substances 
Ecstasy seizures increase in most regions
Ecstasy-group seizures increased by 62% in 2007 to a 
total of 7.9 mt. Notable increases were reported in sub-
regions with significant trafficking activity: West and 
Central Europe, Oceania, East and South-East Asia, and 
North America. Six countries accounted for more than 
80% of reported seizures, with the largest amounts 
reported by the Netherlands (25% of total), followed by 
Australia, USA, Canada, the UK25 and China.  
Seizures reported from Europe account for the majority 
(39%) of global seizures, as significant manufacturing 
continues in the West and Central subregion, most 
notably in the Netherlands and Belgium. However, 
around 2002/03 subregions outside of Europe began 
reporting increased domestic manufacture.
In 2007, 52% of Member States reported seizures of 
ecstasy-group substances in 2007, almost double that of 
1998 (27%). The average amount reported seized per 
country increased five-fold, from about 21 kg in 1998 
to 115 kg in 2007.
West and Central Europe remains a dominant 
source for ecstasy 
Although more ecstasy-group manufacture is taking 
25 Data for the UK (England and Wales) reported in the 2007 ARQ 
are placeholders from 2006, as reporting is delayed. UK data include 
Scotland and Northern Ireland figures from 2007.
26 A reported tablet of “ecstasy” was assumed to contain on average 100 
mg of MDMA.
place outside of Europe, it remains the main illicit man-
ufacturing region. Customs interceptions in 2007 were 
most commonly reported in the Netherlands (88 cases) 
and Belgium (22 cases).27 Increased European seizures 
in 2007 are likely related to increases in MDMA avail-
ability as seen in forensic profiling. Large numbers of 
tablets containing very high levels of MDMA were also 
reported. Following temporary shortages of MDMA 
after the dismantling of one of the largest MDMA labo-
ratories ever discovered in the Netherlands in 2005,28 
markets appeared to rebound by 2007, with MDMA 
content of ‘ecstasy’ tablets returning to previous, or 
higher, levels. Additionally, there were reports of high 
content (100-125 mg) MDMA mixed with alcohol 
called “Original 69” and “Dance Love Sex” appearing 
on the market.29 
Although notable domestic manufacture of MDMA 
occurs in countries in other regions, such as Australia, it 
is clear that exports from West and Central Europe and 
East and South-East Asia continue to play a significant 
role in domestic market supply. West and Central 
Europe, for example, was the source of a record intercep-
tion of ecstasy in Australia in June 2007.30 
27 World Customs Organization (WCO), Annual Customs and Drugs 
Report 2007 (Brussels, 2008).
28 In May 2007, police in Veldhoven, Netherlands, seized a warehouse 
with one of the largest drug caches ever discovered, reportedly con-
taining 780 kg of MDMA and 3.5 million ecstasy tablets.
29 The Netherlands Drug Situation 2008: Report to the EMCDDA by the 
Reitox National Focal Point, Trimbos Institute, Utrecht, Netherlands, 
2009. 
30 Australian authorities completed a year-long controlled delivery of 
nearly 15 million tablets, with a total weight of 4.42 mt, which 
departed from Italy. Australian Crime Commission (2009). Illicit 
Drug Data Report 2006–07, Revised March 2009.
Global ecstasy-group substance  Fig. 96: 
seizures, 1998-2007
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Proportion of ecstasy-group sub-Fig. 97: 
stance seizures, by subregion, 2007
Source: UNODC, Annual Reports Questionnaire data
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Since 2003/04 Canada has emerged as the primary 
source of ecstasy-group substances for North American 
markets, and increasingly for other regions. As of 2007, 
identified ecstasy laboratories were large-capacity facili-
ties primarily controlled by Asian organized crime 
groups, utilizing precursor chemicals trafficked from 
China in sea containers. In 2007, it was estimated that 
50% of domestically produced ecstasy was trafficked 
outside of Canada. Most of this was thought to be des-
tined for the USA, Australia and Japan.
Japan, Indonesia and other countries in East and South-
East Asia have reported significant trafficking of ecstasy. 
Unlike Indonesia, Japan has no domestic ATS manufac-
ture, so increases in ecstasy are all from imports, often 
via organized crime groups. In 2007, Japan identified 
Canada as the single biggest source for seized ecstasy 
tablets, followed by the Netherlands, Germany, and 
Belgium.31 
31 Recent illicit Synthetic Drug Smuggling Situation in Japan. Presented 
by the Customs and Tariff Bureau, Ministry of Finance, Japan at the 
18th Anti-Drug Liaison Officials’ Meeting for International Coop-
eration (ADLOMICO), (Pusan, Republic of Korea, 2008).
In Latin America, there remains concern that ecstasy-
groups drugs, sourced from West and Central Europe 
are increasingly being used, particularly among young, 
affluent urban dwellers. There are few ATS-related traf-
ficking data available in the region, partly due to the fact 
that law enforcement focusses on coca-based substances. 
However, data from Brazil clearly indicate that increas-
ing numbers of tablets are being intercepted, with more 
than 210,000 seized in 2007.32 The increase may also be 
related to domestic manufacture of ecstasy as the first 
clandestine laboratory was discovered in 2008.
 
32 In February 2009, Brazil Federal Police arrested 55 people nation-
wide that were part of an international drug trafficking ring. The 
members–mostly young and middle-class–would traffic cocaine from 
South America to Europe in return for ecstasy to sell in Brazil. 
“Ecstasy Ensnares Upper-Class Teenagers in Brazil,” New York 
Times, 15 February 2009, www.nytimes.com/2009/02/15/world/
americas/15ecstasy.html.
Ecstasy-group tablets seized in Japan Fig. 98: 
and Indonesia, 1998-2007 
Source: UNODC, Annual Reports Questionnaire data
Ecstasy-group tablets seized in Brazil: Fig. 99: 
1998-2007 
Source: UNODC, Annual Reports Questionnaire data
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Year 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Kilogram
equivalents 2,227  958     4,661 5,003  4,597  6,916  4,903  8,245  5,180  4,897  7,948
reported by
** data refer to
2003.
(a) Seizures as reported (street purity); units converted into weight equivalents (100mg / unit)
(b) Total seizures reported by national as well as state and territory law enforcement agencies which may result in double counting.
(c)  Data refer to England and Wales only.
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Ki
lo
gr
am
 e
qu
iv
al
en
ts
(b
)
2,162
35
35
28
21
95
99
110
124
129
136
150
183
222
985
1,002
1,970
68
50
54
49
46
0.000 500.000 1000.000 1500.000 2000.000 2500.000
Netherlands (27%)
Australia (25%)
USA (13%)
Canada (12%)
China (3%)
Malaysia (2%)
Indonesia (2%)
France (2%)
Japan (2%)
Israel (2%)
Turkey (1%)
Germany (1%)
United Kingdom (1%)
Poland (0.9%)
Belgium (0.7%)
Italy (0.6%)
Spain (0.6%)
Hungary (0.6%)
Russian Federation (0.4%)
Ireland (0.4%)
Thailand (0.4%)
Brazil (0.3%)
(b)
(c)
2,924
1,987
1,970
739
132
122
39
27
5
2
West & Central Europe (37%)
North America (25%)
Oceania (25%)
East and South-East Asia (9%)
Near and Middle East /South-West
Asia (2%)
Southeast Europe (2%)
East Europe (0.5%)
South America (0.3%)
Southern Africa (0.1%)
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SEIZURES(a) OF ECSTASY-GROUP SUBSTANCES 
in kg equivalents and in % BY REGION - 2007
SEIZURES(a) OF ECSTASY-GROUP SUBSTANCES in kg equivalents and in % of world total 
  HIGHEST RANKING COUNTRIES - 2007
(a)  Includes substances believed to be ecstasy (eg, MDMA, MDA, MDE) and may not have been confirmed by forensic 
testing. Separate reporting of 'Ecstasy' seizures only started with the new ARQ. Before, Ecstasy seizures were included 
under the category of 'hallucinogens'. Trend data shown above refer to the broader category for 1997-1999 and for 
Ecstasy for 2000-2007.  Over the 2000-2007 period, Ecstasy accounted for 93% of the broader category.
 (b) 1 unit is assumed to be equivalent to 100mg of MDMA.
Global seizures of ecstasy-groupFig. 100: (a) substances, 1997-2007
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Amphetamine-type stimulant  
consumption
The number of ATS consumers is very uncertain
In 2007, there were between 16 and 51 million people 
aged 15-64 who consumed amphetamines-group sub-
stances (annual prevalence 0.4%-1.2%). Ecstasy-group 
users numbered between 12 and 24 million worldwide 
(annual prevalence 0.3%-0.5%). The width of these 
ranges is far greater than for cocaine and heroin.
Illicit drug use is difficult to assess accurately, but ATS 
use even more so, for a variety of reasons. These include 
the speed with which ATS markets can appear and 
expand, the fact that ATS can be manufactured any-
where in the world, the general confusion about what 
users actually consume, and the high reliance upon lim-
ited or non-existent country reporting1. This year, sig-
nificant revisions were made to the approach taken in 
making global and regional estimates of the number of 
people who use drugs. The new estimates reflect the 
uncertainties surrounding these data (which exist due to 
1 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
data gaps and quality) and are presented in ranges rather 
than absolute numbers. Because of this revision, previ-
ous point estimates are not comparable to the current 
ones. 
Amphetamines-group drug consumption
Many countries do not differentiate the type of ATS 
consumed (methamphetamine, amphetamine or other 
synthetic stimulants) so only broad estimates of use of 
specific types can be made, based upon reports and sei-
zure data reported by Member States. 
UNODC estimates that methamphetamine users 
account for 54%-59% of global amphetamines-group 
substances consumers; amphetamine users account for 
32%-35%; and an additional 8%-11% use other non-
specified illegal synthetic stimulants (such as methcathi-
none, pharmaceutical stimulants, et cetera). 
Amphetamines-group users in East and South-East Asia 
consume primarily methamphetamine. Tablets sold as 
Captagon often contain amphetamine and are used 
throughout the Near and Middle East. In Europe, users 
Annual prevalence of amphetamine-type stimulant use, by drug group  Fig. 101: 
(in numbers and prevalence of population)
Source: UNODC estimate.
Note: 2007 estimates cannot be compared to previous UNODC estimates.
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primarily consume amphetamine, with a few exceptions, 
notably the Czech Republic and some neighbouring 
countries where methamphetamine use is predomi-
nant. 
About half of stimulant users in North America use meth-
amphetamine. In Latin America, amphetamines-group 
use was historically thought to be diverted pharmaceuti-
cals, but increasing incidents of ATS manufacture suggest 
that this is changing. Use of amphetamines-group sub-
stances in South Africa2 is believed to be predominately 
methamphetamine; while in Western, Central and East-
ern Africa and some parts of Southern Africa the amphet-
amines-group markets are thought to consist of various 
pharmaceuticals. Finally, users in Oceania are thought to 
primarily use methamphetamine.
Uncertain number of ATS users in Asia;  
South-East Asia probably has the most users  
in the region
At least half of the world’s amphetamines-group users 
– between 5.8-37.0 million – live in Asia. Most of these 
are methamphetamine users in East and South-East 
Asia, which account for between 52-79% of estimated 
users in the region.3 
The substantial uncertainty in this region is related to 
the unknown number of users in China and India. Due 
to a lack of country-level prevalence estimates, subre-
gional estimates cannot be calculated for South Asia, 
Central Asia, or the Near and Middle East.5 
2 Methcathinone–another ATS–is also commonly used in South 
Africa. 
3 The criteria to calculate subregional estimates include recent (since 
1998) representative prevalence estimates from at least two countries 
in a subregion that, combined, account for at least 20% of the sub-
region’s total population aged 15–64 years.
There is more certainty in estimates for the Americas, 
Europe and Oceania. Oceania had the highest estimated 
annual prevalence in the general population aged 15-64 
(2.6%). The total number of amphetamines-group users 
in North America is estimated at around 3.8 million 
people, or some 1.3% of the population aged 15-64. Latin 
America (including Central America, the Caribbean and 
South America subregions) had an estimated two million 
users. In Europe, the number of users is estimated between 
2.4 and 3.1 million (0.4-0.6% of the population). 
Africa is estimated to have between 1.4 and 4.1 million 
users. However, subregional estimates could only be 
calculated for two of the four subregions (North and 
Southern Africa). For much of Africa, little information 
related to ATS consumption is available, which explains 
the greater levels of uncertainty reflected in the preva-
lence estimates for the region. 
The highest annual prevalence ranges in the Oceania 
region are reported by Australia; in North America, by 
the USA; and in Europe, by Scotland (UK) and Estonia. 
In Asia, the highest prevalence ranges are found in the 
Philippines; in the Caribbean, in the Dominican Repub-
lic; in Central America, in El Salvador;4 in South Amer-
ica, in Brazil; and in Africa, in Nigeria and South Africa. 
4 The prevalence estimates for El Salvador may also include non-ATS 
stimulants (for example, diet/slimming pills or caffeine pills) used 
without a prescription.
Estimated Fig. 102: amphetamines-group users in the past year by region, 2007
Sources: UNODC, Annual Reports Questionnaire; Government reports; reports of regional bodies; and UNODC estimates.
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Expert perceptions: ATS growth in developing  
countries outpacing developed countries  
A review of changes in expert perception data5 in the 
individual regions between 1998 and 2007 finds contin-
ued increases in ATS use. Beginning around 2000, the 
rate of increases perceived by experts between developed 
and developing countries diverged, as developing coun-
tries, particularly those in Asia and the Americas, more 
often perceived significant increases in ATS use.6 
Nearly half of experts from 86 countries perceived that 
the ATS situation had worsened in their country over 
the past year, whereas 14% identified some improve-
ment.7 The proportion of countries reporting a perceived 
 
5 Expert perception data is derived from the ARQ, and is unweighted. 
The following points are allocated if experts perceive: ‘strong increase’ 
2; ‘some increase’: 1; stable: 0; ‘some decline’ -1; ‘strong decline’ -2. If 
all countries had reported ‘some increase’, the global trend line would 
have increased by one point each year and would have reached 109 by 
2007.   
6 OECD Member countries include: Australia, Austria, Belgium, 
Canada, Czech Republic, Denmark, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, 
Netherlands, New Zealand, Norway, Poland, Portugal, Republic of 
Korea, Slovakia, Spain, Sweden, Switzerland, Turkey, the United 
Kingdom and the USA.
7 Increases and decreases were coded from some to strong increase/
decrease, and represent the unweighted number of Member States 
and territories responding.
Estimated number of people who used amphetamines at least once in the past year and  Table 23: 
proporton of population aged 15-64, by region, 2007
Sources: UNODC, Annual Reports Questionnaire; Government reports; reports of regional bodies; and UNODC estimates.
ATS use trends as perceived by  Fig. 103: 
experts of developed (OECD) and  
developing (non-OECD) countries, 
1998-2007 (baseline: 1998 = 100)
Sources: UNODC, Annual Reports Questionnaire Data, 
UNODC Field Offices, UNODC’s Drug Use Information  
Network for Asia and the Pacific (DAINAP).
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number of users 
annually (upper)
Percent of  
population aged 
15-64 (lower)
Percent of  
population aged 
15-64 (upper)
Africa
 North Africa
 West and Central Africa
 Eastern Africa
 Southern Africa
1,390,000
240,000
4,090,000
510,000
0.3
0.2
0.8
0.4
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
210,000 650,000 0.2 0.6
Americas
 North America
 Central America
 The Caribbean
 South America
5,650,000
3,760,000
310,000
120,000
1,450,000
5,780,000
3,760,000
310,000
250,000
1,460,000
0.9
1.3
1.3
0.5
0.6
1.0
1.3
1.3
1.0
0.6
Asia
 East/South East Asia
 South Asia
 Central Asia
 Near and Middle East
5,780,000
4,600,000
37,040,000
20,560,000
0.2
0.3
1.4
1.4
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Europe
 Western/Central Europe
 East/South East Europe
2,430,000
1,590,000
840,000
3,070,000
1,690,000
1,380,000
0.4
0.6
0.3
0.6
0.6
0.5
Oceania 570,000 590,000 2.6 2.6
Global 15,820,000 50,570,000 0.4 1.2
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increase in ATS use–predominately methamphetamine–
was highest in Asia (56%). Subregionally, experts per-
ceived a worsening ATS problem in three distinct areas: 
central Asia (for example Azerbaijan and Georgia); 
countries and territories on the east coastal area of Asia 
(for example, China, Republic of Korea and Viet Nam); 
and the Near and Middle East and its close neighbours 
(for example, Cyprus, Jordan, Lebanon, Oman, Pakistan 
and Qatar). 
Methamphetamine was identified as the “most used” 
illicit drug in Cambodia, Japan, Lao People’s Demo-
cratic Republic, the Philippines, the Republic of Korea 
and Thailand.8 Thailand has the largest market for 
methamphetamine in South-East Asia’s Greater Mekong 
Subregion.9 After some apparent reductions in metham-
8 The most recent data reported for Cambodia and Lao PDR is for 
2006 (UNODC, Patterns and Trends of Amphetamine-Type Stimulants 
and Other Drugs of Abuse in East Asia and the Pacific 2006 (June 
2007)). The data for the Republic of Korea do not include cannabis.
9 Cambodia, Lao PDR, Myanmar, Thailand, Viet Nam and bordering 
provinces of south China.
phetamine use in 2003/04, recent trends indicate a 
resurgence of use.10 The 2007 general population esti-
mates suggest that lifetime methamphetamine preva-
lence is 1,7%, and annual prevalence 1.4%. This is 
reflected in treatment and enforcement data. Between 
2004 and 2007, the number of people seeking treatment 
has more than doubled, while arrests for methampheta-
mine-related offenses increased to their highest level ever 
in 2007. 
Methamphetamine use is spreading throughout  
the South and South-East Asia
The routes supplying Thailand with methamphetamine 
changed markedly after 2003/04, with increased use of 
the Mekong River. This led to drugs transiting through 
10 Among other things, the ‘Thai war on drugs’ had the effect of reduc-
ing self-reporting of illicit drug use in surveys; results between 2003 
and 2006 indicate low lifetime prevalence rates . Under-reporting of 
methamphetamine use in Thailand probably continues. See World 
Drug Report 2008 (United Nations publication, Sales No. E.08.
XI.1).
Thailand, number of methamphetamine treatment admissions and arrests, 1998-2007Fig. 104: 
Sources: Office of the Narcotics Control Board, Thailand Narcotics Annual Report 2003; UNODC, Improving ATS Data and Informa-
tion Systems Project; UNODC, Drug Use Information Network for Asia and the Pacific (DAINAP).
Expert perception of changing amphetamine-type stimulant use, by region, 2007Table 24: 
Sources: UNODC, Annual Reports Questionnaire data.
Region
Member 
States 
responding
Use problem 
increased*
Percent use 
problem 
increased
Use  
problem 
stable
Percent use 
problem 
stable
Use  
problem 
decreased*
Percent use 
problem 
decreased
Europe 34 14 41% 16 47% 4 12%
Americas 16 7 44% 8 50% 1 6%
Asia 25 14 56% 6 24% 5 20%
Oceania 0 0 0 0
Africa 11 5 45% 4 36% 2 18%
Global 86 40 47% 34 40% 12 14%
* Identifies increases/ decreases ranging from either some to strong, unweighted by population.
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and into Cambodia, Lao PDR and Viet Nam.11 Rapid 
increases in methamphetamine tablets and high purity 
crystalline methamphetamine uptake soon occurred 
across Cambodia. In 2007, there were 1,719 drug users 
admitted to government-operated centres for drug users, 
a 58% increase over 2006.12 The majority of users were 
admitted for methamphetamine. A recent study of 12 
 
11 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
12 Cambodian National Authority for Combating Drugs (2008). Report 
on illicit drug data and routine surveillance systems in Cambodia 2007.
13 UNODC, Development of Community-Based Drug Use Counsel-
ling, Treatment and Rehabilitation Services in Cambodia: Com-
mune-based Baseline Behaviour Survey in 60 Communes in 12 
Provinces in Cambodia (May 2008).
provinces also showed that the use of methampheta-
mine has spread to many rural provinces of the 
country,15 possibly related to domestic manufacture of 
methamphetamine, first reported in 2006 and more 
significantly again in 2007. Similar changes have 
been reported to varying degrees in neighbouring coun-
tries.
 
14 International Cooperation Division, Narcotics Control Bureau, 
Ministry of Public Security, presentation entitled ‘Drug data collection 
in China’, 4th International Forum on the Control of Precursors for 
ATS (Tokyo, 2008).
15 Methamphetamine, ecstasy, ketamine, phencyclidine, and benzo-
diazepine derivatives. Office of China National Narcotics Control 
Commission, Annual report on drug control in China 2009 (and 
previous years) (Beijing, 2009). 
Asia: ATS use appears to be increasing, but by how much?  
There are no national prevalence estimates of ATS consumption in China and India. These gaps are major given the 
size of these countries’ populations (0.95 billion persons aged 15-64 years in China, and 0.73 billion persons aged 
15-64 years in India). Such gaps have an enormous impact upon the level of certainty of both regional and global ATS 
use estimates. 
Furthermore, with increases in both population and disposable income, their position next to several significant 
manufacturing countries, and expanding domestic manufacture, both countries face substantial risks related to growing 
ATS use. 
India: India last performed a household survey in 2000/01, but questions specific to various types of ATS consumed 
were not included. Due to a lack of data for India, estimates cannot be calculated for the South Asia subregion. How-
ever, given India’s population, its contribution to annual prevalence estimates for Asia (using other regional estimates) 
may be 29%, which represents millions of potential users. 
The last assessment of India’s treatment facilities was conducted in 2001. It found that 0.2% of treatment was for ATS. 
The South Asia subregion is highly vulnerable to an increase in problems related to ATS, however, and it is likely that 
the extent of use and problems related to use of ATS have increased since that time. First, key ATS precursor chemicals 
are readily available and significant ATS manufacture is already taking place. Second, the region is home to a large 
youth population of potential consumers with increasing disposable income. Third, the region’s prevention and treat-
ment regimes are largely focused on other drug types. Finally, the geographic location between the significant ATS 
markets in the Near and Middle East and East and South-East Asia, make the countries particularly vulnerable. 
In India and Bangladesh, methamphetamine trafficking via the border with Myanmar, the source of much of Asia’s 
methamphetamine, is increasing. The threat to South Asia was highlighted in May 2008 when a large sophisticated 
methamphetamine laboratory was seized in Kosgama, Sri Lanka , and in November 2008 when the first operational 
methamphetamine laboratory was seized in Vadodara, India, along with significant amounts of methamphetamine. In 
December 2008, an industrial-scale pseudoephedrine extraction operation with nearly 5 metric tons of methampheta-
mine precursor chemicals was reportedly discovered in Mumbai. 
China: China’s experts report strong increases in the use of methamphetamine, which coincide with increased domes-
tic manufacture and trafficking, and a year-on-year declines in heroin seizures. In just three years (2004–07), the 
proportion of registered drug users for ATS increased more than fivefold, from less than 2% to 11% of registered drug 
users by 2007.13 In 2008, China reported that 19.1% of its registered drug users nationwide used “new types” of 
drugs–predominately ATS-related14–higher than in previous years. However, no general population estimates of the 
extent of use of ATS have ever been reported.
In China, methamphetamine in both crystal and tablet forms is trafficked from Myanmar directly or by transiting Lao 
PDR or Viet Nam. Significant methamphetamine manufacture takes place within China using precursor chemicals 
diverted from industry or by extracting precursor chemicals from pharmaceutical products. The risk to China was 
highlighted by very recent large- scale methamphetamine manufacture found using sophisticated methods that do not 
require controlled precursors. Of note are increasing seizures of ketamine, which although not an ATS is marketed as 
an ATS-type drug, either by itself, or mixed with other drugs like methamphetamine and sold as ecstasy.
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Data from East Asia suggest some  
reductions in use
The Japanese population has experienced several cycles 
of stimulant use since the end of the Second World War. 
However, accurately and reliably assessing use in the 
country’s general population presents particular chal-
lenges, since typical household-type surveys tend to have 
extremely low response rates and there may be sensitivity 
around disclosure of use. Trends in administrative data 
since 1998/99 suggest that problematic methampheta-
mine use may be declining: the number of stimulant 
abuse/dependence cases reported by psychiatric facilities 
declined 11% from 1999 to 2005, but still account for 
over half of reported cases.16 Methamphetamine-related 
arrests continue to decline, yet account for more than 
three-quarters of all drug-related arrests.17 
The Philippines’ recent (2007) household survey con-
cluded that annual prevalence of methamphetamine use 
in the general population declined from 6% (in 2004) 
to between 1.9-2.4%. Treatment admissions for meth-
amphetamine have also declined from 6,195 in 2003 to 
2,562 in 2007, but still account for 60% of new admis-
sions.18 Significant manufacturing and trafficking of 
ATS continue to be problematic for the country.
Some Near and Middle East countries emerge  
as significant amphetamine consumers 
The Near and Middle East has been reporting dramatic 
increases in ATS–predominately fake pharmaceuticals 
16 Ministry of Health and Social Welfare, General situation of adminis-
trative measures against drug abuse (2007).
17 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
18 Treatment data are those provided by the public health system and do 
not include treatment provided by non-government and faith-based 
treatment providers.
sold as Captagon – over the last few years. Saudi Arabia, 
the largest market, has seen increases in problem use that 
coincide with significant increases in region-wide sei-
zures. One specialized drug treatment hospital found 
that between 1998-2006, treatment admissions for 
amphetamines-group use increased nine-fold, and the 
proportion of amphetamines-group treatment relative to 
all admissions tripled (from 25% to 73%).19 
The Islamic Republic of Iran’s recent rapid situation 
assessment of drug users in treatment centres, prisons, 
and of homeless persons found that approximately 
3.6% of these groups of these groups primarily used 
crystalline methamphetamine, whereas no use was 
reported in 2004/5.20 Iran has reported yearly increases 
in methamphetamine seizures, suggesting that availabil-
ity is increasing. 
In Europe, amphetamine use stable or decreasing; 
methamphetamine pockets persist
European amphetamines-group use appears stable, with 
West and Central European countries reporting stability 
or some decline. Perceived increases were subregional, 
with some increase in central Europe (Switzerland, Aus-
tria, Slovakia, Ukraine and the Republic of Moldova) 
and northern areas (Estonia, Latvia, Norway and 
Sweden). 
Annual prevalence continues to decline in the United 
Kingdom, historically Europe’s most significant amphet-
amine market. The annual prevalence rate of 1.0% in 
19 Abu Madini M. S., Rahima S. I. A., Al-Zahrani M. A. & Al-Johi A. 
O. (2008). Two decades of treatment seeking for substance use disorders 
in Saudi Arabia: Trends and patterns in a rehabilitation facility in 
Dammam. Drug and Alcohol Dependence, 97(3), pp 231-236.
20 Drug Control in 2008: Annual report and rapid situation assessment. 
Islamic Republic of Iran, Drug Control Headquarters (Tehran, 2009).
Saudi Arabia (Dammam) amphetamines-group treatment admissions, 1998-2006 Fig. 105: 
Source: Abu Madini M. S., Rahima S. I. A., Al-Zahrani M. A. & Al-Johi A. O. (2008). Two decades of treatment seeking for substance 
use disorders in Saudi Arabia: Trends and patterns in a rehabilitation facility in Dammam. Drug and Alcohol Dependence, 97(3), pp 
231-236.
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2007/08 in England and Wales is one third of the level 
one decade ago. However, the same reduction did not 
take place in Scotland, as rates of annual amphetamine 
use increased from 0.5% in 2000 to 2.2% in 2006.21 
However, some countries in Eastern Europe have wit-
nessed increases in amphetamines-group drug use. The 
Czech Republic is central to Europe’s methampheta-
mine use, with most of the methamphetamine sourced 
from domestic clandestine laboratories. Although 
younger metropolitan users account for the majority, 
increased use is occurring in small towns and rural are-
as.22 First-time treatment demand for methampheta-
mine continues to grow, accounting for nearly two thirds 
of all drug treatment. Many of the country’s “problem 
drug users” inject methamphetamine.
Similarly, experts in the Ukraine are reporting increased 
injecting drug use, particularly ATS: crude home-made 
synthetic stimulants such as methamphetamine, meth-
cathinone and cathinone are often shared by groups of 
young injecting drug users.23 
21 Brown, M. & Bolling, K. (2007). Drugs misuse in Scotland: Findings 
from the 2006 Scottish crime and victimization survey. BMRB Social 
Research, Edinburgh; National Advisory Committee on Drugs and 
Public Health Information and Research Branch (2008). Similar 
patterns were also noted for ecstasy-group substance use for Scotland 
and Northern Ireland.
22 The Czech Republic - 2007 Drug Situation (2008). Czech National 
Monitoring Centre for Drugs and Drug Addiction (Prague, 2008).
23 Pavlenko, V. (2008). Peculiarities of stimulators using in Ukraine by the 
example of Donetsk region, presented at the Global Methamphetamine 
Conference, Prague (September, 2008). International Charitable 
Foundation/ International HIV/AIDS Alliance in Ukraine; Zeziulin, 
O., Dumchev, K., & Schumacher, J. (2008). Injection stimulant use 
and HIV risk in Ukraine, presented at the Global Methamphetamine 
Conference, Prague (September, 2008).  
South African ATS use shows signs of stabilization, 
but little is known about the rest of the continent 
Most subregions of Africa lack basic data on ATS use, 
making it difficult to assess its extent or provide subre-
gional estimates of use. However, ATS consumption has 
been reported in several African countries, including 
Burkina Faso, Côte d’Ivoire, Egypt, Ghana, Nigeria, 
Senegal, Sierra Leone and South Africa. 
South Africa is one of the most significant metham-
phetamine markets in Africa and is one example of the 
rapid increase that can occur in ATS use. In Cape Town 
and the surrounding area, where most of the country’s 
methamphetamine use currently occurs, demand for 
methamphetamine treatment was non-existent before 
2002. By 2008, it accounted for 36% of treatment, 
although recent data suggest that use among youth may 
be on the decline.24 
Egypt has some history of problematic synthetic stimu-
lant use (Maxiton Forte25), however, recent seizure data 
show that little is currently seized. Recent research on 
ATS use suggests that 2.2% of state university students 
across the country had ever used stimulants, of whom 
approximately one third admitted current use.26 In a 
2005/06 national survey assessing drug use in eight 
24 Plüddemann, A., Parry, C., Bhana, A., & Fourie, D. (2008). 
South African Community Epidemiology Network on Drug Use 
(SACENDU) Update (18 November 2008).
25 Maxiton Forte, was the trade name for a pharmaceutical preparation 
containing dexamphetamine, but is no longer manufactured. There 
have been indications that methamphetamine is being sold in Egypt’s 
illicit markets under this brand name, however, to date there is still 
insufficient information about the actual content of this product and 
its source of manufacture.
26 Yousuf J. Egypt, Use of Neuroactive Substances among university stu-
dents: Preliminary Indicators, National Council for the Control of 
Treatment and Addiction (Cairo, 2007).
England and Wales: Annual prevalence Fig. 106: 
of amphetamine use among the gener-
al population (aged 16-59), 1998-2008
Source: Kershaw, C., Nicholas, S., & Walker, A. (2008). Crime 
in England and Wales 2007/08: Findings from the British 
Crime Survey and police recorded crime. Home Office Statisti-
cal Bulletin (ISBN 978-1-84726-753-5)(London, 2008).
Czech Republic ﬁrst-time treatment Fig. 107: 
demand for methamphetamine use, 
1998-2007
Source: The Czech Republic - 2007 Drug Situation (2008). 
Czech National Monitoring Centre for Drugs and Drug  
Addiction (Prague, 2008).
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regions, 10% of the population aged 15 and older had 
ever used drugs, with 0.5% admitting to having ever 
used stimulants.27 
The existence of unregulated (parallel) pharmaceutical 
markets28 throughout Africa is believed to be a signifi-
cant source of ATS.29 These markets exist in large part 
due to limited access to health-care facilities, the high 
cost of drugs, a need for privacy, a general lack of public 
awareness, overly strict drug control regimes, and to 
meet consumer demand for drugs.30 According to 
WHO, between 25-50% of medicines consumed in 
developing countries are counterfeit, and include ATS.31 
Burkina Faso has significant seizures of (non-specified) 
ATS pharmaceuticals termed ‘médicaments de rue’. 
Although representative data on ATS use in Burkina 
Faso is non-existent, authorities in 2005 indicated that 
the most significant (and increasing) drugs of use were 
ATS. The same year, a report on psychiatric hospital 
treatment data in the capital Ouagadougou found that 
28% of treatment episodes were primarily for ampheta-
mines-group substances, the highest of any drug group 
apart from cannabis.32 
27 Ghaz I.H., National Study of Addiction Prevalence of the Use of Drugs 
and Alcohols in Egypt (2005 – 2006), Studies of the National Centre 
for Social and Criminal Research Fund for the Control and Treat-
ment of Addiction and Abuse (Cairo, 2007).
28 Unlicensed individuals and/or business entities that trade in drugs 
that they are not authorized or entitled to deal with or in contraven-
tion of the applicable laws, regulations and norms. These may include 
real or often counterfeit pharmaceuticals.
29 These may also include non-ATS stimulants (for example, slimming/
diet pills and ephedrine).
30 International Narcotics Control Board (2007). Report of the Interna-
tional Narcotics Control Board for 2006. (United Nations publication 
Sales No. E.07.XI.11)
31 World Health Organization, “Counterfeit medicines”, Fact Sheet No. 
275, February 2006.
32 Ouedraogo, A. (2007). Demandes de traitement pour abus de drogues 
In Nigeria, Africa’s most populous country, metham-
phetamine use was previously reported in the northern 
parts of the country. More recent research however has 
identified significant use by young people (age 10-19; 
6.7% lifetime prevalence) and university students (2.1% 
lifetime prevalence) in the south-western city of Ilorin 
and its surrounding catchment area.33 
Methamphetamine use may be declining  
in parts of North America 
North America continues to lead the western hemi-
sphere in ATS use. Recent data, however, suggest 
declines, particularly in methamphetamine use in 
Canada and the USA. Since 1999, Canadian (Ontario)34 
and US students have reported declining methampheta-
mine use, but actual use is probably underreported as 
young people are increasingly using ‘ecstasy’ sourced 
from Canada which often contains methamphetamine 
as the primary psychoactive ingredient.35
Data from the USA household survey of the general 
population (12 and older) show that in 2007, the first 
notable decline in illicit amphetamines-group use took 
place, driven by declines in methamphetamine use.36 
au Burkina Faso. Université de Ouagadougou. 
33 Makanjuola A.B., Daramola T.O. & Obembe A.O. (2007). Psycho-
active substance use among medical students in a Nigerian university. 
World Psychiatry, 6(2): 112–114; Abdulkarim A.A., Mokuolu O.A. 
& Adeniyi A. (2005). Drug use among adolescents in Ilorin, Nigeria. 
Tropical Doctor, 35(4), pp 225-228.
34 These data reflect Ontario students, which have drug use characteris-
tics that are notably different from other provinces and territories. See 
Centre for Addiction and Mental Health. Drug Use Among Ontario 
Students, 1977-2007: Detailed OSDUHS findings (Toronto, 2007).
35 Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
36 Office of National Drug Control Policy. Making the drug problem 
smaller 2001-2008. Executive Office of the President (Washington, 
South Africa (Cape Town area): proportion of methamphetamine as primary substance  Fig. 108: 
for treatment, 1998-2008** 
Source: South African Community Epidemiology Network on Drug Use (SACENDU). Monitoring Alcohol & Drug Use Trends in South 
Africa (July 1996 – June 2008). Research brief, 11(2) (December 2008).
*Beginning mid-2006 totals included treatment in Cape Town, Atlantis and Worcester. **Figures represent data from the first half of 2008.
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Treatment admissions data from Canada (Ontario)37, 
the USA and Mexico suggest that there has been stabili-
zation–at high levels–or perhaps varying degrees of 
decline in the proportions of patients with problematic 
methamphetamine use.38 
Similar declines in methamphetamine use were reported 
in non-representative workplace drug testing, which 
recorded its lowest levels (0.1%) since 2002.39 However, 
stimulant substitution may be occurring in the USA, as 
amphetamines-group stimulants overall continued to 
climb among the general workforce and are at signifi-
cantly higher levels than a decade ago. This is consistent 
with increases in the use of psychostimulants such as 
methylphenidate40 in the USA, which have increased 
dramatically since the 1990s.41
DC, 2009).
37 The data for Canada (Ontario) represent clients that may report 
up to five presenting problem substances at admission (of which 
methamphetamine may not necessarily be the primary problem drug 
of use). Data include clients presenting for both amphetamine or 
methamphetamine (the methamphetamine category was added in 
June 2006). Data are reported on a fiscal year, from April – March. 
38 Caution should be exercised as these system are funded differently 
and data are captured differently. Additionally, while decreases were 
noted in methamphetamine as the primary drug for the USA and 
Mexico, methamphetamine is commonly associated with poly-drug 
users, thus secondary or tertiary methamphetamine use may br 
masked.
39 Quest Diagnostics, Drug Testing Index (May 2009); US Department 
of Justice. (2008) National Methamphetamine Threat Assessment 
2009 (National Drug Intelligence Center, Product No. 2008-Q0317-
006, December 2008); Office of National Drug Control Policy, 
Making the drug problem smaller 2001-2008. Executive Office of the 
President (Washington, DC, 2009).
40 Methylphenidate is an amphetamine-type stimulant typically prescribed 
for Attention Deficit Disorder (ADD) in youth. Substance Abuse and 
Mental Health Services Administration, Office of Applied Studies. The 
DAWN Report–Emergency Department Visits Involving ADHD Stimulant 
Medications Issue 29, 2006 (Rockville, Maryland, 2006). 
41 International Narcotics Control Board (2009). 2008 Psychotropic 
Risks are increasing in Latin America 
Experts in Mexico and the countries on Mexico’s south-
ern border (for example, Guatemala and El Salvador) 
continue to indicate worsening ATS use problems, pos-
sibly related to shifts in manufacture.42 Further south, 
experts from Argentina, Brazil, Ecuador and Paraguay 
Substances: Statistics for 2007 (United Nations publication Sales No. 
E/F/S.09.XI.3)
42 Annual Reports Questionnaire.
Percent methamphetamine treatment in Canada, USA and Mexico (NGO): 1998 – 2007Fig. 109: 
Source: Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set (TEDS) 
2007; National Center of Epidemiology Surveillance and Disease Control, El Sistema de Vigilancia Epidemiológica de las Adicciones 
(SISVEA), report presented at NIDA’s CEWG June 2008; Centre for Addiction and Mental Health (CAMH). Drug and Alcohol Treat-
ment Information System (DATIS) Ontario, Canada (August 2008).
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tration. Results from the 2007 National Survey on Drug Use 
and Health: National Findings. Office of Applied Studies, 
NSDUH Series H-34, DHHS Publication No. SMA 08-4343 
(Rockville, Maryland, 2008).
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also perceive increasing ATS use.43 Historically, stimu-
lants originated primarily from licit channels, often 
through over-prescription or  unregulated parallel mar-
kets. In 2007, Argentina and Brazil had the second and 
third highest calculated rates of consumption of Sched-
ule IV stimulants in the world. 
Between 2001 and 2005, Brazil reported that lifetime 
use of amphetamines-group ssubstances in the general 
population in urban areas more than doubled from 
1.5% to 3.2%, driven in part by comparatively high 
secondary student use (3.4%).44 ATS consumption rates 
tend to be significantly higher for youth than for the 
general population. For example, the annual prevalence 
rates for the amphetamines-group substances for Colom-
bian secondary school students was 3.5% in 2004/05, a 
rate seven times that of the estimate for the general 
population in 2005. (see special features section for fur-
ther information)
Oceania: Use high, though reductions may be 
occurring; island nations under threat
Amphetamines-group use in Oceania may be declining 
overall. However, the trend reflects only the populations 
of Australia and New Zealand.45 Australian household 
surveys (aged 14 and above) appear to show a steady 
decline of methamphetamine use from an annual preva-
lence rate of 3.7% in 1998 to 2.3% in 2007.46 New 
Zealand household surveys (aged 15 to 45) showed a 
similar decrease since the peak of 2001. 
Both countries also collect methamphetamine use data 
on recent detainees (arrestees) through various drug 
monitoring programs.47 In Australia, there has been a 
decline of detainees testing positive for methampheta-
mine to 24% in 2007, with little change in New Zea-
land levels (which are half of those among Australian 
detainees).48
43 Only experts from the Dominican Republic noted a perceived decline 
in ATS use.
44 II Levantamento Domiciliar Sobre o Uso de Drogas Psicotrópicas no 
Brasil: Estudo Envolvendo as 108 Maiores Cidades do País 2005. 
CEBRID - Centro Brasileiro de Informação sobre Drogas Psicotró-
picas: UNIFESP - Universidade Federal de São Paulo. (São Paulo, 
Brazil, 2006).
45 There have been only sporadic ARQ reports from a small number 
Pacific Island Member States over the last decade.
46 It must be noted that the underlying methodology for the surveys 
changed substantially between 1998 and the 2001, thus a direct com-
parison of the household survey data in Australia  could be potentially 
misleading.
47 Drug Use Monitoring in Australia (DUMA) and the New Zealand 
Arrestee Drug Use Monitoring (NZ-ADAM) program assess drug use 
via urine analysis of recent arrestees in select sites. 
48 Includes the first two quarters of 2007 only. There were however, 
significant increases in positive tests for amphetamine reported 
(unweighted multi-site average, 2.7% in 2005 to 13.5% in 2007), 
possibly reflecting some shift in ATS use.
While the overall numbers suggest a possible decline 
over the last several years, use by problematic drug users 
and the associated impacts on public health may be 
increasing. For example, in Australia, data from detain-
ees suggest increasing use of high potency crystalline 
methamphetamine and an increase in injecting meth-
amphetamine.49 New Zealand’s frequent methampheta-
mine users were more likely to have used an ambulance 
and/or hospital emergency room services, or have con-
tacted a drug counsellor or general practitioner in rela-
tion to their problematic methamphetamine use in 
2007, over prior years.50
Although UNODC receives no systematic data from the 
other Oceania countries, there have been sporadic 
reports of amphetamines-group substances being used 
throughout the many island nations. For example, crys-
talline methamphetamine use has been reported in sev-
eral cities of Papua New Guinea. Moreover, a large 
number of traffickers were recently sentenced for moving 
significant amounts of methamphetamine into French 
Polynesia.51 Of the 12 countries worldwide which are 
not yet parties to the 1988 Convention Against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances, 
seven are in the Oceania region, leaving the region vul-
nerable to manufacturing, trafficking, and use.
49 National Alcohol and Drugs Research Centre, University of New 
South Wales - presentation to UNODC,  ‘Australian Drug Monitoring 
Systems: Overview of IDRS and  EDRS’ (Sydney, Australia, 2007). 
50 Wilkins, C., Girling, M. & Sweetsur, P. Recent Trends in Illegal 
Drug use in New Zealand, 2005-2007: Findings from the 2005, 2006 
and 2007 Illicit Drug Monitoring System (IDMS). Centre for Social 
and Health Outcomes Research and Evaluation, Massey University 
(Auckland, New Zealand, 2008).
51 UNODC Global SMART Update 2009, Volume 1 (March).
Australia/New Zealand annual  Fig. 111: 
prevalence of amphetamines-group 
use, 1998-2007
Source: Australian Institute of Health and Welfare 2008. 2007 
National Drug Strategy Household Survey: Drug statistics, 22. 
Canberra: AIHW. Wilkins C. & Sweetsur P. (2008) Trends in 
population drug use in New Zealand: Findings from national 
household surveying of drug use in 1998, 2001, 2003 and 
2006. New Zealand Medical Journal, 121, 61-71.
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Ecstasy-group drug consumption 
Globally, ecstasy-group52 substances (primarily MDMA) 
are consumed by between 11.6-23.5 million people aged 
15-64, or 0.3-0.5% of the population. As a proportion 
of the population, Oceania accounts for the highest 
annual prevalence of any region (3.6-4.0% of the gen-
eral population), but has the fewest users in absolute 
numbers. The region with the highest number of users 
is Asia, with an estimated range between 3.6-13.6 mil-
lion annual users, aged 15-64. Most are living in the 
East and South-East Asia subregion. Due to a lack of 
country-level prevalence estimates, subregional estimates 
cannot be calculated for South Asia, Central Asia, or the 
Near and Middle East.
Ecstasy-group use concentrated in Western Europe 
and North America
UNODC estimates that there are about 2.6 million 
ecstasy-group users in North America, with the majority 
living in the USA. North America’s annual prevalence 
for the general population is about 0.9%, similar to that 
of West and Central Europe. There are between 3.8 and 
4.0 million ecstasy-group users in Europe. Drug use in 
West and Central Europe appears largely stable but con-
tinues to increase in several East and South-East Euro-
pean countries, particularly among young people. 
52 Reports show that unbeknown to many ecstasy users, what is sold to 
them as ecstasy (MDMA) is often a combination of many psychoac-
tive substances, such as methamphetamine and ketamine. Ampheta-
mines and Ecstasy: 2008 Global ATS Assessment (United Nations 
publication, Sales No. E.08.XI.12).
Expert perceptions: Growth in ecstasy-group  
drug use in developing countries outpacing that  
of developed countries  
The unweighted expert perception trends between 1998 
and 2007 reflect continued increases in ecstasy-group 
use.53 Country experts in developed countries have per-
ceived a stable or slightly declining trend since 2004, 
about the time when developing countries (particularly 
in Eastern Europe and Latin America) perceived more 
frequent and more significant increases in their use.54 
In 2007, experts from 63 Member States responded, 
with 32 identifying a stable ecstasy-group trend over 
2006, and 9 identifying a decrease.55 Decreases in devel-
oped countries were driven in part by North America 
and West and Central Europe. 
The most recent student surveys in the USA (2008) and 
Canada (Ontario, 2007) show that little change in annual 
prevalence of ecstasy-group use has occurred since 2003. 
However, in the USA and Canada ‘ecstasy’ is sourced 
primarily from Canadian-based operations, which 
increasingly cut it with other psychoactive ingredients. 
(see special features section for further information)
53 Expert perception data is derived from the ARQ, and is unweighted. 
The following points are allocated if experts perceive: ‘strong increase’ 
2; ‘some increase’: 1; stable: 0; ‘some decline’ -1; ‘strong decline’ -2. If 
all countries had reported ‘some increase’, the global trend line would 
have increased by one point each year and would have reached 109 by 
2007.   
54 The criteria to calculate subregional estimates include recent repre-
sentative prevalence estimates (since 1998) from at least two Member 
States that combined account for at least 20% of the subregion’s 
population aged 15-64.
55 Increases and decreases were coded from strong increase/decrease or 
some increase/decrease, and represent the unweighted number of 
Member States responding.
Estimated Fig. 112: ecstasy-group users, by region (in numbers and annual prevalence)
Sources: UNODC, Annual Reports Questionnaire; Government reports; reports of regional bodies; and UNODC estimates.
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Estimated number of people who used ecstasy at least once in the past year and  Table 25: 
proporton of population aged 15-64, by region, 2007
Sources: Annual Reports Questionnaire data, various Government reports, reports of regional Bodies, UNODC estimates
Ecstasy-group use trends as perceived by experts, by OECD and non-OECD countries,  Fig. 113: 
1998-2007 (baseline: 1998 = 100)56
Note: Ecstasy-group trends were systematically collected only as of 2000, and thus pre-2000 data represent ATS data used as a 
proxy. Sources: UNODC, Annual Reports Questionnaire Data, UNODC Field Offices,  UNODC’s Drug Use Information Network for Asia 
and the Pacific (DAINAP).
Expert perception of changing ecstasy-group use, by region: 2007Table 26: 
Sources: UNODC, Annual Reports Questionnaire Data
Region
Member 
States 
responding
Use  
problem 
increased*
Percent use 
problem 
increased
Use  
problem 
stable
Percent use 
problem 
stable
Use  
problem 
decreased*
Percent use 
problem 
decreased
Europe 30 11 37% 15 50% 4 13%
Americas 13 3 23% 10 77% 0 0%
Asia 15 6 40% 5 33% 4 27%
Oceania 0 0 0 0
Africa 5 2 40% 2 40% 1 20%
Global 63 22 35% 32 51% 9 14%
* Identifies increases/decreases ranging from either some to strong, unweighted by population.
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00
OECD
Non-OECD
Global
Region/Subregion  
(Ecstasy-group)
Estimated 
number of users 
annually (lower)
Estimated 
number of users 
annually (upper)
Percent of  
population age 
15-64 (lower)
Percent of  
population age 
15-64 (upper)
Africa
 North Africa
 West and Central Africa
 Eastern Africa
 Southern Africa
340,000 1,870,000 0.1 0.4
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
210,000 400,000 0.2 0.4
Americas
 North America
 Central America
 The Caribbean
 South America
3,130,000
2,560,000
20,000
30,000
510,000
3,220,000
2,560,000
30,000
130,000
510,000
0.5
0.9
0.1
0.1
0.2
0.5
0.9
0.1
0.5
0.2
Asia
 East/South East Asia
 South Asia
 Central Asia
 Near and Middle East
3,550,000
2,250,000
13,580,000
5,950,000
0.1
0.2
0.5
0.4
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Subregional estimate cannot be calculated
Europe
 Western/Central Europe
 East/South East Europe
3,750,000
2,110,000
1,640,000
3,960,000
2,120,000
1,830,000
0.7
0.8
0.6
0.7
0.8
0.6
Oceania 810,000 880,000 3.6 4.0
Global 11,580,000 23,510,000 0.3 0.5
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Increases still reported in South American  
countries56 
In Latin America, only Colombia has annual prevalence 
rates of ecstasy-group use similar to North America. The 
rate among urban secondary students in Colombia was 
3.0% in 2004/05.57 This is nearly double the rate (1.6%) 
from surveys of secondary school students conducted 
just three years earlier.58 Prior to 2001, there were no 
indications of measurable ecstasy-group drug use among 
students. 
Stabilization in large parts of Europe,  
with possible shifts detected 
Data continue to suggest stabilization in Europe, due in 
large part to stable use in West and Central Europe. 
Most notable are the trends from the UK, for many 
years Europe’s largest ecstasy market, and Spain. Begin-
ning around 2001, annual prevalence trends showed 
decreases in the general population in England and 
Wales (aged 16-59) and Spain (aged 15-64). 
Between 1999 and 2007, European students (aged 
15-16) reported increased lifetime use of ecstasy-group 
substances. However, there were diverging trends by 
subregion. Students in West and Central Europe59 have 
reported relatively stable unweighted lifetime use since 
2003. In contrast, students from Eastern Europe60 
reported nearly 1.5% higher lifetime prevalence rates 
than their West and Central European counterparts. (see 
Special Features section for further information)
Consistent with these data, expert perception in 2007 
showed 11 experts reporting increasing ecstasy-group 
use, of which nearly two thirds were from East and 
South-East European countries. 
56 Ecstasy-group trends were systematically collected only as of 2000. 
There are indications from several countries that late 1990s ATS and 
ecstasy-group trends followed similar patterns, and thus pre-2000 
data represent ATS data used as a proxy.
57 Oficina de las Naciones Unidas contra la Droga y el Delito (ONUDD) 
y la Comisión Interamericana para el Control del Abuso de Drogas 
(CICAD/OEA) (2006). Jóvenes y drogas en países sudamericanos: Un 
desafio para las políticas públicas: Primer estudio comparativo sobre 
uso de drogas en población escolar secundaria de Argentina, Bolivia, 
Brasil, Colombia, Chile, Ecuador, Paraguay, Perú y Uruguay (Lima, 
September 2006).
58 The Inter-American Drug Abuse Control Commission. Multilateral 
Evaluation Mechanism (MEM): Colombia country report 2001-2002. 
(Organization of American States (OAS), 2008).
59 Students of West and Central Europe include: Austria, Belgium 
(Flanders), Cyprus, Denmark, Faroe Islands, Finland, France, Ger-
many (6 states), Greece, Greenland, Iceland, Ireland, Isle of Man, 
Italy, Malta, Netherlands, Norway, Portugal, Sweden, Switzerland 
and the United Kingdom.
60 Students of Eastern Europe include: Bulgaria, Croatia, Czech Repub-
lic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russian 
Federation, (Moscow), Slovakia, Slovenia, and the Ukraine.
Worsening ecstasy situation in parts of Asia may 
reflect other drugs 
For 2007, 40% of experts perceived a growing ecstasy-
group use problem in Asia. Of these, most were situated 
in East and South-East Asia, including China, Indone-
sia, Thailand and Viet Nam. However, like other regions, 
a lack of forensic capacity means that it is not known 
whether ecstasy-group substances actually contain 
MDMA or other psychoactive ingredients. “Club drugs” 
are increasingly being replaced by other substances, such 
as ketamine.61 For example, in Hong Kong, China, the 
market has changed rapidly and dramatically since 2000, 
as ketamine–nearly unheard of in 1998–has supplanted 
ecstasy use. The number of reported drug registry cases 
for ketamine doubled between 2005 and 2007, and now 
accounts for 29% of all newly reported cases in Hong 
Kong, China. Ketamine use has been noted in neigh-
bouring areas and follows reports of significant illicit 
manufacturing operations and seizures throughout the 
subregion.
61 Ketamine is a licit pharmaceutical illicitly used as a hallucinogen 
most often found in powder or liquid form that is increasingly 
encountered on ATS markets, either in connection with the “club-
drug” scene, or found as an active ingredient in what is sold on illicit 
markets as ‘ecstasy’. Ketamine is not currently under international 
control.
Annual prevalence of ecstasy-group Fig. 114: 
use among secondary students in  
select South American countries (rank 
ordered), 2004/05 
Source: Oficina de las Naciones Unidas contra la Droga y el 
Delito (ONUDD) y la Comisión Interamericana para el Control 
del Abuso de Drogas (CICAD/OEA) (2006). Jóvenes y drogas 
en países sudamericanos: Un desafio para las políticas públi-
cas: Primer estudio comparativo sobre uso de drogas en pob-
lación escolar secundaria de Argentina, Bolivia, Brasil, 
Colombia, Chile, Ecuador, Paraguay, Perú y Uruguay. 
(Lima, 2006).
0.4%
0.5%
0.6%
1.1%
1.6%
3.0%
0% 1% 2% 3% 4%
Paraguay
Bolivia
Peru
Ecuador
Chile
Colombia
159
1. Trends in the world drug markets Amphetamine-type stimulants market
England and Wales (UK) and Spain: Fig. 115: 
Annual prevalence of ecstasy-group 
use among the general population, 
1998-2007/08
Source: Kershaw, C., Nicholas, S., & Walker, A. (2008). Crime 
in England and Wales 2007/08: Findings from the British 
Crime Survey and police recorded crime. Home Office Statisti-
cal Bulletin (ISBN 978-1-84726-753-5) (London, 2008); 
Informe de la encuesta domiciliaria sobre alcohol y dogas en 
España (EDADES) 2007/08. Delegación del gobierno para el 
plan nacional sobre drogas. (Madrid, 2008).
Hong Kong, China ecstasy-group  Fig. 116: 
and ketamine drug registry cases, 
1998-2007
Source: Central Registry of Drug Abuse. Narcotics Division 
(ND), Security Bureau, the Hong Kong Special Administrative 
Region, China.
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Australia and New Zealand: Annual prevalence of ecstasy use, 1998-2007Fig. 117: 
Source: Australian Institute of Health and Welfare 2008. 2007 National Drug Strategy Household Survey: detailed findings. Drug  
statistics series no. 22. Cat. no. PHE 107. Canberra: AIHW. Wilkins C. & Sweetsur P. (2008) Trends in population drug use in New 
Zealand: Findings from national household surveying of drug use in 1998, 2001, 2003 and 2006. New Zealand Medical Journal, 
121, 61-71. A216
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High use levels in Oceania, but the ecstasy  
used may vary
Given that the Australian population comprises the 
majority of population in Oceania, what occurs in Aus-
tralia de facto "drives" trends in Oceania. Both Australia 
and New Zealand have reported increased annual preva-
lence of ecstasy-group among the general population 
since 1998, and the most recent studies find that their 
rates reflect some of the highest reported annual preva-
lence of use. Annual use in Australia remained stable 
since 2004, contrary to increases in New Zealand. 
However, due to some of New Zealand’s apparent 
increase may not be of MDMA-containing pills. Until 
2008, New Zealand had a substantial legal “party-pills” 
market which sold, inter alia, benzylpiperazine (BZP), a 
drug with effects similar to MDMA (ecstasy). A 2006 
household survey found that 15.3% of New Zealanders 
(aged 13-45) had used “party-pills” in the past year. In 
some cases these “party-pills” were sold as “ecstasy”.
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DRUG CONTROL AND THE CRIMINAL BLACK MARKET

2.0 Confronting unintended consequences: 
 Drug control and the criminal black market
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Last year’s World Drug Report reviewed 100 years of drug 
control efforts, documenting the development of one of 
the first international cooperative ventures designed to 
deal with a global challenge. This pioneering work 
brought together nations with very different political 
and cultural perspectives to agree on a topic of consider-
able sensitivity: the issue of substance abuse and addic-
tion. Despite wars, economic crises, and other cataclysmic 
events of state, the global drug control movement has 
chugged steadily forward, culminating in a framework 
of agreements and joint interventions with few prece-
dents or peers in international law.
Today, a number of substances are prohibited in the 
domestic legislation of almost every country. As dis-
cussed below, this unanimity has created a bulwark 
shielding millions from the effects of drug abuse and 
addiction. In the past, many of these substances were 
legally produced and, in some cases, aggressively mar-
keted, to devastating effect. The collective nations of the 
world have agreed that this state of affairs was unaccept-
able, and have created an international control system 
that allows crops such as opium poppy to be produced 
for medical use, with very little diversion to the illicit 
market.
Despite this achievement, drug control efforts have 
rarely proceeded according to plan. There have been 
reversals and set-backs, surprising developments and 
unintended consequences. Traffickers have proven to be 
resilient and innovative opponents and cultivators dif-
ficult to deter. The number, nature, and sources of con-
trolled substances have changed dramatically over the 
years. None of this could have been predicted at the 
outset.
But then, very little has been simple or smooth about 
developments in international affairs over the last cen-
tury. Other international problems – including poverty, 
war, weapons proliferation and infectious disease – have 
defied early projections of a swift resolution. Some 
efforts have been more successful than others, but, in all 
cases, the learning process could be described as “chal-
lenging”. Today, the enterprise of global coordination 
and cooperation remains a work in progress. Tremen-
dous gains have been made, however, and the need for 
collaborative solutions to the problems facing us all is 
greater than ever before.
2.1 Why illicit drugs must remain illicit
Oddly, of all areas of international cooperation, drug 
control is uniquely subject to calls that the struggle 
should be abandoned. Despite equally mixed results in 
international interventions,1 no one advocates accepting 
poverty or war as inevitable. Not so with drugs, where a 
range of unintended consequences have led some to 
conclude that the only solution is to legalise and tax 
substances like cannabis, cocaine, ecstasy, methampheta-
mine, and heroin. 
The strongest case against the current system of drug 
control is not the financial costs of the system, or even 
its effectiveness in reducing the availability of drugs.2 
The strongest case against drug control is the violence 
and corruption associated with the black market. The 
main problem is not that drug control efforts have failed 
to eliminate drug use, an aspirational goal akin to the 
elimination of war and poverty. It is that in attempting 
to do so, they have indirectly enriched dangerous crimi-
nals, who kill and bribe their way from the countries 
where drugs are produced to the countries where drugs 
are consumed. 
Of course, the member states of the United Nations cre-
ated the drug conventions, and they can modify or 
annul them at will. But the Conventions would have to 
be undone the way they were done: by global consensus. 
And to date, they are very few international issues on 
which there has been so much positive consensus as drug 
control. Drug control was the subject of broad-based 
international agreements in 1912, 1925, 1931, 1936, 
1946, 1948, and 1953, before the creation of the stand-
ing United Nations Conventions in 1961, 1971, and 
1988. Nearly every nation in the world has signed on to 
these Conventions.3
Nonetheless, there remains a serious and concerned 
group of academics and civil society organisations who 
feel the present system causes more harm than good. 
Plans for drug “legalisation” are diverse, and often fuzzy 
on the details, but one of the most popular alternative 
models involves taxation and control in a manner simi-
lar to tobacco and alcohol.4 This approach has appeal of 
ideological consistency, since all these addictive sub-
stances are treated in the same way.
The practice of banning certain addictive substances 
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while permitting and taxing others is indeed difficult to 
defend based on the relative harmfulness of the substances 
themselves. Legal addictive substances kill far more people 
every year than illegal ones – an estimated 500 million 
people alive today will die due to tobacco.5 But this 
greater death toll is not a result of the licit substances 
being pharmacologically more hazardous than the illicit 
ones.6 This greater death toll is a direct result of their 
being legal, and consequently more available. Use rates of 
illicit drugs are a fraction as high as for legal addictive 
drugs, including among those who access the legal drugs 
illegally (i.e. young people). If currently illegal substances 
were made legal, their popularity would surely increase, 
perhaps reaching the levels of licit addictive substances, 
increasing the related morbidity and mortality.
Is the choice simply one of drug-related deaths or drug-
market-related deaths? Some palliative measures would 
be available under a system of legalisation that are not 
available today. If drugs were taxed, these revenues could 
be used to fund public health programmes aimed at 
reducing the impact of the increase in use. Addicts 
might also be more accessible if their behaviour were 
decriminalised. With bans on advertising and increas-
ingly restrictive regulation, it is possible that drug use 
could be incrementally reduced, as tobacco use is cur-
rently declining in most of the developed world.
Unfortunately, most of this thinking has indeed been 
restricted to the developed world, where both treatment 
and capacity to collect taxes are relatively plentiful. It 
ignores the role that global drug control plays in protect-
ing developing countries from addictive drugs. Without 
consistent global policy banning these substances, devel-
oping countries would likely be afflicted by street drugs 
the way they are currently afflicted by growing tobacco 
and alcohol problems.
In most developing countries, street drugs are too scarce 
and expensive for most consumers. They are scarce and 
expensive because they are illegal. Today, traffickers con-
centrate on getting almost all of the cocaine and heroin 
produced to high-value destinations, placing the burden 
of addiction on those well suited to shoulder it, at least 
financially. If these pressures were removed, lower value 
markets would also be cultivated with market-specific 
pricing, as they presently are for most consumer goods.
For example, cocaine use in the countries where cocaine 
is actually produced is less than half as high as in many 
European countries or the United States. This could 
easily change. Bolivia is a poor country where 42% of 
the population lives on less than US$2 per day8 and 
which produces about 10% of the global cocaine supply. 
According to reported figures, cocaine in Bolivia was 
US$9 per gram in 2005, about 10% of the price in the 
United States. But GDP per capita was 42 times higher 
in the US than in Bolivia, so the price was effectively 
four times higher in Bolivia.9  
In contrast, 27% of the adult population of Bolivia 
smokes cigarettes daily.10 A pack of cigarettes was priced 
at just US$0.62 at official exchange rates in 2006, so 
even the poor find an imported addictive substance 
more affordable than the locally-produced one.11 Bolivia 
is not unique in this respect: in many poor countries, 
more than 10% of household expenditure is for tobac-
co.12
Indeed, the spread of tobacco to the developing world 
gives a hint of what could happen if other addictive 
substances were made legal. Many transition countries 
have much higher tobacco use prevalence than the richer 
ones, and Africa’s tobacco market is presently growing 
by 3.5% per year, the fastest rate in the world.13 By 
2030, more than 80% of the world’s tobacco deaths will 
Global deaths related to substance Fig. 1: 
use in 2002
Source: World Health Organisation7
Annual cocaine prevalenceFig. 2: 
Source: 2009 World Drug Report
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occur in developing countries.14 These countries can 
ill-afford this burden of disease. They are even less capa-
ble of giving up a share of their productive work force to 
more immediately debilitating forms of addiction.
“Vice taxes” are also used to control the spread of legal 
addictive drugs, making them more expensive and thus 
reducing demand. But again, capacity to enforce these 
taxes is less in developing countries, and high taxes gen-
erate large shadow markets, as illustrated by tobacco 
markets today. Recent estimates suggest 10% or more of 
global tobacco consumption is untaxed, and that the 
illicit share of the market is particularly pronounced in 
Africa (15%) and Latin America (20%). An estimated 
600 billion cigarettes are smuggled each year.15 If these 
were priced at just a dollar a pack, this would represent 
a global market worth US$30 billion, comparable to the 
US$65 billion market for illicit opiates and US$71 bil-
lion market for cocaine.18 As with illicit drugs, illicit 
tobacco has been used to fund violence in places as 
diverse as the Balkans19 and West Africa.20
The universal ban on illicit drugs thus provides a great 
deal of protection to developing countries, and must be 
maintained. At the same time, the violence and corrup-
tion associated with drug markets is very real, and must 
be addressed. Fortunately, there is no reason why both 
drug control and crime prevention cannot be accom-
plished with existing resources, if the matter is approached 
in a strategic and coordinated manner.
Control drugs while preventing crime 
Drug addiction represents a large social cost, a cost we 
seek to contain through the system of international drug 
control.  But this system itself has its costs, and these are 
not limited to the expenditure of public funds. Interna-
tional drug control has produced several unintended 
consequences, the most formidable of which is the crea-
tion of a lucrative black market for controlled sub-
stances, and the violence and corruption it generates.
Drug control generates scarcity, boosting prices out of 
proportion to production costs. Combined with the bar-
riers of illegality and prevention efforts, scarcity and 
high prices have helped contain the spread of illicit 
drugs. This has kept drugs out of the hands of an untold 
number of potential addicts. At the same time, however, 
high prices allow transnational traffickers to generate 
obscene profits, simply for being willing to shoulder the 
risk of defying the law.
Given the money involved, competition for the oppor-
tunity to sell is often fierce, resulting in small wars on 
the streets of marginalised areas in the developed and the 
Price of a gram of cocaine as a share Fig. 3: 
of daily GDP per capita in 2005
Source: 2008 WDR, Human Development Report 2007/2008
Share of national tobacco markets that Fig. 5: 
are illicit (recent low end estimates)
Source: Framework Convention Alliance, 200717
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developing world alike. Profits are ploughed back into 
increasing the capacity for violence and into corrupting 
public officials. Together, violence and corruption can 
drive away investment and undermine governance to the 
point that the rule of law itself becomes questionable.
As a result, some have argued that the costs of control-
ling illicit drugs outweigh the benefits – in effect, that 
the side effects are so severe that the treatment is worse 
than the disease. But this is a false dilemma. It is incum-
bent on the international community to achieve both 
objectives: to control illicit drugs and to limit the costs 
associated with this control. More creative thinking is 
needed on ways of reducing the violence and corruption 
associated with containing the drug trade. Progress must 
be made toward simultaneously achieving the twin goals 
of drug control and crime prevention.  
To do this, there are several ways present efforts could be 
improved and expanded. First, it is possible for law 
enforcement to do what it does much better:
High volume arrests are the norm in many parts of the  s
world, but their eﬃcacy is questionable – to conserve 
resources, prison space should be reserved primarily for 
traﬃckers, particularly violent ones.
Drug addicts provide the bulk of drug demand; treat- s
ing this problem is one of the best ways of shrinking 
the market.
The links between drug users and drug dealers also  s
need to be severed, closing open drug markets and 
disrupting information networks using the techniques 
of problem-oriented policing and situational crime 
prevention.
Second, both local and international efforts need to be 
strategically coordinated to address the particularities of 
specific drug problems:
The right “balance” between supply-side and de- s
mand-side interventions depends very much on the 
particularities of the situation, and may require re-
sources and expertise beyond those found in agencies 
traditionally involved in prevention, treatment, and 
law enforcement.
At all points in the market (production, traﬃcking,  s
consumption), strategies should be based on the specif-
ic characteristics of the drug involved and the context 
in which it has become problematic.
Focus should be placed on shrinking the markets, not  s
just disabling speciﬁc individuals or groups.
Where drug ﬂows cannot be stopped, they should be  s
guided by enforcement and other interventions so that 
they produce the least possible damage.
Finally, the international community must rally together 
to assist more vulnerable members in resisting the incur-
sion of drugs:
Post-conﬂict reconstruction and development aid  s
should be integrated with crime prevention eﬀorts.
Better use should be made of the Conventions, particu- s
larly toward international action on precursor control, 
money laundering, asset forfeiture, organised crime, 
and corruption.
Information systems need to be improved so that prob- s
lems can be tracked and interventions evaluated.
2.2 Move beyond reactive law enforcement
Drug possession and sale are illegal in most countries of 
the world, and, as a result, the drug problem was long 
seen as primarily a criminal justice issue. Those who take 
the “drug war” metaphor literally may feel this effort is 
best advanced by people in uniform with guns. Law 
enforcement must continue to play a key role, of course, 
keeping drugs illegal and scarce, but much can be done 
to make the criminal justice response more effective and 
efficient.
In the end, the criminal justice system is a very blunt 
instrument for dealing with drug markets. As necessary 
as the deterrent threat remains, the arrest, prosecution, 
and incarceration of individuals is an extremely slow, 
expensive, and labour intensive process. The key to dis-
rupting drug markets and the associated violence and 
corruption must lie in making the business of drug deal-
ing more complicated, making it more difficult for 
buyers and sellers to connect. To do this, the techniques 
of situational crime prevention and problem-oriented 
policing should be employed.
Stop jailing petty offenders
Current street enforcement actions could be divided 
into two categories:
Opportunistic enforcement, usually against those  s
found in possession of drugs when stopped for an un-
related reason.
Pro-active enforcement, including buy-and-bust ac- s
tions against dealers at open markets; searches of sus-
pect premises or persons; and more sophisticated long-
term investigations.
All of these actions are justified under the law, but all 
absorb scarce criminal justice resources. The decision to 
perform any given form of enforcement has opportunity 
costs for other approaches. It is important, then, to 
weigh the impact of any given action both in terms of 
its efficacy in reducing the size of the black market and 
any potential side-effects it might have.
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“Selective enforcement” evokes a whole range of justified 
concerns, but the fact remains that, in all areas of law 
enforcement, the application of the sanctions of arrest 
and prosecution is a matter of discretion. The number of 
cases that go to trial is everywhere a small fraction of 
those brought to the attention of the police. Cases 
unlikely to produce the desired outcome (generally, a 
conviction) are abandoned at various stages of the process 
in favour of those more likely to be successful. These cases 
should be weighed not just according to their viability, 
but also with regard to their strategic and social impact.
Unfortunately, the quantitative performance manage-
ment systems used in civil service worldwide do not 
encourage this sort of thinking. If the primary perform-
ance indicator of the police is volumes of arrests and 
seizures, little thought will be given to the impact of 
these arrests and seizures. Not surprisingly, these arrests 
and seizures are unlikely to have much positive impact. 
Research indicates that more enforcement is not neces-
sarily better.21 Conservation of resources requires that 
police commanders carefully gauge the amount of 
enforcement required to produce the desired effect.
As is discussed further below, there is much to be gained 
by targeting high profile, high volume, and violent crim-
inals, be they users or dealers. Resources that could have 
been focused on these individuals are often wasted on 
the opportunistic arrest and incarceration of large vol-
umes of petty offenders. In the case of casual users, the 
sanction of imprisonment is excessive; since many are 
more mainstream than marginal, considerably less 
expensive options exist for deterring casual use behav-
iour, such as the measures currently taken when under-
age drinking and smoking are encountered. Evidence-based 
treatment is the appropriate response to addiction.
For low-level dealers and other drug market functionar-
ies, these offenders often come from population groups 
that are too large to incapacitate and nearly impossible 
to intimidate. Incapacitation of individuals is fruitless 
when social conditions generate whole classes of people 
with strong incentives to offend. When these incentives 
are strong enough and alternatives scarce, all deterrence 
fails. Those willing to risk death by ingesting a kilogram 
of condom-wrapped cocaine bullets are unlikely to be 
put off by the possibility of a jail sentence. Drug addicts 
and sex workers are equally hard to scare into good 
behaviour. While the threat of arrest must remain in 
place to dissuade those who value their future, those 
who have given up hope are not so easily frightened. 
Arrest drives focusing on rounding up large numbers of 
these “undeterrables” result in a net loss in enforcement 
effectiveness.
To avoid these losses, police need alternative avenues of 
response, particularly when confronted with non-prior-
ity cases of drug possession. In the opinion of the Inter-
national Narcotics Control Board, the 1988 Convention 
requires that illicit possession of controlled substances 
must be prohibited, but it does not require criminal 
prosecution for small quantities.23 At times, drug pos-
session can serve as a pretext to detain an otherwise 
dangerous or suspect individual, but otherwise, the law 
must allow for non-custodial alternatives when a police 
officer stumbles upon small amounts of drugs. It is 
important that the incident be documented and the 
opportunity availed to direct the user to treatment if 
required, but it is rarely beneficial to expend limited 
prison space on such offenders. According to surveys, 
between a quarter and a half of the population of many 
countries in Europe and North America has been in pos-
session of illicit drugs at one time or another in their 
lives. Most remained productive citizens. In only a small 
share of these cases would arrest, and the lifelong stigma 
it brings, have been appropriate.
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Portugal is an example of a country that recently decided 
not to put drug users in jail. According to the Interna-
tional Narcotics Control Board, Portugal’s “decriminali-
sation” of drug usage in 2001 falls within the Convention 
parameters: drug possession is still prohibited, but the 
sanctions fall under the administrative law, not the crim-
inal law.24 Those in possession of a small amount of 
drugs for personal use are issued with a summons rather 
than arrested. The drugs are confiscated and the suspect 
must appear before a commission. The suspect’s drug 
consumption patterns are reviewed, and users may be 
fined, diverted to treatment, or subjected to probation. 
Cases of drug trafficking continue to be prosecuted, 
and the number of drug trafficking offences detected in 
Portugal is close to the European average.
These conditions keep drugs out of the hands of those 
who would avoid them under a system of full prohibi-
tion, while encouraging treatment, rather than incar-
ceration, for users. Among those who would not welcome 
a summons from a police officer are tourists, and, as a 
result, Portugal’s policy has reportedly not led to an 
increase in drug tourism.25 It also appears that a number 
of drug-related problems have decreased.26
The approach is not uncontroversial. Portugal did expe-
rience an increase in drug use after this policy was imple-
mented, but so did many European countries during 
this period. Cannabis use increased only moderately, but 
cocaine and amphetamine use rates apparently doubled 
off a low base. More alarmingly, cocaine seizures 
increased seven-fold between 2001 and 2006. While 
cocaine seizures in a number of European countries 
increased sharply during that period, in 2006, Portugal 
suddenly had the sixth-highest cocaine seizure total in 
the world. The number of murders increased 40% 
during this same period of time,27 a fact that might be 
related to the trafficking activity. Although the rate 
remains low and Lisbon is one of Europe’s safest cities, 
Portugal was the only European country to show a sig-
nificant increase in murder during this period.
This rapid increase in trafficking was probably related to 
the use of Guinea-Bissau and Cape Verde, former colo-
nies, as transit countries. Most of the traffickers arrested 
in Portugal in 2007 were of West African origin. As 
international awareness of the problem increased, 
cocaine seizures fell in a number of European countries, 
but France and Portugal, two countries with former 
colonies in the region, showed the most pronounced 
decreases.
Creative approaches of this sort seem to have been 
reserved for the parties on the extreme ends of the traf-
ficking chain: the farmers and the users. Because these 
two groups have been seen, in effect, as victims, a variety 
of social solutions have been explored as alternatives to 
harsh law enforcement, including alternative develop-
Annual prevalence for adult (15-64) Fig. 7: 
drug use in Portugal, 2001 and 2007
Source: EMCDDA28
Kilograms of cocaine seized in  Fig. 8: 
Portugal, 2001-2007
Source: UNODC ARQ
Citizenship of those arrested in Portu-Fig. 9: 
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ment and a range of prevention and rehabilitation 
schemes. Drug traffickers do not elicit similar amounts of 
sympathy. Seen as actors driven by raw profit, they are 
held responsible for most of the violence and corruption 
associated with the drug trade, and the response has been 
to hit them hard, arresting as many offenders and seizing 
as many drugs as possible. In some parts of the world, 
drug enforcement has been used as a pretext to wage war 
on marginalised communities, resulting in serious human 
rights violations.30 Some countries even impose the death 
penalty for drug offences, contrary to Article 3 of the 
Universal Declaration of Human Rights.
But even when it comes to notorious and dangerous 
dealers, there may be alternatives to incarceration. One 
technique has been piloted in a number of locations in 
the United States. Investigators compiled detailed dossi-
ers on all known dealers in their jurisdiction, with 
enough evidence to ensure a likely conviction. These 
dossiers were simultaneously presented to all the sus-
pects with a warning: desist or face prosecution. Support 
services and networks were mobilised to make the option 
of desisting feasible. The idea is to get a large share of 
the participants to withdraw at the same time, causing 
the market to collapse. When confronted in this way, it 
appears that many opt out of drug markets.31 The threat 
of drug arrest has also been used to deter violent offend-
ers.32 While these interventions are labour intensive, 
they are less costly than processing a similar number of 
offenders through the criminal justice system.
While incarceration will continue to be the main 
response to detected traffickers, it should only be applied 
in exceptional cases to users. All this is not to say that 
drug use should be ignored; it must be addressed. Drug 
flows, and their devastating consequences for producer 
and transit countries, would not exist if it were not for 
demand in the wealthier nations. While “demand reduc-
tion” is not generally associated with law enforcement, 
there are ways the criminal justice system can contrib-
ute. Demand-side interventions have the advantage of 
taking business away from traffickers without violent 
confrontation, unlike police operations aimed at taking 
the traffickers away from the business.
Mainstream the half-a-percent
One of the most efficient ways to deter traffickers would 
be to undermine their user base. Annual prevalence 
statistics make it sound like drug users comprise a sig-
nificant share of the global adult population, but, in 
fact, a small part of this group consumes the vast bulk of 
the imported drugs: the addicts. While around 5% of 
the adult population used some illicit drug in the last 
year (140-250 million users), only about 18-38 million 
could be classified as “problem drug users”.33 While 
definitions of “problem drug use” vary, the European 
Monitoring Centre for Drugs and Drug Addiction pro-
vides estimates for the rates of problem drug use in the 
adult populations of a number of European countries. 
The size of these populations range from less than a 
thousand in Cyprus to some 400,000 in the United 
Kingdom. Taking the extreme example, it is estimated 
that about one quarter of the UK’s problem drug users 
reside in London, about 74,000 users, just under 1% of 
the city’s population.34
Those who are continuously intoxicated or regularly 
binge are the real source of demand on which traffickers 
rely. Removing a significant portion of this source of 
demand, even temporarily, would rip the heart out of 
Estimated number of “problem drug users” in some European countries various years  Fig. 10: 
2002-2006
 Source: EMCDDA; UN Population Division
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any drug market. Cannabis provides a good example of 
this phenomenon. Cannabis is generally consumed com-
munally – surveys across countries show most users 
consume with other people most of the time. Often this 
involves passing around a common joint or pipe. With 
fairly good quality cannabis, only a few deep inhalations 
are needed to produce the desired effect among those 
who don’t use frequently enough to have developed a 
tolerance. The volume of cannabis consumed by any 
given user in such a session is trivial, a fraction of a 
gram, and many casual users only experience one or a 
few such sessions each year.
In contrast, about 9% of those who consume cannabis 
will, at some point in their lives, go through a period of 
heavy daily use and develop a tolerance.35 For those 
whose situations allow, they may be continuously intox-
icated. Estimates of the amounts consumed by heavy 
users vary, but are on the order of several grams per day. 
In this way, daily or continuous users smoke the vast 
bulk of the cannabis consumed. The same is generally 
true in most other drug markets – a small share of the 
user population appears to consume the bulk of the drug 
supply.36
There are a number of ways this share could be removed 
from a drug market, but, due to the nature of addiction, 
they are unlikely to go willingly. Drug use arrestees 
should not be incarcerated, but rather diverted to evi-
dence-based treatment or conditional release. Remain-
ing drug-free as a condition for release has been found 
to be successful where random but regular drug testing 
results in quick (but not necessarily lengthy) jail time for 
those who fail to pass.37 In a city like London, removing 
the addicts would be a mammoth task, but, as of 2005, 
Her Majesty’s Prison Service already had some 12,000 
drug offenders in custody in England and Wales alone.38 
In less problematic and less populated areas, a far smaller 
body of addicts would need be removed to substantially 
reduce the profitability of the market.
Unlike cannabis, those who are addicted to less ubiqui-
tous drugs tend to congregate around open drug mar-
kets. This gives them continuous access, the company of 
those similarly situated, a competitive market for their 
business, and access to criminal employment activities. 
The ecology of an open drug market is premised on 
particular conditions, however, the most prominent of 
which is the neglect of the state. Disrupting this ecology 
is a matter of bringing some kind of order to these 
under-regulated zones.
Close open drug markets
Arresting individuals and seizing their drugs is a tech-
nique akin to manually pulling weeds. But there are 
ways of making the environment less receptive to drug 
markets, effectively making the ground less fertile. These 
interventions are rooted in the thinking of situational 
crime prevention, going beyond arrests and seizures to 
address the social conditions on which drug markets are 
reliant. 
In crime prevention theory, a false dichotomy is often 
presented between solutions involving law enforcement, 
which are viewed as short-term correctives, and so-called 
“social crime prevention”, which is usually portrayed as 
a long term project. In the world of short political time 
horizons, the latter often gets neglected in favour of the 
former.  But there is a third way: interventions aimed at 
changing social conditions quickly, to impact the condi-
tions under which drug markets thrive.39 This sort of 
thinking is found in the practices of situational crime 
prevention.
While law enforcement personnel are not typically adept 
at manipulating social circumstances, they can also play 
a key role. With training, they can work with addicts in 
a way that helps them move beyond their destructive 
behaviour without necessarily using the sanction of 
arrest. The techniques of problem oriented policing can 
also help them to recognise and disable the mechanics of 
drug markets.  
For example, drug dealers pay a price for remaining 
underground. They cannot advertise without exposing 
themselves to law enforcement. Users generally find 
vendors in one of two ways. One is an open drug market, 
a specific geographic area or location where anyone can 
show up and buy drugs. The second is through a net-
work of social or information connections. Both are 
vulnerable to disruption.
Many open drug retail markets are found in neglected 
urban spaces, which also harbour fugitives, sex workers, 
runaways, and illegal immigrants, and anyone else who 
wants to avoid the law. These areas are growing in a rap-
idly urbanising world, especially in developing countries. 
Tons of cannabis consumed globally Fig. 11: 
by frequency of use in 2006 
Source: 2006 World Drug Report
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Unable to accommodate the rapid inflow of people, these 
cities are at risk of acquiring slums and informal settle-
ments beyond the capacity of the state to control, where 
the norms and informal social controls of the countryside 
are lost, where anonymity and transience allow drug 
markets to germinate. In some parts of the world, there 
are whole regions where drugs and other contraband are 
available for those in the know, including some free-trade 
areas, breakaway states, and conflict zones.
What these areas have in common is the absence of the 
rule of law. This does not mean these areas are com-
pletely unregulated; a closer look generally reveals the 
presence of a different kind of authority, an authority 
with an interest in the appearance of chaos. If these 
authorities could be called to account, these areas could 
be reclaimed, with serious consequences for the drug 
markets.
For example, traditional law enforcement has a hard 
time operating in slum areas. Drug addicts, like the poor 
farmers on the other end of the market chain, can be 
extremely difficult to deter. Street dealers also represent 
a formidably hard target. Often they are gang members, 
whose whole ethos revolves around conflict with the 
police. Prison is an expected part of their life cycle, and 
death a price they are willing to pay for posthumous 
respect. Many deal drugs for very low wages, so non-fi-
nancial motives are foremost among the reasons for their 
continued participation in the market. In this world, 
arrests and seizures don’t seem to have lasting impact.
But street drug markets do not exist in a vacuum. The 
drama is played out on a very particular kind of a stage, 
and it is the stage manager, not the actors, that must be 
addressed. The property in these areas is owned by 
someone, someone whose neglect of their property 
allows illicit activity to continue. Unlike the street 
addicts and gang members, this someone has something 
of value to lose – their property. Surprisingly, run-down 
urban properties are often highly prized among slum 
lords for the incomes they generate, since marginal 
people will pay a premium to avoid excessive attention, 
or because they simply have no choice.40
Legislation that requires that owners take responsibility 
for what goes on in their establishments could go a long 
way toward restoring order. Those who fail to comply 
would face an escalating series of fines, ultimately result-
ing in forfeiture of the property. As actions under the 
civil law, a lower standard of proof would be required 
than under the criminal law, and procedures could be 
streamlined to reduce delays due to litigation. Either 
through voluntary compliance or by literally taking 
ownership of the situation, the state could once again 
reassert control over these neglected areas. Ownership 
could be transferred to law-abiding citizens within and 
from outside the marginal area, and these residents 
would have a personal stake in assuring their property 
remains crime-free.41
Not every drug market is so tightly associated with a 
particular piece of property, of course, but the general 
principle behind this sort of intervention still applies: it 
makes little sense to try to deter those with nothing to 
lose. Many are drug users themselves, and may not be 
rationally planning their actions in accordance with 
their own best interests. They are generally not the ones 
making the important market decisions in any case. If 
these people are moved toward the mainstream, drawn 
in instead of pushed down, the market loses its most 
important foot soldiers. 
Instead, punitive measure should be taken against those 
who are making real profit from the state of affairs. 
Some of these players are simply negligent, others are 
complicit. In either case, they are participating in drug 
markets because they make money doing so. Threats to 
that money can be expected to produce results.
These types of interventions need not have great resource 
implications. Some forms of regulation are essentially 
self-enforcing. For example, laws limiting tobacco smok-
ing in public places would be a failure if they relied on 
the state for enforcement – there are simply too many 
smokers to control. Instead, anti-smoking laws rely on 
two non-state sources for compliance.  One is the owners 
of the public establishments themselves, who comply 
because, as property owners, they are motivated to 
remain in compliance with the law.  
The second is non-smokers, who, by virtue of the law, 
are given a chop moral basis to object to public smoking. 
The paradigm shift in the anti-tobacco campaign came 
when the issue ceased to be framed as a matter of per-
sonal choice and began to be seen as an issue of public 
health. Drug markets are no less hazardous for those 
involuntarily exposed to their “second hand smoke”. 
Similar vehicles must be designed to empower the major-
ity of people who want no part of drug markets in their 
communities. Partnerships between local community-
based or faith-based organisations and state agencies 
charged with addressing the drug issue could provide 
both information and networks for uprooting open drug 
markets.
Of course, closing an open retail drug market does not 
mean the problem has been solved. Addicts need their 
drugs, and will continue to source them through infor-
mation networks. But closing open drug markets can 
have several benefits:
Open drug markets have a devastating eﬀect on the  s
marginal neighbourhoods that host them; removing 
them can allow these communities to heal and become 
reintegrated.
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The under-regulated zones that host many open mar- s
kets also host marginalised populations prone to sub-
stance abuse, including runaways, people with mental 
health problems, and sex workers; closing the market 
would break this important spatial connection.
Open drug markets allow virtually anyone to show up  s
and buy; closing them should slow the expansion of the 
user base beyond the aﬀected area.
Closing open markets removes the territorial element  s
on which so much drug related violence is based.  
Removal of the territorial element may take drug  s
markets out of the hands of street gangs.
In terms of violence, one of the worst things that can 
happen in a drug market is for it to fall into the hands 
of street gangs. Street gangs appear to have evolved inde-
pendently in many parts of the world, while missing in 
other areas entirely. They hold in common an ethos of 
opposition to the law, however, so interventions designed 
to deter most people may, perversely, encourage illegal 
activity in gang members. While there is considerable 
heterogeneity, most gangs are defined by their associa-
tion with a particular territory (“turf ”) and their capac-
ity for violence, whether or not they deal drugs.
Drugs may increase the incentives and occasions for 
violence, but much of the violence of drug-dealing gangs 
is related to issues of “respect”, and is often committed 
contrary to their market interests.42 There is evidence 
that street gang members are among the lowest-paid 
actors in the entire distribution chain.43 They sell drugs 
because that is what street gang members do, because it 
is a job that can be done while standing on a street 
corner, and because it is perceived as affording greater 
dignity that fast-food work, not because it pays well. But 
given limited alternative forms of employment for 
uneducated young men with criminal records, it may be 
the only job on offer. And the prospect of possible future 
riches may be enough to justify continued participation 
despite relentless evidence that their efforts are fruitless.
Removing drugs as an income stream may decrease the 
attractions of gang membership and result in long-term 
violence reduction. And the surest way of taking drugs 
out of the hands of gangs is to close spatially-linked drug 
markets. 
Disrupt information networks
In addition to open markets, drugs are dealt through 
personal networks. These markets rely on trust – new 
participants are only introduced through the endorse-
ment of existing members. This slows their growth and 
leaves them fragile. An inherent weakness of black mar-
kets is that most of the participants are untrustworthy. 
Removal of key links, the use of informants, and sting 
operations (or the rumour of sting operations) can cause 
extended networks to collapse, and reconstitution may 
be difficult.44
Similar principles apply further up the trafficking chain, 
at the wholesale level. People who broker drug deals 
have only their connections to sell, and therefore take 
great pains to ensure their suppliers never meet their 
customers.45 If the brokers are removed, they are not 
always easily replaced. This weakness was recently 
exploited to disrupt the heroin markets in Australia, 
with very positive consequences. 
The causes of the  “heroin drought” have been debated,46 
and it is highly likely that a number of factors played a 
role,  but the balance of the evidence suggests that law 
enforcement action was important. Australian authori-
ties had determined that heroin trafficking was proceed-
ing in very large shipment through a limited number of 
nodal points (“brokers”) who had connections to both 
Southeast Asian suppliers and a vast network of street 
retailers. Evidence suggests that coordinated, interna-
tional-level law enforcement operations over a number 
of years may have progressively removed some of these 
key brokers, disrupting large-scale shipment to the 
country, reducing the quantity and quality of heroin 
available to street-level dealers. In the interim, many 
addicts went into withdrawal, and some appear not to 
have resumed heroin use; the market remains smaller to 
this day. By the time connections were resurrected, the 
market was not nearly as large. The smaller market 
attracted fewer new users. Violence, drug-related crime, 
overdoses, and overall use declined dramatically.47
2.3 Create flow-specific drug strategies
In addition to refining local enforcement techniques, 
there is a broader need to approach the drug problem 
strategically. Drug strategies are usually devised at a 
national level, but this is not always the most useful 
frame of analysis. The most important manifestations of 
the problem are highly local, and not every area is equally 
affected. Coming to terms with “the world drug prob-
lem” can be overwhelming when the issues are not 
described with sufficient specificity. When broken down 
into specific flows affecting specific areas in different 
ways, the problem becomes more manageable.
At the same time, local issues are deeply connected to 
what is going on internationally. As is discussed below, 
the particularities of each situation are tremendously 
important in designing interventions, but these interven-
tions can only be effective if they are coordinated across 
borders. Failure to coordinate local initiatives reduces the 
impact and results in displacement, an effect that has 
become a recurrent theme in global drug control.
Develop a truly “balanced approach”
The incompatibility of the problem and the primary 
tools used to engage it has long been recognised, and a 
“balanced approach” between supply-side (enforcement) 
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and demand-side (prevention and treatment) interven-
tions has become a commonplace of best international 
practice. The Conventions, however, are rooted in 
supply reduction: transnational trafficking is an interna-
tional issue, whereas efforts to address demand are largely 
domestic. Coordinated action on supply has a 70 or 
80-year head start on demand-side work. As was observed 
in this Report some 12 years ago, countries are fre-
quently criticised for failing to hold up their end in 
cooperative supply control efforts, but rarely is a nation 
taken to task for doing too little in prevention and treat-
ment. Partly as a result, in most countries, far more 
resources have been assigned to supply reduction than to 
demand reduction. 
The situation is even more pronounced in developing 
countries. International assistance in fighting drug supply 
has been eagerly accepted, since it often takes the form 
of military hardware, technology, and training. These 
tools can be used to shore up shaky administrations and 
combat political opponents. Law enforcement assistance 
can also further the foreign policy interests of the donor. 
In comparison, the promotion of treatment centres or 
prevention campaigns is relatively unattractive. 
Aside from resource distribution, the concept of a “bal-
anced approach” suggests that someone is weighing the 
alternatives, assessing drug problems and designing 
coordinated interventions as part of an integrated strat-
egy. It suggests that actors working on both sides of the 
drug problem are in communication with one another 
about current developments.
Unfortunately, in these respects, a truly balanced 
approach is rarely realised. Institutional barriers discour-
age cooperation between government sectors. More 
often, departments of law enforcement, education, and 
public health fight each other for resources in what is 
seen as a zero-sum game. Even when oversight or strate-
gic offices are established, they seldom have the author-
ity to overcome this insular bureaucratic tendency.
Different markets call for different interventions at dif-
ferent times. Resource allocations need to be similarly 
dynamic and problem-specific. Further, these resources 
and the programmes they fund should not be limited to 
those departments who have traditionally dominated 
anti-drug efforts.  Criminal justice agencies lack the 
tools to take on all aspects of the drug trade, and many 
do not make full use of the tools they have. Police and 
prosecutors must continue their work, keeping drugs 
illegal, but more dramatic change requires a mandate 
and a skills set not generally found among criminal jus-
tice actors. It may be that drug markets are deeply tied 
to issues in housing, or foreign affairs, or land use, or 
transportation, or immigration, or urban development. 
Until the full range of governmental powers is available 
to the drug control effort, it is likely that the same agen-
cies will continue to do the same work in very much the 
same way.
Moving beyond the capacities of any particular govern-
ment, international action should also include those 
involved in development work and peace building. This 
point is discussed further below.
Target specific drug problems
There is also a common tendency to treat the galaxy of 
illicit substances as an undifferentiated mass. Different 
drugs come from different places, attract different con-
sumers, and are associated with different problems, but 
they are rarely the subject of distinct strategies. Drug 
policy is too often “one size fits all”, when what is needed 
are interventions tailored to deal with each substance and 
the unique issues it raises in each location it touches.
Number of burglaries and the share of inmates testing positive to heroin in AustraliaFig. 12: 
Source: Australian Institute of Criminology, Drug Use Monitoring in Australia and Australian Crime Facts & Figures.
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Cultivation
Different drugs pose different issues from the point of 
cultivation onward. For example, cannabis is grown in 
at least 176 countries around the world. It can be grown 
indoors or outdoors, and is often cultivated in small 
plots by the users themselves. Because cannabis produces 
high yields and requires no chemical processing before 
use, it is the only common illicit drug (except maybe 
opium) where users can comfortably generate their own 
supply.48 Since it requires relatively little maintenance, 
it is often grown on vacant land in developing countries, 
by small scale farmers also cultivating other crops. As 
little is invested, eradication does not provide much 
disincentive to trying again. Law enforcement can dis-
courage large-scale plantations, which are clearly main-
tained by well-resourced farmers with a great deal to 
lose, but the point of diminishing returns is quickly 
reached in ferreting out smaller grows. The eradication 
of feral cannabis (“ditchweed”) can actually aid illicit 
cultivators, as it reduces pollination by lower potency 
strains and, if carried out vigorously enough, allows 
outdoor cultivation of sinsemilla.49 
Synthetic drugs pose similar challenges as cannabis, in 
that they can be manufactured anywhere the necessary 
chemicals are available. Unlike cannabis, however, for 
most synthetic drugs the skills needed to access and 
process the needed chemicals are not widely spread,50 
and, consequently, the market tends to favour more 
organised groups. Global precursors control is clearly 
key in disabling this market.
In contrast, most of the cultivation of drug crops like 
coca and opium poppy is confined to small areas within 
two or three countries. Most of the world’s heroin supply 
is produced on a land area about the size of Greater 
London (170,000 ha).  This area is by no means the only 
part of the world where opium poppy could grow; its 
range is actually quite wide.  The world’s heroin supply 
comes from this region because it is controlled by insur-
gents. Most of the world’s most dangerous substances 
come from areas with serious governance problems, 
because large-scale cultivation requires swathes of terri-
tory which are effectively outside the control of the 
national government.  Since insurgent groups typically 
tax cultivation in the areas under their control, the two 
issues become inextricably intertwined. Reducing culti-
vation in these areas is contingent upon establishing 
political stability and the rule of law. This can be seen in 
Afghanistan, one of the areas where insurgency and drug 
production are most clearly symbiotic. The 2009 Winter 
Opium Poppy Assessment found a strong relationship 
between poppy cultivation villages and poor security.
Trafficking
Differences on the production end also affect the way the 
different drugs are trafficked. Since cannabis can be pro-
duced virtually anywhere by anyone, it need not be traf-
ficked internationally. Surveys in a number of countries 
indicate that most users get their cannabis for free at least 
part of the time, and low-end cannabis is relatively cheap 
in most markets. This reduces the attraction of the drug 
for organised crime groups in many parts of the world, 
particularly where drug law enforcement is low, includ-
ing much of the developing world. There are obvious 
exceptions (over 1000 tons of low-grade herbal cannabis 
is confiscated annually on the southwest border of the 
United States), and transnational organised crime is 
most prevalent today in two markets: hashish and the 
“new” cannabis (buds of sinsemilla, bred for high potency, 
usually produced indoors, often hydroponically). 
In contrast, ecstasy production is a more complicated 
matter than growing cannabis, so transnational traffick-
Drug yield in dose units per square Fig. 13: 
meter of illicit crops
Source: UNODC yield studies
Share of villages cultivating poppy  Fig. 14: 
with good and poor security 
Source: Opium Winter Rapid Assessment 200951
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ing is more commonly involved. Ecstasy distribution is 
also generally more structured and hierarchical. Although 
social network distribution is common, consumption of 
ecstasy is often tied to particular events or dance clubs, 
and control of these venues means control of the drug 
market. This control is exercised by club or event secu-
rity, who have the power to authorise particular dealers 
or products, often in complicity with the club owners or 
event organisers.
Consumption
Cocaine is often consumed in “binges”, whereas heroin 
addicts need a predictable supply to avoid withdrawal. 
These differences shape the market and its consequences. 
Heroin addicts have the time and disposition to plan 
and execute property crime, such as burglaries. Users in 
the midst of a crack binge operate on a much shorter 
time schedule, and are more likely to take property by 
force in a robbery.52 Heroin addicts do trade sex for 
drugs but crack is much better suited for sex work, since 
it boosts energy, alertness, and confidence – all assets 
when negotiating delicate transactions on the streets.
These differences are real and have implications for con-
trol strategies, but they should not be mistaken for 
inherent properties of the drug. The same drug can have 
very different sorts of impacts in different social con-
texts.53 The classic example is alcohol, which is associ-
ated with violence and sexual aggression in some 
societies, but not in others. Cannabis is also associated 
with violence in some societies, a fact that Western con-
sumers may find difficult to believe.54 Cocaine use 
among the affluent has very different implications than 
cocaine use among the dispossessed. Any drug-specific 
strategy should take local context into account.
Drug problems, and the appropriate response to them, 
also vary over time. The ratio between all drug users and 
the number of addicts depends on where the given 
market is in the epidemiological cycle of the drug. In the 
early days of an epidemic, strong law enforcement is 
often successful; later, when a large body of addicts have 
become entrenched, treatment tends to provide the best 
return on investment.55
Focus on markets, not individuals
It is often difficult for law enforcement agencies to par-
ticipate in strategic approaches to crime problems because 
the case-specific nature of their work. In the past several 
decades, international law enforcement has struggled to 
come to grips with the phenomenon of transnational 
criminality generally. Penal law is matter of national 
legislation and custom, and, historically, has dealt with 
matters of primarily local interest. The global rise in 
prominence of “organised crime” prompted the creation 
of a United Nations convention: the 2000 United Nations 
Convention against Transnational Organized Crime.
But this agreement itself highlights the difficulties of 
coming to consensus on the nature of the problem. 
Remarkably, the convention nowhere defines “organised 
crime”.56 Instead, the Convention settles for a rather 
broad description of “organized criminal group”, com-
prising the following elements:
a group of three or more persons that was not   s
randomly formed;
existing for a period of time; s
acting in concert with the aim of committing at least one  s
crime punishable by at least four years incarceration;
in order to obtain, directly or indirectly, a   s
ﬁnancial or other material beneﬁt.
Since most “groups” of any sort usually involve three or 
more people working in concert for a period of time, the 
defining characteristic of organised crime under the 
Convention is its seriousness and profit-driven nature. 
The Convention does not require that the groups oper-
ate transnationally, and so the definition encompasses 
strictly local forms of crime-for-profit.57 Beyond the fact 
that money must be made, the range of relevant criminal 
activities is theoretically unbounded. In practice, how-
ever, the backbone of global organised crime has long 
been transnational trafficking, in particular the illicit 
trade in drugs.
The focus in the Convention on the group, rather than 
the activities of that group, is not unique to the Conven-
tion. It is a manifestation of a recurring perceptual prob-
lem in law enforcement. Police officers, investigators, 
and prosecutors are employed to make cases against 
individuals and groups of individuals. They lack the 
authority and the tools to take on an entire trafficking 
flow. As a result, they tend to conceptualise organised 
crime as the activities of a collection of particular people, 
rather than a market with a dynamism of its own.
Today, organised crime is less a matter of a group of 
individuals who are involved in a range of illicit activi-
ties, and more a matter of a group of illicit activities in 
which some individuals are presently involved. If these 
individuals are arrested and incarcerated, the activities 
continue, because the market, and the incentives it gen-
erates, remain. 
Sometimes, taking action against the market may mean 
forgoing action against individuals. It is important that 
the deterrent message reaches those who actually making 
the key decisions, rather than the undeterrable masses 
who often make up the face of drug trafficking. The 
decision makers are generally rational and profit-ori-
ented, as opposed to their front-line employees, whose 
behaviour may have more to do with issues of liveli-
hood, identity and emotion. Sending negative economic 
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feedback can be more effective than endless low-level 
enforcement.
For example, since 2000, the authorities at Schipol Air-
port in the Netherlands were faced with a tide of cocaine 
coming in on commercial flights from the Netherlands 
Antilles. Over 6000 couriers were arrested in less than 
three years. The couriers were largely body packers, each 
carrying about a kilogram of cocaine in their intestines. 
For the traffickers behind these couriers, the difference 
in the price of a kilogram of cocaine in Curacao and a 
kilogram of cocaine in Amsterdam was sufficient to 
cover the cost of the flight, the fee for the courier, and 
quite a few losses. The couriers themselves were dispos-
able, cheap, and inexhaustible, like cardboard boxes. 
Losing a few was of no consequence if enough drugs got 
through to turn a healthy profit.
Dutch airport security was constrained by the same 
issues that constrain law enforcement agents everywhere. 
Processing a subject through the criminal justice system 
takes a tremendous amount of time. In addition to 
intake, the arresting officer may be called upon to testify 
at trial, and may be compelled to appear multiple times 
before actually taking the stand. As a result, there are 
limits on the number of suspects who can be arrested on 
any given flight. Traffickers know this, and “shotgun” 
multiple couriers on a single flight.  In the case of the 
Antilles, this could be 30 couriers on a flight or more, 
overwhelming the system.
Under these circumstances, arresting individual couriers 
was futile. It sent no message back to those who were 
making the decisions, since not enough couriers could 
be arrested to impact on the bottom line. Rather than 
focusing on the couriers, the emphasis shifted to the 
drugs. A system called “100% control” was imple-
mented, with scanners and profiling on both ends of the 
flight. Europol described the mechanics of the policy in 
this way:
Crews, passengers, their luggage, the cargo and the planes 
are systematically searched. Couriers with amounts of 
less than 3 kg of cocaine are not detained, unless they are 
arrested for the second time or another criminal offense 
is involved. Instead, the drugs are confiscated and the 
smugglers are sent back. Couriers who have been identi-
fied are registered on a blacklist, which is provided to 
KLM, Dutch Caribbean Airlines and Suriname Air-
ways.59
While it would be extremely difficult to process 30 sus-
pects per flight through the criminal justice system, it 
was a relatively simple matter to hold them all and wait 
for the drugs to pass. When the level of seizures reached 
a point that trafficking through the airport was no longer 
profitable, the flow of couriers stopped. The responsible 
parties had finally received the message.
Of course, despite the undeniable success of the 100% 
control strategy, cocaine continued to flow into Europe. 
The drug supply had not been stopped, but it had been 
guided. The ability of government to shape drug mar-
kets is not without value, however, and can be used to 
limit the unintended consequences of enforcement.
Guide the market
Law enforcement has not succeeded in stopping the flow 
of drugs from their origins to their destinations, but this 
does not mean it has had no impact on drug markets. As 
mentioned above, the production costs of drugs com-
prise only a tiny fraction of their retail cost, and this fact 
is entirely attributable to their illegality. In addition to 
affecting the amount of drugs getting though, there are 
other ways that interdiction work affects the drug mar-
kets. The impact of law enforcement should be used to 
guide the market in ways that maximise positive side 
effects and minimise negative ones.
For example, the phenomenon of “displacement” is 
often used to criticise drug control efforts. Crackdowns 
in one country or region cause cultivators and traffickers 
to move operations to another. This ability of enforce-
ment to displace production and trafficking from one 
area of the world to another is a valuable tool if wielded 
with some foresight. In particular, it is important not to 
displace trafficking into areas where the social impact is 
likely to be particularly devastating.
Drug flows do not impact all that they touch in the same 
way. For example, over decades tons of heroin have tran-
sited the Balkans on their way from Afghanistan to 
Western Europe. The present estimate is that about 80 
tons of heroin transits this region each year. It appar-
ently does so with surprisingly little impact on the coun-
tries through which it passes. The available data suggest 
rates of drug use, murder, and other forms of crime in 
Couriers Detected Arriving at Schiphol Fig. 15: 
from Curacao, by Quarter
Source: World Bank and UNODC, Crime, violence, and  
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the Balkans are lower than in West Europe. This may be 
because the flow through these countries is highly organ-
ised, reliant on high-level corruption, and close to the 
destination markets.61
In contrast, the flow of cocaine through Central America 
and the Caribbean appears to be directly related to the 
violence afflicting those regions. For example, in 2004 
the murder rate in the rural and largely indigenous Gua-
temalan province of Petén, close to the Mexico border, 
was higher than that in Guatemala City. The most 
remarkable thing about this otherwise pacific province is 
its notorious role in drug trafficking. Petén has less than 
half a million people and saw its first paved road in 
1982, but has long been the site of clandestine landing 
strips for traffickers who proceed by land across the 
Mexican border.64
Total recorded robbery and assault  Fig. 16: 
victimisation rates per 100,000  
adjusted for under-reporting
Source: UNODC, Crime and its impact on the Balkans60
Guatemalan murder rates per 100,000 by province in 2004Fig. 17: 
Source: UNODC, Crime and Development in Central America62
Average annual drug use prevalence, Fig. 18: 
2005 estimate
Source: UNODC, Crime and its impact on the Balkans63
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Recently, another highly vulnerable area became part of 
a major cocaine trafficking flow for the first time: West 
Africa, one of the poorest and least stable areas of the 
world. From sometime around 2004, Colombian traf-
fickers increasingly made use of West African countries 
as a transit area for their cocaine shipments to Europe. 
Between 2004 and 2008, at least 46 tons of cocaine were 
seized in the region and approximately 3.4 tons of 
cocaine were seized in Europe from some 1400 couriers 
on commercial air flights from West Africa.
The impact on the region was immediate and devastat-
ing. Drug traffickers used their financial leverage to cor-
rupt top political, military, and law enforcement officials 
in several countries in the region. There were many inci-
dents in which drug seizures disappeared or traffickers 
escaped inexplicably. In Guinea-Bissau, there was a stand-
off between the police and the military over the search 
of a plane later determined to have contained cocaine. In 
Sierra Leone, the minister of transport stepped down 
after his brother was implicated in a large air shipment. 
Reports began to circulate, including in the affidavits of 
trafficking suspects, that trafficking through Guinea was 
controlled by the son of the president who had ruled that 
country since 1984, Lansana Conté.  After Conté’s death 
at the end of 2008, his son was arrested and confessed to 
his participation on national TV, alongside the former 
president’s brother-in-law, head of intelligence, and head 
of the national drug squad.
Around 2006, cocaine trafficking through West Africa 
began to attract international attention, including that 
of the United Nations Security Council. A wide range of 
players began to offer emergency assistance, including 
resources for law enforcement, intelligence, and direct 
interdiction. Air flights from the region began to receive 
special scrutiny. In short, the region was put under a 
spotlight, presenting less than optimal conditions for 
drug traffickers.
By 2008, seizure volumes were in sharp decline, and as 
of May 2009, there have been no multi-ton seizures 
reported. The number of air couriers detected in Euro-
pean airports has plummeted. According to the database 
of one network of European airports, of all cocaine cou-
riers detected, the share coming from West Africa 
dropped from 59% in the second quarter of 2007 to 6% 
in the first quarter of 2009.
While many of the vulnerabilities that made West Africa 
attractive to cocaine traffickers remain in place, the 
increase in international attention appears to have been 
sufficient to persuade them to find paths of less resist-
ance. It is possible, if not likely, that they would return 
should international attention falter. But for now, West 
Africa has been spared the corrupting influence of a 
cocaine flow valued at more than the GDPs of some 
countries in the region. 
Cocaine continues to find its way to Europe, of course, 
and there are no indications that the loss of this route 
significantly curtailed supply. There are few regions of 
the world as vulnerable as West Africa, however, and 
international attention has apparently given this poor 
region a reprieve. The threat was addressed early enough 
that the impact need not be long-lasting. On the whole, 
this was a very positive result.
This example shows that while international cooperative 
efforts have not plugged every hole, they can present 
significant disincentives, guiding markets. Aside from 
guiding flows, there are many other ways enforcement 
could be used strategically to reduce violence, corrup-
tion, and other unintended consequences. For example, 
the decision to target violent drug traffickers has the 
Share of detected cocaine couriers whose ﬂight originated in West Africa Fig. 19: 
Source: UNODC, Transnational trafficking in West Africa: A threat assessment65
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effect of advantaging non-violent offenders. The size of 
the drug market may remain the same, but the state has 
provided an economic incentive to avoid violence.66 
With some practice, these sorts of interventions could 
also be used as part of a broader plan to significantly 
undermine specific trafficking organisations or even 
whole markets.
2.4 Strengthen international resistance  
to drug markets
In addition to creating viable international and local 
strategies for dealing with drug problems, it is important 
that the actors themselves be strengthened. The weak 
link in drug control has long been those parts of the 
world where the rule of law is absent. Building institu-
tional strength and capacity in these countries is key to 
the mission of supporting democracy, economic growth, 
and human rights. 
It is also important that the bedrock of international 
cooperation be strengthened, through enhanced use of 
the United Nations Conventions. In addition to the 
drugs Conventions, those on Transnational Organised 
Crime and Corruption present great opportunities for 
reducing the size of drug markets and associated prob-
lems.
Spread the rule of law
As mentioned above, large-scale illicit crop cultivation 
seems to require political instability because accountable 
governments can be compelled to take action against 
drug production in areas under their control. It is no 
coincidence that most of the world’s cocaine and heroin 
supplies come from countries with insurgency problems. 
Almost all of the world’s cocaine supply comes from 
three countries and almost all the world’s heroin supply 
comes from two. This is not because coca and opium 
poppy could not be cultivated in other areas – in the 
past, most of the world’s supply of these drugs came 
from countries not presently leading illicit production. 
All of these countries have problems with the rule of law 
in the cultivation areas.
But while cultivators may enjoy zones of chaos, some 
traffickers may prefer authoritarian regimes. Areas too 
fraught by conflict lack the infrastructure and the pre-
dictability to be good commercial nodes, whether the 
trade is licit or illicit. In contrast, areas under control of 
an absolute, and absolutely corrupt, leadership allow 
what would normally be clandestine activities to be con-
ducted openly, greatly increasing efficiency. Rather than 
risk the unpredictable cost of interdiction, traffickers 
may opt for the more predictable costs of corruption.
In the end, the two phenomena go hand in hand. Abso-
lutist governments are often formed (and tolerated) in 
response to the threat of instability. This threat typically 
exists because some portion of the population is poor 
and marginalised, and the state is either unwilling or 
unable to meet its needs. As a result, dealing with drug 
cultivation countries and transit countries often boils 
down to the same thing. The rule of law must be 
strengthened in all its aspects, including promoting 
democracy, increasing the capacity for law enforcement, 
and ensuring the protection of human rights, as well as 
promoting economic development.
Economic development is also key in promoting politi-
cal stability. Civil war has been linked to both low 
income and low growth.67 Unfortunately, political sta-
bility is also key to economic growth. As one authority 
points out “Civil war is development in reverse.”68 To 
break out of this cycle, measures taken to establish civil 
order can establish the foundation for investment and 
growth. In this way, all aspects of international coopera-
tion are related. Development assistance, post-conflict 
planning, and crime prevention must be coordinated, 
for any weakness in the chain can lead to the collapse of 
the whole. 
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Confronting unintended consequences: Drug control and the criminal black market
Make better use of the international tools  
and interventions
The 1988 Convention established the means to move 
beyond arrests and seizures in dealing with international 
drug problems. The anti-trafficking measures, including 
those aimed at chemical precursors, money laundering, 
and asset forfeiture, greatly expanded the tools available 
to law enforcement. Two decades later, much more 
could be done to apply these tools to transnational traf-
ficking flows. Cooperative work on money laundering 
and asset forfeiture in particular could greatly be 
expanded.
Those involved in work on transnational drug issues are 
very familiar with the three drug Conventions, but may 
be less familiar with those on Transnational Organised 
Crime and Corruption. This is a pity because these two 
under-utilised instruments could be used to great effect 
in combating drug markets and related violence and 
corruption.
The United Nations Convention on Transnational 
Organised Crime is key in establishing the legislative 
framework needed to address the drug business, and in 
building the mechanisms for international cooperation. 
But there is a large gap in the rate of ratification and the 
implementation of its provisions. Many countries have 
passed legislation that is rarely used, but has tremendous 
potential if applied strategically. For example, the Con-
vention allows for the criminalisation of membership in 
an organised crime group without the need to prove any 
particular individual was associated with any particular 
offence. This can be used to confront organised crime 
groups with the certainty of arrest if drug market activity 
or violence does not stop, as discussed above.
Another underutilised opportunity for cooperation lies 
in the area of money laundering and asset forfeiture. 
Perhaps because law enforcement officials lack financial 
expertise, police departments across the globe find the 
process of tracing and seizing money far more difficult 
than tracking contraband. Even more unusual is inter-
national cooperation in the recovery of illicit assets. But 
much of the costs of enforcement could be redeemed if 
asset forfeiture were taken seriously. If legal challenges 
and administrative difficulties have proven insurmount-
able, a renewed effort must be made to streamline the 
process so that money made in crime can be used to 
prevent it in the future.
The same is true in the area of corruption. By providing 
criminals with virtual immunity from prosecution, cor-
ruption can nullify the deterrence effect normally 
expected from the enforcement of the drug control 
system. In adopting the United Convention against 
Corruption, the Member States have equipped them-
selves with a powerful instrument to remove an essential 
lubricant of criminal black markets. But despite the fact 
that the convention entered into force four years ago 
and has already been signed by 140 countries, this effort 
has also fallen short of its potential when it comes to its 
concrete application. 
When dealing with corruption, the basic principle of 
focusing on those who can be deterred applies once 
again. A dealer risks very little in offering a bribe, an but 
official risks quite a lot in receiving it. In a word, they 
can be deterred. Those who might be expected to 
encounter traffickers in their daily business should 
expect to be especially scrutinised, if not audited. Trans-
parency should be the price of the job. 
Corruption and drug markets are locked in a mutually 
re-enforcing cycle. Drug money is a powerful corrupting 
force, but many drug markets would be impossible 
without corruption. Anti-corruption work has the 
potential to simultaneously improve governance while 
undermining the ability of criminals to operate with 
impunity. Once the cycle is reversed, growing confi-
dence in government will improve citizen cooperation, 
further undermining corrupt officials and the criminals 
that rely on them.
In parallel to these efforts to strengthen international 
resistance to drug markets broadly, there is a need to act 
on an emergency basis in those parts of the world where 
the rule of law has collapsed, and ensure that crime pre-
vention is at the head of the agenda when reconstruction 
begins. Tottering states everywhere both generate and 
attract organised crime. Crime predictably comes with 
periods of transition and upheaval, and planning should 
proceed with this fact in mind.
Peacekeeping and crime prevention must go hand in 
hand. Their object is the same: the provision of safety 
and security. Their opponents are also often the same: 
the agents of instability that profit off human misery. 
Even after the open hostilities have ceased, however, 
these same agents continue to operate in states strug-
gling to get back on their feet. As has become evident in 
Afghanistan, those who earn their money from instabil-
ity will go to great lengths to ensure this instability 
persists. Peacekeeping and reconstruction missions are 
not complete until these countries are able to cope with 
the security challenges confronting them, be they armed 
insurgencies or organised crime. Reconstruction and 
development cannot proceed without the rule of law in 
place. 
Improve information systems
As the first part of this World Drug Report demon-
strates, there remains a great deal of uncertainty around 
the extent and nature of drug production, trafficking 
and consumption. This is not because these data involve 
clandestine markets and are therefore unattainable. The 
methods and techniques for extracting reliable informa-
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tion about drug activities have been honed over decades. 
In many cases, all that is needed is the small amount of 
effort required to gather and submit administrative data, 
data that are gathered in the normal course of business 
for government in any case.
A renewed effort must be made to bolster our collective 
knowledge base around global drug issues.  This infor-
mation is in the strategic security interests of all parties 
concerned. Information-sharing obligations embedded 
in the Conventions are not consistently fulfilled by a 
number of key parties. Without this information, it 
become very difficult to describe the present situation or 
the direction things are going.  It also becomes impos-
sible to gauge the impact of specific and collective inter-
ventions.
2.5 Take the crime out of drug markets
The discussion above has outlined some of the ways that 
global drug control efforts could be improved to reduce 
the size of the drug markets and the associated violence 
and corruption. First, it suggests several ways current 
enforcement practices could be refined:
Drugs must remain prohibited because the fact of il- s
legality alone reduces the number of potential addicts, 
particularly in developing countries.
Drug control must be conducted in ways designed to  s
limit associated violence and corruption.
Drug enforcement should focus less on high volumes  s
of arrests and more on reducing the size of drug mar-
kets through targeted enforcement and situational 
crime prevention.
The incarceration of drug users should be exceptional;  s
rather, users should be tracked and addicts brought 
into treatment.
The addict population should be a priority, as they pro- s
vide the bulk of the demand.
Open drug markets must be closed, using the tech- s
niques of situational crime prevention and problem-
oriented policing.
The discussion then endorses the creation of multidisci-
plinary strategies tailored to meet the problems posed by 
particular drugs in particular places:
Planning s  for drug control must not be centred on law 
enforcement agencies, and should involve coordinated 
actions from actors in a range of disciplines and gov-
ernment agencies.
Enforcement agencies can participate, but need to  s
move beyond a focus on punitively incarcerating in-
dividuals to look at ways of disabling the market, even 
when this means forgoing arrests.
Although entrenched markets may be diﬃcult to dis- s
able, they can be guided by enforcement action so that 
they do the least possible damage.
Finally, this chapter looks at ways the international com-
munity can build resistance to drug markets:
Both cultivation and transit countries suﬀer from weak- s
ness in the rule of law; supporting the growth of insti-
tutional strength and integrity in these countries will 
make them more resistant to the traﬃcking of drugs 
and other forms of contraband.
There remains great potential in the Conventions on  s
Transnational Organised Crime and Corruption to col-
lectively address the problem of global drug markets.
There is a strong need to improve and develop inter- s
national information sharing systems, so that progress 
can be measured and interventions evaluated.
A common thread throughout these proposals is the 
need to integrate the marginalised individuals, areas, 
and nations that cultivate, consume, and distribute 
drugs. These people need to be brought in, not pushed 
down. They will find it impossible to develop without 
getting beyond crime, but it is very difficult to get 
beyond crime without some prospect of development. It 
is incumbent on all in the international community to 
ensure that no one is faced with impossible choices, and 
that behaviour that benefits all of us is in the interest of 
each of us.
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3. STATISTICAL ANNEX
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3.1.1 Afghanistan
1 The information in this section comes from the Afghanistan Opium 
Survey 2008 (UNODC/Ministry of Counter Narcotics, Afghani-
stan, November 2008), and can also be found at http://www.unodc.
org/unodc/en/crop-monitoring/index.html. Source unless otherwise 
indicated: National monitoring system supported by UNODC.
2 The figures in brackets represent the lower and upper limits of the 
90% confidence interval
3 The area available for agriculture has been updated by UNODC 
based on Landsat 7 ETM images.
4 Population 24.1 million in  Afghan year 1385 (April 2006 to March 
2007) and 24.5 million in Afghan year 1386 (April 2007 to March 
2008);  source: Afghan Government, Central Statistical Office.
5 GDP Afghan year 1385 (April 2006 to March 2007), revised figure, 
and GDP for  Afghan year 1386 (April 2007-March 2008; pre-
liminary estimates);  GDP growth in constant Afghanis amounted to 
16.2% in the Afghan year 1386, up from 11.2% in the Afghan year 
1385;  source: Government of Afghanistan, Central Statistical Office. 
The inflation (change in the Consumer Price Index) amounted 
to 16.9% in 2007 and 27.1% over the first two quarters of 2008 
(Source: IMF International Financial Statistics, October 2008). 
Foreign  exchange rate of the Afghan currency  remained practically 
unchanged (2006: Afghanis 49.93; 2007: Afghanis 49.96; first two 
quarters of 2008: Afghanis 49.65 for  US$ 1). 
Fact Sheet1 - Afghanistan Opium Survey 20082
 2007 Change on 2007 2008
Net opium poppy cultivation (after eradication)
193,000 ha
(177,000-209,000 ha)
-19% 157,000 ha
(130,000-190,000 ha)
 in per cent of agricultural land3 2.5% 2.1%
Number of poppy-free provinces (out of 34) 13 +38% 18
Eradication 19,047 ha -71% 5,480 ha
Weighted average opium yield 42.5 kg/ha +15% 48.8 kg/ha
Potential production of opium
8,200 mt
(7,530-8,960 mt)
-6%
7,700 mt
(6,330-9,308 mt)
Number of households involved in  
opium cultivation
509,000
(437,000-653,000)
-28%
366,500
(315,000-470,000)
Number of persons involved in  
opium poppy cultivation 3.3 million -28% 2.4 million
 in per cent of total population4 13.7% 9.8%
Average farm-gate price (weighted by production) 
of fresh opium at harvest time US$ 86/kg -19% US$ 70/kg
Average farm-gate price (weighted by production) 
of dry opium at harvest time US$ 122/kg -22% US$ 95/kg
Current GDP5 US$ 8.2 billion US$ 10.2 billion
Total farm-gate value of opium production
US$ 1 billion
(0.912-1.088)
-27%
US$ 730 million
(601-885)
 in per cent of GDP 12% 7%
Potential export value of opium, morphine and 
heroin (border areas of neighbouring countries)
US$ 4 billion
(3.5-4.5 billion)
US$ 3.4 billion
(2.7-4.3 billion)
Indicative gross income from opium per ha/year US$ 5,200 -10% US$ 4,662
Indicative gross income from wheat per ha/year US$ 546 +198% US$ 1,625
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Cultivation and eradication 
The total opium poppy cultivation in 2008 in Afghani-
stan was estimated at 157,000 ha, a reduction of 19% 
compared to 2007. Almost the entire cultivation (98%) 
was confined to seven out of 34 provinces, all of which 
had security problems: five of these provinces were in 
the south (Hilmand, Kandahar, Uruzgan, Daykundi and 
Zabul provinces) and two in the west of Afghanistan 
(Farah and Nimroz provinces). In 2008, 18 provinces 
were poppy-free, five more than 2007. This included the 
eastern province of Nangarhar, which, in 2007, had the 
second largest area under opium poppy cultivation in 
the country. Only a very small portion of the total cul- 
 
 
tivation took place in the north (Baghlan and Faryab 
provinces), north-east (Badakhshan province) and east 
(Kunar, Laghman and Kapisa provinces). Together, these 
provinces accounted for less than 2% of cultivation. 
Eradication activities in 2008 were severely affected by 
resistance from insurgents. In 2008, a total of 5,480 ha 
of eradicated opium poppy fields were verified by the 
Ministry of Counter Narcotics, Afghanistan/UNODC. 
This included governor-led eradication (4,306 ha) and 
eradication led by the centrally controlled Poppy Eradi-
cation Force (1,174 ha). 
Region 2007 (ha) 2008 (ha)
Change  
2007-2008
2007 (ha) as  
% of total
2008 (ha) as  
% of total
Southern 133,546 132,760 -1% 69% 84%
Northern 4,882 766 -84% 3% 0.5%
Western 28,619 22,066 -23% 15% 14%
North-eastern 4,853 200 -96% 3% 0.1%
Eastern 20,581 1,151 -94% 11% 0.7%
Central 500 310 -38% 0.3% 0.2%
Rounded total 193,000 157,000 -19% 100% 100%
Afghanistan, regional distribution of opium poppy cultivation (ha), 2007-2008
Afghanistan, opium poppy cultivation (ha), 1994-2008
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Prices
Farm-gate prices for dry opium at harvest time decreased 
by 22% to US$ 95/kg in 2008, compared to US$ 122/
kg in 2007 (price weighted by production). Regional 
trader prices for dry opium decreased in all regions 
except the Central Region. Prices fell by 30% in the 
Eastern Region, 20% in the Northern, 20% in the 
Southern and 17% in the Western Region. In general, 
in 2008, regional trader price differences were less pro-
nounced than in the three previous years. Regional 
prices tended to be higher in the Eastern and Western 
 
 
Regions, which are thought to be the two main exit 
routes for opium and heroin exports, and low in the 
South, where the bulk of opium production occurs. Low 
prices can be a consequence of many factors, including 
difficult marketability of opium due to law enforcement 
activities, cost of transport from northern to southern 
Afghanistan for heroin production and onward traffick-
ing to other countries, or a high volume of opium being 
offered on the market.
Afghanistan, potential opium production (mt), 1994-2008
Production
The total opium production in 2008 was estimated at 
7,700 mt, a reduction of 6% compared to 2007. Due to 
higher than average yields in the seven provinces where 
most of the opium poppy cultivation took place, the 
decrease in production was smaller than the decrease in 
cultivation. 
Taking domestic consumption of opium, seizures and 
opium exports into account, Afghanistan’s morphine 
and heroin production destined for export was estimated 
at 630 mt in 2008, a decrease of 5% compared to 666 
mt in 2007. 
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Farm-gate value
The gross income for farmers who cultivated opium 
poppy was estimated at US$ 730 million in 2008. This 
is a decrease from 2007, when farm-gate income for 
opium was estimated at US$ 1 billion. The farm-gate 
value of opium as a proportion of GDP decreased in 
2008 to 7% compared to 12% in 20076. The total 
farm-gate income from opium in Afghanistan is calcu-
lated based on dry opium prices at harvest time.
6 These percentages were calculated considering the 2007 GDP esti-
mated by the Central Statistical Office of Afghanistan at US$ 10.2 
billion.
Households involved
In 2008, the survey estimated that 366,500 families 
were involved in opium poppy cultivation compared to 
509,000 families in 2007 (a decrease of 28%). Given an 
average of 6.5 members per family, this represents an 
estimated total of about 2.4 million persons, or 9.8% of 
Afghanistan’s population of 24.5 million. 
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1 The information in this section comes from the report on Coca Cul-
tivation in Bolivia (UNODC/Government of Bolivia, June 2009), 
and can also be found at http://www.unodc.org/unodc/en/crop-
monitoring/index.html
2 Source: Instituto Nacional de Estadística de Bolivia (INE).
3 Excluding coca leaf maceration pits.
Cultivation and eradication 
In 2007, the total area under coca cultivation in Bolivia 
increased by 6% to 30,500 ha, the third consecutive 
yearly increase. Overall, cultivation levels remained well 
below the levels reached in the early and mid-1990s. 
Increases in the country’s two largest cultivation regions, 
the Yungas of La Paz and Chapare, occurred roughly at 
the same rate. 
The Government of the Plurinational State of Bolivia 
reported 5,484 ha of eradication of coca bush, which is 
less than in 2007 but more than in 2005. 
2007
Change on 
2007
2008
Coca cultivation
 Of which in the Yungas of La Paz
  in Chapare
  in Apolo
 Of which permitted by Bolivian law 1008
28,900 ha
19,800 ha
8,800 ha
300 ha
12,000 ha
+6%
+5%
+8%
+0%
30,500 ha
20,700 ha
9,500 ha
300 ha
12,000 ha
Production of sun-dried coca leaf
Potential production of cocaine HCl
51,000 mt
104 mt
+6%
+9%
54,000 mt
113 mt
National weighted average farm-gate price of coca leaf 
(outside state market) US$ 4.1/kg +32% US$ 5.4 Kg
Total farm-gate value of coca leaf production
GDP2
 Farm-gate value of coca leaf production in  
 per cent of GDP
 Farm-gate value of coca leaf production in  
 per cent of value of 2007 agricultural sector
US$ 214 million
US$ 9.1 billion
2.4%
16%
n.a.
Reported eradication of coca bush* 6,269 ha -13% 5,484 ha
Reported seizure of sun-dried coca leaves* 1,730 mt +21% 2,095 mt
Reported seizure of cocaine base* 14,912 kg +25% 18,584 kg
Reported seizure of cocaine HCl* 2,923 kg +148% 7,246 kg
Reported destruction of coca laboratories3* 4,087 +22% 4,999
Of which cocaine HCl processing laboratories 6
* As reported by the Government of the Plurinational State of Bolivia.
Fact Sheet Bolivia Coca Survey 20081
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Production
In 2007, potential cocaine production in Bolivia 
increased by 9% to113 mt. The increase in cocaine pro-
duction is more pronounced than for the area under 
coca cultivation. This is because areas of relatively low 
yield where coca leaf is produced for traditional pur-
poses have not been included. 
Prices
Farm-gate prices of sun-dried coca leaf in Chapare 
Region outside the state-controlled market experienced 
a strong increase in 2008 and reached a level of over US$ 
6/kg (average US$5.5/kg), which was last reached in 
2002. However, information from the first months of 
2009 indicates a return to prices of around US$ 4/kg 
after good coca leaf harvests in the preceding rainy 
season. Coca leaf prices in the Yungas of La Paz, on the 
other hand, remained relatively stable over the course of 
the year. The monthly average price ranged from 36 
bolivianos (Bs) or US$ 5.1/kg to Bs 39 or US$ 5.3/kg. 
The annual average is of Bs 38 was similar to 2007, 
however, expressed in US$ terms, it increased from US$ 
4.8/kg in 2007 to US$ 5.2/kg in 2008 due to a change 
in the currency exchange rate. 
The annual average price of sun-dried coca leaf in the 
state-controlled market increased significantly both in 
Bolivianos and US$ terms, from an average of Bs 35 or 
US$ 4.6/kg in 2007 to Bs 44 or US$ 6.1/kg in 2008 
(weighted by the amount of coca leaf traded in the state-
controlled markets of Sacaba in Chapare region and 
Villa Fatima in La Paz). 
Bolivia, coca cultivation (ha), 1994-2008
Bolivia, potential cocaine production (mt), 1994-2008
Note: Production estimates for 2004 and 2005 were updated in 2007 based on a new UNODC study on coca leaf yield in the Yungas of La Paz.  
Sources: 1994-2002: Comisión Interamericana para el Control del Abuso de Drogas (CICAD) and US Department of State, Interna-
tional Narcotics Control Strategy Report. Since 2003: UNODC calculations, partly based on UNODC coca leaf yield surveys. 
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2007 Change on 2007 2008
Net coca cultivation (rounded total) 
Of which in Pacific region
Central region
Putumayo-Caquetá region 
Meta-Guaviare region
elsewhere
99,000 ha
25,960 ha
20,950 ha
21,130 ha
19,690 ha
11,170 ha
-18%
+15%
-11%
-34%
-38%
-44%
81,000 ha
29,920 ha
18,730 ha
13,960 ha
12,150 ha
6,200 ha
Potential production of cocaine 600 mt -28% 430 mt
Average farm-gate price of coca paste
US$ 943/kg
COP 1,959,000/kg
+2%
-4%
US$ 963/kg
COP 1,887,855/kg
Average wholesale price of cocaine* 
US$ 2,198/kg
COP 4,567,000/kg
+7%
0%
US$ 2,348/kg
COP 4,580,000/kg
Total farm-gate value of the production of 
coca leaf and its derivatives US$ 934 million - 53% US$ 441 million
 in per cent of GDP
 in per cent of agricultural sector
0.5%
5%
0.3%
2%
Reported aerial spraying of coca bush* 153,134 ha -13% 133,496 ha
Reported manual eradication of coca bush* 66,805 ha +43% 95,634 ha
Reported seizure of cocaine* 126,641 kg +63% 206,100 kg
Reported destruction of coca processing 
laboratories* 2,360 -6% 2,207
Of which cocaine HCl processing lab. 265 636
Reported opium poppy cultivation* 714 ha -45% 394 ha
Potential opium latex production 34 mt* n.a. 31 mt**
Potential heroin production (rounded) 1.4 mt* n.a. 1.3 mt**
Average farm-gate price of opium latex US$ 286/kg +11% US$ 318/kg
Average heroin price US$ 10,780/kg -8% US$ 9,950/kg
Reported seizure of heroin 537 kg 696  kg
Fact sheet – Coca Survey 20081
* As reported by the Government of Colombia. Figures for 2008 are preliminary.
** Own calculations based on regional yield figures and conversion ratios from US Department of State.1
1 The information in this section comes from the report on Coca Cultivation in Colombia (UNODC/Government of Colombia, June 2009), and can 
also be found on the internet (http://www.unodc.org/unodc/en/crop-monitoring/index.html). Source unless otherwise indicated: National monitor-
ing system supported by UNODC.
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Cultivation and eradication
In 2008, the area under coca cultivation decreased by 
18% to 81,000 ha, roughly the same level as in 2006. 
Most of the decrease of 18,000 ha took place in the 
regions of Meta-Guaviare, Putumayo-Caquetá and Ori-
noco. On the other hand, a significant increase was 
observed in the Pacific region as well as in some smaller 
cultivation regions. Thus, the Pacific region remained 
the region with the largest area under coca cultivation, 
with just below 30,000 ha or 38% of the total area, fol-
lowed by the Central region (23%), Putumayo-Caquetá 
(17%) and Meta-Guaviare (15%). 
The Colombian authorities continued to intensify 
manual eradication activities, which increased by 43% 
and reached a record high of 95,634 ha in 2008. In the 
Departments of Putumayo and Antioquía (Central 
region) alone, 30,834 ha and 19,366 ha were eradicated, 
respectively. In addition, in 2008, more than 133,000 ha 
of coca bush were sprayed in 14 Departments. Most 
spraying took place in the Department of Nariño (Pacific 
region), where over 54,000 ha were sprayed, followed by 
Guaviare, Putumayo, Caquetá and Antioquía. 
Colombia, Coca cultivation and reported eradication/spraying (ha), 1994-2008
Sources: Cultivation: 1994-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; since 1999: 
National Illicit Crop Monitoring System supported by UNODC; eradication/spraying: Government of Colombia. 
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
200,000
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
H
ec
ta
re
s
Net coca cultivation area (end of  year f igure) Spraying (cumul.) M anual eradication
Colombia, coca cultivation by region, 2008
Source: National Illicit Crop Monitoring System supported by UNODC
 Sierra Nevada 
560 ha, 1%
 M eta-Guaviare 
12,150 ha, 15%
 Pacif ic
29,920 ha, 38%
 Amazonia 
2,020 ha, 2%
 Orinoco
3,620 ha, 4%
 Central
18,730 ha, 23%
 Putumayo-Caquetá, 
13,960 ha, 17%
199
3. Statistical Annex Production
Production
In 2008, the potential cocaine production in Colombia 
was estimated at 430 mt, much lower than in any of the 
four preceding years for which comparable data is avail-
able. The reduction in potential cocaine production 
(-28%) was more pronounced than the decrease in area 
under coca cultivation (-18%). Among other reasons, 
this was due to strong area decreases in some of the main 
coca cultivation regions (Meta-Guaviare, Putumayo-
Caquetá and Orinoco), which were only partly counter-
balanced by area increases in Pacific and other regions 
with average or below average yields. Lower coca leaf 
yields in Meta-Guaviare and Putumayo-Caquetá also 
contributed to the overall reduction in potential cocaine 
production.
Prices for coca leaf, cocaine and opium
UNODC’s monitoring of coca leaf prices in Colombia 
is not yet fully developed and the availability of monthly 
average farm-gate prices differs from region to region 
and over the course of a year. Thus, small-scale price 
changes should be interpreted with caution. Farm-gate 
prices are also thought to be influenced by armed groups 
who are able to control prices in their region of influ-
ence. 
Farm-gate prices in Colombian pesos (COP) for coca 
leaf and derivatives changed little in 2008 compared to 
2007. Over the last three years, farm-gate prices for coca 
leaf and paste were decreasing, despite higher costs of 
agricultural inputs and precursors necessary for produc-
ing coca paste. On average, the per kilo price of fresh 
coca leaf decreased from COP 2,400/kg or US$ 1.2/kg 
in 2007 to COP 2,200/kg or US$ 1.1/kg in 2008. 
Farm-gate prices of coca paste have seemed relatively 
stable or slightly declining since 2004. Regional price 
averages ranged between a maximum of COP 2,056,000/
kg in the Central region and a minimum of COP 
1,714,583/kg in the Pacific region. In 2007, both the 
regional maximum and minimum prices were slightly 
higher with a maximum of 2,121,107/kg observed in 
the Central region and the minimum at COP 1,772,677/
kg in the Putumayo-Caquetá region. 
Coca leaf, which in Colombia is sold as fresh leaf (not 
sun-dried as in Bolivia and Peru), and coca paste, which 
many farmers in Colombia produce on the farm, are 
traded in Colombian pesos. Cocaine at the wholesale 
level, however, is thought to be traded mainly in US 
dollars. Wholesale prices of cocaine in Colombian cities 
Colombia, potential cocaine production (mt), 1994-2008
Note: Cocaine production estimates for 2004 and later are not directly comparable with previous years. 
Sources: see Table 5 Global illicit cultivation of coca bush and production of coca leaf and cocaine. 
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increased by 7% in US dollar terms from US$ 2,198/kg 
in 2007 to US$ 2,348/kg in 2008. In Colombian peso 
terms, however, prices did practically not change, due to 
a stronger peso. 
The trend of increasing farm-gate prices observed since 
2004 in both US dollar and Colombian peso terms for 
opium latex continued in 2008. However, wholesale 
prices for heroin decreased compared to 2007. Accord-
ing to reports of the Government of Colombia, the area 
under opium poppy cultivation shrank to a few hundred 
hectares. 
Colombia, annual wholesale prices of cocaine HCl (US$/kg and '000 COP/kg), 1991-2008
Note: Prices of unknown purity in major cities of Colombia. Source: Colombian Directorate of Anti-Narcotics (DIRAN).
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Cultivation and eradication
In 2008, opium poppy cultivation was found in all six 
surveyed provinces in the north of Lao PDR (Phongsaly, 
Luang Namtha, Oudomxay, Luang Prabang, Xieng 
Khouang and Huaphanh provinces). The total area 
under opium poppy cultivation in the Lao PDR increased 
by 7% in 2008 to 1,600 ha. Overall, the level of opium 
poppy cultivation in the country remains extremely low 
and is restricted to isolated plots in remote areas. 
According to Government reports, eradication took 
place on 575 ha (during or after the helicopter survey). 
In the majority of cases, eradication took place when 
opium harvesting was already underway. The largest area 
eradicated was in Phongsaly where 310 ha or 54% of the 
total eradication was undertaken, followed by Huaphanh 
(53 ha) and Oudomxay (47 ha). 
1 The information in this section comes from the report on Opium 
Poppy Cultivation in South East Asia (UNODC/Governments of 
Lao PDR, Myanmar and Thailand, December 2008), and can also 
be found on the Internet (http://www.unodc.org/unodc/en/crop-
monitoring/index.html).
2 Source of cultivation, yield and production estimates: National moni-
toring systems supported by UNODC. The figures in brackets repre-
sent the lower and upper limits of the 90% confidence interval.
3 In the absence of a yield survey in 2008, the yield per hectare for 
2007 was used.
4 Source: Lao PDR National Commission on Drug Control and 
Supervision (LCDC), Provincial authorities survey. Due to the lim-
ited market for opium, a clear distinction between farm-gate, whole-
sale and retail prices could not be established.
5 Source: LCDC. The 2006 and 2007 eradication campaigns were con-
ducted before and after the survey. In 2008, eradication was mainly 
conducted during and after the survey.
6 The number does not take into account the possible relapse of 
recently treated addicts. There were 7,774 addicts, who had been 
treated since 2003, who relapsed. The total number (cumulative – 
since 2003) of current addicts in 2008 is 12,680. The relapse rate is 
34%.
2007 Change on 2007 2008
Opium poppy cultivation2
1,500 ha
(1,230-1,860 ha)
+7%
1,600 ha
(711-2,687 ha)
Average dry opium yield 6 kg/ha - 6 kg/ha3
Potential production of dry opium 9.0 mt +7% 9.6 mt
Average retail/wholesale price of opium4 US$ 974/kg +26% US$ 1,227/kg
Eradication5 779 ha -26% 575 ha
Number of new opium addicts 7,700 -36% 4,9066
Average drug prevalence rate (in northern Lao PDR) 0.30% 0.19%
Fact Sheet – Lao PDR Opium Survey 20081
Lao PDR, opium poppy cultivation* and  
eradication (ha), 2003-2008
* after eradication
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Prices 
Opium prices were collected at the provincial level by 
local authorities during or soon after the 2008 opium 
harvest.7 The average opium price increased to US$ 
1,227/kg in 2008, a 26% increase over the same period 
in 2007. Strong regional disparities in price indicated 
that there were significant local variations in supply and 
market access. Opium prices ranged between US$ 556/
kg and US$ 744/kg in Phongsaly and Huaphanh prov-
inces, where opium poppy production still exits, and 
reached record levels of US$ 2,209/kg and 2,124/kg in 
Vientiane, the capital city, and Luang Prabang province 
where opium poppy cultivation has been completely 
eliminated, or is very scarce, and while demand is high. 
Addiction
In line with a decrease in opium cultivation, the Gov-
ernment reports a decline in the prevalence rate of opium 
use the northern provinces from 0.6% in 2006 to 0.3% 
in 2007 and 0.2% in 2008 (expressed as a percentage of 
the population aged 15 and above). Relapse, however, 
continues to be a problem. In 2008, 4,906 opium 
addicts were identified as having relapsed. The total 
number of addicts amounted to 12,680 persons. 
7 Since 2006, no clear distinction can be made between retail, wholesale 
and farm-gate prices. Only limited amounts of opium are thought to 
be sold in or to markets outside the province of origin.
Lao PDR, potential opium production (mt), 1994-2008
Lao PDR, annual opium prices (US$/kg),  
2002-2008
Production
The potential production of opium in the year 2008 was 
estimated at 9.6 mt, representing a 7% increase in pro-
duction over 2007 based on the estimated area under 
cultivation. Bad weather conditions in northern Lao 
PDR did not permit the survey team to undertake a 
yield survey in 2008. Observations made from the heli-
copter indicated that the crop health was similar to that 
 
 
of 2007, that is, characterised by poor fields and low 
plant vigour. At the harvest stage, the capsules observed 
were small and capable of producing only a limited 
amount of opium gum. Therefore, the 2007 yield esti-
mate of 6 kg/ha was also used to estimate production in 
2008.
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1
1 The information in this section comes from the report on Opium 
Poppy Cultivation in South-East Asia (UNODC/Governments of 
Lao PDR, Myanmar and Thailand, December 2008), and can also 
be found on the Internet (http://www.unodc.org/unodc/en/crop-
monitoring/index.html). Source unless otherwise indicated: National 
monitoring system supported by UNODC. 
234
2 The figures in brackets represent the lower and upper limits of the 
90% confidence interval.
3 Source: Central Committee for Drug Abuse Control, Myanmar 
(CCDAC).
4 For 2007: yearly average price. For 2008: price at harvest time.
Year 2007
Change on 
2007
Year 2008
Opium poppy cultivation in Myanmar2
27,700 ha
(22,500-32,600 ha)
+3%
28,500 ha
(17,900-37,000 ha)
Opium poppy cultivation in Shan State 25,300 ha 0% 25,300 ha
Average opium yield (weighted by area) 16.6 kg/ha -13% 14.4 kg/ha
Potential production of dry opium in Myanmar  
(including the Shan State) 460 mt -11% 410 mt
Opium poppy eradication in Myanmar3 3,598 ha +34% 4,820 ha
Average farm-gate price of opium4 US$ 261/kg +15% US$ 301/kg
Total potential value of opium production US$ 120 million +2% US$ 123 million
Estimated number of households involved in opium 
poppy cultivation in Myanmar 163,000 +3% 168,000
Number of persons involved in opium poppy cultivation 
in Myanmar 815,000 +3% 840,000
Estimated number of households involved in opium 
poppy cultivation in the Shan State 148,900 0% 148,900
Average yearly household income in opium producing 
households (Shan State) of which from opium sales
Per capita income in opium producing households 
(Shan State)
US$ 501
US$ 227
US$ 100
+37%
+11%
+37%
US$ 687
US$ 253
US$ 137
Household average yearly income in non-opium poppy 
producing households (Shan State)
Per capita income in non-opium producing households 
(Shan State)
US$ 455
US$ 91
+58%
+58%
US$ 721
US$ 144
Addiction prevalence rate in Shan State and Kachin 
(population aged 15 and above) 0.75 % +47% 1.1 %
Fact Sheet - Myanmar Opium Survey 2008 1
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Cultivation and eradication
In 2008, the total area under opium poppy cultivation 
in Myanmar was estimated at 28,500 ha. Despite the 
small increases observed in the past two years, opium 
poppy cultivation in Myanmar remains far below the 
levels reached in the 1990s. The vast majority of the 
opium poppy cultivation in Myanmar continued to take 
place in South Shan (53%) and East Shan State (33%). 
In 2008, the most important increase in opium poppy 
cultivation was observed in East Shan State, with 36% 
more opium poppy under cultivation as compared to 
2007, whereas in South Shan State cultivation decreased 
by 17%. 
According to official reports from the Government of 
Myanmar, a total of 4,820 ha were eradicated in 2007-
2008, which is an increase of 34% compared to the 
eradication in 2006-2007 when 3,598 hectares were 
eradicated. Eradication in Kachin State was four times 
higher than a year earlier but still below the level reported 
in 2005. Eradication in East Shan State increased by 
13% and in South Shan State by 33%. In Chin State, 
eradication teams eradicated all the opium poppy found 
in the region, which was mainly concentrated in the 
border areas. 
Myanmar, opium poppy cultivation (ha), 1994-2008
Myanmar, distribution of opium poppy cultivation by region, 2008
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Production
Based on a total of 312 fields measured in the survey, the 
weighted national average opium yield for 2008 is esti-
mated at 14.4 kg/ha, leading to an estimated potential 
opium production of 410 mt. In 2007, the estimated 
yield was 16.6 kg/ha and the estimated potential opium 
production was 460 mt.
Due to the lower yield, opium production in 2008 was 
lower than in 2007 although the area under opium 
poppy cultivation was roughly the same. Most opium 
was produced in the Shan State (88%), particularly in 
South Shan (56%) and East Shan (30%). 
Prices
In 2008, the average farm-gate price of opium at harvest 
time was estimated at US$ 301/kg. This represents an 
increase of 15% compared to the average price reported 
in 2007 (US$ 261/kg). A similar price increase was 
observed between 2006 and 2007. In 2008, prices con-
tinued to differ strongly across states, with Kachin State 
reporting the highest price (US$ 518/kg) and South 
Shan State reporting the lowest (US$ 265/kg). The larg-
est increase in price compared to last year was observed 
in Kachin and North Shan States; both states where 
little opium poppy cultivation took place. Whereas in 
South Shan and East Shan States, which together pro-
duced 88% of the opium, the price increase was less 
pronounced. 
Opium poppy eradication as reported by the Government, 2002-2008
Myanmar, potential opium production (mt), 1994-2008
Administrative Unit 2002 2003 2004 2005 2006 2007 2008
North Shan State 6,223 235 172 1,211 76 916 932
South Shan State 511 182 2,170 1,203 3,175 1,316 1,748
East Shan State 14 91 195 124 32 1101 1,249
Special Region 2 (Wa) 94 55 0 0 0 0 0
Shan State 6,842 563 2,537 2,538 3,283 3,333 3,929
Kachin State 97 56 126 1,341 678 189 790
Kayah State 527 9 83 8 0 12 12
Other States 3 8 74 20 9 64 89
Total 7,469 638 2,820 3,907 3,970 3,598 4,820
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Myanmar, prices for dry opium (US$/kg), 1999-2008
The wholesale opium prices collected in the Mong Pawk 
area, which is located in Special Region 2 (Wa region), 
Shan State, by and large reflect the increase in farm-gate 
prices. The monthly opium wholesale prices, which 
were close to the average farm-gate price before the 
opium ban in the Wa region, seemed to have increased 
more rapidly than the farm-gate prices. This could be 
due to the higher risk premium, which traders have to 
consider in a region where opium poppy is banned. 
However, it has to be noted that wholesale prices were 
collected on the open opium market in Mong Pawk 
town until an opium ban was introduced by the author-
ities in mid-2005, but had to be collected from a wider 
range of places and under more difficult conditions after 
the ban. This limits comparability. 
Household income and strategies
In 2008, the average annual cash income of an opium 
poppy growing household was estimated at US$ 687, 
while that of a non-opium poppy cultivating household 
was slightly higher, at US$ 721. As in past years, in most 
states, the average household cash income in villages that 
never grew opium poppy was higher than the average 
household income in villages in the same region that 
were still growing poppy in 2008 or had grown in the 
past. Villages reporting opium poppy cultivation were 
also characterised by lower food security compared to 
opium poppy-free villages. The survey findings suggest 
that non-poppy growing villages could achieve a higher 
level of food security through cultivation of rice. The 
importance of rice cultivation for food security and 
poppy cultivation is emphasized by the fact that villages 
with access to paddy land (irrigated rice fields) were less 
likely to grow opium poppy. The situation was different 
in South Shan State, where the average income in poppy 
growing villages was higher than non-poppy growing 
villages and over half of the average household cash 
income in poppy growing villages was reported to stem 
from opium. This may be due to the relatively large scale 
of poppy cultivation and higher than average opium 
yields in this region. 
In 2008, the survey findings also indicated that house-
holds in former poppy growing villages could not find 
adequate means of substituting their lost cash income 
from opium. Villages growing opium poppy showed a 
significantly higher intensity of shifting cultivation, 
both in terms of acreage of forest cleared and duration 
of fallow periods, compared to non-growing villages. 
The most common coping strategy for the farmers who 
had stopped opium poppy cultivation was to grow more 
rice and maize and to sell livestock. There is also some 
evidence of migration occurring in the Wa region where 
opium poppy cultivation was abandoned in 2005. 
Addiction
Within the surveyed area in 2008, the average level of 
addiction was higher in villages with opium poppy cul-
tivation compared to non-growing villages. As in previ-
ous years, opium addiction continues to be a 
predominantly male phenomenon. The level of amphet-
amine-type stimulant (ATS) and heroin addiction was 
low compared to opium abuse in both growing and 
non-growing villages. The survey did not cover urban 
areas where these types of addiction are thought to be 
higher.
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* As reported by the Government of Peru.
 
1 The information in this section comes from the report on Coca 
Cultivation in Peru (UNODC/Government of Peru, June 2009), 
and can also be found on the Internet (http://www.unodc.org/unodc/
en/crop-monitoring/index.html). Source unless otherwise indicated: 
National monitoring system supported by UNODC.
2 Includes all coca leaf potentially produced. For the calculation of coca 
leaf available for cocaine production, 9,000 mt of sun-dried coca leaf 
were deducted from this figure, which, according to Government 
sources, is the amount used for traditional purposes.
3 The weighted average price takes into account that different amounts 
of coca leaf are sold in different coca cultivation regions at different 
price levels. The exact volume of coca leaf traded and the prices of the 
transaction are not known. As an approximation, the annual average 
prices of the main coca cultivation regions  were multiplied with the 
potential annual coca leaf production in these regions to calculate the 
weights. These regions represent 82% of estimated amount of coca 
leaf available for cocaine production.
4 Excluding coca leaf macerations pits.
2007 Change on 2007 2008
Coca cultivation
Of which in Alto Huallaga
  Apurímac-Ene
  La Convención-Lares
  Elsewhere
53,700 ha
17,200 ha
16,000 ha
12,900 ha
7,600 ha
+4%
+3%
+4%
+2%
+12%
56,100 ha
17,800 ha
16,700 ha
13,100 ha
8,500 ha
Weighted average sun-dried coca leaf yield 2,200 kg/ha 2,200 kg/ha
Potential production of sun-dried coca leaf2
Potential production of sun-dried coca leaf available 
for cocaine production
Potential production of cocaine HCl
116,800 mt
107,800 mt
290 mt
+5%
+5%
+4%
122,300 mt
113,300 mt
302 mt
Average farm-gate price of sun-dried coca leaf
Average farm-gate price of sun-dried coca leaf 
(weighted)3
Average farm-gate price of coca paste
Average price of cocaine HCl*
US$ 2.5/kg
US$ 2.5/kg
US$ 600/kg
US$ 851/kg
+36%
+24%
+21%
+10%
US$ 3.4/kg
US$ 3.1/kg
US$ 723/kg
US$ 940/kg
Potential farm-gate value of sun-dried coca leaf US$ 292 million US$ 379 million
Reported eradication of coca cultivation*
Reported seizure of sun-dried coca leaves*
Reported seizure of coca paste*
Reported seizure of cocaine HCl*
Reported destruction of coca laboratories4*
Of which cocaine HCl processing laboratories
12,072 ha
1,858 mt
6,260 kg
8,119 kg
665
16
-16%
+82%
+107%
+84%
+19%
10,143 ha
n.a.
11,375 kg
16,836 kg
1,224
19
Reported seizure of opium latex* 126 kg n.a.
Fact sheet – Peru Coca Survey 20081
209
3. Statistical Annex Production
Production
In 2008, total production of sun-dried coca leaf was 
estimated at 122,300 mt. After a deduction of 9,000 mt, 
which, according to Government reports, is the amount 
used for traditional purposes, 113,300 mt would be 
available for cocaine production. Based on a conversion 
rate of 375 kg of sun-dried coca leaf for one kilogram of 
pure cocaine, this corresponds to a potential cocaine 
production of 302 mt. 
Cultivation and eradication
In 2008, the area under coca cultivation in Peru increased 
by 4% or 2,400 ha to 56,100 ha, which is the third, 
albeit relatively small, consecutive increase in three years. 
Peru remains the world’s second largest cultivator of 
coca bush after Colombia. Peru’s three largest cultivation 
region, Alto Huallaga, Apurímac-Ene and La Conven-
ción-Lares, represented 85% of the area under coca 
cultivation in 2008. The rate of expansion was average 
or below average in these regions, which nonetheless 
contributed most to the increase in absolute terms, and 
even more in most of the smaller production areas. 
The area under coca cultivation eradicated, 10,430 ha in 
2008, decreased by 16% compared to 2007 and was 
lower than in any year since 2003. 
Government reports on eradication indicate that opium 
poppy cultivation continues to exist in Peru. However, 
the area currently cultivated with opium poppy is not 
known. 
Peru, coca cultivation and eradication (ha), 1994 to 2008
Sources: Cultivation: 1994-1999, US Department of State. Since 2000, National monitoring system supported by UNODC.  
Eradication: CORAH (Coca Eradication in the Upper Huallaga Valley), DEVIDA (Peru National Comission for a Drug-Free Life). 
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Prices
In 2008, prices for coca leaf - which in Peru is traded as 
sun-dried leaf - coca paste and cocaine all increased com-
pared to 2007, despite increases in coca leaf production. 
The simple average farm-gate price of sun-dried coca 
leaf traded outside the Government-controlled market 
was US$ 3.4/kg, over one third more than in 2007, 
compared to just US$ 1.7/kg for coca leaf traded under 
Government control. Wage labour costs for coca har-
vesting increased noticeably in the main coca cultivation 
regions, for example in Monzón in Alto Huallaga from 
under 14 Peruvian soles per day in 2007 to more than 
23 soles in 2008. Costs of other agricultural inputs such 
as fertilizer (urea) also went up, which may explain at 
least partly the price increase in coca leaf. 
Some farmers produce coca paste, called locally pasta 
básica de cocaína lavada. Farm-gate prices of coca paste 
increased by 21% in 2008 and reached US$ 723/kg. 
Higher prices for precursor chemicals were observed in 
coca cultivating regions, which may have contributed to 
the increase. Production costs and price mechanisms for 
illicit trading and trafficking of coca derivatives are not 
well understood and are thought to be influenced by the 
presence of armed groups in coca cultivating regions. 
However, the proportional price increase in 2008 was 
smaller the more refined the product, that is largest at 
the level of the coca leaf (36%) and smallest at the level 
of cocaine HCl (10%), which may indicate that local 
factors played a more important role than external ones.
Peru, potential cocaine production (mt), 1994 to 2008
Sources: US Dept. of State (1994-1999), National monitoring system supported by UNODC (since 2000) based on conversion rates 
for coca leaf to cocaine from US Dept. of State.
Note: Production estimates from 2003 to 2005 were revised in 2007 based on updated information available on the amount of coca 
leaf necessary to produce 1 kg of cocaine.
Peru, monthly farm-gate prices of sun-dried coca leaf and coca paste (US$/kg)
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3.2 Seizures
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A complete set of seizures tables can be found on the UNODC website at: 
www.unodc.org
214
3.3 Seizures of illicit laboratories
A complete set of seizures tables can be found on the UNODC website at: 
www.unodc.org
3.4 Prices
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3.4.1 Opiates: Wholesale, street prices and purity levels
 
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Austria 270       250         203        132           138        103        87           70           94          57           75           44            92           68          75           74            69              99              
Belgium 90         105          105        77             75          75          56           37           41          41           37           27            29           31          32           31            32              33              
Denmark 287       265          151        139           228        191        157         188         147        175         116         111          126         122        94           123          100            92              
Finland 800       696          770        724           606        455        414         257         254        250         207         121          188         195       195        182          125            151            
France 145       153          150        135           144        170        156         113         119        111         32      34            47           57          68           69            67              55              
Germany 105       75            96          74             91          90          74           51           43          45           39           38            38           46          49           48            46              48              
Greece 120       175          63          44             105        88          77           80           55          55           55           53            45           65          51           31            75              75              
Italy 167       148          140        29             55          41          115         98           120        95           71           68            59           63          69           68            66              66              
Luxembourg 172       150         150       150          172        202        138         141         133        126         69           67            67          45          101         102          102            96              
Netherlands 49         50           55          49             55          61          48           55           34          30           25           43            35           40          57           38            38              33              
Norway 1,680    525          510        275           349        300        282         198         186        166         128         157          165         198        148         220          220            240            
Iceland 184       376         374       407          380        410        377         372         372        372        372        372         372        372       372        372          372            102            
Portugal 83         82            72          63             65          79          68           55           74          37           45           45            41           54          52           52            52              52              
Spain 175       185         180       126          132        120        112         88           82          75           59           57            61           75          81           80            78              86              
Sweden 225       210         195       180          165        337        346         135         130        126 113 129 133 128 119 92 92 92              
Switzerland 312       221          248        126           164        190        116         81           96          167         53           45            39           48         48          48            39              42              
United Kingdom 157       144          144       134           129        125        108         118         120        108         107         86            91           100        110         93            71              101            
Ireland 196       180         180       168          161        179        275         228         213        204         176         170          179         179        248         252          251            274            
092$SU ni dethgiewnu egarevA        222          210        168           179        179        167         131         128        124         99           93            100         105        109         110          105            96              
inflation adjusted 2007 US$ 460       337          311        242           250        243        221         170         163        155         119         108          116         118        120         116          108            96              
Weighted average in US$ 173       149          147        107           118        119        118         93           94          87           64           59            62           70          75           72            67              72              
Inflation adjusted in 2007 US$ 275       227          217        153           166        162        155         121         120        108         77           69            72           79          83           76            69              72              
Weighted average in Euro 136       120          113        91             100        91          93           82           84          81           69           66            66           62          61           57            53              52              
Adjusted for inflation in 2007 Euro 205       172          156        121           129        115        114         99           101        96           80           75            74           68          65           61            56              54              
Sources: UNODC ARQ data, EUROPOL and UNODC estimates (in italics)
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
USA - street price 224       261          296        275           274        255        212         233         206        196         192         164 158 150 142 138 132 131            
Inflation adjusted in 2007 US$ 355       397          438        395           383        347        280         301         263        244         232         192          182         169        156         147          136            131            
Purity adjusted 1,016  932        801      672        668      593      558      529      469      468       458       432        405       406      418      384        388          364          
Purity & inflation adjusted 1,612    1,419       1,184     964           934        807        737         683         597        582         552         505          467         458        459         408          399            364            
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Austria 55,244 46,145 63,000 36,000 37,752 30,491 30,222 28,831 34,565 31,087 25,026 19,553 23,547 33,900 37,260 36,168 37,640 54,810     
Belgium 30,000 30,000 28,500 26,600 29,586 32,580 24,307 21,761 20,847 18,557 18,360 20,292 22,229 20,960 23,040 23,336 18,820 20,554     
Denmark 110,000 100,000 85,000 95,000 117,625 106,805 86,806 100,465 65,693 61,507 23,585 32,889 20,803 41,770 32,820 37,741 35,967 33,091     
Finland 353,774 353,774 353,774 353,774 353,774 353,774 321,586 199,442 197,856 194,357 161,034 44,840 51,804 51,800 68,314 69,192 69,192 54,810     
France 180,000 72,250 80,000 63,750 75,000 66,035 46,603 32,230 25,885 25,596 22,158 26,906 23,547 28,250 31,050 31,450 35,550 27,405     
Germany 45,244 36,145 41,667 35,206 36,448 35,256 27,890 25,686 25,608 24,770 20,263 17,816 20,325 21,510 25,723 25,765 22,510 25,810     
Greece 90,000 70,000 35,000 28,000 29,536 34,362 39,090 28,775 21,020 20,714 17,320 16,592 17,425 18,650 17,540 14,782 19,450 19,450     
Italy 67,500 60,000 108,000 42,581 47,690 35,786 48,152 37,795 36,459 36,894 31,163 32,979 33,669 29,830 30,109 30,496 28,830 31,676     
Luxembourg 86,000 75,000 75,000 49,500 86,000 57,079 59,852 54,786 52,630 50,368 48,000 50,369 50,369 24,700 43,473 44,030 44,030 31,451     
Netherlands 23,850 25,000 26,550 23,850 23,850 24,384 20,572 13,810 14,056 16,985 14,703 15,757 29,199 17,730 17,730 18,240 16,625 16,957     
Norway 220,000 200,000 212,500 151,099 101,744 85,000 72,520 62,209 64,918 49,872 44,561 35,874 37,676 48,234 52,790 53,490 53,325 58,235     
Portugal 50,000 55,000 46,667 31,500 32,428 43,171 45,902 38,841 30,483 29,339 25,398 31,310 25,839 31,000 34,075 34,512 34,512 20,554     
Spain 160,000 125,000 122,500 91,000 74,418 79,880 84,395 63,880 52,755 53,820 43,596 32,000 41,202 48,420 46,350 47,055 47,371 47,671     
Sweden 140,000 130,000 115,000 95,000 117,625 62,655 64,829 65,771 63,190 61,022 41,626 33,702 34,738 41,900 31,648 35,970 35,970 37,059     
Switzerland 124,000 153,800 228,875 47,460 52,823 54,850 41,665 37,234 34,294 33,422 29,568 16,082 19,149 22,340 23,580 25,420 21,470 23,180     
United Kingdom 53,940 43,940 43,500 43,210 42,500 42,004 34,846 39,491 41,667 29,126 26,718 25,926 30,620 34,340 39,041 33,249 28,320 27,163     
Ireland 63,940 53,940 53,500 53,210 52,500 81,479 77,643 36,531 34,396 43,478 37,600 36,441 36,441 30,510 30,510 33,967 33,967 33,967     
Average unweighted in US$ 109,029 95,882 101,120 74,514 77,135 72,094 66,287 52,208 48,019 45,936 37,099 28,784 30,505 32,108 34,415 34,992 34,326 33,167
infl.adj. in US$ 172,963 145,965 149,439 106,920 107,918 98,084 87,598 67,445 61,082 57,170 44,670 33,699 35,158 36,182 37,775 37,150 35,313 33,167
840,69$SU ni egareva dethgieW   69,304     79,023   55,551      56,652   52,828   48,491    39,325    36,587   34,398    28,942    25,998     28,574    30,357   32,470    31,902     30,811       30,050       
Inflation adj. (kg) in 2007 US$ 152,370 105,504 116,785 79,710 79,260 71,874 64,081 50,801 46,540 42,810 34,848 30,438 32,933 34,209 35,640 33,869 31,696 30,050
Inflation adj. (gram) in 2007 US$ 152 106 117 80 79 72 64 51 47 43 35 30 33 34 36 34 32 30
Weighted in Euro (g) 75 56 61 47 48 41 38 35 33 32 31 29 30 27 26 25 25 22
Adjusted for inflation in 2007 Euro (g) 114 80 84 63 62 51 47 42 39 38 36 33 34 29 28 27 26 22
Sources: UNODC ARQ data, EUROPOL and UNODC estimates (in italics)
USA 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Average in US$ in kg 162,500 155,000 150,000 146,000 142,500 146,000 141,875 129,375 125,000 107,000 81,200 59,500 50,750 65,500   68,800    65,000     65,000       71,200       
Average in US$ in gram 163 155 150 146 143 146 142 129 125 107 81 60 51 66 69 65 65 71
Inflation adj. (g) in 2007US$ 258 236 222 209 199 199 187 167 159 133 98 70 58 74 76 69 67 71
Source: UNODC ARQ 
Retail prices (street price), US$/gram
Wholesale, US$/kg
Source: ONDCP, The Price and Purity of Illicit Drugs: 1981-2007 (Reports prepared by the Institute for Defense Analysis for ONDCP. 1990-2000 (prices for 1 gram or less, at street purity), ONDCP, ONDCP, The Price & Purity of Illicit Drugs 1981-2003 
(prices for < 2 grams) for 2001-03, Community Epidemiology Network - June 2005 (for 2004) and ONDCP (based on STRIDE) for 2005 to 2007.
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3.4.2 Cocaine: Wholesale, street prices and purity levels
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Austria 198        180       167        120        126        156        138        118        113        93          94          78          71          90          103        101        78             99             
Belgium 80         90          68          95          82          93          90          57          55          60          55          51          50          51          51         51         60             67             
Denmark 144        135        111        90          150       176        169        108        119        165        106        120        91          122        82          82          81             74             
Finland 159       150       126       105       165       191       184       123       179        157       138       121        111        151        146        125        100           110
France 99          119        140        153        151        174        125        87          84          82          50          87          75          90          99          94          74             96             
Germany 120        103        111        95          109        103        90          77          72          68          57          58          57          68          73          79          74             86             
Greece 150       120       105        54          116        111        144        91          54          82          69          72          75          96          93          79          110           110           
Iceland 167        203        207        200        211        228        226        238        149        134       121       109        150        207        156        156       164          164           
Italy 108        120        164        90          104        113        129        109        129        135       100       89          90          101        113        114        104           112           
Luxembourg 150       150       150       150       172        194        127        115        110        119        119       119        107       96          114        105        106           89             
Netherlands 66          70         74          66          60         79          52          64          38          33          33         33         33         50          59         59         60            59             
Norway 176        170        255        156        145        150       153        177        133        128        114        157        165        170        155        155       151          164           
Portugal 63          57          60          57          59          66          64          57          51          43          56          48          36          47          49          55          56             55             
Spain 110        100        100        63          78          91          72          68          68          63          52          52          56          70          76          76          76             83             
Sweden 160       152       183       123       148       118        118        98          88          97          77          79          87          99          93          92          101          96             
Switzerland 178        144        188        136        146        148        127        117        110        109       77          69          74          89          86         86         74            75             
United Kingdom 131        127        69          123        113        111        102        124        128        104        94          94          84          90          91          79          87            91             
Ireland 141       137       120       110       100       119        32          34          32          30          28         28         94         79          87          88          88             96             
Average unweighted in US-$ 133        129        133        110        124        134        119        103        95          95          80          81          84          98          96          93          91             96             
Inflation adjusted in 2007 US$ 211        197        197        158        174        183        157        134        121        118        96          95          96          111        105        99          94             96             
Weighted average in US-$ 117        115        118        104        112        118        105        92          92          88          70          74          72          84          88          87          82             92             
Inflation adjusted in 2007 US-$ 186        175        174        149        157        161        139        119        117        109        85          87          83          94          97          92          85             92             
Weighted average in Euro 92          93          91          89          94          91          83          81          82          82          76          83          76          74          71          69          68             67             
Inflation adjusted in 2007 Euro 139        133        125        118        122        115        103        98          98          97          88          94          85          81          76          72          70             67             
Sources: UNODC ARQ data and  EUROPOL; UNODC estimates in italics
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
USA street price in US$ 154        142        119        121        111        123        120        105        103        101        115        113        96          102        92          90          96             106           120           
Inflation adjusted in 2007 US$ 244        216        176        173        156        168        159        135        130        126        139        132        111        115        102        95          99             106           115           
Purity adjusted (100%) 265        226        178        175        166        202        165        161        149        155        186        194        137        148        134        132        130           162           225           
Purity and inflation adjusted 421        343        263        251        232        275        217        208        189        193        224        227        158        166        147        140        134           162           216           
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Austria 66,000 66,000 54,000 40,000 41,946 52,084 45,875 56,723 54,440 38,859 47,094 43,995 42,385 59,300 55,894 59,757 50,185 61,661
Belgium 25,000 24,000 38,250 28,000 26,920 30,560 21,927 17,025 19,167 23,859 22,376 26,771 28,111 29,610 32,480 32,480 32,480 47,958
Denmark 80,000 85,000 85,000 82,500 58,516 60,034 46,141 38,640 44,517 78,900 43,462 47,839 37,823 53,160 45,896 50,321 40,520 40,445
Finland 79,500 75,000 62,750 52,500 82,500 95,450 91,750 61,550 89,350 78,460 68,321 59,492 51,804 62,150 68,315 68,315 56,611 61,660
France 117,000 38,250 45,000 38,250 40,000 39,877 48,077 43,554 42,159 27,714 27,000 34,978 37,676 45,200 49,683 50,321 50,190 61,661
Germany 69,000 53,100 60,300 54,142 57,692 54,676 53,925 45,294 41,210 39,639 33,752 33,235 34,476 40,110 44,243 46,525 45,320 48,826
Greece 75,000 90,000 95,000 36,000 46,413 53,098 72,015 43,795 49,180 49,320 41,237 40,359 42,385 53,680 57,446 62,902 62,735 62,735
Italy 54,000 48,000 94,000 41,935 51,097 51,455 55,633 50,629 49,091 47,250 46,000 40,529 41,412 47,440 51,759 52,188 52,920 56,029
Luxembourg 93,919 95,939 113,521 50,847 157,593 141,343 47,625 43,103 41,072 47,718 47,718 47,718 47,718 47,718 31,052 31,450 31,450 31,451
Netherlands 26,500 28,000 29,500 26,500 24,680 33,232 23,894 29,698 22,355 27,500 27,500 27,500 27,500 27,400 33,775 33,775 35,000 42,409
Norway 120,000 120,000 127,500 110,000 39,971 50,000 41,670 60,028 81,699 57,545 51,417 51,569 54,159 56,500 65,209 65,209 56,400 61,661
Portugal 39,500 39,285 33,000 27,000 27,950 34,483 42,591 37,908 33,447 30,000 28,000 29,080 31,046 32,410 36,399 36,399 31,365 34,256
Spain 65,000 60,000 55,000 35,000 36,434 41,322 38,760 36,806 38,924 38,898 30,882 38,898 31,511 38,830 42,167 41,321 41,210 46,274
Sweden 80,000 85,000 91,375 61,450 73,825 55,556 59,255 45,573 50,484 48,508 38,394 34,693 35,763 43,130 39,560 40,068 39,270 51,883
Switzerland 63,900 94,250 116,250 50,847 72,012 75,949 51,587 40,780 41,152 41,000 35,482 23,392 19,274 37,230 44,008 44,008 41,090 44,351
United Kingdom 47,850 46,475 20,625 43,210 45,000 46,774 40,625 47,500 47,500 33,981 38,168 36,008 35,848 40,880 50,036 50,036 50,943 74,447
Ireland 45,000 45,000 40,000 50,000 45,000 42,000 31,646 33,733 31,530 29,891 29,891 29,891 29,891 30,510 38,557 38,506 39,636 82,214
Average unweighted 67,481 64,312 68,298 48,717 54,562 56,347 47,823 43,079 45,722 43,473 38,629 37,997 36,987 43,839 46,263 47,270 44,549 53,525
inflation adjusted 107,051 97,904 100,934 69,903 76,336 76,660 63,198 55,651 58,160 54,104 46,512 44,485 42,629 49,400 50,780 50,184 45,829 53,525
Weighted average in US$ 67,793  51,895  57,392  43,998  47,040  48,150  47,754  43,975  43,434  38,491  35,580  36,095  35,950  42,322  46,913  47,772  46,996      55,958      
Weighted average in US$ per gram 68          52          57          44          47          48          48          44          43          38          36          36          36          42          47          48          47             56             
Inflation adjusted in 2007 US$ 107,547 79,002 84,816 63,132 65,812 65,509 63,106 56,809 55,250 47,904 42,841 42,259 41,433 47,690 51,493 50,717 48,347 55,958
Inflation adjusted (gram) 108 79 85 63 66 66 63 57 55 48 43 42 41 48 51 51 48 56
Weighted in Euro (g) 53 42 44 38 40 37 38 39 39 36 38 40 38 37 38 38 39 41
Inflation adjusted in 2007 Euro (g) 80 60 61 50 51 47 47 47 46 43 45 46 42 41 40 41 41 42
Sources: UNODC ARQ,  EUROPOL;  UNODC estimates in italics
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
US wholesale price 45,430  48,300  48,100  44,730  42,180  38,640  35,700  34,320  31,960  30,870  29,580  21,500  23,000  21,500  22,066  20,500  26,500      31,000      
US wholesale price per gram 45          48          48          45          42          39          36          34          32          31          30          22          23          22          22          21          27             31             
Inflation adjusted in 2007 US$  (g) 72          74          71          64          59          53          47          44          41          38          36          25          27          24          24          22          27             31             
Sources: ONDCP 1990-2000 (prices for 10-100 gram, at street purity), UNODC ARQ 2001-2007 (mid-point of min/max prices).
Retail price (street price), US$/gram
Wholesale price, US$/kg
Sources: for 1990-06: Office of National Drug Control Policy,  The Price and Purity of Illicit Drugs: 1981-2007. Washington, DC, July 2008 and UNODC calculations for 2007 and 2008 based on ONDCP,  The Price and Purity of Cocaine (STRIDE data); 
the purity adjusted price according to the first publication amounted to US$ 122 per gram in 2007 at 64% purity; according to STRIDE dataset (second source) street prices increased  24%, purity adjusted prices rose 72% over 2006-08 period, mainly due
to falling purity levels (69% in 2006; 51% in 2008). 
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3.4.3 Cannabis: Wholesale, street prices and purity levels
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3. Statistical Annex Prices
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3. Statistical Annex Prices
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3.4.4 Amphetamine-type stimulants: Wholesale, street prices and purity levels
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3.5.1 Annual Prevalence
 3.5.1.1 Opiates
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3. Statistical Annex Consumption
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 3.5.1.2 Cocaine
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3. Statistical Annex Consumption
 3.5.1.3 Cannabis
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3. Statistical Annex Consumption
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 3.5.1.4 Amphetamine-type stimulants (excluding ecstasy)
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3. Statistical Annex Consumption
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3. Statistical Annex Consumption
 3.5.1.5 Ecstasy
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3. Statistical Annex Consumption
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7
1.
1
0.
7
20
06
O
A
S 
(M
EM
)
El
 S
al
va
do
r
13
 -
 1
7
3.
2
1.
5
20
03
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
El
 S
al
va
do
r
13
 -
 1
7
1.
1
0.
5
20
03
A
RQ
C
ra
ck
El
 S
al
va
do
r
13
 -
 1
7
1.
6
0.
7
20
03
A
RQ
La
rg
e 
ci
tie
s
G
ua
te
m
al
a
12
 -
 1
9
0.
4
0.
1
20
04
A
RQ
C
ra
ck
G
ua
te
m
al
a
12
 -
 1
9
1.
3
0.
5
20
04
A
RQ
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H
on
du
ra
s
Se
co
nd
ar
y/
 
H
ig
h 
Sc
ho
ol
0.
4
0.
2
0.
1
20
05
O
A
S 
(M
EM
)
C
ra
ck
H
on
du
ra
s
12
 -
 1
7
0.
2
20
05
A
RQ
C
ra
ck
H
on
du
ra
s
Se
co
nd
ar
y/
 
H
ig
h 
Sc
ho
ol
2.
1
0.
9
0.
4
20
05
O
A
S 
(M
EM
)
H
on
du
ra
s
12
 -
 1
7
0.
9
20
05
A
RQ
N
ic
ar
ag
ua
12
 -
 1
8
1.
2
20
04
A
RQ
C
ra
ck
N
ic
ar
ag
ua
12
 -
 1
8
2.
3
20
04
A
RQ
A
M
ER
IC
A
S
N
o
rt
h
 A
m
er
ic
a
C
an
ad
a
12
 -
 1
7
4.
4
20
06
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
); 
Li
m
ite
d 
ge
og
ra
ph
y
M
ex
ic
o
12
 -
 1
9
3.
3
1.
5
20
06
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
); 
Se
le
cr
 
re
gi
on
s
M
ex
ic
o
12
 -
 1
9
1.
5
20
06
A
RQ
C
ra
ck
; S
el
ec
t 
re
gi
on
s
U
SA
G
ra
de
 1
0
5.
3
3.
4
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
U
SA
G
ra
de
 1
0
2.
3
1.
3
20
07
A
RQ
C
ra
ck
U
SA
G
ra
de
 1
0
4.
8
3.
1
20
07
A
RQ
A
M
ER
IC
A
S
So
u
th
 A
m
er
ic
a
A
rg
en
tin
a
13
 -
 1
7
0.
8
20
07
A
RQ
C
ra
ck
A
rg
en
tin
a
13
 -
 1
7
4.
1
2.
5
20
07
A
RQ
Bo
liv
ia
13
 -
 1
8
0.
8
0.
4
20
04
A
RQ
C
ra
ck
Bo
liv
ia
15
 -
 1
6
1.
9
0.
9
0.
4
20
04
C
IC
A
D
/ O
A
S
Br
az
il
15
 -
 1
6
1.
9
1.
8
1.
2
20
05
C
IC
A
D
/ O
A
S
C
oc
ai
ne
, i
nc
lu
de
s 
co
ca
 
pa
st
e
C
hi
le
G
ra
de
s 
8 
- 
12
3.
0
1.
6
0.
7
20
05
O
A
S 
(M
EM
)
C
ra
ck
C
hi
le
15
 -
 1
6
4.
3
2.
6
1.
0
20
05
C
IC
A
D
/ O
A
S
C
ol
om
bi
a
15
 -
 1
6
2.
0
1.
7
0.
5
20
05
C
IC
A
D
/ O
A
S
Ec
ua
do
r
12
 -
 1
7
0.
6
20
05
A
RQ
C
ra
ck
Ec
ua
do
r
15
 -
 1
6
2.
7
1.
3
0.
6
20
05
C
IC
A
D
/ O
A
S
G
uy
an
a
12
 -
 1
8
0.
5
0.
2
0.
1
20
02
A
RQ
C
ra
ck
; L
im
ite
d 
G
eo
gr
ap
hy
G
uy
an
a
12
 -
 1
8
0.
7
0.
3
0.
1
20
02
A
RQ
Li
m
ite
d 
ge
og
ra
ph
y
Pa
ra
gu
ay
15
 -
 1
6
1.
1
0.
7
0.
5
20
05
C
IC
A
D
/ O
A
S
Pa
ra
gu
ay
St
ud
en
ts
 
(u
nd
ef
in
ed
)
0.
3
20
05
O
A
S 
(M
EM
)
C
ra
ck
; A
ge
s 
no
t 
sp
ec
ifi
ed
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Pe
ru
St
ud
en
ts
 (a
ge
s 
13
-1
7)
0.
8
20
05
O
A
S 
(M
EM
)
C
ra
ck
Pe
ru
15
 -
 1
6
1.
9
1.
2
0.
5
20
05
C
IC
A
D
/ O
A
S
Su
rin
am
e
Se
co
nd
ar
y/
 
H
ig
h 
Sc
ho
ol
0.
6
0.
2
0.
1
20
06
O
A
S 
(M
EM
)
Su
rin
am
e
Se
co
nd
ar
y/
 
H
ig
h 
Sc
ho
ol
0.
6
0.
3
0
20
06
O
A
S 
(M
EM
)
C
ra
ck
U
ru
gu
ay
13
 -
 1
7
5
3.
7
20
07
A
RQ
Li
m
ite
d 
ge
og
ra
ph
y
V
en
ez
ue
la
10
 -
 2
3
0.
3
20
05
A
RQ
C
ra
ck
V
en
ez
ue
la
10
 -
 2
3
0.
3
20
05
A
RQ
A
SI
A
C
en
tr
al
 A
si
a 
 a
n
d
 T
ra
n
sc
au
ca
si
an
 c
o
u
n
tr
ie
s
A
rm
en
ia
15
 -
 1
6
1
20
07
ES
PA
D
A
SI
A
Ea
st
 a
n
d
 S
o
u
th
-E
as
t 
A
si
a
H
on
g 
K
on
g 
SA
R,
 C
hi
na
11
 -
 2
0
0.
0
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Th
ai
la
nd
Y
ou
th
 
(u
nd
ef
in
ed
)
0.
3
20
03
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
); 
A
ge
s 
no
t 
sp
ec
ifi
ed
A
SI
A
N
ea
r 
an
d
 M
id
d
le
 E
as
t 
/S
o
u
th
-W
es
t 
A
si
a
Is
ra
el
12
 -
 1
8
2.
3
2
20
05
A
RQ
C
ra
ck
Is
ra
el
12
 -
 1
8
2.
5
2.
1
20
05
A
RQ
Le
ba
no
n
15
 -
 1
6
1.
2
20
01
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
); 
Ra
pi
d 
A
ss
es
sm
en
t
EU
R
O
PE
Ea
st
 E
u
ro
p
e
Be
la
ru
s
15
 -
 1
6
0.
4
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
); 
Li
m
ite
d 
ge
og
ra
ph
y
Be
la
ru
s
15
 -
 1
6
0.
2
20
07
A
RQ
C
ra
ck
; L
im
ite
d 
ge
og
ra
ph
y
Be
la
ru
s
15
 -
 1
6
0.
2
20
07
A
RQ
Li
m
ite
d 
ge
og
ra
ph
y
Ru
ss
ia
n 
Fe
de
ra
tio
n
15
 -
 1
6
1
0.
6
20
07
A
RQ
/ E
SP
A
D
C
ra
ck
Ru
ss
ia
n 
Fe
de
ra
tio
n
15
 -
 1
6
0.
4
20
07
A
RQ
U
kr
ai
ne
15
 -
 1
6
0
20
07
ES
PA
D
C
ra
ck
U
kr
ai
ne
15
 -
 1
6
1
20
07
ES
PA
D
EU
R
O
PE
So
u
th
ea
st
 E
u
ro
p
e
A
lb
an
ia
14
 -
 1
9
1.
4
20
04
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
A
lb
an
ia
14
 -
 1
9
1.
4
20
04
A
RQ
Bu
lg
ar
ia
15
 -
 1
9
5.
7
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
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C
ro
at
ia
16
3
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
C
ro
at
ia
16
2.
7
20
07
A
RQ
C
ra
ck
Ro
m
an
ia
15
 -
 1
6
0
20
07
ES
PA
D
C
ra
ck
Ro
m
an
ia
15
 -
 1
6
2
20
07
ES
PA
D
Tu
rk
ey
15
 -
 1
6
1.
6
0.
8
20
03
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
EU
R
O
PE
W
es
t 
&
 C
en
tr
al
 E
u
ro
p
e
A
us
tr
ia
15
 -
 1
6
2.
5
20
07
ES
PA
D
C
ra
ck
A
us
tr
ia
15
 -
 1
6
3.
4
20
07
ES
PA
D
Be
lg
iu
m
15
 -
 1
6
4
20
07
A
RQ
Se
le
ct
 r
eg
io
ns
 
(F
la
nd
er
s)
Be
lg
iu
m
15
 -
 1
6
2
20
07
A
RQ
C
ra
ck
; S
el
ec
t 
re
gi
on
s 
(F
la
nd
er
s)
C
yp
ru
s
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
C
yp
ru
s
15
 -
 1
6
3
20
07
ES
PA
D
C
ze
ch
 R
ep
.
15
 -
 1
6
1
20
07
ES
PA
D
C
ra
ck
C
ze
ch
 R
ep
.
15
 -
 1
6
1.
0
0.
5
0.
3
20
07
G
ov
t.
/ E
SP
A
D
D
en
m
ar
k
15
 -
 1
6
3.
2
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Es
to
ni
a
15
 -
 1
6
2.
9
20
07
A
RQ
C
ra
ck
Es
to
ni
a
15
 -
 1
6
2
20
07
A
RQ
Fa
ro
e 
Is
l.
15
 -
 1
6
1
20
07
ES
PA
D
C
ra
ck
Fa
ro
e 
Is
l.
15
 -
 1
6
1
20
07
ES
PA
D
Fi
nl
an
d
15
 -
 1
6
1
20
07
ES
PA
D
C
ra
ck
Fi
nl
an
d
15
 -
 1
6
1
20
07
ES
PA
D
Fr
an
ce
15
 -
 1
6
6
20
07
ES
PA
D
C
ra
ck
Fr
an
ce
15
 -
 1
6
5
20
07
ES
PA
D
G
er
m
an
y
15
 -
 1
6
2.
3
20
07
A
RQ
C
ra
ck
; S
el
ec
t 
re
gi
on
s
G
er
m
an
y
15
 -
 1
6
3.
5
20
07
A
RQ
Se
le
ct
 r
eg
io
ns
G
re
ec
e
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
G
re
ec
e
15
 -
 1
6
1
20
07
ES
PA
D
G
re
en
la
nd
15
 -
 1
6
1
1
20
03
ES
PA
D
H
un
ga
ry
15
 -
 1
7
1.
7
20
07
A
RQ
C
ra
ck
; S
el
ec
t 
re
gi
on
s 
(B
ud
ap
es
t)
H
un
ga
ry
15
 -
 1
7
2.
7
20
07
A
RQ
Se
le
ct
 r
eg
io
ns
 
(B
ud
ap
es
t)
Ic
el
an
d
15
 -
 1
6
1
20
07
ES
PA
D
C
ra
ck
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Ic
el
an
d
15
 -
 1
6
3
20
07
ES
PA
D
Ire
la
nd
15
 -
 1
6
4
20
07
ES
PA
D
C
ra
ck
Ire
la
nd
15
 -
 1
6
4
20
07
ES
PA
D
Is
le
 o
f 
M
an
15
 -
 1
6
5
10
20
07
ES
PA
D
C
ra
ck
Is
le
 o
f 
M
an
15
 -
 1
6
10
20
07
ES
PA
D
Ita
ly
15
 -
 1
6
3
20
07
ES
PA
D
C
ra
ck
Ita
ly
15
 -
 1
6
5
20
07
ES
PA
D
La
tv
ia
15
 -
 1
6
1.
4
20
07
A
RQ
C
ra
ck
La
tv
ia
15
 -
 1
6
1.
6
20
07
A
RQ
Li
ec
ht
en
st
ei
n
12
 -
 1
6
0.
8
0.
6
20
05
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Li
th
ua
ni
a
15
 -
 1
6
1.
5
20
07
ES
PA
D
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Li
th
ua
ni
a
15
 -
 1
6
1.
2
20
07
ES
PA
D
C
ra
ck
Lu
xe
m
bo
ur
g
15
 -
 1
6
1.
5
1.
5
19
99
A
RQ
M
al
ta
15
 -
 1
6
1.
9
20
07
A
RQ
C
ra
ck
M
al
ta
15
 -
 1
6
3.
7
20
07
A
RQ
M
on
ac
o
15
 -
 1
6
4
20
07
ES
PA
D
C
ra
ck
M
on
ac
o
15
 -
 1
6
6
20
07
ES
PA
D
N
et
he
rla
nd
s
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
N
et
he
rla
nd
s
15
 -
 1
6
3
20
07
ES
PA
D
N
or
w
ay
15
 -
 1
6
1
20
07
ES
PA
D
C
ra
ck
N
or
w
ay
15
 -
 1
6
1
20
07
ES
PA
D
Po
la
nd
15
 -
 1
6
0.
9
0.
3
20
07
A
RQ
C
ra
ck
Po
la
nd
15
 -
 1
6
1.
8
1
20
07
A
RQ
Po
rt
ug
al
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
Po
rt
ug
al
15
 -
 1
6
2
20
07
ES
PA
D
Sl
ov
ak
ia
15
 -
 1
9
2.
3
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Sl
ov
ak
ia
15
 -
 1
9
1.
4
20
07
A
RQ
C
ra
ck
Sl
ov
en
ia
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
Sl
ov
en
ia
15
 -
 1
6
3
20
07
ES
PA
D
Sp
ai
n
14
 -
 1
8
5.
7
4.
1
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
Sp
ai
n
14
 -
 1
8
2.
6
1.
9
20
07
A
RQ
C
ra
ck
Sp
ai
n
14
 -
 1
8
5.
0
3.
6
20
07
A
RQ
Sw
ed
en
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
Sw
ed
en
15
 -
 1
6
2
20
07
ES
PA
D
Sw
itz
er
la
nd
15
 -
 1
6
2
20
07
ES
PA
D
C
ra
ck
Sw
itz
er
la
nd
15
 -
 1
6
3
20
07
ES
PA
D
U
ni
te
d 
K
in
gd
om
15
 -
 1
6
3
20
07
ES
PA
D
C
ra
ck
U
ni
te
d 
K
in
gd
om
15
 -
 1
6
5
20
07
ES
PA
D
O
C
EA
N
IA
O
ce
an
ia
A
us
tr
al
ia
12
 -
 1
7
0.
8
0.
4
20
07
A
RQ
C
oc
ai
ne
, a
ny
 (H
C
l a
nd
/ 
or
 C
ra
ck
)
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3.
6.
3 
C
an
n
ab
is
u
se
 (
u
n
le
ss
 o
th
er
w
is
e 
n
o
te
d
) 
am
o
n
g
st
 y
o
u
n
g
 p
eo
p
le
 (
o
rd
er
ed
 a
lp
h
ab
et
ic
al
ly
 b
y 
re
g
io
n
s)
Li
fe
-t
im
e
A
nn
ua
l
La
st
 m
on
th
 
R
eg
io
n
Su
b
re
g
io
n
C
ou
nt
ry
/ T
er
rit
or
y
C
ov
er
ag
e 
(a
ge
/g
ra
de
)
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
ev
er
 u
se
d
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
us
ed
 a
t 
le
as
t 
on
ce
 in
 t
he
 
pa
st
 y
ea
r 
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
us
ed
 a
t 
le
as
t 
on
ce
 in
 t
he
 
pa
st
 m
on
th
Y
ea
r 
of
 
Es
tim
at
e
So
ur
ce
N
ot
es
A
FR
IC
A
Ea
st
 A
fr
ic
a
Et
hi
op
ia
Y
ou
th
 (u
nd
ef
in
ed
)
11
19
99
A
RQ
A
ge
s 
no
t 
sp
ec
ifi
ed
K
en
ya
10
 -
 2
4
18
.9
10
.9
20
04
G
ov
t.
St
ud
en
ts
 a
nd
 n
on
-
st
ud
en
ts
M
ad
ag
as
ca
r
15
 -
 1
9
18
.5
20
04
A
RQ
M
au
rit
iu
s
14
 -
 1
8
10
.9
2.
2
20
04
A
RQ
Se
yc
he
lle
s
11
 -
 1
6
0.
31
20
01
A
RQ
A
FR
IC
A
N
o
rt
h
 A
fr
ic
a
A
lg
er
ia
15
 -
 1
6
20
05
A
RQ
Eg
yp
t
15
 -
 1
5
18
.9
20
06
A
RQ
M
or
oc
co
15
 -
 1
7
6.
6
4.
6
2.
9
20
05
M
ed
SP
A
D
Se
le
ct
 r
eg
io
ns
 (R
ab
at
)
A
FR
IC
A
So
u
th
er
n
 A
fr
ic
a
So
ut
h 
A
fr
ic
a
13
 -
 1
7
24
.8
12
.9
20
06
A
RQ
Se
le
ct
 r
eg
io
ns
 (C
ap
e 
To
w
n)
A
FR
IC
A
W
es
t 
an
d
 C
en
tr
al
 A
fr
ic
a
G
ha
na
13
 -
 1
5
17
.1
20
07
A
RQ
A
M
ER
IC
A
S
C
ar
ib
b
ea
n
A
nt
ig
ua
 &
 B
ar
bu
da
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
24
.9
13
.4
8.
4
20
05
O
A
S 
(M
EM
)
Ba
ha
m
as
10
 -
 1
9
14
.1
8.
3
20
03
A
RQ
Ba
rb
ad
os
St
ud
en
ts
 (a
ge
s 
13
, 
15
, a
nd
 1
7)
17
.4
10
.6
6
20
06
O
A
S 
(M
EM
)
D
om
in
ic
a
St
ud
en
ts
 (a
ge
s 
13
, 
15
, a
nd
 1
7)
29
.4
17
.9
11
.8
20
06
O
A
S 
(M
EM
)
D
om
in
ic
an
 R
ep
.
12
 -
 2
0
2.
2
20
00
A
RQ
G
re
na
da
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
27
.5
15
.9
8.
7
20
05
O
A
S 
(M
EM
)
H
ai
ti
15
 -
 1
6
2.
6
1.
8
20
05
A
RQ
C
an
na
bi
s 
re
si
n
H
ai
ti
15
 -
 1
6
3
1.
7
20
05
A
RQ
Ja
m
ai
ca
A
ge
s 
11
 -
 1
9
25
.1
14
.6
8.
5
20
06
O
A
S
St
. L
uc
ia
St
ud
en
ts
 (a
ge
s 
13
, 
15
, a
nd
 1
7)
25
.5
15
.9
8.
8
20
05
O
A
S 
(M
EM
)
C
A
N
N
A
B
IS
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St
. V
in
ce
nt
 &
 G
re
na
di
ne
s
St
ud
en
ts
 (a
ge
s 
13
, 
15
, a
nd
 1
7)
17
.8
11
.7
5.
2
20
06
O
A
S 
(M
EM
)
Tr
in
id
ad
 &
 T
ob
ag
o
St
ud
en
ts
 (a
ge
s 
13
, 
15
, a
nd
 1
7)
12
.0
6.
6
2.
8
20
06
O
A
S 
(M
EM
)
Tu
rk
s 
&
 C
ai
co
s 
Is
l.
11
 -
 2
0
21
.4
14
.5
20
02
A
RQ
A
M
ER
IC
A
S
C
en
tr
al
 A
m
er
ic
a
Be
liz
e
10
 -
 2
5
7.
6
19
98
A
RQ
Se
le
ct
 r
eg
io
ns
C
os
ta
 R
ic
a
G
ra
de
s 
7,
 9
 a
nd
 1
1 
(a
ge
s 
13
 -
 1
7)
7.
4
4.
6
2.
3
20
06
O
A
S 
(M
EM
)
El
 S
al
va
do
r
13
 -
 1
7
4.
7
2.
6
20
03
A
RQ
G
ua
te
m
al
a
12
 -
 1
9
2.
0
1.
0
20
04
A
RQ
H
on
du
ra
s
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
2.
9
1.
1
0.
4
20
05
O
A
S 
(M
EM
)
N
ic
ar
ag
ua
12
 -
 1
8
5.
2
20
04
A
RQ
A
M
ER
IC
A
S
N
o
rt
h
 A
m
er
ic
a
C
an
ad
a
12
 -
 1
7
30
.2
20
06
A
RQ
M
ex
ic
o
12
 -
 1
9
8.
8
5.
8
20
06
A
RQ
Se
le
ct
 r
eg
io
ns
U
SA
G
ra
de
 1
0
31
24
.6
20
07
A
RQ
A
M
ER
IC
A
S
So
u
th
 A
m
er
ic
a
A
rg
en
tin
a
13
 -
 1
7
10
.9
7.
6
20
07
A
RQ
Bo
liv
ia
15
 -
 1
6
5.
1
2.
7
1.
2
20
04
C
IC
A
D
/ O
A
S
Br
az
il
15
 -
 1
6
7.
7
6.
3
4.
4
20
05
C
IC
A
D
/ O
A
S
C
hi
le
15
 -
 1
6
18
.7
14
.6
6.
3
20
05
C
IC
A
D
/ O
A
S
C
ol
om
bi
a
15
 -
 1
6
9.
6
8.
4
3.
0
20
05
C
IC
A
D
/ O
A
S
Ec
ua
do
r
15
 -
 1
6
7.
5
3.
7
1.
9
20
05
C
IC
A
D
/ O
A
S
G
uy
an
a
12
 -
 1
8
6.
8
3.
5
1.
8
20
02
A
RQ
Pa
ra
gu
ay
15
 -
 1
6
3.
9
3.
1
1.
9
20
05
C
IC
A
D
/ O
A
S
Pe
ru
15
 -
 1
6
5.
5
3.
4
1.
7
20
05
C
IC
A
D
/ O
A
S
Su
rin
am
e
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
6.
8
4.
1
2.
3
20
06
O
A
S 
(M
EM
)
U
ru
gu
ay
13
 -
 1
7
19
.5
14
.8
20
07
A
RQ
V
en
ez
ue
la
10
 -
 2
3
1.
1
20
05
G
ov
t.
A
SI
A
C
en
tr
al
 A
si
a 
 a
n
d
 T
ra
n
sc
au
ca
si
an
 c
o
u
n
tr
ie
s
A
rm
en
ia
15
 -
 1
6
3
20
07
ES
PA
D
A
ze
rb
ai
ja
n
15
 -
 1
6
30
20
07
A
RQ
G
eo
rg
ia
15
 -
 1
6
7
20
05
A
RQ
K
az
ak
hs
ta
n
15
 -
 1
6
4.
6
2.
7
20
07
A
RQ
K
yr
gy
zs
ta
n
15
 -
 1
8
0.
3
20
01
A
RQ
A
SI
A
Ea
st
 a
n
d
 S
o
u
th
-E
as
t 
A
si
a
H
on
g 
K
on
g 
SA
R,
 C
hi
na
11
 -
 2
0
0.
0
20
07
A
RQ
Ja
pa
n
13
 -
 1
5
0.
4
20
06
A
RQ
K
or
ea
, R
ep
.
11
 -
 1
2
0.
1
20
07
A
RQ
Se
le
ct
 r
eg
io
ns
M
ac
au
 S
A
R,
 C
hi
na
18
 -
 2
5
2.
8
20
02
A
RQ
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M
ya
nm
ar
13
 -
 2
1
0.
9
0.
5
20
04
A
RQ
Th
ai
la
nd
Y
ou
th
 (u
nd
ef
in
ed
)
4.
4
20
03
A
RQ
A
ge
s 
no
t 
sp
ec
ifi
ed
A
SI
A
N
ea
r 
an
d
 M
id
d
le
 E
as
t 
/S
o
u
th
-W
es
t 
A
si
a
Is
ra
el
12
 -
 1
8
7.
7
5.
8
20
05
A
RQ
Jo
rd
an
18
 -
 2
5
2.
5
20
01
A
RQ
Le
ba
no
n
15
 -
 1
6
4.
4
20
01
A
RQ
C
an
na
bi
s 
re
si
n;
 R
ap
id
 
Si
tu
at
io
n 
A
ss
es
sm
en
t
A
SI
A
So
u
th
 A
si
a
Ba
ng
la
de
sh
13
 -
 1
8
5
3
20
01
A
RQ
In
di
a
12
 -
 1
8
3
20
01
A
RQ
N
ep
al
15
 -
 1
6
0.
1
0.
1
(b
la
nk
)
A
RQ
EU
R
O
PE
Ea
st
 E
u
ro
p
e
Be
la
ru
s
15
 -
 1
6
6.
8
20
07
A
RQ
Ru
ss
ia
n 
Fe
de
ra
tio
n
15
 -
 1
6
19
12
20
07
A
RQ
/ E
SP
A
D
U
kr
ai
ne
15
 -
 1
6
14
20
07
ES
PA
D
EU
R
O
PE
So
u
th
ea
st
 E
u
ro
p
e
A
lb
an
ia
14
 -
 1
9
5.
5
20
04
A
RQ
Bu
lg
ar
ia
15
 -
 1
9
30
.3
20
.5
20
07
A
RQ
C
ro
at
ia
16
27
.5
20
.5
20
07
A
RQ
Ro
m
an
ia
15
 -
 1
6
4
20
07
ES
PA
D
Tu
rk
ey
15
 -
 1
6
4.
3
3.
3
20
03
A
RQ
EU
R
O
PE
W
es
t 
&
 C
en
tr
al
 E
u
ro
p
e
A
us
tr
ia
15
 -
 1
6
19
.3
14
.8
6.
9
20
07
ES
PA
D
Be
lg
iu
m
15
 -
 1
6
24
20
07
ES
PA
D
Se
le
ct
 r
eg
io
ns
 (F
la
nd
er
s)
C
yp
ru
s
15
 -
 1
6
5
20
07
ES
PA
D
C
ze
ch
 R
ep
.
15
 -
 1
6
45
.1
34
.8
18
.1
20
07
G
ov
t.
/ E
SP
A
D
D
en
m
ar
k
15
 -
 1
6
25
.5
20
07
A
RQ
Es
to
ni
a
15
 -
 1
6
26
.3
19
.2
20
07
A
RQ
Fi
nl
an
d
15
 -
 1
6
8
20
07
A
RQ
Fr
an
ce
15
 -
 1
6
31
20
07
ES
PA
D
G
er
m
an
y
15
 -
 1
6
25
.2
17
.2
20
07
A
RQ
Se
le
ct
 r
eg
io
ns
G
re
ec
e
15
 -
 1
6
6
20
07
ES
PA
D
H
un
ga
ry
15
 -
 1
7
20
.7
15
.2
20
07
A
RQ
Ic
el
an
d
15
 -
 1
6
9
20
07
ES
PA
D
Ire
la
nd
15
 -
 1
6
20
20
07
ES
PA
D
Ita
ly
15
 -
 1
6
23
20
07
ES
PA
D
La
tv
ia
15
 -
 1
6
18
.1
11
.8
20
07
A
RQ
Li
ec
ht
en
st
ei
n
12
 -
 1
6
16
.2
11
.2
20
05
A
RQ
Li
th
ua
ni
a
15
 -
 1
6
18
.2
11
.7
4.
7
20
07
ES
PA
D
Lu
xe
m
bo
ur
g
11
 -
 1
7
27
.4
22
.4
19
99
A
RQ
M
al
ta
15
 -
 1
6
12
.9
10
.6
20
07
A
RQ
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M
on
ac
o
15
 -
 1
6
28
20
07
ES
PA
D
N
et
he
rla
nd
s
15
 -
 1
6
28
20
07
ES
PA
D
N
or
w
ay
15
 -
 1
6
6
20
07
ES
PA
D
Po
la
nd
15
 -
 1
6
15
.7
10
.9
20
07
A
RQ
Po
rt
ug
al
15
 -
 1
6
13
20
07
ES
PA
D
Sl
ov
ak
ia
15
 -
 1
9
39
.8
27
.2
20
07
A
RQ
Sl
ov
en
ia
15
 -
 1
6
22
20
07
ES
PA
D
Sp
ai
n
14
 -
 1
8
36
.2
29
.8
20
07
A
RQ
Sw
ed
en
15
 -
 1
6
7
20
07
ES
PA
D
Sw
itz
er
la
nd
15
 -
 1
6
33
20
07
ES
PA
D
U
ni
te
d 
K
in
gd
om
15
 -
 1
6
29
20
07
ES
PA
D
O
C
EA
N
IA
O
ce
an
ia
A
us
tr
al
ia
12
 -
 1
7
9.
3
6.
8
20
07
A
RQ
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3.
6.
4 
A
m
p
h
et
am
in
e-
ty
p
e 
st
im
u
la
n
ts  
u
se
 (
u
n
le
ss
 o
th
er
w
is
e 
n
o
te
d
) 
am
o
n
g
st
 y
o
u
n
g
 p
eo
p
le
 (
o
rd
er
ed
 a
lp
h
ab
et
ic
al
ly
 b
y 
re
g
io
n
s)
Li
fe
-t
im
e
A
nn
ua
l
La
st
 m
on
th
 
R
eg
io
n
Su
b
re
g
io
n
C
ou
nt
ry
/ T
er
rit
or
y
C
ov
er
ag
e 
(a
ge
/g
ra
de
)
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
ev
er
 u
se
d
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
us
ed
 a
t 
le
as
t 
on
ce
 in
 t
he
 
pa
st
 y
ea
r 
%
 o
f 
yo
un
g 
pe
op
le
 w
ho
 
us
ed
 a
t 
le
as
t 
on
ce
 in
 t
he
 
pa
st
 m
on
th
Y
ea
r 
of
 
Es
tim
at
e
So
ur
ce
N
ot
es
A
FR
IC
A
So
u
th
er
n
 A
fr
ic
a
So
ut
h 
A
fr
ic
a
13
 -
 1
7
8.
8
4.
7
20
06
A
RQ
M
et
ha
m
ph
et
am
in
e;
 
C
ap
e 
To
w
n
W
es
t 
an
d
 C
en
tr
al
 A
fr
ic
a
G
ha
na
13
 -
 1
5
7.
6
20
07
A
RQ
A
m
ph
et
am
in
es
 (i
nc
ld
s.
 
no
n-
A
TS
 s
tim
ul
an
ts
)
G
ha
na
13
 -
 1
5
5
20
07
A
RQ
M
et
ha
m
ph
et
am
in
e 
A
M
ER
IC
A
S
C
ar
ib
b
ea
n
A
nt
ig
ua
 &
 B
ar
bu
da
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
2.
6
1.
5
1.
1
20
05
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
Ba
ha
m
as
10
 -
 1
9
0.
5
0.
3
20
03
A
RQ
M
et
ha
m
ph
et
am
in
e
Ba
ha
m
as
10
 -
 1
9
1.
8
0.
5
20
03
A
RQ
Ba
rb
ad
os
A
ge
s 
13
, 1
5,
 
an
d 
17
3.
5
2.
4
1.
6
20
06
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
D
om
in
ic
a
A
ge
s 
13
, 1
5,
 
an
d 
17
4.
3
2.
2
1.
6
20
06
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
D
om
in
ic
an
 R
ep
.
12
 -
 2
0
2
20
00
A
RQ
G
re
na
da
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
3.
1
1.
6
1.
2
20
05
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
H
ai
ti
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
24
.4
11
.7
7.
5
20
05
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
Ja
m
ai
ca
A
ge
s 
11
 -
 1
9
6.
3
3.
5
2.
4
20
06
O
A
S
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
St
. L
uc
ia
A
ge
s 
13
, 1
5,
 
an
d 
17
6
3.
7
2.
2
20
05
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
St
. V
in
ce
nt
 &
 G
re
na
di
ne
s
A
ge
s 
13
, 1
5,
 
an
d 
17
2.
9
1.
7
1.
2
20
06
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
Tr
in
id
ad
 &
 T
ob
ag
o
A
ge
s 
13
, 1
5,
 
an
d 
17
3.
4
2.
1
1.
6
20
06
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
Tu
rk
s 
&
 C
ai
co
s 
Is
l.
11
 -
 2
0
0.
9
0.
3
20
02
A
RQ
M
et
ha
m
ph
et
am
in
e 
A
M
ER
IC
A
S
C
en
tr
al
 A
m
er
ic
a
C
os
ta
 R
ic
a
G
ra
de
s 
7,
 9
 a
nd
 
11
 (a
ge
s 
13
 -
 
17
)
4.
9
2.
8
1.
7
20
06
O
A
S 
(M
EM
)
A
M
PH
ET
A
M
IN
ES
-G
R
O
U
P
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El
 S
al
va
do
r
13
 -
 1
7
0.
3
0.
1
20
01
A
RQ
M
et
ha
m
ph
et
am
in
e 
El
 S
al
va
do
r
13
 -
 1
7
2.
9
1.
5
20
01
A
RQ
G
ua
te
m
al
a
12
 -
 1
9
7.
3
3.
8
20
02
A
RQ
A
m
ph
et
am
in
e
H
on
du
ra
s
12
 -
 1
7
7.
4
3.
1
2.
0
20
05
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
A
M
ER
IC
A
S
N
o
rt
h
 A
m
er
ic
a
C
an
ad
a
12
 -
 1
7
4.
5
20
06
A
RQ
A
m
ph
et
am
in
e 
M
ex
ic
o
12
 -
 1
9
3.
3
2
20
06
A
RQ
A
m
ph
et
am
in
e;
 S
el
ec
t 
re
gi
on
s 
M
ex
ic
o
12
 -
 1
9
2.
3
0.
8
20
06
A
RQ
M
et
ha
m
ph
et
am
in
e;
 
Se
le
ct
 r
eg
io
ns
  
U
SA
G
ra
de
 1
0
2.
8
1.
6
20
07
A
RQ
M
et
ha
m
ph
et
am
in
e 
U
SA
G
ra
de
 1
0
11
.1
8
20
07
A
RQ
A
m
ph
et
am
in
e
A
M
ER
IC
A
S
So
u
th
 A
m
er
ic
a
A
rg
en
tin
a
15
 -
 1
6
4.
5
3.
0
1.
9
20
05
C
IC
A
D
/ O
A
S
Bo
liv
ia
15
 -
 1
6
7.
1
3.
6
2.
1
20
04
C
IC
A
D
/ O
A
S
Br
az
il
15
 -
 1
6
4.
9
4.
3
3.
0
20
05
C
IC
A
D
/ O
A
S
C
hi
le
15
 -
 1
6
4.
4
2.
6
1.
0
20
05
C
IC
A
D
/ O
A
S
C
ol
om
bi
a
15
 -
 1
6
6.
4
3.
7
2.
8
20
05
C
IC
A
D
/ O
A
S
Ec
ua
do
r
15
 -
 1
6
3.
0
1.
6
1.
1
20
05
C
IC
A
D
/ O
A
S
G
uy
an
a
12
 -
 1
8
1.
5
0.
8
0.
3
20
02
A
RQ
M
et
ha
m
ph
et
am
in
e 
G
uy
an
a
12
 -
 1
8
2.
0
0.
7
0.
4
20
02
A
RQ
Pa
ra
gu
ay
15
 -
 1
6
4.
1
2.
6
1.
2
20
05
C
IC
A
D
/ O
A
S
Pe
ru
15
 -
 1
6
1.
2
0.
6
0.
4
20
05
C
IC
A
D
/ O
A
S
Su
rin
am
e
Se
co
nd
ar
y/
 H
ig
h 
Sc
ho
ol
4.
8
2.
7
1.
5
20
06
O
A
S 
(M
EM
)
St
im
ul
an
ts
 (i
nc
ld
s 
A
m
ph
et
am
in
es
)
U
ru
gu
ay
13
 -
 1
7
1.
7
20
07
A
RQ
V
en
ez
ue
la
10
 -
 2
3
0.
9
0.
5
20
05
A
RQ
A
m
ph
et
am
in
e 
A
SI
A
C
en
tr
al
 A
si
a 
 a
n
d
 T
ra
n
sc
au
ca
si
an
 c
o
u
n
tr
ie
s
A
rm
en
ia
15
 -
 1
6
0
20
07
ES
PA
D
K
az
ak
hs
ta
n
Y
ou
th
 
(u
nd
ef
in
ed
)
0.
8
20
07
A
RQ
A
ge
s 
no
t 
sp
ec
ifi
ed
K
az
ak
hs
ta
n
Y
ou
th
 
(u
nd
ef
in
ed
)
0.
5
20
07
A
RQ
A
m
ph
et
am
in
e;
 A
ge
s 
no
t 
sp
ec
ifi
ed
 
A
SI
A
Ea
st
 a
n
d
 S
o
u
th
-E
as
t 
A
si
a
H
on
g 
K
on
g 
SA
R,
 C
hi
na
11
 -
 2
0
0.
0
20
07
M
et
ha
m
ph
et
am
in
e
H
on
g 
K
on
g 
SA
R,
 C
hi
na
11
 -
 2
0
0.
1
20
07
Ja
pa
n
13
 -
 1
5
0.
4
20
06
A
RQ
M
et
ha
m
ph
et
am
in
e 
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M
ya
nm
ar
13
 -
 2
1
0.
4
0.
2
20
04
A
RQ
M
et
ha
m
ph
et
am
in
e;
 
Y
an
go
n
Th
ai
la
nd
Y
ou
th
 
(u
nd
ef
in
ed
)
2.
4
20
03
A
RQ
M
et
ha
m
ph
et
am
in
e;
 
A
ge
s 
no
t 
sp
ec
ifi
ed
 
A
SI
A
N
ea
r 
an
d
 M
id
d
le
 E
as
t 
/S
o
u
th
-W
es
t 
A
si
a
Is
ra
el
12
 -
 1
8
3.
4
2.
7
20
05
A
RQ
A
m
ph
et
am
in
e 
Jo
rd
an
18
 -
 2
5
2.
6
20
01
A
RQ
U
nv
er
si
ty
 s
tu
de
nt
s
Le
ba
no
n
15
 -
 1
6
0.
5
20
01
A
RQ
Ra
pi
d 
Si
tu
at
io
n 
A
ss
es
m
en
t
EU
R
O
PE
Ea
st
 E
u
ro
p
e
Ru
ss
ia
n 
Fe
de
ra
tio
n
15
 -
 1
6
2.
3
20
07
A
RQ
A
m
ph
et
am
in
e 
U
kr
ai
ne
15
 -
 1
6
1
20
07
ES
PA
D
EU
R
O
PE
So
u
th
ea
st
 E
u
ro
p
e
A
lb
an
ia
14
 -
 1
9
4.
9
20
04
A
RQ
Bu
lg
ar
ia
15
 -
 1
9
9
20
07
A
RQ
A
m
ph
et
am
in
e 
Bu
lg
ar
ia
15
 -
 1
9
3.
6
20
07
A
RQ
M
et
ha
m
ph
et
am
in
e 
C
ro
at
ia
16
3.
7
20
07
A
RQ
A
m
ph
et
am
in
e 
Ro
m
an
ia
16
 -
 1
6
2.
1
20
03
Tu
rk
ey
15
 -
 1
6
2
1
20
03
ES
PA
D
EU
R
O
PE
W
es
t 
&
 C
en
tr
al
 E
u
ro
p
e
A
us
tr
ia
15
 -
 1
6
7.
9
20
07
ES
PA
D
M
ay
 in
cl
ud
e 
no
n-
A
TS
 
st
im
ul
an
ts
Be
lg
iu
m
15
 -
 1
6
5
20
07
ES
PA
D
Se
le
ct
 r
eg
io
ns
 
(F
la
nd
er
s)
C
yp
ru
s
15
 -
 1
6
3
20
07
ES
PA
D
C
ze
ch
 R
ep
.
15
 -
 1
6
3.
5
2.
1
1.
2
20
07
G
ov
t.
/ E
SP
A
D
M
et
ha
m
ph
et
am
in
e 
D
en
m
ar
k
15
 -
 1
6
5
20
07
A
RQ
Es
to
ni
a
15
 -
 1
6
3.
8
20
07
A
RQ
Fa
ro
e 
Is
l.
15
 -
 1
6
1
20
07
ES
PA
D
Fi
nl
an
d
15
 -
 1
6
1
20
07
A
RQ
A
m
ph
et
am
in
e 
Fr
an
ce
15
 -
 1
6
4
20
07
ES
PA
D
G
er
m
an
y
15
 -
 1
6
5.
8
20
07
A
RQ
A
m
ph
et
am
in
e 
G
re
ec
e
15
 -
 1
6
3
20
07
ES
PA
D
G
re
en
la
nd
15
 -
 1
6
0
0
20
03
ES
PA
D
H
un
ga
ry
15
 -
 1
7
5.
1
20
07
A
RQ
A
m
ph
et
am
in
e 
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Count Count Count Count
Rate Rate Rate Rate
Africa Africa
Algeria Count 5,702c 2004 4,210c 2006 Algeria Count 1,979ª 2003 2,733ª 2007
Rate 18 13 -40 Rate 6 8 23
Mauritius Count 3,115c 2004 3,851c 2006 Mauritius Count 452 ª 2005 396 ª 2007
Rate 253 308 18 Rate 36 31 -16
Morocco Count 6,860c 2,005 9,038c 2006 Morocco Count 9,615ª 2004 9,194 ª 2007
Rate 22 29 24 Rate 32 29 -8
Namibia Count 549 ª 2004 575 ª 2007 Namibia Count 225 ª 2004 288 ª 2007
Rate 28 28 1 Rate 11 14 19
South Africa Count 61,631ª 2004 93,121ª 2007 South Africa Count 12,263ª 2004 14,697ª 2007
Rate 130 192 32 Rate 26 30 15
Central America and Caribbean Central America and Caribbean
Bahamas Count 1,537ª 2004 1,363ª 2007 Bahamas Count 138ª 2004 110ª 2007
Rate 481 411 -17 Rate 43 33 -30
Belize Count 1,375ª 2005 987 ª 2007 Belize Count 310ª 2005 399 ª 2007
Rate 499 343 -45 Rate 113 139 19
Costa Rica Count 5,290 ª 2003 14,817 ª 2005 Costa Rica Count 1,024 ª 2004 1,205 ª 2006
Rate 127 342 63 Rate 24 27 12
El Salvador Count 1,388 ª 2004 1,866ª 2006 El Salvador Count 808 ª 2005 968ª 2007
Rate 21 28 24 Rate 12 14 14
Panama Count 1,484c 2002 3,150c 2006 Panama Count 882ª 2005 855ª 2006
Rate 48 96 49 Rate 27 26 -5
North America North America
Canada Count 19,483c 2005 21,530c 2006 Canada Count 8,937ª 2005 3,996ª 2007
Rate 60 66 9 Rate 28 12 -128
Mexico Count 38,799c 2005 55,667c 2006 Mexico Count 20,443 ª 2005 21,890 ª 2007
Rate 37 53 30 Rate 20 21 5
USA Count 1,508,469* 2005 1,518,975* 2007 USA Count 337,882 * 2005 322,207 * 2007
Rate 503 497 -1 Rate 113 105 -8
South America South America
Argentina Count 22,244 ª 2004 21,544ª 2006 Argentina Count 8,646 ª 2003 10,531 ª 2005
Rate 58 55 -5 Rate 23 27 15
Chile Count 10,976 ª 2005 15,637ª 2007 Chile Count 6,050 ª 2005 9,534ª 2007
Rate 67 94 28 Rate 37 57 35
Ecuador Count 2,235 ª 2005 2,633 ª 2007 Ecuador Count 1,304ª 2005 854ª 2007
Rate 17 20 13 Rate 10 6 -56
Guyana Count 242 ª 2003 405ª 2005 Guyana Count 247 ª 2003 285ª 2005
Rate 33 55 40 Rate 33 39 13
Uruguay Count 1,594c 2004 1,566c 2006 Uruguay Count 329ª 2004 466ª 2006
Rate 48 47 -2 Rate 10 14 29
Year
Change 
in rate
Year
Change 
in rate
Country Year Year Country 
RECORDED DRUG-RELATED CRIME/POSSESSION/ABUSE1 RECORDED DRUG TRAFFICKING CRIME
1 The column headed ‘recorded drug-related crime/possession/abuse’ contains both data reported in the Annual Reports Questionnaire as ‘possession/
abuse’ and in the Survey of Crime Trends and Operations of Criminal Justice Systems (UN-CTS) as ‘drug-related crime’. The definition applied 
by the Tenth UN-CTS for ‘drug-related crime’ is ‘intentional acts that involve the cultivation, production, manufacture, extraction, preparation, 
offering for sale, distribution, purchase, sale, delivery on any terms whatsoever, brokerage, dispatch, dispatch in transit, transport, importation, 
exportation and possession of internationally controlled drugs. Where applicable, reference may be made to the provisions of the Single Convention 
on Narcotic Drugs of 1961 and other regulations adopted in pursuance of the provisions of the Convention on Psychotropic Substances of 1971 
and/or the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988’. Where UN-CTS respondents indicated that 
drug trafficking crimes were included in drug-related crime, the count for drug trafficking was deducted from the count for drug-related crime before 
inclusion in the table.
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Central Asia/Transcaucasia Central Asia/Transcaucasia
Armenia Count 411c 2004 553c 2006 Armenia Count 411ª 2005 471ª 2007
Rate 14 18 26 Rate 14 16 13
Azerbaijan Count 2,053c 2004 2,266c 2006 Azerbaijan Count 901c 2005 905c 2006
Rate 25 27 8 Rate 11 11 0
Georgia Count 1,427c 2004 1,926c 2006 Georgia Count 94ª 2003 61ª 2007
Rate 32 43 26 Rate 2 1 -48
Kyrgyzstan Count 2,452ª 2005 1,162ª 2007 Kyrygyzstan Count 294ª 2005 283ª 2007
Rate 47 22 -114 Rate 6 5 -6
Uzbekistan Count 5,301ª 2005 4,301ª 2007 Uzbekistan Count 9,261ª 2005 9,814ª 2007
Rate 20 16 -27 Rate 35 36 3
East Asia East Asia
Brunei Count 295c 2004 162c 2006 Brunei Count 0c 2005 0c 2006
Rate 81 42 -91 Rate 0 0 N.A.
Hong Kong Count 3,669 ª 2005 4,854 ª 2007 Hong Kong Count 2,339 ª 2005 3,655ª 2007
Rate 52 67 23 Rate 33 51 35
Japan Count 23,681c 2005 21,298c 2006 Japan Count 1,477ª 2005 1,518ª 2007
Rate 21 17 -24 Rate 1 1 0
Korea Count 3,268 ª 2005 6,469ª 2007 Korea Count 758 ª 2005 2,845ª 2007
Rate 7 13 49 Rate 2 6 73
Singapore Count 661 ª 2005 1,844 ª 2007 Singapore Count 61 ª 2005 101 ª 2007
Rate 15 42 64 Rate 1 2 50
Near Middle East/South West Asia Near Middle East/South West Asia
Iran Count 288,483ª 2004 285,152 ª 2007 Iran Count 124,278ª 2004 126,236 ª 2007
Rate 420 619 32 Rate 165 182 9
Jordan Count 2,514ª 2005 2,874ª 2007 Jordan Count 746ª 2005 833ª 2007
Rate 45 49 7 Rate 13 14 4
Lebanon Count 1,507 ª 2005 1,648ª 2007 Lebanon Count 546 ª 2005 570ª 2007
Rate 38 40 7 Rate 14 14 2
Syria Count 3,198ª 2005 5,002ª 2007 Syria Count 831ª 2005 1711ª 2007
Rate 17 25 33 Rate 4 9 49
United Arab Emirates Count 506c 2004 971c 2006 United Arab Emirates Count 368ª 2004 202ª 2006
Rate 13 24 46 Rate 9 5 -78
South Asia South Asia
Bangladesh Count 8,089ª 2005 8,476ª 2007 Bangladesh Count 14,133c 2005 15,331c 2006
Rate 5 5 1 Rate 9 10 6
Nepal Count 201c 2002 221c 2006 Nepal Count 214c 2005 221c 2006
Rate 1 1 1 Rate 1 1 1
Sri Lanka Count 28,007 ª 2005 43,280 ª 2007 Sri Lanka Count 34 ª 2005 13 ª 2007
Rate 146 224 35 Rate 0.2 0.2 0
Count Count Count Count
Rate Rate Rate Rate
Year
Change 
in rate
Year
Change 
in rate
Country Year Year Country 
RECORDED DRUG-RELATED CRIME/POSSESSION/ABUSE RECORDED DRUG TRAFFICKING CRIME
Sources:        
(c) United Nations Survey of Crime Trends and Operations of Criminal Justice Systems. Definition of 'drug-related crime' applied by UNCTS: 
"Drug-related crime is defined as intentional acts that involve the cultivation, production, manufacture, extraction, preparation, offer-
ing for sale, distribution, purchase, sale, delivery, delivery on any terms whatsoever, brokerage, dispatch, dispatch in transit, transport, 
importation, exportation and possession of internationally controlled drugs. Where applicable, reference may be made to the provisions 
of the Single Convention on Narcotic Drugs of 1961 and other regulations adopted in pursuance of the porivsions of the Convention 
on Psychotropic Substances of 1971 and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Sub-
stances of 1998." Definition of 'drug-trafficking' applied by UNCTS: "Drug offences, which are not in connection with personal 
use."     
(ª) United Nations Annual Reports Questionnaires.Definitiona applied by UNARQ: "Possession/abuse of drugs" and  "Trafficking of drugs, 
including arrests made in the context of illicit cultivation and manufacture of drugs".     
(#) European Monitoring Centre for Drugs and Drug Addiction, Drug Law Offences. Definitions applied by EMCDDA: "Drug-law offences 
which are related to drug use and/or possesion for use." and "Drug-related dealing/trafficking/production refers to drug law offences 
which are related to drug dealing and/or drug trafficking/smuggling and/or drug production or any other offence related to these types 
of illicit activities."     
(*) National government sources. NOTE: The definition applied by national sources may not correspond to that applied by cross-national 
data collection instruments. United States of America: http://www.whitehousedrugpolicy.gov/publications/policy/ndcs09/ndcs09_data_
supl/index.html, Australia: http://www.crimecommission.gov.au/content/publications/iddr_2006_07/iddr_2006-07.pdf  
(^) Statistical Office of the European Communities, Statistics in Focus. Definition applied by Eurostat: "Drug-trafficking includes illegal 
possession, cultivation, production, supplying, transportation, importing, exporting, financing etc. of drug operations which are not 
solely in coonection with personal use."     
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Rate 43 54 21 Rate 54 52 -3
Russian Federation Count 96,890ª 2003 175,241ª 2005 Russian Federation Count 212,019ª 2006 231,218ª 2007
Rate 67 122 45 Rate 148 162 9
Ukraine Count 40,688c 2005 40,444c 2006 Ukraine Count 24,329c 2005 24,186c 2006
Rate 87 87 0 Rate 52 52 0
South East Europe South East Europe
Bosnia and Herzegovina Count 236c 2005 193c 2006 Bosnia and Herzegovina Count 1355c 2005 1322c 2006
Rate 6 5 -23 Rate 35 34 -3
Bulgaria Count 2,409ª 2004 2,524ª 2006 Bulgaria Count 448ª 2004 168ª 2006
Rate 31 33 6 Rate 6 2 -163
Croatia Count 5,124ª 2005 5,033ª 2007 Croatia Count 576ª 2005 646ª 2007
Rate 113 110 -3 Rate 13 14 11
FYROM Count 292c 2005 261c 2006 FYROM Count 98c 2005 54c 2006
Rate 14 13 -12 Rate 5 3 -82
Montenegro Count 355c 2005 438c 2006 Montenegro Count 294^ 2005 549^ 2007
Rate 58 73 21 Rate 48 92 47
Romania Count 944c 2004 1620c 2006 Romania Count 1,314c 2005 1,608c 2006
Rate 4 8 50 Rate 6 7 19
Serbia Count 336c 2005 268c 2006 Serbia Count 4,968c 2005 4,839c 2006
Rate 3 3 0 Rate 50 49 -3
Turkey Count 4,760ª 2005 11,354ª 2007 Turkey Count 7,022ª 2005 9,774ª 2007
Rate 7 15 57 Rate 10 13 26
West Central Europe West Central Europe
Austria Count 25,089ª 2005 21,196ª 2007 Austria Count 2,224ª 2005 2,426ª 2007
Rate 303 254 -19 Rate 27 29 8
Belgium Count 25,683ª 2005 23,720ª 2007 Belgium Count 8,650ª 2005 12,695ª 2007
Rate 247 227 -9 Rate 83 121 31
Cyprus Count 404c 2005 454c 2006 Cyprus Count 289ª 2005 264ª 2007
Rate 48 54 11 Rate 35 31 -13
Czech Republic Count 648c 2005 674c 2006 Czech Republic Count 2,267ª 2005 2,248ª 2006
Rate 6 7 14 Rate 22 22 0
Denmark Count 16,630c 2004 20,327c 2006 Denmark Count 2,738^ 2005 3,258^ 2007
Rate 308 374 18 Rate 51 60 15
UK: England and Wales Count 153,203c 2005 167,732c 2006 UK: England and Wales Count 25,276^ 2005 28,130^ 2007
Rate 287 312 8 Rate 47 52 9
Estonia Count 1,099c 2004 981c 2006 Estonia Count 686^ 2005 1,449^ 2007
Rate 82 73 -11 Rate 51 109 53
Finland Count 15,064ª 2005 15,479ª 2007 Finland Count 5,177^ 2005 5,115^ 2007
Rate 287 293 2 Rate 99 97 -2
France Count 101,047ª 2005 134,320ª 2007 France Count 19,258ª 2005 21,397ª 2007
Rate 166 218 24 Rate 32 35 9
Germany Count 232,502ª 2004 205,164ª 2007 Germany Count 62,131ª 2004 53,770ª 2007
Rate 281 248 -13 Rate 75 65 -16
Greece Count 12,823ª 2004 13,948ª 2006 Greece Count 4,667ª 2005 3,943ª 2006
Rate 116 125 7 Rate 42 35 -20
Hungary Count 7,012 ª 2005 4,117 ª 2007 Hungary Count 7,627^ 2005 4,676^ 2007
Rate 70 41 -71 Rate 76 47 -62
Ireland Count 9,867 ª 2005 18,439 ª 2007 Ireland Count 3,160c 2005 3,632c 2006
Rate 238 429 44 Rate 76 86 11
Italy Count 7,603c 2005 8,542c 2006 Italy Count 24,456c 2005 23,764c 2007
Rate 13 15 13 Rate 42 40 -3
Latvia Count 545ª 2005 1,531 ª 2007 Latvia Count 326ª 2005 626 ª 2007
Rate 24 67 64 Rate 14 27 48
Lithuania Count 682 ª 2005 718 ª 2007 Lithuania Count 329 ª 2005 395 ª 2007
Rate 20 21 5 Rate 10 12 18
Netherlands Count 6,348ª 2005 5,889ª 2007 Netherlands Count 14,161ª 2005 13,186ª 2007
Rate 39 36 -8 Rate 87 80 -8
UK: Northern Ireland Count 1,924c 2002 2,411c 2006 UK: Northern Ireland Count 349c 2005 473c 2006
Rate 113 139 19 Rate 20 27 26
Norway Count 16,866ª 2005 17,408ª 2007 Norway Count 5,747# 2003 6,056# 2005
Rate 364 371 2 Rate 126 131 4
Poland Count 50,114ª 2005 51,352ª 2007 Poland Count 24,433ª 2005 39,591ª 2007
Rate 131 135 3 Rate 64 104 38
Portugal Count 5,370# 2004 6,216# 2006 Portugal Count 3,535^ 2005 3,281^ 2007
Rate 51 59 14 Rate 34 31 -9
UK: Scotland Count 34,634c 2004 33,532c 2006 UK: Scotland Count 9,613c 2005 9,827c 2007
Rate 680 656 -4 Rate 189 213 12
Slovakia Count 1,993c 2004 1,732c 2006 Slovakia Count 843^ 2005 470^ 2007
Rate 37 32 -15 Rate 16 9 -80
Slovenia Count 2,944# 2004 3,197# 2006 Slovenia Count 1,026^ 2005 1,429^ 2007
Rate 147 160 8 Rate 51 71 28
Spain Count 188,125 ª 2005 253,559 ª 2007 Spain Count 22,493 ª 2005 25,238 ª 2007
Rate 433 573 24 Rate 52 57 9
Sweden Count 14,388# 2004 17,819# 2006 Sweden Count 4,670c 2005 7,026c 2007
Rate 160 196 19 Rate 52 77 32
Switzerland Count 40,432ª 2005 37,030ª 2007 Switzerland Count 2,757ª 2005 2,809ª 2007
Rate 545 495 -10 Rate 37 38 1
Oceania Oceania
Australia Count 62,209* 2004/05 66,530* 2006/07 Australia Count 14,613* 2004/05 15,709* 2006/07
Rate 308 322 4 Rate 72 76 5
New Zealand Count 8,672c 2002 8,694c 2006 New Zealand Count 4,293c 2005 4,271c 2006
Rate 212 210 -1 Rate 105 103 -2
East Europe East Europe
Belarus Count 2,376 ª 2003 2,278 ª 2005 Belarus Count 783 ª 2003 1,094 ª 2005
Rate 24 23 -4 Rate 8 11 27
Moldova Count 1,681ª 2004 2,087ª 2006 Moldova Count 2,086c 2005 1,997c 2006
Count Count Count Count
Rate Rate Rate Rate
Year
Change 
in rate
Year
Change 
in rate
Country Year Year Country 
RECORDED DRUG-RELATED CRIME/POSSESSION/ABUSE RECORDED DRUG TRAFFICKING CRIME
The column headed ‘recorded drug-related crime/possession/abuse’ contains both data reported in the Annual Reports Questionnaire as ‘possession/abuse’ 
and in the Survey of Crime Trends and Operations of Criminal Justice Systems (UN-CTS) as ‘drug-related crime’. The definition applied by the Tenth UN-CTS 
for ‘drug-related crime’ is ‘intentional acts that involve the cultivation, production, manufacture, extraction, preparation, offering for sale, distribution, pur-
chase, sale, delivery on any terms whatsoever, brokerage, dispatch, dispatch in transit, transport, importation, exportation and possession of internationally 
controlled drugs. Where applicable, reference may be made to the provisions of the Single Convention on Narcotic Drugs of 1961 and other regulations 
adopted in pursuance of the provisions of the Convention on Psychotropic Substances of 1971 and/or the Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances of 1988’. Where UN-CTS respondents indicated that drug trafficking crimes were included in drug-related crime, the count for 
drug trafficking was deducted from the count for drug-related crime before inclusion in the table.
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3. Statistical Annex Consumption
Trends in selected categories of police recorded crime in countries consistently reporting over  
the period 1995-2004 (1995 = 100)
Comparison of drug-trafﬁcking and drug-related crime rates for selected countries, 2006
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Considerable efforts have been made over the last few 
years to improve the estimates presented in this report. 
Nonetheless, challenges remain in making such esti-
mates because of the gaps and variable quality of the 
data available. 
A major problem relates to the irregularity and incom-
pleteness in reporting by Member States. First, the 
irregular intervals at which some Governments report 
may result in absence of data in some years. The lack of 
regular data, for which UNODC tries to compensate by 
referring to other sources, can influence the reported 
trend in a given year. Second, submitted questionnaires 
are not always complete or sufficiently comprehensive. 
Third, as will become clear in this section, many of the 
data collected are themselves subject to limitations and 
biases. These issues affect the quantity, quality and com-
parability of information received.
Attempts have been made to provide information about 
the accuracy of the data throughout this Report. This 
section presents detailed information on the data sources 
and methods used to make the estimates featured 
throughout the Report. This information can be used to 
inform the reader’s understanding of the quality of the 
data presented.
Sources of information
Under the international drug control conventions, 
Member States are formally required to provide drug-re-
lated information annually, as detailed by the Commis-
sion on Narcotic Drugs, to the ‘Secretary-General of the 
United Nations’ (that is, the Secretariat of UNODC). The 
Commission on Narcotic Drugs developed the Annual 
Reports Questionnaire (ARQ) to collect these data. 
The 2009 World Drug Report is based primarily on data 
obtained from the ARQs returned by Governments to 
UNODC over the June 2008 to May 2009 period. 
Where no ARQ was submitted in this year, data from 
the previous ARQ submission were used. The data col-
lected during this period (2008-2009) normally refer to 
the drug situation in 2007. 
UNODC sent out the questionnaire to 192 countries, 
where some were also forwarded on to autonomous ter-
ritories. UNODC received 118 replies to its question-
naire on Drug Use Demand (Part II) and 116 replies to 
its questionnaire on Illicit Supply of Drugs (Part III).a 
The best coverage was from countries in Europe (84% 
of all countries in Europe returned Part II and 87% Part 
III of the ARQ), followed Asia (76% both Demand and 
Supply), and the Americas (60% of the countries pro-
viding the Demand, and 57% the Supply ARQ). In the 
case of Africa, only a third of countries replied to the 
Supply ARQ and 38% to the Demand ARQ. In the 
Oceania region, two countries supplied information, 
equivalent to 14% of the countries in the region. 
Member States’ responses to the ARQs are shown on the 
subsequent maps. 
Typically, the ability of Member States to provide infor-
mation on illicit drug supply is significantly better than 
their ability to provide demand-related information. 
However, as noted above, two more Member States 
responded to the Demand ARQ than the Supply ARQ. 
Both the Demand and Supply ARQ’s have sets of “key” 
questions (see below). ARQs where more than 50% of 
these key questions were completed are defined as having 
been ‘substantially filled in’; the rest were classified as 
having been ‘partially filled in’. This term reflects whether 
countries provided some replies to the “key” questions, 
but that not all of the data were provided, since in many 
cases Member States do not have the information. The 
analysis of the ‘Supply ARQs’ submitted this year 
revealed that 84% of them were ‘substantially’ com-
pleted compared to just 59% of the ‘Demand ARQs’. 
In order to identify the extent to which Member States 
are able to provided at least some information, a number 
of key questions in the ARQs were identifiedb: 
For the ‘Supply ARQs (Part III)’, this included replies  s
to the questions on ‘drug seizures’, i.e. on the quanti-
ties seized (replied by 95% of the countries returning 
the ARQ), the number of seizure cases (70%), ‘traﬃck-
ing’ (origin of drugs and/or destination (88%)), ‘drug 
prices’ (90%), and ‘drug related arrests’ and/or ‘convic-
tions’ (92%). 
a From 115 and 113 Member States, respectively with additional 
responses from their territories. 
b Each key question includes several subsections, typically by drug 
group (i.e. cannabis, cocaine, opiates, etc.). If Member States provide 
any quantifiable data in any part of key question’s subsection, the 
key question is classified as “filled-in.” There is no assessment of the 
accuracy of completeness of the data or information provided.
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For the Demand ARQs (Part II), the key questions  s
used for the analysis referred to ‘trends in drug use’ and 
‘ranking of drugs in terms of their prevalence among 
the general population‘ (replied by 91% of the Mem-
ber States); ‘prevalence estimates’ (general population 
(50%), students (59%) and ‘drug treatment’ (74%)). 
Information provided by Member States in ARQs form 
the basis for the estimates and trend analysis provided in 
the World Drug Report. Often, this information and 
data are not sufficient to provide an accurate or compre-
hensive picture of the world’s drug situation. When 
necessary and where available, the data from the ARQs 
are thus supplemented with data from other sources. 
As in previous years, seizure data made available to 
UNODC via the ARQs was complemented primarily 
with data and reports from international organizations 
such as INTERPOL, the World Customs Organization 
(WCO), EUROPOL, the Organization of American 
States (OAC)/ Inter-American Drug Abuse Control 
Commission (CICAD), and data provided to UNODC 
by the Heads of National Law Enforcement Agencies 
(HONLEA) at their regional meetings, data provided 
through UNODC’s ‘Data for Africa‘ project, and 
UNODC’s ‘Drug Use Information Network for Asia and 
the Pacific’ (DAINAP). In addition, Government reports 
and on-line electronic resources are used if they are 
located. Other sources considered included data pub-
lished by the United States Department of State’s Bureau 
for International Narcotics and Law Enforcement Affairs 
in its International Narcotics Control Strategy Report 
(INCSR).
Price data for Europe was complemented with data from 
Europol. Precursor data presented are basically those 
collected by the International Narcotics Control Board 
(INCB). Demand-related information was obtained 
through a number of additional channels, including 
UNODC’s Global Assessment Programme (GAP), the 
drug control agencies participating in UNODC’s 
DAINAP network, as well as various national and 
regional epidemiological networks such as the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and the Inter-American Drug Use Control 
Commission (CICAD). National government reports 
and scientific literature were also used as sources of 
information. This type of supplementary information is 
useful and needed as long as Member States lack the 
monitoring systems necessary to produce reliable, com-
prehensive and internationally comparable data.
To this end, UNODC encourages and supports the 
improvement of national monitoring systems. Major 
progress has been made over the last few years in some 
of the main drug producing countries. In close coopera-
tion with UNODC’s Illicit Crop Monitoring Pro-
gramme (ICMP) and with the support of major donors 
these countries have developed monitoring systems 
designed to identify extent of and trends in the cultiva-
tion of narcotic plants. These data form another basis for 
the trend analysis presented in the World Drug Report. 
There remain significant data limitations on the demand 
side. Despite commendable progress made in a number 
of Member States, in the area of prevalence estimates, 
for example, far more remains to be done to provide a 
truly reliable basis for trend and policy analysis and 
needs assessments. The work being done for the 2009 
World Drug Report provides yet another opportunity to 
emphasise the global need for improving data collection 
and monitoring to improve the evidence base for effec-
tive policy. 
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Supply side data
Drug cultivation, production  
and manufacture 
In line with decisions of the Member States (1998 
UNGASS and subsequent Commission on Narcotic 
Drugs resolutions), UNODC launched an Illicit Crop 
Monitoring Programme (ICMP) in 1999. The objective 
of the programme is to assist Member States in establish-
ing national systems to monitor the extent and evolu-
tion of the illicit cultivation of narcotics crops on their 
territories. The results are compiled by UNODC to 
present global estimates on an annual basis. Data on 
cultivation of opium poppy and coca bush and produc-
tion of opium and coca leaf, presented in this report for 
the main producing countries (Afghanistan, Myanmar 
and Lao PDR for opium and Colombia, Peru and 
Bolivia for coca) have been derived from these national 
monitoring systems operating in the countries of illicit 
production, covering the period up to, and including 
2008. The Government of Morocco, in cooperation 
with UNODC, also conducted surveys on illicit can-
nabis cultivation and cannabis resin production in 2003, 
2004 and 2005. Estimates for other countries presented 
in this report have been drawn from replies to UNODC’s 
Annual Reports Questionnaire, from various other 
sources including reports from Governments, UNODC 
field offices and the United States Department of State’s 
Bureau for International Narcotics and Law Enforce-
ment Affairs.
Area under cultivation
Heroin, cocaine and cannabis (herb and resin) are so-
called plant-based drugs. A first step towards estimating 
their global production is to estimate the area cultivated 
with opium poppy, coca bush and cannabis. Three dif-
ferent methods of illicit area monitoring are used by 
UNODC supported national monitoring systems:
Area estimation from satellite imagery s
Area estimation from helicopter survey s
Area estimation from village survey s
In the coca cultivating countries Bolivia, Colombia 
and Peru, the area under coca bush is identified on 
satellite images, which cover the whole area where coca 
cultivation is thought to take place. In Bolivia, aerial 
photography is occasionally used as well. The UNODC 
supported cannabis survey in Morocco used a similar 
approach. 
In Myanmar, areas with a high density of opium poppy 
are covered with a sample of satellite images. The final 
area estimate is derived by extrapolation. In low density 
areas, the area estimate is derived from the village survey 
(sample survey), which is conducted in all poppy grow-
ing areas. In Lao PDR, the survey is conducted by heli-
copter over sample sites. Digital photographs of all 
opium poppy fields falling into these sites are taken, 
geo-referenced and analysed in a geographic information 
system. The area estimate is derived by extrapolation. 
In Afghanistan, similar to the method used in Myanmar, 
satellite imagery over sample sites are analysed and the 
area measured is extrapolated. In addition, a nationally 
representative survey of villages is conducted in order to 
collect information on the socioeconomic status of farm-
ers, including areas with high, low and zero levels of 
poppy cultivation. In regions with a low level of poppy 
cultivation, which are not covered by imagery, the area 
estimate is derived from the village survey. 
In some countries, the methods used have changed over 
the years as new technologies became available and to 
adapt to the dynamics of illicit cultivation. Only the 
methods used in the most recent year reported are 
described here briefly. A full technical description of the 
methods used in all years can be found in the respective 
national survey reports available at http://www.unodc.
org/unodc/en/crop-monitoring/index.html .
Yieldc
As a second step in the production estimation chain, the 
number of harvests per year and the total yield of pri-
mary plant material has to be established. The UNODC-
supported national surveys use measure yield in the field 
and interviews with farmers, using results from both to 
produce the final data on yield. 
For cannabis, the yield of cannabis plant material per 
hectare can be established by directly harvesting the 
plant material. Opium yield surveys are more complex. 
Harvesting opium with the traditional lancing method 
can take up to 2 weeks as the opium latex that oozes out 
of the poppy capsule has to dry before harvesters can 
scrap it of and several lancings take place until the plant 
has dried. To avoid this lengthy process, yield surveyors 
measure the number of poppy capsules and their size in 
sample plots. Using a formula developed by scientists 
based on research experiments, the measured poppy 
capsule volume indicate how much opium gum each 
plant potentially yields. Thus, the per hectare opium 
yield can be estimated. Different formulas were devel-
oped for Southeast and Southwest Asia. In Afghanistan 
and Myanmar, yield surveys are carried out annually. 
Coca bush, a perennial plant cultivated in tropical cli-
mate, allows several harvest per year. The number of 
harvests varies, as does the yield per harvest. In Bolivia 
and Peru, the UNODC supports monitoring systems 
that conduct coca leaf yield surveys in several regions, by 
c Further information on the methodology of opium and cannabis 
leaf yield surveys conducted by UNODC can be found in United 
Nations (2001): Guidelines for Yield Assessment of Opium Gum and 
Coca Leaf from Brief Field Visits. New York. (ST/NAR/33).
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harvesting sample plots of coca fields over the course of 
a year, in the rhythm indicated by the coca farmer. In 
Colombia, where the security situation did not allow for 
surveyors to return to the sample fields, only one harvest 
was measured, and the other harvests were estimated 
based on information from the farmer. In all three coca 
countries, yield surveys are carried out only occasionally, 
due to the difficult security situation in many coca 
regions, and because of funding constraints. 
Conversion factors
The primary plant material harvested - opium in the 
form of gum or latex from opium poppy, coca leaves 
from coca bush, and the cannabis plant - undergo a 
sequence of extraction and transformation processes, 
some of which are done by farmers onsite, others by 
traffickers in clandestine laboratories. Some of these 
processes are complex, involve chemical precursors and 
may be done be different people in different places 
under a variety of conditions, which are not always 
known. In the case of opium gum, e.g., traffickers extract 
the morphine contained in the gum in one process, and 
transform the morphine into heroin base in a second 
process, and finally produce heroin hydrochloride. In 
the case of cocaine, coca paste is produced from either 
sun-dried (in Bolivia and Peru) or fresh coca leaves (in 
Colombia), which is later transformed into cocaine base, 
from where cocaine hydrochloride is produced. 
The results of each step, e.g. from coca leaf to coca paste, 
can be estimated with a conversion factor. Such conver-
sion factors are based on interviews with the people who 
are involved in the process, e.g. farmers in Colombia, 
who reported how much coca leaf they needed to pro-
duce 1 kg of coca paste or cocaine base. Tests have also 
been conducted, where so-called ‘cooks’ or ‘chemists’ 
demonstrate how they do the processing under local 
conditions. A number of studies conducted by enforce-
ment agencies in the main drug producing countries 
have provided the orders of magnitude for the transfor-
mation from the raw material to the end product. The 
problem is that this information is usually based on just 
a few case studies which are not necessarily representa-
tive of the entire production process. Farmer interviews 
are not always possible due to the sensitivity of the topic, 
especially if the processing is done by specialists and not 
by the farmers themselves. Establishing conversion ratios 
is complicated by the fact that traffickers may not know 
the quality of the substances they use, which may vary 
considerably, they may use a range of substances for the 
same purpose depending on their availability and costs, 
and the conditions under which the processing takes 
place (temperature, humidity, etc.) differ. 
It is important to take into account that the margins of 
error of these conversion ratios - used to calculate the 
potential cocaine production from coca leaf or the heroin 
production from opium - are not known. In order to be 
precise, these calculations would require detailed infor-
mation on the morphine content of opium or the 
cocaine content of the coca leaf, as well as detailed infor-
mation on the efficiency of clandestine laboratories. 
This information is very limited. This also applies to the 
question of the psychoactive content of the narcotic 
plants. One study conducted in Afghanistan by UNODC 
over two years indicated, for instance, that the morphine 
content of Afghan opium was significantly higher than 
had been thought earlier. Based on this study, and in 
combination with information on the price structured, 
it became clear that the conversion ratio that had been 
used (10:1) had to be changed. In 2005, therefore, the 
transformation ratio was estimated at 7:1, following 
additional information obtained from interviews with 
morphine/heroin producers in Afghanistan.
Many cannabis farmers also conduct the first processing 
steps, either by removing the upper leaves and flowers of 
the plant to produce cannabis herb or by threshing and 
sieving the plant material to extract the cannabis resin. 
The herb and resin yield per hectare can be obtained by 
multiplying the plant material yield with an extraction 
factor. In Morocco, this factor was established by using 
information from farmers on the methods used and on 
results from scientific laboratoriese. Information on the 
yield was obtained from interviews with cannabis farm-
ers. Greater details on the methodology to estimate 
global cannabis herb and resin production are provided 
in the Cannabis Production section of this Report. 
‘Potential’ heroin or cocaine production shows the level 
of production of heroin or cocaine if all of the cultivated 
opium or coca leaf were transformed into the end 
products in the respective producer country. Part of the 
opium or the coca leaf is directly consumed in the pro-
ducing countries or in neighbouring countries, prior to 
the transformation into heroin or cocaine. In addition, 
significant quantities of the intermediate products, coca 
paste or morphine, are also consumed in the producing 
countries. These factors are partly taken into account: 
for example, consumption of coca leaf considered licit in 
Bolivia and Peru is not taken into account for the trans-
formation into cocaine. Potential production is a hypo-
thetical concept to be used at the global level and not as 
an indication of heroin or cocaine production at the 
country levelf. The overall accuracy of the global heroin 
d Prices suggested that, using a 10:1 conversion ratio of opium to 
heroin, laboratory owners would have been losing money.
e For greater detail on studies with cannabis farmers, see: UNODC 
(2007). Enquête sur le cannabis au Maroc 2005. Vienna: United 
Nations Office on Drugs and Crime. 
f The calculation of ‘potential’ cocaine production estimates for Peru, 
for instance, probably exceeds actual local cocaine production as 
some of the coca paste or cocaine base produced in Peru is thought 
to be exported to neighbouring Colombia and other countries for 
further processing into cocaine.
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and cocaine estimates has certainly improved over the 
last few years and can used with a good level of confi-
dence. 
ATS manufacture estimates
The approach taken to estimate ATS manufacture 
changed significantly in this year’s Report. Since 2003, 
UNODC triangulated three estimates: 1) estimates 
based upon ATS consumption; 2) estimates based upon 
ATS drug seizures, and 3) estimates based on seized 
precursor chemicals likely used in the illicit manufacture 
of ATS.g There have been significant changes, however, 
in both ATS use and manufacture, which severely limit 
the usefulness of this approach.h 
In this Report, UNODC therefore presented a model 
based only on estimated consumption, to produce a 
range of ATS manufacture. This approach utilizes the 
estimated range of annual global users, and multiplies 
this by the average amount of pure ATS believed to be 
consumed (i.e. among both casual and problem users) 
for each drug type. The average user of amphetamines-
group substance was estimated to consume 12 grams of 
pure meth/amphetamine per year (range 1.6 – 34.4); 
and the average ‘ecstasy’ user was estimated to consume 
5 grams of pure MDMA per year (0.8 – 13.6). The 
amount of seized drugs for each group are added to the 
total quantity of ATS and ecstasy estimated to be con-
sumed globally. Totals are derived to estimate the lower 
and upper range of likely manufacture for ampheta-
mines-group and ecstasy-group substances. 
There are a range of issues with this approach related to 
the quality of the data on the level and amount of con-
sumption of ATS and ecstasy by users, and uncertainty 
around the applicability of data on consumption pat-
terns from studies of ATS and ecstasy users in a limited 
number of countries to all such users in all countries. 
Further, estimates using a similar consumption-based 
approach for cannabis produced estimates with a much 
lower range compared to other methods of estimating 
cannabis production. Considerable caution should 
therefore be taken when considering the estimates pro-
duced by this method.
UNODC is reviewing this approach to estimating ATS 
manufacture, and is in discussions with experts in the 
field to develop a more sophisticated approach to deter-
mining global levels of ATS manufacture.
g See Ecstasy and Amphetamines, Global Survey 2003 (United Nations 
publication, Sales No. E.03.XI.15).
h See Amphetamines and Ecstasy: 2008 Global ATS Assessment (United 
Nations publication, Sales No. E.08.XI.12).
Drug trafficking
The information on drug trafficking, as presented in this 
report, is mainly drawn from the Annual Reports Ques-
tionnaires (ARQ). Additional sources, such as other 
Government reports, INTERPOL, the World Customs 
Organization (WCO), reports by the Heads of National 
Law Enforcement Agency (HONLEA), data provided 
via UNODC’s ‘Data for Africa‘ project, data provided 
via UNODC’s, ‘Drug Use Information Network for 
Asia and the Pacific’ (DAINAP), and UNODC’s field 
offices, were used to supplement the information. Prior-
ity was given to officially transmitted data in the Annual 
Reports Questionnaire. The analysis of quantities seized, 
shown in this report, was provided from 107 ARQ’s over 
the June 2008–May 2009 period. Including informa-
tion from other sources, UNODC was able to obtain 
seizure data from 143 countries for 2007. Seizures are 
thus the most comprehensive indicator of the drug situ-
ation and its evolution at the global level. Although 
seizures may not always reflect trafficking trends cor-
rectly at the national level, they tend to show reasonable 
representations of trafficking trends at the regional and 
global levels.
There are some technical problems as – depending on 
the drugs - some countries report seizures in weight 
terms (kilogram - kg), in volume terms (litres - l) while 
other countries report seizures in ‘unit terms’. In the 
online inter-active seizure report (www.unodc.org), sei-
zures are shown as reported. In the World Drug Report, 
seizure data have been aggregated and transformed into 
a unique measurement: seizures in ‘kilogram equiva-
lents’. For the purposes of the calculations a ‘typical 
consumption unit’ (at street purity) was assumed to be: 
cannabis herb: 0.5 g, cannabis resin: 0.135 g; cocaine 
and ecstasy: 0.1 g, heroin and amphetamines: 0.03 g; 
LSD: 0.00005 g (50 micrograms). A litre of seizures was 
assumed to be equivalent to one kilogram. For opiate 
seizures (unless specified differently in the text), it was 
assumed that 10 kg of opium were equivalent to 1 kg of 
morphine or heroin. Though all of these transformation 
ratios can be disputed, they provide a means of combin-
ing all the different seizure reports into one comprehen-
sive measure. The transformation ratios have been 
derived from those normally used by law enforcement 
agencies, in the scientific literature and by the Interna-
tional Narcotics Control Board, and were established in 
consultation with UNODC’s Laboratory and Scientific 
Section. No changes in the transformation ratios used in 
last year’s World Drug Report were made. 
Seizures are used as an indicator for trends and patterns 
in trafficking. In combination with changes in drug 
prices or drug purities, changes in seizures can indicate 
whether trafficking has increased or declined. Increase in 
seizures in combination with stable or falling drug prices 
is a strong indication of rising trafficking activities. 
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Increasing seizures and rising drug prices, in contrast, 
may be a reflection of improved enforcement effective-
ness. Changes in trafficking can also serve as an indirect 
indicator for global production and use of drugs. Sei-
zures are, of course, only an indirect indicator for traf-
ficking activities, influenced by a number of additional 
factors, such as variations in law enforcement practices 
and changes in reporting modalities. Seizures can also 
sometimes be double counted when more than one 
organization is involved. 
Overall seizures have proven to be a good indicator to 
reveal underlying trafficking trends if analyzed over long 
periods of time and across large geographical entities. 
While seizures at the national level may be influenced by 
large quantities of drugs in transit or by shifts in law 
enforcement priorities, it is not very likely that the same 
is true at the regional or at the global level. If a large 
drug shipment, while in transit, is taken out of the 
market in one country, fewer drugs will be probably 
seized in the neighbouring countries. Similarly, if 
enforcement efforts and seizures decline in one country, 
the neighbouring countries are likely to suffer from 
intensified trafficking activities, resulting in rising levels 
of seizures. The impact of changes in enforcement pri-
orities of an individual country are, in general, not sig-
nificant at the regional or global level. 
Drug price and purity data 
UNODC also collects and publishes price and purity 
data. These data, if properly collected, can be very pow-
erful indicators of market trends. Trends in supply can 
change over a shorter period of time when compared 
with changes in demand and shifts in prices and purities 
are good indicators for increases or declines of market 
supply. Research has shown that short-term changes in 
the consumer markets are first reflected in purity changes 
while prices tend to be rather stable over longer periods 
of time. UNODC collects its price data from the Annual 
Reports Questionnaire, and supplements this data with 
other sources, such as price data collected by Europol 
and other organisations. Prices are collected at farm-gate 
level, wholesale level (‘kilogram prices’) and at retail level 
(‘gram prices’). Countries are asked to provide mini-
mum, maximum and typical prices and purities. 
When countries do not provide typical prices/purities, 
UNODC calculates the mid-point of these estimates as 
a proxy for the ‘typical’ prices/purities (unless scientific 
studies are available which provide better estimates). 
What is not known, in general, is how data were col-
lected and how reliable it is. 
Although improvements have been made in some coun-
tries over the last few years, a number of law enforce-
ment bodies in several countries have not yet established 
a regular system for collecting purity and price data. 
Data on drug consumption
Overview
UNODC estimates of the extent of illicit drug use in the 
world have been published periodically since 1997. The 
latest estimates, presented in this report, are based on 
information received until April 2009. 
Assessing the extent of drug use (the number of drug 
users) is a particularly difficult undertaking because it 
involves measuring the size of a ‘hidden’ population. 
Margins of error are considerable, and tend to multiply 
as the scale of estimation is raised, from local to national, 
regional and global levels. Despite some improvements 
in recent years, estimates provided by Member States to 
UNODC are still very heterogeneous in terms of quality 
and reliability. These estimates cannot simply be aggre-
gated globally to arrive at an “exact” number of drug 
users in the world. In this year’s World Drug Report, the 
new country data presented (not reported in previous 
World Drug Reports) are expressed in ranges where point 
estimates could not be produced given the level of uncer-
tainty. Regional and global estimates are also reported as 
ranges reflecting the lack of information in some coun-
tries. It can be noted that the level of confidence expressed 
in the estimates vary across regions and across drugs. 
This approach marks a departure from the approaches 
used in all previous World Drug Reports. Comparisons 
are therefore not valid for this year’s global and regional 
estimates with those made in previous years. 
A global estimate of the level of use of specific drugs 
involved the following steps:
Identiﬁcation and analysis of appropriate sources; 1. 
Identiﬁcation of key benchmark ﬁgures for the level of 2. 
drug use in all countries where data are available (an-
nual prevalence of drug use among the general popula-
tion aged 15-64) which then serve as ‘anchor points’ 
for subsequent calculations;
‘Standardisation’ of existing data if reported with a dif-3. 
ferent reference population than the one used for the 
Report (for example, from age group 12 and above to a 
standard age group of 15-64) ;
Adjustments of national indicators to annual prevalence 4. 
rate if annual prevalence is not available (for example, 
lifetime prevalence or current use to annual prevalence 
or school survey results to annual prevalence among 
the general population). This included the identiﬁca-
tion of adjustment factors based on information from 
neighbouring countries with similar cultural, social 
and economic situations;
Imputation for countries where data is not avail-5. 
able based on data from countries in the same region. 
Ranges were calculated considering the 10th and 90th 
percentile of the regional distribution. 
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Extrapolation of available results from countries in 6. 
a region to the region as a whole. Regional estimates 
were calculated only for regions where data for at least 
two countries covering at least 20% of the population 
was available;
Aggregation of regional results to arrive at global results.7. 
Country-level estimates of the number of 
people who have used drugs at least once  
in the past year
Estimates of illicit drug consumption for a large number 
of countries have been received by UNODC over the 
years (in the form of Annual Reports Questionnaires 
(ARQ) submitted by Governments), and have been 
identified from additional sources, such as other govern-
mental reports and research results from scientific litera-
ture. Officially transmitted information in any specific 
year, however, would not suffice to establish global esti-
mates. Over the period June 2008 to May 2009, for 
instance, 115 countries provided UNODC with 
responses to the ARQ on Drug Use (Part II), but less 
than half of them (42 countries) provided new quantita-
tive estimates and most of these estimates did not refer 
to 2007 but to some previous year. For countries that 
did not submit information, or in cases where the data 
were older than 10 years, other sources were identified, 
where available. In addition, a number of estimates 
needed to be ‘adjusted’ (see below). Since 1998, with the 
inclusion of estimates referring to previous years, 
UNODC has collected quantitative estimates of drug 
use among the general population for 128 countries and 
territories and 99 for student/youth populations. In 
cases of estimates referring to previous years, the preva-
lence rates were left unchanged and applied to new 
population estimates for the year 2007. Results from 
these countries were extrapolated to the sub-regional 
level and then aggregated into the global estimate
Detailed information is available from countries in 
North America, a large number of countries in Europe, 
a number of countries in South America, the two main 
countries in the Oceania region and a limited number of 
countries in Asia and in Africa. For other countries, 
available qualitative information on the drug use situa-
tion only allows for some ‘guess estimates’. 
One key problem in national data reported is still the 
level of accuracy, which varies strongly from country to 
country. While a number of estimates are based on 
sound epidemiological surveys, some are the result of 
guesswork. In other cases, the estimates simply reflect 
the aggregate number of drug users found in drug regis-
tries which probably cover only a small fraction of the 
total drug using population in a country.
Even in cases where detailed information is available, 
there is often considerable divergence in definitions used 
- registry data (people in contact with the treatment 
system or the judicial system) versus survey data (usually 
extrapolation of results obtained through interviews of a 
selected sample); general population versus specific sur-
veys of groups in terms of age (such as school surveys), 
special settings (such as hospitals or prisons), lifetime, 
annual or monthly prevalence, et cetera.
In order to reduce the error from simply aggregating such 
diverse estimates, an attempt was made to standardize - 
as a far as possible - the very heterogeneous data set. 
Thus, all available estimates were transformed into one 
single indicator - annual prevalence among the general 
population aged 15 to 64 - using transformation ratios 
derived from analysis of the situation in neighbouring 
countries, and if such data were not available, on 
estimates from the USA, the most studied country world-
wide with regard to drug use.
The basic assumption is that the level of drug use differs 
between countries, but that there are general patterns 
(for example, lifetime prevalence is higher than annual 
prevalence; young people consume more drugs than 
older people) which apply to most countries. It is also 
assumed that the ratio between lifetime prevalence and 
annual prevalence among the general population or 
between lifetime prevalence among young people and 
annual prevalence among the general population, do not 
vary too much among countries with similar social, 
cultural and economic situation. Various calculations of 
long-term data from a number of countries seem to 
confirm these assumptions.
Indicators used 
The most widely used indicator at the global level is the 
annual prevalence rate: the number of people who have 
consumed an illicit drug at least once in the last twelve 
months prior to the study. As “annual prevalence” is the 
most commonly used indicator to measure prevalence, 
it has been adopted by UNODC as a key indicator to 
measure the extent of drug use. It is also part of the 
Lisbon Consensusi on core epidemiological demand 
i The basic indicators to monitor drug use, agreed by all participating 
organizations that formed part of the Lisbon Consensus in 2000, 
and endorsed by the Commission on Narcotic Drugs, are: 
-  Drug consumption among the general population 
 (estimates of prevalence and incidence); 
- Drug consumption among the youth population  
 (estimates of prevalence and incidence); 
- High-risk drug use (estimates of the number of injecting drug  
 users and the proportion engaged in high-risk behaviour,  
 estimates of the number of daily drug users); 
- Utilization of services for drug problems  
 (number of individuals seeking help for drug problems); 
- Drug-related morbidity (prevalence of HIV, hepatitis B virus and  
 hepatitis C virus among illicit drug consumers); 
- Drug-related mortality  
 (deaths directly attributable to drug consumption).  
 While in the analysis of the drug use situation and drug use trends 
all these indicators were considered, when it came to provide a global 
comparison a choice was made to rely on the one key indicator that is 
most available and provides an idea of the magnitude for the drug use 
situation: annual prevalence among the population aged 15 to 64.
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indicators (CN.7/2000/CRP.3). 
The use of “annual prevalence” is a compromise between 
“lifetime prevalence” data (drug use at least once in a 
lifetime) and data on current use (drug use at least once 
over the last month). Lifetime prevalence data are often 
collected, but they are less useful in providing informa-
tion about recent trends in the levels of drug use across 
countries. Data on current use could provide informa-
tion to study even more recent trends. However, they 
often require larger samples in order to obtain meaning-
ful results, and are thus more costly to generate, notably 
if it comes to drugs other than cannabis which is wide-
spread. 
The “annual prevalence” rate is usually shown as a per-
centage of the youth and adult population. The defini-
tions of the age groups vary, however, from country to 
country. Given a highly skewed distribution of drug use 
among the different age cohorts in most countries (youth 
and young adults tend to have substantially higher prev-
alence rates than older adults or retired persons), differ-
ences in the age groups can lead to substantially diverging 
results. Typical age groups used by UNODC Member 
States are: 12+; 14+: 15+; 18+; 12-60; 16-59; 18-60; 
15-45; 15-75; and, increasingly, aged 15-64. The revised 
version of the Annual Reports Questionnaire (ARQ) 
stipulates the age group 15-64 as the key population 
group to be measured. Where the age groups reported 
by Member States did not differ significantly from this 
age group, they were presented as reported and the age 
group specified. Where studies were based on signifi-
cantly different age groups, results were adjusted to the 
age group of 15-64. 
The methods used for collecting data on illicit drug use 
vary from country to country. This reduces comparabil-
ity. The options for post adjustment to reduce these 
differences are limited. UNODC thus welcomes efforts 
at the regional level to arrive at more comparable data 
(as is currently the case in Europe under the auspices of 
EMCDDA and in the Americas under the auspices of 
CICAD).
Diverging results have also been obtained for the same 
country by applying differing methodological approaches. 
In such cases, the sources were analysed in-depth and 
priority was given to the most recent data and to the 
methodological approaches that are considered to pro-
duce the best results. For example, it is generally accepted 
that household surveys are reasonably good approaches 
to estimating cannabis, ATS or cocaine use among the 
general population, at least in countries where there are 
no adverse consequences for admitting illicit drug use. 
Thus, household survey results were usually given prior-
ity over other sources of prevalence estimates, such as 
reported registry data from the police or from treatment 
providers. 
However, when it comes to heroin use (or drug inject-
ing), annual prevalence data derived from national 
household surveys tend to grossly under-estimate such 
use j, because heroin users often do not live in “typical” 
households (and may be homeless, in hospitals or in 
prisons); heroin use is often highly stigmatised so that 
the willingness to openly report heroin use may be lower; 
and users are often geographically concentrated in cer-
tain areas. A number of “indirect” methods have been 
developed to provide estimates for this group of drug 
users. They include various multiplier methods (such as 
treatment multipliers, police data multipliers, HIV/
AIDS multipliers or mortality multipliers), capture-re-
capture methods and multivariate indicators. In coun-
tries where evidence existed that the primary “problem 
drug” in those countries was opiates, and an indirect 
estimate existed for “problem drug use” or injecting 
drug use (largely Western European countries), this was 
used in preference to household survey estimates of 
heroin use. 
For other drug types, priority was given to annual prev-
alence data found by means of household surveys. A 
number of countries, however, did not report annual 
prevalence data, but lifetime or current use of drug con-
sumption, or they provided annual prevalence data but 
for a different age group. In order to arrive at basically 
comparable results, it was thus necessary to extrapolate 
from reported current use or lifetime prevalence data to 
annual prevalence rates and/or to adjust results for dif-
ferences in age groups.
j The problem of under-estimation is more widespread for heroin, 
but does also exist for other drugs such as cocaine or methampheta-
mine. 
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Extrapolation methods used 
The methods used for these adjustments and extrapola-
tions are best explained by providing a number of con-
crete examples: 
Adjustment for differences in age groups 
The approach to age adjustments is highlighted using an 
example from New Zealand. New Zealand carried out a 
household survey in 2006, covering the population aged 
15-45.  According to this survey, annual prevalence of 
ecstasy use was found to affect 3.4% of the population 
aged 15-45, equivalent to about 71,200 people. Given 
the strong association between ecstasy use and younger 
age groups it can be assumed that there is little ecstasy 
use in the 45+ age group. Thus, dividing the ecstasy 
using population established above by the population 
size 15-64 (2.764 million) gives an estimated prevalence 
rate of 2.6%. 
The situation is slightly more complex when it comes to 
cannabis. New Zealand reported a cannabis prevalence 
rate of 17.9% among the population aged 15-45; it is 
more likely that use would continue past the age of 45 
years, based on studies of cannabis users in other coun-
tries. An estimate of cannabis use among those aged 
15-64 years was therefore derived from an extrapolation 
from the age structure of cannabis users found in Aus-
tralia, which was then applied to existing data for New 
Indirect methods of estimating heroin use  
Treatment multiplier: If a survey among heroin users reveals, for instance, that one quarter of them were in treatment 
in the last year, the multiplication of the total treatment population with a multiplier of four provides an estimate 
of the likely total number of problem heroin users in a country. 
Police data multiplier: Similarly, if a survey among heroin users reveals that one out of five was arrested in the previ-
ous year, a multiplication of the persons arrested for heroin possession by the multiplier (five) provides another 
estimate for the number of heroin users. 
Establishing various multipliers and applying them to the registered drug using population provides a range of likely 
estimates of the heroin use population in a country. Either the mid-point of the range, the median or the mean of 
these estimates can be subsequently used to arrive at a national estimate.
Capture-recapture models are another method based on probability considerations.a If in one register (for example, 
an arrest register) 5000 persons are found (for possession of heroin) and in a second register (such as a treatment 
register) 2000 persons are found (for treatment of heroin use), and 400 persons appear in both registers, the total 
population of heroin dependent users can be estimated through the following calculations. It can be assumed that 
20% (400/2000) of heroin-dependent users have been arrested, so that the total heroin-using population could be 
around 25,000 (5000/20%).b Results can usually be improved if data from more than two registers are analysed 
(such as data from an arrest register, treatment register, ambulance register, mortality register, substitution treatment 
register, HIV register, et cetera). More sophisticated capture-recapture models exist, and are used by some countries 
to make calculations based on more than two registries. 
Another approach is the use of multivariate indicators. For this approach, a number of local/regional studies are 
conducted, using various multiplier and/or capture-recapture methods. Such local studies are usually far cheaper 
than comprehensive national studies. They serve as anchor points for the subsequent estimation procedures. The 
subsequent assumption is that drug use at the local level correlates with other data that are readily available. For 
instance, heroin arrest data, heroin treatment data, IDU-related HIV data, etc. are likely to be higher in communi-
ties where heroin use is high and lower in communities where heroin use is low. In addition, heroin use may cor-
relate with some readily available social indicators (higher levels in deprived areas than in affluent areas; higher levels 
in urban than in rural areas et cetera). Taking all of this additional information into account, results from the local 
studies are then extrapolated to the national level.
a Such methods were originally developed to estimate the size of animal population. If, for instance, 200 fish are caught (‘ capture’), marked, 
and released back into the lake, and then the next day 100 fish are caught, of which 10 were already marked (‘re-captured’), probability 
considerations suggest that the number of fish captured the first day were a 10% sample of the total population. Thus the total population 
of the lake can be estimated at around 2000 fish.
b The advantage of this method is that no additional field research is necessary. There are, however, problems as the two ‘ sampling processes’ 
for the registries in practice are not independent from each other so that some of the underlying assumptions of the model may be violated 
(e.g. the ratio could be higher as some of the people arrested are likely to be transferred to a treatment facility; thus the ratio does not cor-
respond any longer to the true proportion of people arrested among the addicts population, and may lead to an under-estimation of the 
total heroin addict population).
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Zealand. Based on the assumption that the age structure 
of cannabis users in New Zealand is similar to the one 
found in Australia the likely annual prevalence rate of 
cannabis use in New Zealand for the population aged 
15-64 can be estimated at around 13.3%; this is the 
estimate reported in the Statistical Annex. Similar 
approaches were also used for the age-group adjustments 
of data from other countries. 
A number of countries reported prevalence rates for the 
age groups 15+ or 18+. In these cases it was generally 
assumed that there was no significant drug use above the 
age of 65. The number of drug users based on the popu-
lation age 15+ (or age 18+) was thus simply shown as a 
proportion of the population age 15-64. 
Extrapolation of results from lifetime prevalence 
to annual prevalence  
Some countries have conducted surveys in recent years 
but did not ask the question whether drug consumption 
took place over the last year. In such cases, results were 
extrapolated to arrive at annual prevalence estimates. 
Let’s assume for example that a country in Europe 
reported a life time cocaine use of 2% and an annual 
prevalence rate is estimated based on this life time data. 
Taking data for lifetime and annual prevalence of cocaine 
use in countries of Western Europe it can be shown that 
there is a strong positive correlation between the two 
measures (correlation coefficient R = 0.94); that is, the 
higher the lifetime prevalence, the higher is the annual 
prevalence and vice versa. Based on the resulting regres-
sion curve (y = annual prevalence and x = lifetime prev-
alence) it can be estimated that a West European country 
with a lifetime prevalence of 2% is likely to have an 
annual prevalence of around 0.7% (see figure). Almost 
the same result is obtained by calculating the ratio of the 
unweighted annual prevalence rates of the West Euro-
pean countries and the unweighted lifetime prevalence 
rate (0.93/2.61 = 0.356) and multiplying this ratio with 
the lifetime prevalence of the country concerned (2% * 
0.356 = 0.7%). 
A similar approach used was to calculate the overall ratio 
by averaging the annual/lifetime ratios, calculated for 
each countryk. Multiplying the resulting average ratio 
(0.387) with the lifetime prevalence of the country con-
cerned provides the estimate for the annual prevalence 
(0.387 * 2% = 0.8%). Given this close relationship 
between lifetime and annual prevalence (and an even 
stronger correlation between annual prevalence and 
monthly prevalence), extrapolations from lifetime or cur-
rent use data to annual prevalence data was usually given 
preference to other kinds of possible extrapolations.
k For each country the ratio between annual prevalence and lifetime 
prevalence is calculated. The results are than averaged: In our exam-
ple: ( 0.64 + 0.32 +  0.43 +  0.14 +  0.32 + 0.38 + 0.35 + 0.32 + 0.75 
+ 0.31 + 0.32 +  0.33 + 0.46+ 0.34) : 14 = 0.387. 
Good quality results (showing only a small potential 
error) can only be expected from extrapolations done for 
a country in the same region. If instead of using the 
West European average (0.387), the ratio found in the 
USA was used (0.17), the estimate for a country with a 
lifetime prevalence of cocaine use of 2% would decline 
to 0.3% (2% * 0.17). Such an estimate is likely to be 
correct for a country with a drug history similar to the 
USA, which has had a cocaine problem for more than 
two decades which is different from Western Europe, 
where the cocaine problem is a phenomenon of the last 
decade.
Data from countries in the same region with similar 
patter in drug use were used, wherever possible, for 
extrapolation purposes. 
Extrapolations based on treatment data 
For a number of developing countries, the only drug-
related data available on the demand side was treatment 
demand. In such cases, the approach taken was to look 
for other countries in the region with a similar socio-
economic structure, which reported annual prevalence 
data and treatment data. A ratio of people treated per 
1000 drug users was calculated for each country. The 
results from different countries were then averaged and 
the resulting ratio was used to extrapolate the likely 
number of drug users from the number of people in 
treatment.    
Extrapolations based on school surveys 
Analysis of countries which have conducted both school 
surveys and national household surveys shows that there 
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is, in general, a positive correlation between the two 
variables, particularly for cannabis, ATS and cocaine. 
The correlation, however, is weaker than that of lifetime 
and annual prevalence or current use and annual preva-
lence among the general population. But it is stronger 
than the correlation between opiate use and IDU-related 
HIV cases, and between treatment and drug use.
These extrapolations were conducted using the ratios 
between school surveys and household surveys of coun-
tries in the same region or with similar social structure. 
Two approaches were taken: a) the unweighted average 
of the ratios between school and household surveys in 
the comparison countries; and b) a regression-based 
extrapolation, using the relationships between estimates 
from the other countries to predict the estimate in the 
country concerned based upon the school survey estimate 
in that country. 
A range was generated by these two estimates. These 
were used as the low and high range of the estimates of 
the annual prevalence of drug use among those aged 
15-64 years in that country.
A note on ranges at the country level
As is no doubt clear from the discussion above, in many 
instances there is uncertainty about the exact values for 
extrapolated or imputed data. Different approaches can 
be used within a study, or to make estimates of the 
prevalence of drug use across studies. In this year’s World 
Drug Report, where a number of estimates existed, or a 
variety of approaches to making estimates could be used, 
ranges were reported at the country level. This was 
intended to reflect the variation that can occur even 
within a country when different approaches to estimat-
ing the level of drug use are taken.
Making regional and global estimates of the 
number of people who use drugs
For this purpose the estimated prevalence rates of coun-
tries were applied to the population aged 15-64, as 
provided by the United Nations Population Division for 
the year 2007. The methods of calculating regional and 
global numbers were changed in this year’s report rela-
tive to previous years.  
Due to the considerable uncertainty and in the spirit of 
reflecting data gaps, no “absolute” numbers are pro-
vided, but rather, ranges have been produced. These 
reflect the uncertainty that exists when data are being 
either extrapolated or imputed. Ranges (not absolutes) 
are provided for estimated numbers and prevalence. 
Larger ranges will exist for those regions where there is 
less certainty about the likely level of drug use – in other 
words, those regions for which fewer direct estimates are 
available, for a comparatively smaller proportion of the 
region’s population.
The data being used to generate the estimates comprise 
only those estimates considered sufficiently robust and/
or recent to be published at the country level in the 
2009 World Drug Report’s tables. Unpublished estimates 
are not de facto included in estimates of prevalence at 
the country, subregional or global level.
Efforts were made to produce subregional and regional 
estimates. Such estimates were only made where direct 
estimates were published for at least two countries that 
comprise at least 20% of the subregion or region’s popu-
lation aged 15-64. Countries with one published esti-
mate (typically those countries with a household survey, 
or an indirect prevalence estimate that did not report 
ranges) did not have uncertainty estimated. The same 
estimate was used for the lower and upper range.
In estimating ranges for populations in countries with 
no published estimate, the 10th and 90th percentile in 
the range of direct estimates was used to produce a lower 
and upper estimate. This produces conservative (wide) 
intervals for regions where there is geographic variation 
and/or variance in existing country-level estimates; but 
it also reduces the likelihood that very skewed estimates 
will have a dramatic effect upon regional and global 
figures (since these would most likely fall outside the 
10th and 90th percentile). 
World Drug Report estimates of the total 
number of people who used illicit drugs at 
least once in the past year
The approach used in this year’s Report was the same as 
that of previous years, with the exception that ranges are 
now reported. Two ranges were produced, and the lowest 
and highest estimate of each the approaches were taken 
to estimate the lower and upper ranges, respectively, of 
the total illicit drug using population. This estimate is 
obviously tentative given the limited number of coun-
tries upon which the data informing the two approaches 
were based (see the list of countries below). The two 
approaches were as follows:
Approach 1. The global estimates of number of people 
using each of the five drug groups in the past year were 
summed together. To adjust for the fact that people use 
more than one drug type and these five populations 
overlap, the total was then adjusted downward. The size 
of this adjustment was made based upon household 
surveys conducted in the USA, Canada, Australia, the 
United Kingdom, Italy, Brazil, Mexico and Germany, 
which all assessed all five drug types, and reported an 
estimate of total illicit drug use. Across all of these 
studies, the extent to which adding each population of 
users overestimated the total population was an average 
of  116%. The summed total was then therefore divided 
by 1.17.
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Approach 2. This approach was based on the average 
proportion of the total drug using population that com-
prises cannabis users. The average proportion was 
obtained from household surveys conducted in the USA, 
Canada, Australia, the United Kingdom, Italy, Brazil, 
Mexico and Germany, which all assessed all five drug 
types, and reported an estimate of total illicit drug use. 
Across all of these studies, the average proportion of 
total drug users that comprised cannabis users was 76%. 
The range of cannabis users at the global level was there-
fore divided by 0.76.
World Drug Report estimates of the  
number of “problem drug users”
There is clear utility in making estimates of the number 
of drug users who are experiencing problems related to 
their use. It is this subgroup of drug users who are most 
likely to come to the attention of health and law enforce-
ment, and who drug use has been estimated to cause the 
majority of the public health and public order burden.
The number of problem drug users are typically esti-
mated with the number of dependent drug users. Some-
times an alternative approach is used, employing a 
definition of injecting or long duration use of opioids, 
amphetamines or cocaine, as the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) uses 
to guide country level indirect prevalence estimation 
studiesl.
Making such estimates is a challenging undertaking, 
even at the country level. These challenges become even 
more salient when attempting to make regional and 
global estimates of the size of this population, where 
there are additional issues of data gaps at country and 
subregional levels on dependent or injecting drug use. 
The most common approach is to use some kind of 
extrapolation techniques.
In this Report, as in previous years, the following 
approach was taken. Each of the five range estimates for 
number of people using each of the five drug groups was 
l See http://www.emcdda.europa.eu/themes/key-indicators/pdu.
converted into a “heroin user equivalent”. This was cal-
culated through the use of “relative risk coefficients” (see 
below) derived using the UNODC’s Harm Indexm. This 
allows for aggregating results from different drugs into 
one single reference drug (in this case, heroin). Using 
this coefficient, each of the five drug use estimates was 
converted into an estimate of the number of “heroin 
user equivalents”. A lower range was calculated through 
summing each of the five lower range estimates; the 
upper end of the range was calculated by summing the 
upper range of the five estimates. 
To obtain an estimate of the number of “problem drug 
users”, these totals were multiplied by the proportion of 
past year heroin users in the United States National 
Survey on Drug Use and Health (range 53-68% over the 
past six years of the NSDUH). Hence, The LOW esti-
mate of “problem drug users” is the lower proportion 
(53%) multiplied by the lower estimated size of the 
heroin use equivalent population (34.1 million heroin 
user equivalents).The HIGH estimate of “problem drug 
users” is the higher proportion (68%) multiplied by the 
higher estimated size of the heroin use equivalent popu-
lation (56.3 million heroin user equivalents).
Concluding remarks 
It goes without saying that each method of extrapolating 
results from other countries has weaknesses. These esti-
mates should still be interpreted with caution. The 2009 
World Drug Report reflects the different uncertainty that 
exists in the data. UNODC made an attempt to  reduce 
the risk of bias by extrapolating data using, as far as pos-
sible, data from nearby countries in the region.  
The global estimates presented in this report reflect 
likely orders of magnitude, as opposed to precise statis-
tics on the prevalence and evolution of global drug use. 
More precise ranges can be produced when a greater 
number of countries provide estimates based on rigorous 
scientific methods. 
m For considerable detail on the logic and data underlying this Harm 
Index, please consult the 2005 World Drug Report.
Treatment index IDU index Toxicity index Deaths index
“Relative risk 
coefficient”*
Opiates 100 100 100 100 100
Cocaine 85.3 47.8 88 18.5 59.9
Amphetamines 20.1 59.5 32 6.8 29.6
Ecstasy 3.8 6.1 20.7 1 7.9
Cannabis 9 0 1.5 0.6 2.8
* Unweighted average across the four indices.
“Relative risk coefﬁcient”
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